

Realigned into Readiness







COMPANY'S OBJECTIVES

Vision and Mission	4
Financial Highlights	6
Company Information	8
Board of Directors	11
Chairman's Review	19
CEO's Message	21

DIRECTORS' REPORT

Directors' Report	22
Directors' Report (Urdu)	69
Notice of Annual General Meeting (AGM)	71
Statement of Compliance	76

FINANCIAL PERFORMANCE OF SIX YEARS & VALUE ADDITION

Six Years at a Glance	80
Horizontal & Vertical Analysis	82
Statement of Value Addition	83



UNCONSOLIDATED FINANCIAL STATEMENTS

Independent Auditor's Review Report	86
Independent Auditor's Report	87
Statement of Financial Position	92
Statement of Profit or Loss	94
Statement of Comprehensive Income	95
Statement of Changes in Equity	96
Statement of Cash Flows	97
Notes to the Financial Statements	99

CONSOLIDATED FINANCIAL STATEMENTS

Independent Auditor's Report	169
Statement of Financial Position	174
Statement of Profit or Loss	176
Statement of Comprehensive Income	177
Statement of Changes in Equity	178
Statement of Cash Flows	179
Notes to the Financial Statements	181

SHAREHOLDERS' INFORMATION

Pattern of Shareholding	254
Proxy Form	

OUR MISSION

Healthcare with compassion for all

OUR VISION

To be the region's leader by providing quality healthcare services

OUR VALUES

Compassion, Commitment, Teamwork,
Quality, Respect and Accountability

OUR STRATEGIC PRIORITIES

- ▶ Physician partnership and enhanced clinical quality
- ▶ Provide seamless/easy access care delivery
- ▶ Financial strength/viability
- ▶ Strategic growth



FINANCIAL HIGHLIGHTS

PROFIT
ACHIEVED

Rs. 2,329

Million

TOTAL
ASSETS

Rs. 21,431

Million

CONTRIBUTION
TO NATIONAL
EXCHEQUER

Rs. 4,571

Million

SHAREHOLDERS'
EQUITY

Rs. 14,307

Million

DEBT:EQUITY
RATIO

11 : 89

EARNINGS
PER SHARE

Rs. 36.84

CASH
DIVIDEND

50%

INCREASE
IN NET
REVENUE

18.7%

DIVIDEND
PAYOUT

13.6%



COMPANY INFORMATION

Board of Directors

Dr. Habib Ur Rahman
Chairman

Dr. Zeeshan Bin Ishtiaque
Chief Executive Officer

Dr. Manzoor H. Qazi
Director

Mr. Qasim Farooq Ahmad
Vice Chairman

Dr. Samea Kauser Ahmad
Director

Syed Ilyas Ahmed
Director

Dr. Mohammad Naseem Ansari
Independent Director

Dr. Ioan Philippe Cleaton-Jones
Director

Shah Naveed Saeed
Independent Director

Dr. Mohammad Salim Khan
Independent Director

Mr. Taimoor Shah
Director

Audit Committee

Shah Naveed Saeed Chairman

Dr. Manzoor H. Qazi Member

Dr. Samea Kauser Ahmad Member

Syed Ilyas Ahmed Member

Human Resource & Remuneration Committee

Dr. Mohammad Naseem Ansari Chairman

Dr. Habib Ur Rahman Member

Dr. Zeeshan Bin Ishtiaque Member

Dr. Manzoor H. Qazi Member

Syed Ilyas Ahmed Member

Mr. Qasim Farooq Ahmad Member



Corporate Governance & Nominations Committee

Dr. Manzoor H. Qazi	Chairman
Dr. Zeeshan Bin Ishtiaque	Member
Dr. Samea Kauser Ahmad	Member
Dr. Ioan Philippe Cleaton-Jones	Member

Risk Management Committee

Mr. Qasim Farooq Ahmad	Chairman
Dr. Mohammad Naseem Ansari	Member
Mr. Taimoor Shah	Member
Dr. Mohammad Salim Khan	Member

Chief Operating Officer

Mr. Taimoor Shah

Chief Medical Officer

Dr. Khawaja Junaid Mustafa

Chief Financial Officer

Mr. Shams Ur Rehman Abbasi

Company Secretary

Mr. Muhammad Naeem

Head of Internal Audit

Mr. Muhammad Saeed

Auditors

M/s BDO Ebrahim & Co
Chartered Accountants

Legal Advisor

M/s Bashir Ahmad Ansari & Company

Share Registrar

M/s Corplink (Private) Limited

Wings Arcade, 1-K, Commercial,
Model Town, Lahore

Registered Office

Sector H-8/4, Islamabad

Bankers

Meezan Bank Limited
Al Baraka Bank (Pakistan) Limited
Bank Alfalah Limited
United Bank Limited
Habib Bank Limited
Faysal Bank Limited
MCB Bank Limited
Dubai Islamic Bank (Pakistan) Limited
Bank Al Habib Limited
National Bank of Pakistan





BOARD OF DIRECTORS

BOARD OF DIRECTORS



Dr. Habib Ur Rahman

Chairman

Dr. Habib Ur Rahman is also serving as Director on the Boards of following Shifa International Hospitals Group companies:

- Shifa CARE (Private) Limited
- Shifa Development Services (Private) Limited
- Shifa Medical Center Islamabad (Private) Limited
- Shifa National Hospital Faisalabad (Private) Limited

Dr. Habib Ur Rahman graduated from King Edward Medical College. He received his internal medicine training at D. C. General Hospital, Howard University, Washington D.C. and Wayne State University, Detroit, Michigan and Wright State University, Dayton Ohio. He completed his fellowship of Cardiovascular Disease from Mount Sinai Hospital, University of Connecticut, Hartford, Connecticut. He is Board Certified by American Board of Internal Medicine and also American Board of Cardiovascular Diseases. He has extensive experience in cardiology as well as in education, training and management. He has been Consultant Cardiologist and Head of Cardiology at Graham Hospital, Canton, Illinois and later at Byrd Regional Hospital at Leesville, Louisiana in USA. In addition to teaching experience in Wright State University, Connecticut he is presently member of the Senate of Shifa Tameer-e-Millat University. He has been member of different scientific councils and committees including Pakistan Lifesavers Foundation, Pakistan Cardiac Society and Faculty of Cardiology, College of Physicians and Surgeons Pakistan. He is among the founding members of Shifa International Hospital and Shifa Foundation.



Dr. Zeeshan Bin Ishtiaque

Chief Executive Officer

Dr. Zeeshan Bin Ishtiaque is an accomplished healthcare leader with a rich background in healthcare management, quality assurance, and corporate leadership. He currently serves as the Chief Executive Officer of Shifa International Hospitals, a 500-bed, JCI-accredited multispecialty facility.

Throughout his career, Dr. Zeeshan has made notable contributions to the society at large. He actively contributes to various international bodies, national clusters, and policymaking forums, championing improved healthcare quality. His involvement with Shifa Foundation and projects in collaboration with the United Nations underscores his commitment to societal betterment. Furthermore, he has been deeply engaged with several government and non government organizations, demonstrating his dedication to uplift communities.

Prior to his current role, Dr. Zeeshan served as the Chief Medical Officer, where he consistently raised the healthcare standards, provided strategic leadership, fostered a culture of excellence, and ensured strict compliance with international standards and regulations.

His global influence is also evident in his role as an International Physician Surveyor and Team Lead for Joint Commission International. With his expertise, he has conducted surveys in nearly 50 countries, making a significant impact on healthcare services and Patient safety worldwide.

Dr. Zeeshan earned his MBBS from Nishtar Medical College Multan, Pakistan, in 2005. He later pursued an MD in 2009 and a DCPS-Healthcare Systems Management degree in 2011. He is recognized as a Fellow of the American College of Healthcare Executives, a Fellow of the American Board of Quality Assurance and Utilization Review Physicians, and holds the distinction of being a Certified Professional in Healthcare Quality.



Dr. Manzoor H. Qazi

Non-Executive Director

Dr. Manzoor H. Qazi is serving as Director on the Boards of following Shifa International Hospitals Group companies:

- Shifa Medical Center Islamabad (Private) Limited
- Shifa National Hospital Faisalabad (Private) Limited

Dr. Manzoor H. Qazi is a founding member of Shifa International Hospital and has been a board member since its inception. He was appointed as Chief Executive of the company on 10th October 2011 and remained the Chief Executive till March 30, 2023. He received his medical degree from King Edward Medical College Lahore. Later he was trained in USA at Little Company of Mary Hospital in Chicago and Flushing Hospital in New York for Internal Medicine and later in Louisiana State University for Cardiology. He is Board certified in Internal Medicine and Cardiology from American Board of Internal Medicine and Cardiology. He has an extensive experience of practice of cardiology as well as administration and management. He was Consultant Cardiologist and President Medical Staff at Byrd Regional Hospital, Leesville, Louisiana for several years. He has also served as President of local chapter of American Heart Association and State Medical Society. He previously has been fellow American College of Cardiology, American Chest Physician and American Board of Quality Assurance and Utilization Review for Physicians. He was actively involved in the initial planning and founding stages of Shifa and later on in the management of the Hospital and has been Medical Director of Shifa International Hospitals Limited since its conception, through planning and implementation until when he accepted the position of Chief Executive Officer. Dr. Qazi retired from the office of Chief Executive Officer on March 30, 2023 and is now working as a Director of the Company. He is also member BOG of Shifa Foundation, a non-profit organization involved in healthcare for poor and medical education.



Mr. Qasim Farooq Ahmad

Vice Chairman

Mr. Qasim Farooq Ahmad is also serving as Director on the Board of

- Shifa CARE (Private) Limited
- SIHT (Private) Limited

Mr. Qasim Farooq Ahmad brings young blood and new dimension to the Board of Shifa International Hospitals. He did his Bachelor of Science in Information Systems and Bachelors of Arts in Economics from Stony Brook University, Stony Brook NY. He furthered his education with a Master of Science degree in Computer Science from Columbia University, New York, in 2007. He has over 20 years of diverse experience in the technology sector focusing on production systems engineering with a strong background in software engineering. This includes 7 years of extensive experience working with high volume financial and reporting applications for companies on Wall Street such as Lehman Brothers and Barclays Capital. Current major responsibilities include change management, incident management, performance planning, capacity planning, business continuity planning and disaster recovery, Sarbanes Oxley compliance and vendor management for all Fund Systems which includes the Front, Middle and Back Office applications. His previous experiences as the lead developer for the NYC Law Department include analysis, design, development and implementation of different technical projects.

BOARD OF DIRECTORS



Dr. Samea Kauser Ahmad

Non-Executive Director

Dr. Samea Kauser Ahmad is also serving as Director on the Board of:

- Shifa Development Services (Private) Limited
- Shifa Medical Center Islamabad (Private) Limited
- Shifa National Hospital Faisalabad (Private) Limited

Dr. Samea is a graduate of Ayub Medical College, Abbottabad. She joined the Board in 2011 and has been helpful in guiding the Board and the administration towards the future direction of the corporation. She has been serving as the Vice Chairperson of Tameere-Millat Foundation (TMF) for the past 10 years. Greatly inspired and influenced by the philanthropic work of her father, Dr. Zaheer Ahmad, she was determined to carry on the vision and legacy laid down by him. As Vice Chairperson, Dr. Samea governs the running and management of over 50 educational institutions in the TMF network, all across Pakistan. In addition, Dr. Samea also serves as a member of the Senate of the federally registered Shifa Tameer-e-Millat University



Syed Ilyas Ahmed

Non-Executive Director

Syed Ilyas Ahmed has a long and illustrious career spanning over 45 years in healthcare management and its implementation. He has served in different capacities; Secretary, Scientific Governing Board and Head of Administration in Salahuddin University Hospital, Tripoli, Libya. After returning to Pakistan, he joined The Kidney Center, Karachi as its Chief Executive (1993 – 2000). Later he proceeded to Islamabad in Shifa International Hospitals Ltd and accepted the post of Chief Operating Officer (2001 – 2005). At present he is Chief Advisor Operations at Tabba Heart Institute, Karachi. During his phenomenal professional tenure, he successfully managed premier healthcare facilities, both in Pakistan and abroad. His acumen includes but not limited to, strategic planning, policies and procedures, budgeting and fiscal control, human resource, public relations and quality assurance management. He introduced ISO Quality Management System in Pakistan for the first time in 1995 and is known as Baba-e-ISO in quality conscious circles in Pakistan. Mr. Ahmed, during his university days was a Badminton Champion and accomplished Debater, Gymkhana Secretary and Magazine Editor of University of Karachi (1968-72). He was President of Sind Pharmacy Graduates Association (1970-72). He plays golf and has a refined taste in literature and shows keen interest in a wide range of aesthetic disciplines including culture and history.



Dr. Mohammad Naseem Ansari

Independent Director

Dr. Mohammad Naseem Ansari is also serving as Director on the Board of SIHT (Private) Limited.

Dr. Mohammad Naseem Ansari graduated from the Punjab University, Department of Pharmaceutical Science. He went for his postgraduate studies at Columbia University, New York City, USA and was granted a full talent scholarship. He has a very rich and illustrious career spanning over forty years both State side and upon his return to Pakistan. After the completion of his studies, he joined Mt. Sinai Hospital and School of Medicine, New York City for the internship and training program. He served there in different administrative capacities for about eighteen years. He returned Pakistan in 1988 and joined Shifa International Hospitals Limited from its inception and was assigned different roles such as Director Operations during the construction phase and Chief Operative Officer and Chief of Special Services once in operations. He was instrumental along with the other members in the establishment of Shifa College of Medicine in 1988 under the aegis of Shifa Foundation and became its first Chief Operating Officer. After the establishment of Shifa Tameer-e-Millat University in March 2012 he served at different administrative positions at STMU. He is a member of American Hospital Association and also the "Rho Chi" Honor Society, Columbia University, New York City, USA. He also served on the board of International School of Islamabad as a member and then as the Board Chair for a few years. He also has the honor and privilege of serving on the Board of Shifa International Hospitals Limited, Islamabad.



Dr. Ioan Philippe Cleaton-Jones

Non-Executive Director

Ioan P. Cleaton-Jones is the Senior Director for Healthcare Delivery at the William Davidson Institute at the University of Michigan, USA. His work includes training and mentoring C-suite and other senior healthcare executives in emerging markets to equip them with tools for commercial success. He also advises financial institutions investing in private healthcare in emerging markets.

Ioan also serves as Director on board of Grupo OSME, a privately owned healthcare provider in Northern Mexico.

During his 30-year international career in healthcare, he has worked on predominantly private sector healthcare projects and investments in 35 countries on 5 continents, including 29 emerging markets. As an institutional investor and transaction adviser, he has invested USD1.4 billion invested in emerging market private healthcare. He has been an invited speaker on investing in emerging market healthcare at numerous international conferences. He has also been an invited guest lecturer at the University of Michigan's Schools of Business, Medicine, and Public Health as well as Columbia University's School of Public Health.

As an independent consultant and investor, Ioan advised a New York hedge fund on strategic investments in biotechnology, pharmaceuticals, medical devices and healthcare IT. Furthermore, his strategic advisory roles with organizations such as a major U.S. managed care company, the Inter-American Development Bank, IDB Invest, the African Development Bank, and The Global Fund to Fight AIDS, TB, and Malaria, highlight his versatility in addressing diverse healthcare challenges.

He served as Principal Healthcare Specialist at the World Bank Group's International Finance Corporation (IFC) where he spent eleven years. Prior to IFC, he worked internationally as a healthcare-focused management consultant with Shift Health in Canada, KPMG in South Africa and Angle Technology in the UK. Earlier in his career, he practiced medicine, mostly as an emergency room physician, at hospitals in South Africa and the UK.

He holds an MBA from the University of Southampton, UK as well as BSc and MBChB degrees from the University of the Witwatersrand, South Africa.

BOARD OF DIRECTORS



Mr. Shah Naveed Saeed

Independent Director

Mr. Shah Naveed Saeed is a seasoned professional with over 30 years of experience in the fields of accounting, auditing, and financial management. His extensive educational background includes a range of prestigious qualifications: Chartered Global Management Accountant from the American Institute of Certified Public Accountants (2012), Certified Public Accountant from the University of Illinois (1985), and Chartered Accountancy from the Institute of Chartered Accountants of Pakistan (1980). He also holds a certificate in Advanced Accounting & Auditing from DePaul University, Chicago (1984).

Currently, Mr. Saeed serves as the Managing Partner at Naveed Zafar Ashfaq Jaffery & Co., Chartered Accountants, located in Islamabad. This firm is a member of Prime Global, an international association of independent accounting firms.

Mr. Saeed's career includes a notable tenure with the World Bank, where he worked as a Senior Financial Management Consultant in the Pakistan Country Office for over 20 years. This role allowed him to gain substantial experience in Public Financial Management (PFM), contributing to various significant projects and reforms.

He has also served as a director on the board of Shifa International Hospitals Limited from 29.03.2010 to 27.04.2018 and from 28.05.2018 to 14.05.2019.

He holds memberships in several prestigious professional bodies. He is a Fellow Member of the Institute of Chartered Accountants of Pakistan (ICAP) and a Chartered Global Management Accountant affiliated with CIMA/AICPA. He has previously served on the Public Sector and Technical Advisory Committees of ICAP and is a past member of the American Institute of Certified Public Accountants and ISACA, USA.

Mr. Saeed has attended numerous training courses offered by ICAP, AICPA, LUMS, and other international institutes. These courses cover diverse areas such as financial management, business process re-engineering, change management, risk-based audits, forensic accounting, procurement audits, and various international standards including IAS and IFRSs.

His core competencies are vast and varied. He possesses in-depth knowledge of International Standards on Auditing (ISAs), International Financial Reporting Standards (IFRSs), IPSASs, INTOSAI Auditing Standards, and US Governmental Auditing Standards. Mr. Saeed has developed Financial Management Systems and Reporting Manuals for both public and private sector entities. His expertise extends to designing and reviewing accounting and costing systems, policy development, and

implementation, including risk management and standard operating procedures.

In his role, he has provided guidance to the heads of internal audit for various clients, focusing on internal audit along with information technology-related controls for the COSO framework and application security. He has managed IT internal audits, the IT controls environment, and IT facilities and equipment procurement processes, providing recommendations for improvement.

Mr. Saeed is responsible for delivering comprehensive audit and assurance services, including independent audits of international non-profit entities, UNDP projects, and other multi-donor agency-funded initiatives both in Pakistan and abroad. He has conducted corporate fraud investigations for regulators and performed pre-award assessments for prospective grant recipients under the USAID Pakistan program.

Additionally, he has developed computerized models for decommissioning cost provisioning and conducted related studies for petroleum clients. As an engagement partner, he has overseen independent audits of funds and grants provided by multi-donor agencies.

His extensive experience in PFM includes working as an accredited Financial Management Consultant with the World Bank since 1998. He has been a part of the core team for the 'Tax Base Expansion' study of Sindh Sales Tax on Services, including the preparation of audit and HR manuals and IT assessments. Mr. Saeed has evaluated PFM reforms and conducted PEFA assessments for various government entities.

He has also served on the Pakistan CFAA committee, responsible for reviewing and finalizing assessment reports. His expertise in public sector accounting and auditing standards includes updating gap analysis reports in compliance with IPSAS and INTOSAI.

Moreover, Mr. Saeed has provided financial advisory services, including financial modeling and company formation. He has conducted training programs on IFRS, IAS, and ISAs within his firm and for various multinational clients, with a strong emphasis on quality control. He has also served as an independent director and chairman of the internal audit committee of a public listed company in the healthcare sector.

Shah Naveed Saeed's rich professional journey, marked by significant achievements and contributions, highlights his profound expertise and dedication to the fields of accounting and financial management.



Dr. Mohammad Salim Khan

Independent Director

Dr. Mohammad Salim Khan is a graduate of Khyber Medical College, Peshawar. He completed his training in radiation oncology in the United Kingdom and later worked there as a senior registrar and as a lecturer at the University of Newcastle upon Tyne. After working briefly as a radiation oncologist in Jeddah, Saudi Arabia, he moved to Canada. There he worked for over twelve years as a consultant radiation oncologist at the Allan Blair Cancer Centre, Regina, and as an assistant professor in the College of Medicine, University of Saskatchewan, Saskatoon.

He returned to Pakistan in 1998 with over twenty-five years of experience overseas and joined Shifa International Hospital during its formative years. At Shifa, in addition to working as a radiation oncologist and as an assistant and associate professor at Shifa College of Medicine, he held several other major administrative positions. He served as a director on the board of Shifa International Hospital for nine years and as a medical director of the hospital for over six years. Shifa International Hospital got its first accreditation with the Joint Commission International USA during this time.

Dr Salim Khan has also served as a director on the board of Shifa Foundation for several years.

He retired from active medical practice in January 2020.



Mr. Taimoor Shah

Executive Director

Taimoor Shah is a seasoned healthcare and technology leader with a robust background in engineering. Currently serving as the Chief Operating Officer of Shifa International Hospitals Limited and Director of SIHT (Pvt.) Limited (eShifa), Taimoor is at the forefront of transforming healthcare delivery through innovation and strategic leadership. His extensive experience, including global consultancy with Joint Commission International (JCI), enables him to merge technology and healthcare quality, driving impactful results across diverse regions.

Taimoor's journey began in academia, where he served as a Teaching Assistant in Computer Hardware Design at the University of South Australia. His passion for innovation led him to work as a Research Engineer, where he developed advanced in-vivo imaging technologies. He further enhanced his technical expertise with roles at Motorola Mobility and Sydac Pty Ltd, specializing in software development and project management.

In 2010, Taimoor transitioned to the healthcare sector as a Project Manager and Consultant at Lifelong Education, where he led projects that improved hospital operations and ensured ISO compliance. He joined Shifa International Hospitals in 2012 as Associate Director of Quality Assurance, playing a pivotal role in the hospital's successful JCI accreditation and launching key quality improvement initiatives.

By 2019, Taimoor had risen to Chief Operating Officer, overseeing operations and spearheading technology-driven strategies that align with business goals. As Executive Director of eShifa, he has led the platform's growth, making it a leader in telehealth and home healthcare services.

Taimoor holds a Master's in Engineering Management and a Bachelor's in Engineering (Computer Systems). He is a Project Management Professional (PMP), a Certified Professional in Healthcare Quality, and a Fellow of the American College of Healthcare Executives. His leadership extends to serving on the Board of Governors at Shifa Foundation and additionally serving as nominee director and chairman of Shifa Development Services (Pvt.) Limited, a subsidiary company of Shifa International Hospitals Limited.



Despite continuing economic pressures and a healthcare environment that remains complex, Shifa has delivered consistent results. Our ability to maintain performance in such times reflects the strength of our systems and the dedication of our people.

CHAIRMAN'S REVIEW

As I write to you once again, I do so with a profound sense of gratitude and satisfaction. The year under review has been a period of both challenges and achievements for Shifa International Hospitals Limited. It has reminded us once again that resilience, innovation, and an unwavering commitment to quality are not just values we speak of – they are the principles that define us.

Despite continuing economic pressures and a healthcare environment that remains complex, Shifa has delivered consistent results. Our ability to maintain performance in such times reflects the strength of our systems and the dedication of our people. I wish to acknowledge, with deep appreciation, the tireless efforts of our doctors, nurses, and support staff. Their compassion and professionalism allow us to provide exceptional patient care. They remain the bedrock of our reputation and the true drivers of our success.

This year, we made important progress in the digitization of healthcare services. Digital tools are transforming the way we operate and the way patients experience healthcare. From electronic medical records to diagnostic support and operational efficiency, technology is helping us enhance safety, reliability, and accessibility. The adoption of digitization is not only modernizing patient services but also preparing Shifa for the healthcare landscape of the future.

At the same time, we remain fully committed to protecting the interests of our shareholders and other stakeholders. Every decision we make is guided by prudence, responsibility, and a clear focus on long-term value creation. By investing wisely and operating efficiently, we continue to strengthen our position in Pakistan's healthcare sector and safeguard the trust placed in us.

Environmental responsibility also remains close to our hearts. Climate change is both a national as well as a global challenge, demanding urgent collective action. At Shifa, we have been steadily adopting energy efficiency and environmentally responsible practices across our operations. These steps may appear small individually, but together they help reduce risks, cut costs, and make a meaningful contribution to the world we will leave for future generations. We all are witnessing with heavy hearts the environmental havoc across Pakistan. The loss of lives, shelters, livelihoods, flora, and fauna is heartbreaking, and a stark reminder of the urgent need for national action to mitigate such threats in the future.

Looking ahead, we must also recognize the immense opportunity that lies before us. With growing healthcare expertise and human resource, Pakistan has the potential to become a hub of medical tourism in the region. Our doctors, facilities, and services can attract patients from across borders who seek quality care at affordable costs. At Shifa, we are already focusing on this area with dedication. We believe the outcomes of these efforts will be both encouraging and productive, contributing to the economy while strengthening Pakistan's position as a regional center for healthcare excellence.

And not the least, this year also saw our nation tested by war with India. We bow our heads before Allah Almighty for guiding Pakistan to stand firm and ultimately return as a united and triumphant nation. The courage and resolve of our people and forces remain a source of pride for every Pakistani. As a healthcare institution, we reaffirm our readiness to stand shoulder to shoulder with the government and the armed forces in any emergency or national service. Serving our people in times of need is not only our duty but also an honor.

As we consider the future, I remain optimistic. Our strong governance framework, a capable leadership team, and the continued support of our community give us the confidence to move forward with clarity and purpose. We will continue to push boundaries, embrace innovation, and strengthen our culture of excellence. Above all, we will remain faithful to our mission of delivering compassionate, world-class healthcare to the people of Pakistan.

On behalf of the Board, I extend heartfelt thanks to our shareholders, partners, consultants, employees, patients, and their families. Your support is our greatest source of strength. May Allah Kareem bless our efforts and guide us in our mission to advance healthcare in the region.

Long Live Pakistan!



DR. HABIB UR RAHMAN

Chairman

Islamabad

September 30, 2025



This year has been one of meaningful milestones. Our financial performance, as detailed in this report, continues to show steady and consistent growth. The safeguarding and strengthening of shareholders' equity remain at the heart of our mission, and the stability of our share price is a visible reassurance of this commitment.

CEO'S MESSAGE

It is with immense gratitude and humility that I present this message as the Chief Executive Officer of Shifa International Hospitals Limited. The Directors' Report and Financial Statements for the year under review, which follow, will provide you with the details of our performance. What I wish to share here are my reflections on the year gone by and the road that lies ahead.

This year has been one of meaningful milestones. Our financial performance, as detailed in this report, continues to show steady and consistent growth. The safeguarding and strengthening of shareholders' equity remain at the heart of our mission, and the stability of our share price is a visible reassurance of this commitment. In a time when markets have been volatile and uncertainty has been the norm, "SHFA" has remained steady. This stability is not accidental. It is the outcome of prudent management, disciplined decision-making, and an unwavering dedication to the trust our shareholders place in us.

The progress on Shifa National Hospital Faisalabad is not only a soon-to-realize expansion in geography but also in spirit. It represents our determination to take quality healthcare across Pakistan, to extend the legacy of Shifa beyond the capital, and to provide families in central Punjab with the same excellence and compassion that has become synonymous with our name. Expansions, to me, are not merely additions of bricks and mortar; they are reflections of our resolve to extend care, compassion, and excellence to wider communities.

Likewise, on Shifa Medical Center Islamabad, we are in the preparatory phase, laying the groundwork following the approval of our esteemed shareholders for its full acquisition. While this is a journey that will unfold over time, it does reflect continuity of our vision to strengthen Shifa's footprint thoughtfully and sustainably. This initiative, when realized, will not stand in isolation. It will be another step in the continuum of Shifa's growth, positioning us for long-term leadership in quality healthcare delivery.

Beyond the numbers, we are also reimagining how we work. And how we think and act as an enterprise. Over the past year specifically, we have laid the foundations for a decision-making approach that is enterprise-wide, integrated, and future-focused. This is not just about efficiency, though efficiency is a natural outcome. It is about ensuring that our resources are allocated wisely, that our teams are empowered, and that our growth is sustainable. It is about creating an organization where ideas can travel across boundaries, where innovation is embraced, and where every decision strengthens the whole. This evolution is already visible in how we manage

our operations, how we design our strategies, and how we anticipate the needs of the communities we serve.

The past year also reminded us of the unpredictability of the world we live in. The conflict with India in May and the devastating floods across our homeland in August were sobering events, stark reminders of the fragility that surrounds us. Yet, just as Pakistan emerged stronger and prouder in the face of adversity, so too does Shifa draw strength from challenges. These events have not dampened our resolve. They have fortified it. They call upon us to be more resilient, more resourceful, and more determined to carry our mission forward. We believe that just as adversity has been the mother of resilience for our nation, so too can it be the driving force behind our institutional strength. I feel both humbled and proud that, in times of war at the borders or floods within our homeland, we stood alongside the national institutions, serving our nation and communities through our areas of expertise.

At Shifa, we believe that our work is more than a professional obligation. It is a trust, a responsibility, and indeed a form of service in the path of Allah Subhanahu Wa Ta'ala. The wisdom that has guided us in previous years continues to inspire us – the call to grow, to improve, and to never let two days be the same. Without quoting, I remind myself and all of us of this timeless guidance. Our journey must always be one of progress, reflection, and renewal. Each sunrise must find us better, stronger, and truer to our mission than the day before.

As I reflect on our journey, I am profoundly aware that none of this would be possible without the dedication of the Shifa family. To our caregivers, doctors, nurses, and every staff member who serves with quiet devotion, you are the heartbeat of this institution. To our patients and their families, who entrust us with their health, we owe our deepest gratitude. And to our shareholders, whose faith and support empower every step we take, we renew our commitment to safeguarding your trust and building value for the long term.

In closing, I extend my heartfelt gratitude to all who walk this journey with us. With the blessings of Allah Subhanahu Wa Ta'ala, and the determination of our people, I am confident that Shifa International Hospitals Limited will continue to rise as a beacon of healthcare, compassion, and excellence.

May Allah Subhanahu Wa Ta'ala guide us, protect us, and bless us with continued strength. Amen!



Shifa
International
شفا انٹرنیشنل ہسپتال

SHIFA
DENTAL
CLINIC

KEEP LEFT
بائیں طرف چلیں

DIRECTORS' REPORT

The Directors of your Company are pleased to present the Annual Report with the audited financial statements of the Company for the year ended June 30, 2025.

FINANCIAL PERFORMANCE

A brief financial analysis is presented as under:

For the year ended June 30,	(Rupees in '000')		
Operating Results	2025	2024	Change %
Revenue – net	27,967,661	23,563,840	18.7
Other income	402,822	190,123	111.9
Operating costs	(23,737,514)	(20,944,954)	13.3
Profit before levies and income tax	4,134,716	2,256,177	83.3
Profit for the year	2,328,980	1,362,074	71.0
Earnings per share – Rupees	36.84	21.55	71.0

The Company delivered a robust performance during the year under review, demonstrating strong operational adaptability and disciplined strategic execution. Revenue grew by 18.7 percent, while net profit registered an impressive increase of 71.0 percent, leading to earnings per share of Rs. 36.84, up from Rs. 21.55 in the prior year.

This remarkable growth in profitability was underpinned by consistent top-line expansion, disciplined cost management, and sound financial oversight. Operating expenses grew at a moderated pace relative to revenue, indicating improved operational leverage. In addition, finance costs declined by 19.8 percent, primarily owing to the timely servicing of financial obligations, which further supported the bottom line. Other income showed a healthy increase, contributing positively to the overall financial performance.

This performance is a testament to the Company's strong governance practices, operational discipline, and successful implementation of strategic goals. Backed by healthy liquidity and a solid capital structure, the Company remains well-equipped to continue its growth journey and generate sustainable long-term value for its shareholders.

RETURN TO SHAREHOLDERS

The Board of Directors has recommended final cash dividend of Rs. 5 per share (50 percent) for the year ended June 30, 2025.

CONTRIBUTION TO THE NATIONAL EXCHEQUER

The Company's contribution to the national exchequer during the year under review is as following:

Sr. No.	Description	(Rs. in '000')
1	Direct taxes	1,555,745
2	Indirect taxes	1,221,022
3	Tax deducted and deposited from suppliers, employees, etc.	1,794,720
	Total	4,571,487

PRINCIPAL ACTIVITIES, DEVELOPMENT AND PERFORMANCE

During the reporting year, the Admission & Discharge (A&D) and Corporate Billing Department (CBD) continued to play a pivotal role in ensuring smooth patient flow and timely service delivery across the hospital. Building on the progress of previous years, both departments worked to further streamline processes, reduce bottlenecks, and ensure that patients and their attendants experienced greater convenience throughout their journey of care.

In line with earlier initiatives, special emphasis was placed on leveraging technology and process innovation to improve coordination and accuracy in patient services. The gradual adoption of digital tools, automation of workflows, and the introduction of simplified communication channels helped strengthen operational efficiency while ensuring that services remained patient-centered.

Continuing the spirit of last year, efforts were also directed toward enhancing institutional client services. The CBD maintained its focus on transparent and timely settlement of accounts, while also strengthening engagement with corporate partners to ensure smoother financial interactions and better client experience. These measures not

only foster institutional trust but also reinforce the hospital's reputation as a reliable partner for healthcare coverage.

As part of its forward-looking strategy, the departments are aligning themselves with the hospital's broader transformation goals. The coming year will emphasize the use of advanced technology platforms, refined SOPs, and staff capacity-building initiatives. This approach will allow for greater accuracy, shorter turnaround times, and improved service delivery for patients, attendants, and corporate clients alike.

Overall, the performance during the year under review reflects the hospital's ongoing commitment to continuity of care, process excellence, and patient satisfaction. By building on past progress and embracing innovation, these functions remain integral to sustaining the hospital's operational strength and enhancing patient trust.

STRATEGIC PLANS FOR THE NEXT FISCAL YEAR

Looking ahead, the hospital remains focused on advancing technology and process improvements to enhance the experiences of patients, attendants, and institutional clients, while continuing to build on broader organizational initiatives introduced in prior years.



Digital Transformation and Efficiency

Key initiatives in the coming year include the introduction of secure digital payment modes such as mobile wallets, online bank transfers, and POS-based solutions. These will reduce cash handling, shorten waiting times, and provide flexibility for patients and attendants. In collaboration with the IT Department, web-based portals will be developed for e-invoicing, insurance claim submissions, and reimbursement tracking, strengthening transparency and responsiveness with institutional clients and insurance partners.

Financial and Service Optimization

Panel rate reviews will continue in alignment with market conditions and utilization trends to ensure competitiveness and financial sustainability. Alongside this, process automation and cost optimization will remain central priorities, enabling better use of resources and improved efficiency across departments.

Patient Care and Clinical Expansion

Building on the hospital's earlier momentum, plans include expanding access to specialty services, extending consultant availability to evenings and

weekends, and streamlining admission and discharge processes for greater patient convenience. Capacity enhancements through additional inpatient beds and redesigned outpatient spaces will further support patient flow and service quality.

Strategic Growth and Outreach

Beyond the hospital premises, outreach OPD clinics will be expanded to major cities within the hospital's catchment area, allowing patients to benefit from expert consultations closer to home while generating referrals to the main facility. eShifa, our home health and digital care partner, will continue to extend access and continuity of care through telemedicine and at-home services.

Commitment to Excellence

In line with the progress of recent years, the hospital remains dedicated to investing in people, technology, and quality initiatives. These efforts will ensure that operational efficiency, patient experience, and sustainable growth continue to move forward in unison, reinforcing the hospital's role as a trusted provider of advanced healthcare in the region.





DESCRIPTION OF PRINCIPAL RISKS AND UNCERTAINTIES

Shifa International Hospitals Ltd. (SIH) operates in a dynamic healthcare environment where internal and external risks may affect performance and sustainability. Key risks and mitigation measures include:

Regulatory Compliance

The healthcare sector is heavily regulated. Non-compliance may cause penalties, financial loss, or reputational harm. SIH maintains a dedicated compliance team, conducts regular audits, and updates processes to ensure adherence to evolving regulations.

Operational Risks

Medical errors, equipment issues, and supply chain disruptions can compromise safety and efficiency. SIH reduces these risks through clinical protocols, preventive equipment maintenance, and contingency supply chain planning supported by strategic sourcing and strong supplier relationships.

Financial Risks

Rising costs, delayed insurance payments, inflation, and limited capital access may strain finances. SIH addresses these through cost controls, efficiency initiatives, financial planning, and favorable negotiations with insurers to maintain stable cash flows.

Market and Competition

Healthcare competition demands innovation and adaptability. SIH invests in research, market analysis, and service quality enhancements to strengthen its position and patient satisfaction.

Cybersecurity Risks

Digital reliance exposes SIH to cyber threats. The hospital safeguards data with next-generation firewalls, strict access controls, data encryption, continuous monitoring, and a trained incident response team.

Pandemic and Epidemic Risks

Outbreaks like COVID-19 increase costs and disrupt operations. SIH has preparedness plans, PPE stockpiles, and telemedicine services to maintain continuity of care during crises.

Environmental and Geopolitical Risks

Natural disasters or unrest can damage infrastructure and supply chains. SIH conducts risk assessments and disaster drills, maintains business continuity protocols, reinforces critical systems, and coordinates with authorities for effective response.

COMPANY'S RISK MANAGEMENT FRAMEWORK AND INTERNAL CONTROLS

SIH has a structured Risk Management Framework to identify, assess, and mitigate risks affecting operations, finances, and reputation.

The Internal Control System supports this framework by ensuring efficiency, compliance, and accurate financial reporting. Controls include clear policies, approval hierarchies, internal audits, and system monitoring.

SIH continuously reviews and strengthens these practices to safeguard assets, enhance resilience, and support sustainable growth.

EXPANSION ACTIVITIES DURING THE YEAR

During the reporting year, Shifa International Hospitals Limited undertook extensive development projects focused on enhancing clinical infrastructure and diagnostic capabilities. These expansions aim to elevate patient care, improve operational efficiency, and align facilities with international standards.

Strengthening Critical Care with New Medical ICU (B-3 Wing)

The previous Obs & Gynae wing was transformed into a state-of-the-art 8-bed Medical ICU (including 3 ward and 5 private beds), reinforcing the hospital's capacity to manage high-acuity patients with advanced critical care services.

Launch of One-Stop Pleural Clinic

A centralized clinic was established under the Pulmonology Department to provide comprehensive diagnosis and treatment of pleural disorders, improving accessibility and care quality.

Oncology Diagnostics Upgrade – PET-CT Imaging

A cutting-edge 40 PET-CT system with 128-slice CT integration was installed, enhancing early cancer detection, treatment monitoring, and follow-up. This marks a major step in elevating the hospital's oncology services.

Dental Imaging and Operatory Expansion

Installation of Cone Beam CT (CBCT) technology replaced older OPG systems, offering superior 3D imaging for dental and maxillofacial procedures. A



modern dental operatory was also added to elevate procedural capabilities.

Radiology Advancement with 640-Slice CT Scanner

A high-end CT scanner was introduced, alongside comprehensive renovations to patient areas and supporting systems, ensuring an advanced and patient-friendly diagnostic environment.

Expansion at Dar Ul Shifa (DUS)

A new 4-bed inpatient unit was commissioned to manage overflow from the main campus, easing ER and OPD patient transitions.

Dermatology Clinic Upgradation

The clinic was restructured for improved patient flow and service delivery, including the addition of a dedicated doctor's room.

Bone Marrow Transplant Unit Enhancement

Two new BMT inpatient rooms were added to accommodate increased demand, reducing wait times and ensuring quality care.

ENT Clinic Expansion – Second VRA Room

A second VRA (Visual Reinforcement Audiometry) room was built to expand audiological testing capacity, enhancing service availability for pediatric and adult patients.

Daycare Anesthesia Optimization

Restructuring of the Daycare Anesthesia Unit included dedicated ECG, phlebotomy, and anesthesia assessment rooms, streamlining pre-procedure evaluations and improving patient experience.



THE IMPACT OF THE COMPANY'S BUSINESS ON THE ENVIRONMENT

Shifa International Hospitals Limited remains committed to operating as a responsible healthcare provider with a strong emphasis on environmental stewardship, resource efficiency, and sustainable development. The hospital has taken measurable actions to reduce its environmental footprint and align with global sustainability standards.

Membership in International Sustainability Platform

SIH became a standalone associate member of the International Hospital Federation's Geneva Sustainability Centre, reinforcing its role as a regional leader in climate-conscious healthcare. The Centre equips healthcare organizations to create low-carbon, equitable, and resilient systems, enabling SIH to access advanced tools, knowledge, and strategies.

Carbon Footprint Tracking (GHG Emissions)

SIH has initiated comprehensive GHG emissions calculations (Scope 1, 2, and 3) using the Climate Impact Checkup Tool.

Scope 1: Emissions from combustion, hospital vehicles, and onsite waste management.

Scope 2: Emissions from electricity usage.

Scope 3: Emissions from commuting, business travel, and indirect services.

This effort will guide targeted carbon reduction strategies.

Hospital Waste Management

In compliance with Hospital Waste Management Rules, 2005 and WHO guidelines, SIH has implemented a robust hazardous waste system.

In this regard, the organization has established a comprehensive and advanced waste management system that integrates globally recognized best practices to minimize environmental impact, based on its Hazardous Material and Waste Management Policy, which is aligned with evidence-based guidelines on healthcare waste management issued by the WHO. Hazardous waste is treated through high-temperature thermal oxidation, with emissions analyzed on a quarterly basis. The byproduct generated in the form of ash is disposed of in a designated burial pit located in an uninhabited area, in accordance with the Environmental and Social Screening Report prepared at the time of its construction.

Hazardous Material Control

Pakistan's commitment to international environmental agreements including the Minamata, Rotterdam, Basel, and Stockholm Conventions reflects its dedication to safeguarding human health and the environment from hazardous substances and waste. In alignment with these national commitments, all hazardous materials at SIH are labeled as per GHS, handled and disposed of under MSDS guidelines, with a comprehensive inventory maintained and staff regularly trained for safe use.

Waste Minimization

Shifa International Hospitals Limited minimizes waste through prevention, strict segregation, and recycling, ensuring nonhazardous materials are separated at source, stored safely, and processed via approved vendors thus significantly reducing landfill burden and environmental impact.

Energy Efficiency Initiatives

Alongside the PV Solar and Waste Heat Recovery systems, SIH has advanced energy efficiency by replacing tube lights with LEDs, installing VFDs for smarter motor control, and optimizing elevator operations hence significantly reducing consumption and costs.

Water Conservation Measures

To promote sustainable water management, SIH has introduced measures to cut consumption and enable reuse. Initiatives include sprinkler irrigation, recycling RO reject water for laundry, scrubbing, and irrigation, and ongoing efforts to minimize reject volumes while optimizing treated high-salinity water for both potable and non-potable use.

ENERGY CONSERVATION

Shifa International Hospitals (SIH) continues to prioritize sustainable energy practices to address Pakistan's ongoing energy challenges. The hospital has implemented two major energy conservation initiatives:

Renewable Energy via Solar Power

SIH has installed an 895 kW (DC) photovoltaic solar system, operational since November 2022. This system harnesses Islamabad's high solar radiation potential to produce clean energy. In FY2024, it generated approximately 1.15 million kWh of electricity, avoiding around 599.4 metric tons of CO₂ emissions. This initiative significantly reduces reliance on fossil fuels and supports the hospital's long-term sustainability goals.

Waste Heat Recovery (WHR) Boilers

To utilize thermal energy from gas generators, SIH has deployed WHR boilers with a steam generation capacity of 2,400 kg/hr. These boilers convert flue gas heat into steam, which is used in various hospital operations, including laundry and kitchen services. This effort led to a further reduction of approximately 192.32 metric tons of CO₂ emissions during the reporting period.

Together, these initiatives underscore SIH's commitment to environmental stewardship and resource efficiency.





ENVIRONMENTAL PROTECTION MEASURES

Shifa International Hospital (SIH) has implemented a robust and strategic environmental protection framework to align with sustainable healthcare goals, legal compliance, and climate resilience. Key initiatives include:

EHS&S Policy Framework

A revised Environment, Health, Safety & Sustainability (EHS&S) Policy underscores SIH's commitment to sustainable operations, legal compliance, infrastructure resilience, and climate awareness.

Environmental Sustainability Program

In response to climate change, SIH launched a structured sustainability program focusing on low-carbon, resilient healthcare. It aligns with JCI and SDG 13 goals, promoting energy efficiency, waste reduction, and staff engagement across the hospital governance structure.

Environmental Risk & Climate Vulnerability Assessment

SIH proactively identifies and prioritizes environmental risks such as floods, heatwaves, and air quality deterioration through structured assessments. Adaptive strategies are integrated into disaster preparedness and emergency drills to ensure operational continuity.

Environmental Sustainability Plan

An annual plan outlines GHG emissions tracking, carbon reduction, water and energy conservation, and waste reuse. It includes performance indicators and aligns with SDGs, ensuring continuous environmental accountability.

ENVIRONMENTAL MONITORING & LEGAL COMPLIANCE

SIH ensures compliance with national standards through regular monitoring activities under the SMART program:

- **Stack Emissions** – Monitored quarterly for all combustion sources.
- **Water Quality** – Potable, dialysis, and bottled water are tested per relevant standards.
- **Legionella Monitoring** – Conducted in cooling towers to ensure HVAC safety.
- **Indoor Air Quality** – Particle and microbial load monitoring in sterile areas.
- **Noise Monitoring** – Assessed in critical plant locations.
- **Ash Analysis** – Mineral composition evaluated using advanced techniques.
- **In-house Monitoring** – Tracks a broad spectrum of environmental parameters.



WATER REUSE & CONSERVATION

Through advanced membrane-based treatment systems, SIH recycles up to 10,000 liters of reject water daily, totaling 3 million liters annually. Boiler reject water is also repurposed for laundry, incineration, and irrigation, saving over 3,400 cubic meters. SIH's sprinkler system conserves 40 percent more water than traditional methods, meeting landscaping and horticultural needs with only 55 million liters annually and reducing energy use by over 500 kWh.

OCCUPATIONAL SAFETY AND HEALTH

Shifa International Hospital Limited upholds a strong commitment to the health, safety, and wellbeing of its staff, patients, contractors, and visitors. It has implemented comprehensive systems and programs to mitigate workplace hazards, promote a safe care environment, and ensure operational continuity.

ISO 45001:2018 Certification

SIH's Occupational Health & Safety Management System is certified under ISO 45001:2018. A successful surveillance audit by SGS in April 2025 identified four Opportunities for Improvement (OFIs) and no non-conformities, confirming the hospital's ongoing compliance with international occupational safety standards.

Hazard Vulnerability Analysis & Risk Assessment (HVA & RA)

Annual and situational HVA & RA are conducted by a multidisciplinary team to identify and manage risks such as fire, chemical exposure, biohazards, ergonomic hazards, and noise. Appropriate control

measures are implemented to ensure a safe environment for patients, staff, and infrastructure.

Preconstruction & Infection Control Risk Assessments (PCRA & ICRA)

Before any construction, renovation, or maintenance, PCRA and ICRA are conducted to assess potential risks to patient care and environmental safety. Mitigation plans cover infection control, air quality, fire safety, noise, vibration, hazardous materials, and emergency preparedness.

Medical Monitoring Program

To detect and prevent occupational illnesses, SIH carries out annual medical checkups for staff, especially those in direct and indirect patient care roles. This includes vaccination protocols and targeted testing, ensuring early detection and response to health risks related to workplace exposures.

Emergency & Disaster Management

SIH operates a robust Hospital Incident Command System (HICS) for coordinated emergency response. Regular drills and tabletop exercises are held to test preparedness. Notably, enterprise-wide HICS was activated in May 2025 during a real war scenario to ensure operational resilience.

Facility Management & Safety (FMS) Training

Staff receive regular training on FMS protocols through in-person sessions, online presentations, and video modules. Awareness assessments are conducted to evaluate knowledge retention and ensure staff readiness in critical safety areas.

Comprehensive Safety Programs

SIH has implemented multiple safety programs to safeguard people and infrastructure, supported by dedicated manuals and policies. Key programs include:

- Fire Safety Management
- Hazardous Material & Waste Management
- Occupational Health & Safety
- Disaster Management
- Radiation, Laser, and Laboratory Safety

INFECTION PREVENTION AND CONTROL

The Infection Prevention and Control (IPC) Department effectively monitored Healthcare-Associated Infections (HAIs) across the 550-bed tertiary care facility, maintaining HAI rates within the benchmark of 5.2 per 1,000 device-days, except for a temporary spike in August 2024. In response, enhanced interventions included intensified hand hygiene training, implementation of evidence-based care bundles (CAUTI, CLABSI, VAP), updated disinfection protocols, and real-time HAI data visualization.

Awareness and capacity-building efforts included celebrating Global Handwashing Day and International Infection Prevention Week through educational events, webinars, and recognition initiatives. Staff capacity was strengthened via international training collaborations with St. Jude Children's Research Hospital and hands-on training in Cairo, along with a completed IPC diploma by team members.

Key quality improvement (QI) projects were undertaken in NICU, Emergency, MICU, and SICU units, focusing on infection prevention, sepsis readiness, and blood culture contamination reduction. The department also initiated development of a digital HAI surveillance and reporting system in collaboration with MIS and contributed to the national Fleming Fund AMR surveillance program.

Through proactive monitoring, training, stakeholder engagement, and innovation, the IPC department significantly enhanced patient safety and care quality across the hospital.

CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES

Shifa Foundation, the CSR arm of Shifa International Hospitals, actively engaged in a broad spectrum of programs targeting health, education, nutrition, WASH (Water, Sanitation & Hygiene), food security, protection, and sustainable livelihoods. In FY 2024–2025, the Foundation reached millions across 60+ districts of Pakistan, contributing directly to several UN Sustainable Development Goals (SDGs). These interventions focused on improving health outcomes, access to clean water, educational opportunities, and gender mainstreaming.





Corporate Philanthropy

As a PCP and EAD-accredited nonprofit, Shifa Foundation implemented high-impact philanthropic activities which included:

- Distribution of food packages and safe drinking water.
- Advanced medical treatment for underserved populations.
- Active engagement with universities and expansion of a volunteer base to enhance outreach.
- Support for victims of natural disasters through emergency health and hygiene response programs.

These acts of corporate philanthropy were fundamental to addressing urgent needs and promoting social equity.

Community Investment and Welfare Schemes

In 2024–25, SIH advanced its community impact through education, skill development, and social welfare programs through Shifa Foundation. Shifa Center of Professional Excellence (SCOPE) strengthened professional capacity via continuing medical education, life support training, and research initiatives. Shifa Foundation expanded its outreach, benefiting thousands nationwide through donor-supported projects and close coordination with government bodies to ensure sustainable outcomes. Strong collaborations with UNICEF, WFP, Nutrition

International, and local authorities including BISP further enhanced program delivery, earning recognition for effective and impactful service to communities.

Maternal & Newborn Nutrition Program

8,317 pregnant women received MMS through antenatal care integration.

SOPRAN Initiative

Reached 40,000 adolescent girls in 498 schools with weekly iron and folic acid supplementation.

RURAL DEVELOPMENT PROGRAMS

In 2024–25, Shifa Foundation advanced rural well-being through improved access to clean water, sanitation, and food security. Water points and sanitation facilities were constructed and rehabilitated, complemented by health and hygiene awareness sessions in Balochistan that strengthened safe practices. In flood-affected Sindh, integrated response efforts provided safe drinking water, livelihood cash grants, and kitchen gardening toolkits, while malnutrition screening and treatment for children and PLWs promoted community health. These initiatives not only addressed immediate needs but also fostered resilience and sustainable livelihoods.



WELFARE SPENDING FOR UNDER PRIVILEGED CLASSES

A significant portion of Shifa Foundation's programs was directed towards improving the lives of the underprivileged through:

- Emergency primary care services reaching over 4,500 individuals.
- Distribution of 140 clean delivery kits to support maternal health.
- Management of nutrition-related complications through RUTF and SNF in under-resourced provinces.
- Provision of education and psychosocial support to students affected by corporal punishment.

- Implementation of the Gender Policy 2025-2026 to promote gender-inclusive programming.
- Mental health interventions based on data from biomarker assessments in 235 students and teachers.

CONSUMER PROTECTION MEASURES

Shifa International Hospital reaffirmed its commitment to ensuring the safety, trust, and convenience of its patients, visitors, and staff by implementing several targeted consumer protection initiatives during the reporting period. These measures focused on enhancing physical security, streamlining services, and integrating advanced technologies for a secure and patient-centered environment.

Key Security & Service Enhancements

Deployment of SSG Commandos

10 highly trained SSG Commandos were inducted to reinforce hospital security. Their expertise has elevated the institution's readiness and response capabilities, ensuring a safer environment across all zones of the hospital.

Opening of New Visitor Parking at Gate 1

A new designated parking area was made operational near Gate 1, improving traffic flow, reducing congestion, and enhancing convenience for patients and visitors.

Expansion of Valet Services

Valet operations were significantly strengthened by increasing staffing capacity. The team now manages up to 350 vehicles per day (previously 200), providing faster, more efficient parking services for patients and visitors.

Licensed Weapons & SOP Implementation

The hospital security team has been equipped with licensed weapons to improve armed response capabilities. A detailed Standard Operating Procedure was developed to govern responsible weapon

handling, usage protocols, and compliance, ensuring safety without compromise.

Ongoing and Future Projects

AI-Enabled CCTV Surveillance System (In Progress)

An advanced AI-based software is being integrated with the existing CCTV infrastructure. This system will allow automatic recognition and alerting of flagged individuals, enhancing real-time threat detection and situational awareness.

Faisalabad Site – Security & Fire Safety Systems (Planned)

A complete security setup, including CCTV, RFID access control, walk-through gates, and fire detection systems, is being installed to ensure a secure and monitored environment at the Faisalabad project site.

Medical Centre – Bahria Civic Centre (Planned)

Similar safety infrastructure, comprising surveillance cameras, access control, and fire safety systems, will be deployed at the upcoming medical center in Bahria Civic Centre to ensure compliance with institutional safety standards.



BUSINESS ETHICS AND ANTI-CORRUPTION MEASURES

SIH is committed to upholding the highest standards of business ethics and implementing rigorous anti-corruption measures. Our comprehensive Code of Conduct outlines the ethical principles and standards expected of all employees, directors, and stakeholders addressing, conflict of interest, confidentiality and fair dealing.

Anti-Corruption Policy

SIH enforces a strict zero-tolerance policy towards corruption and bribery. Our Anti-Corruption Policy specifies prohibited activities, reporting mechanisms, and disciplinary actions for violations. We encourage reporting of unethical behavior through a confidential whistleblower mechanism, ensuring protection against retaliation.

Employee Orientation and Third Party Due Diligence

New employees receive thorough orientation on the Code of Conduct to ensure they understand our ethical standards and anti-corruption measures. Additionally, we conduct comprehensive due diligence on third-party partners, suppliers, and contractors to ensure compliance with our ethical standards.

Monitoring and Compliance

Robust monitoring and compliance mechanisms are in place to detect and prevent unethical practices. Regular audits and compliance checks are conducted to ensure adherence to our policies and procedures reinforcing our commitment to transparency, integrity, and ethical conduct.

EMPLOYMENT OF SPECIAL PERSONS

The Company is dedicated to providing equal opportunities for differently abled individuals. Currently, we have onboard 19 such staff members, reflecting our commitment to non-discrimination, inclusivity and equal employment opportunities for all.

GENDER PAY GAP

The mean and median pay gap for women is 11% and 20% higher than that of men.

CODE OF CONDUCT

The Company has adopted a Code of Conduct that requires all employees to maintain a work environment featuring fairness, respect and integrity and to comply with ethical practices. Provisions



of the code include, but are not limited to, legal compliance, restraint on political activities, soliciting gifts, avoiding conflict of interest, non-discrimination or harassment on the basis of gender, race, color, age, etc., maintaining confidentiality of information, complying with the laws, rules vis-à-vis environmental protection, etc. The Code of Conduct is applicable to all the directors, officers, employees, consultants and agents of the Company.

WHISTLEBLOWING POLICY

The Company places the highest importance on conducting its business with honesty, integrity, transparency, openness, and accountability. To reinforce these values, a Whistleblowing Policy has been introduced, enabling stakeholders to detect, identify, and report unlawful activities, mismanagement, misuse of authority, or any matter inconsistent with Company policies. The policy is designed to guide and encourage individuals to raise concerns confidentially, with the assurance that they will be protected from any form of victimization.

Through this framework, the Company reaffirms its unwavering commitment to upholding ethical practices and accountability in all its operations.

GRIEVANCE POLICY

The Company is committed to ensuring that all employee grievances are heard and addressed promptly. Employees are encouraged to raise concerns with their immediate supervisors as the first point of contact. Grievances from workers engaged through third-party contracts are also given due importance and relayed to the respective vendors by the concerned area supervisors for resolution. This reflects the Company's strong commitment to fostering a fair, responsive, and supportive work environment.



BOARD OF DIRECTORS

The total number of Directors of the Company are 11 as listed below:

- a. Male: Ten (10)
- b. Female: One (01)

The Board derives its powers and obligations from various provisions contained in the Memorandum & Articles of Association of the Company, Companies Act, 2017 ("the Act"), the Listed Companies (Code of Corporate Governance) Regulations, 2019 (the "Code") and other relevant laws. The Board met six (06) times during the year ended June 30, 2025.

Currently the Board is comprised of three independent, six non-executive (including one female director) and two executive directors, as follows:

Category	Names
Independent Directors	Dr. Mohammad Naseem Ansari Dr. Mohammad Salim Khan Shah Naveed Saeed
Non-Executive Directors	Dr. Habib Ur Rahman Dr. Manzoor H. Qazi Mr. Qasim Farooq Ahmad Dr. Samea Kauser Ahmad Syed Ilyas Ahmed Dr. Ioan Philippe Cleaton-Jones
Executive Directors	Dr. Zeeshan Bin Ishtiaque (Chief Executive Officer) Mr. Taimoor Shah

In compliance with the non-mandatory provisions contained in the Code regarding diversity in the Board, the Company's Board consists of six Medical Doctors, one IT Professional, two Pharmacists, a Healthcare Management Professional and a Chartered Accountant.



BOARD AUDIT COMMITTEE

The Board Audit Committee (BAC) comprises of three non-executive directors and one independent director as under:

Shah Naveed Saeed

Chairman, Independent Director

Dr. Manzoor H. Qazi

Member, Non-Executive Director

Dr. Samea Kauser Ahmad

Member, Non-Executive Director

Syed Ilyas Ahmed

Member, Non-Executive Director

Every member of the BAC possesses exceptional qualifications. The BAC met five (05) times during the year under review.

The BAC's Terms of Reference (ToRs) have been developed in accordance with the guidelines outlined in the Code, and the BAC operates in alignment with these provisions. The ToRs encompass various responsibilities, such as establishing systems to protect Company assets, ensuring the maintenance of sufficient accounting records, overseeing internal controls and risk management, ensuring compliance with regulatory and legal requirements, and reviewing periodic financial statements, among other duties. While this list of ToRs is comprehensive, the BAC is also open to addressing any other issues or matters as assigned by the Board to fulfill its ultimate goal of safeguarding the Company's interests.

The Chairman of BAC conveys the committee's observations and recommendations to the Board. In addition to its regular meetings, the BAC held one meeting with the External Auditors, excluding the Head of Internal Audit and CFO, and another meeting with the Head of Internal Audit, excluding the CFO and External Auditors.

During the year, a significant change in the composition of the BAC took place. Dr. Habib Ur Rahman, Chairman of the Board, who had served as a member of the BAC since 2003, concluded his tenure

on the Committee during the year under review. In his place, Dr. Manzoor H. Qazi was nominated as a member. The Board Audit Committee formally recorded its deepest appreciation to Dr. Habib Ur Rahman for his invaluable guidance, exceptional professional insight, and dedicated service during his long association with the Committee.

HUMAN RESOURCE & REMUNERATION COMMITTEE

The Human Resource & Remuneration (HR & R) Committee has the following members:

Dr. Mohammad Naseem Ansari

Chairman, Independent Director

Dr. Habib Ur Rahman

Member, Non-Executive Director

Dr. Zeeshan Bin Ishtiaque

Member, Chief Executive Officer

Dr. Manzoor H. Qazi

Member, Non-Executive Director

Syed Ilyas Ahmed

Member, Non-Executive Director

Mr. Qasim Farooq Ahmad

Member, Non-Executive Director

The Terms of Reference (ToRs) mandate that the HR & R Committee's main focus is to evaluate compensation packages necessary for attracting and retaining executive directors and senior personnel, in accordance with market standards, regulatory requirements, and stakeholder interests. Furthermore, a noteworthy provision stipulates that a majority of the HR & R Committee members must be non-executive directors, including at least one independent director. Similarly, the Chairman of the HR & R Committee is also required to be an independent director.

The HR & R Committee functions in accordance with approved ToRs. The HR & R Committee met once during the year under review.

CORPORATE GOVERNANCE & NOMINATIONS COMMITTEE

The Corporate Governance & Nominations (CG & N) Committee is composed of the following members:

Dr. Manzoor H. Qazi

Chairman, Non-Executive Director

Dr. Zeeshan Bin Ishtiaque

Member, Chief Executive Officer

Dr. Samea Kauser Ahmad

Member, Non-Executive Director

Dr. Ioan P. Cleaton-Jones

Member, Non-Executive Director

The Terms of Reference for the CG & N Committee have been established in alignment with the provisions set forth in the Code. The Committee is primarily tasked with evaluating the Board's structure, size, and composition, among other key responsibilities.

During the year under review the Committee did not hold any meeting.

RISK MANAGEMENT COMMITTEE

Under the provisions of the Code, the Board also has a Risk Management Committee (RMC). The RMC has the following directors as members:

Mr. Qasim Farooq Ahmad

Chairman, Non-Executive Director

Dr. Mohammad Naseem Ansari

Member, Independent Director

Mr. Taimoor Shah

Member, Executive Director

Dr. Mohammad Salim Khan

Member, Independent Director

RMC's ToRs require to undertake monitoring and undertaking review of all material controls including financial, operational & compliance and ascertain that risk mitigation measures are robust.

During the year under review, one meeting of the RMC was held.



FREQUENCY & ATTENDANCE OF BOARD & AUDIT COMMITTEE MEETINGS

During the year under review, a total of six (06) meetings for the Board of Directors and five (05) meetings for the BAC respectively were held through video link and in person. The attendance of the Directors is as under:

Name of Director	No. of Board Meetings Attended	No. of Audit Committee Meetings Attended
Dr. Habib Ur Rahman*	6	1
Dr. Zeeshan Bin Ishtiaque	6	N/A
Dr. Manzoor H. Qazi*	6	3
Mr. Qasim Farooq Ahmad	6	N/A
Dr. Samea Kauser Ahmad	6	5
Syed Ilyas Ahmed	6	5
Dr. Mohammad Naseem Ansari	6	N/A
Dr. Ioan Philippe Cleaton-Jones	6	N/A
Shah Naveed Saeed	5	5
Dr. Mohammad Salim Khan	6	N/A
Mr. Taimoor Shah	6	N/A

* Dr. Habib Ur Rehman resigned as Member of the BAC. During his term he attended one meeting of the BAC. Subsequently Dr. Manzoor H. Qazi was appointed as a member of the BAC.

DIRECTORS' REMUNERATION

The Board of Directors of the Company approves and fixes the remuneration of the Board members in accordance with the Articles of Association of the Company, the Act and the Code. The details of aggregate amount of remuneration separately of executive and non-executive directors, including salary/fee, perquisites, benefits and performance linked incentives etc. have been disclosed in note 37 of Notes to the Unconsolidated Financial Statements.

BOARD EVALUATION

As per the requirements of the Code, the Board annually conducts self-evaluation of its performance which covers structure & characteristics of the Board, roles & responsibilities, relationship with management and hospital specific measures, etc.

The overall performance of the Board was determined to be good on the basis of approved criteria.

SECURITY CLEARANCE OF FOREIGN DIRECTOR

A Foreign Director elected to the Board requires security clearance from the Ministry of Interior, facilitated through the Securities and Exchange Commission of Pakistan (SECP). All necessary legal formalities and requirements from the Company's end have been duly met and fulfilled in this regard

TRADING OF SHARES

All direct or indirect trading and holdings of the Company's shares by Directors, Chief Executive, substantial shareholders, executives or their spouses notified in writing to the Company Secretary along with the price, number of shares and nature of transaction were notified by the Company Secretary to the Board, the SECP, where required, and the PSX. Pattern of Shareholding as at June 30, 2025, annexed herewith, disclose the holdings by Directors, Chief Executive, substantial shareholders or their spouses.

PATTERN OF SHAREHOLDING

The total number of Company's shareholders as at June 30, 2025 was 2,834 as against 2,431 on June 30, 2024. The pattern of shareholding as at June 30, 2025 is included in this Annual Report.

DIRECTORS' TRAINING PROGRAM

Ten out of eleven Directors (90.90%) have completed the Directors' Training Program (DTP) as laid down under Regulation 19(1) of the Code.

The detail of the certified directors is as under:

- Dr. Habib Ur Rahman
- Dr. Zeeshan Bin Ishtiaque
- Dr. Manzoor H. Qazi
- Dr. Samea Kauser Ahmad
- Syed Ilyas Ahmed
- Dr. Mohammad Naseem Ansari
- Mr. Shah Naveed Saeed
- Dr. M. Salim Khan
- Dr. Ioan P. Cleaton-Jones*
- Mr. Taimoor Shah

* Dr. Ioan P. Cleaton-Jones has completed the Executive Education Program in Corporate Governance from the Columbia Business School at Columbia University, New York, USA

As per the criteria set under sub regulation 19 (2) of the Code, Mr. Qasim Farooq Ahmed, has a minimum education of 14 years and has remained a director on the Board of the Company for over 15 years, thereby being exempt from the DTP.

Moreover, the Company also arranged DTP for a male & one female executive as required under the sub-regulation 19 (3) (i) of the Code.

CORPORATE BRIEFING SESSION

The Pakistan Stock Exchange encourages sound corporate governance practices and in compliance with the mandatory requirement of holding corporate briefing by listed companies a Corporate Briefing Session was held through video link for the investors and shareholders of the Company on November 25, 2024. A detailed presentation was given on the Company's performance and financial results for the financial year ended June 30, 2024 followed by a brief on the Company's future plans by the management of the Company. The management satisfactorily answered all the questions and queries raised by the participants during the session.

STATEMENT OF DIRECTORS' RESPONSIBILITY

The Directors hereby confirm compliance with the Corporate and Financial Reporting Framework of the Securities and Exchange Commission of Pakistan and the Code for the following matters:

- i. The Financial Statements, prepared by the management of the Company, present fairly its state of affairs, the results of its operations, cash flows and changes in equity.
- ii. Proper books of accounts of the Company have been maintained as required by the Companies Act, 2017.
- iii. Appropriate accounting policies have been consistently applied in preparation of the Financial Statements and accounting estimates are based on reasonable and prudent judgment.
- iv. International Accounting Standards, as applicable in Pakistan, have been followed in preparation of Financial Statements.

- v. The system of internal control is sound in design and has been effectively implemented and monitored.
- vi. There has been no material departure from the best practices of Corporate Governance, as detailed in the Code.
- vii. There are no significant doubts upon Company's ability to continue as a going concern.

RELATED PARTY TRANSACTIONS

All the related party transactions have been approved by the Board of Directors in accordance with the Company's policy on the related party transactions. The Company maintains a complete record of all such transactions, along with the terms and conditions. The disclosure of such related party transactions has been given in note 36 of Notes to the Unconsolidated Financial Statements.

MATERIAL CHANGES

There is no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statement relates and the date of the report.

STATUTORY AUDITORS OF THE COMPANY

The Board of Directors, as recommended by the Audit Committee, has proposed the appointment of M/s BDO Ebrahim & Co. Chartered Accountants as Auditors of the Company for the year ending June 30, 2026.



SUBSIDIARY / ASSOCIATED COMPANIES

As on June 30, 2025 the detail of the subsidiaries / associated undertakings of the Company along with percentage shares held in each subsidiary/associated undertaking is as under:

Sr. No.	Name of the Company	Status	Percentage
1	Shifa National Hospital Faisalabad (Pvt.) Limited	Subsidiary	60
2	Shifa Medical Center Islamabad (Pvt.) Limited	Subsidiary	56
3	Shifa Development Services (Pvt.) Limited	Subsidiary	55
4	Shifa CARE (Pvt.) Limited	Associate	50
5	SIHT (Pvt.) Limited	Associate	45.3

Shifa National Hospital Faisalabad (Pvt.) Limited (SNHF)

The Company, in collaboration with Interloop Holdings (Pvt.) Limited, is currently undertaking the construction of a state-of-the-art hospital facility in Faisalabad. Based on a revised feasibility study, the Company has committed to invest Rs. 1.6 billion in the Project to achieve the updated development targets. As of the reporting date, an amount of Rs. 1.056 billion has already been injected by the Company, primarily to support the completion and operationalization of Phase 1.

At present the erection of grey structure of both IPD and OPD towers has been completed. Wiring, plumbing and firefighting related works have been started vertically and expected to be completed by end of calendar year 2025. The Project continues to move forward as per the planned schedule and is expected to be operational within the targeted timeline.

Shifa Medical Center Islamabad (Pvt.) Limited (SMCI)

Pursuant to the share acquisition of Shifa Medical Center Islamabad (SMCI) by the Company, as approved by the shareholders in the Extraordinary General Meeting held on June 5, 2025, a total of 103,349,961 shares were transferred to Shifa International Hospitals Limited (SIHL) subsequent to the year end. As a result, SIHL's shareholding in SMCI has increased to approximately 99 percent. The

next strategic initiative will be the merger of SMCI into SIHL, which is currently under consideration and will be undertaken in accordance with the applicable legal and regulatory framework.

Shifa Development Services (Pvt.) Limited (SDS)

As of the reporting date, the subsidiary has no ongoing projects. Furthermore, it continues to face significant financial challenges, which cast uncertainty over its ability to sustain operations in the future.

Shifa CARE (Pvt.) Limited (SCPL)

Currently, the SCPL has no ongoing projects. Furthermore, it continues to face significant financial challenges, due to which it may not be able to continue its business.

SIHT (Pvt.) Limited (SIHT)

During the year the Company had paid Rs. 300 million to purchase equity interest in SIHT (Private) Limited (JCIA Accredited home health Company), from Shifa Foundation, increasing the Company's ownership in SIHT to 45.3 percent.

Shifa Neuro Sciences Institute Islamabad (Pvt.) Limited

In line with the Company's strategy to optimize operational efficiency and enhance group synergies, Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNSI), a wholly owned subsidiary, has



been merged into Shifa International Hospitals Limited with effect from March 25, 2025. The Scheme of Amalgamation, along with the requisite documentation, was submitted to the Securities and Exchange Commission of Pakistan (SECP), which formally acknowledged the submission. This strategic consolidation is expected to streamline operations and support long-term growth objectives.

OPERATING & FINANCIAL DATA

Summary of key operating and financial data of last six years has been given on page no. 80.

COMPANY'S WEBSITE

The Company's official website can be accessed at www.shifa.com.pk



CORPORATE RESTRUCTURING, BUSINESS EXPANSION, ALONG WITH FUTURE PROSPECTS, RISKS AND UNCERTAINTIES

The Company continues to strengthen its foundations through measured expansion and operational excellence, while remaining mindful of emerging risks and opportunities.

As part of our continued journey to strengthen and expand our healthcare footprint, the development of Shifa National Hospital Faisalabad remains firmly on track, with operations planned to commence within the current fiscal year. This marks another milestone in our commitment to bringing quality healthcare closer to communities across the country. In parallel, the shareholders have approved the acquisition of Shifa Medical Center Islamabad, with planning already underway to make it operational not later than couple of years, further consolidating our presence in the capital.

Under our Peripheral Clinics Program, the clinic at Bahria Town Rawalpindi is in its final stages and is expected to be operational shortly, thereby enhancing accessibility and convenience for patients in the localities of the H-8 hospital. In addition, we have successfully installed and made operational a PET Scan facility, enabling us to offer a full spectrum of oncology services. This advancement not only enhances our clinical capabilities but is also expected to contribute positively to patient outcomes and the Company's revenue streams.

On the operational front, the re-appropriation of IPD beds continues to be a regular practice, allowing us to optimize space utilization and meet evolving patient demands efficiently. Furthermore, the Company has adopted an enterprise model approach that sits well with our expansion strategy. By integrating operations, strengthening digital systems, and fostering cross-functional alignment, this approach consolidates our efforts and amplifies their overall impact across the organization. These strategic measures, both in expansion and optimization, reflect our consistent focus on balancing growth with sustainable service delivery.

While prospects remain strong, we acknowledge certain risks and challenges. The proliferation of fake news poses a reputational risk, which we are actively mitigating by strengthening our digital and online presence in a systematic and planned manner. Alongside this, we remain committed to promoting ethical and responsible journalism that highlights preventive healthcare and discourages sensationalism. On a macro level, while the current economic indicators appear promising, external factors such as the recent cross-border conflict and the repatriation of Afghan nationals may potentially influence patient volumes and overall progress.



Despite these uncertainties, patient confidence in our services remains intact, as evidenced by our real-time feedback mechanisms, and we are well-positioned to address challenges proactively. Our continued focus on patient-centric growth, ethical practices, and operational excellence will guide us in navigating the dynamic environment ahead.

BRIEF NOTE ON FUTURE OUTLOOK

Looking forward, the outlook for the Company remains robust. With the upcoming launch of Shifa National Hospital Faisalabad, operationalization of Shifa Medical Center Islamabad within due course, and the expected opening of the Bahria Town Peripheral Clinic, we are poised to significantly increase our reach and impact. The addition of advanced diagnostic services such as PET Scan, coupled with the adoption of an enterprise approach – integrating operations, advancing digital systems, and fostering cross-functional alignment – will further strengthen our ability to deliver comprehensive, high-quality care.

While mindful of external risks and uncertainties, our resilience, adaptive strategies, and strong patient trust provide a solid foundation for sustainable growth. We remain confident that the future will bring new opportunities to serve the community with excellence, compassion, and innovation.

ACKNOWLEDGEMENT

The Board earnestly appreciates the consultants, management and staff for their untiring efforts to deliver seamless and consistent quality healthcare despite all the challenges. The Board is also thankful to the shareholders, bankers, patients and regulators for their continued confidence and support of our operations.

On behalf of the Board

DR. HABIB UR RAHMAN
Chairman

ISLAMABAD
September 06, 2025

DR. ZEESHAN BIN ISHTIAQUE
Chief Executive Officer


مستقبل کا خاکہ


آنے والے وقت میں کمپنی کا مستقبل حوصلہ افزا نظر آتا ہے۔ شفا ہسپتال فیصل آباد کی متوقع لانچ، شفا میڈیکل سینٹر اسلام آباد کا فعال ہونا اور بحریہ ٹاؤن پیریلر کلینک کے افتتاح سے ادارے کی پہنچ اور اثر میں نمایاں اضافہ ہوگا۔ جدید تشخیصی سہولیات مثلاً پی ای ٹی اسکین کا اضافہ اور انٹر پرائز ماڈل کے تحت آپریشنز کے انضمام و ڈیجیٹل سسٹمز کی ترقی ادارے کی جامع اور معیاری طبی سہولیات فراہم کرنے کی صلاحیت میں مزید مضبوط کریں گے۔

بیرونی خطرات اور غیر یقینی عوامل کے باوجود ادارے کی لچک، مؤثر حکمت عملیاں اور مریضوں کا اعتماد پائیدار ترقی کے لیے مضبوط بنیاد فراہم کرتے ہیں۔ ادارہ پر امید ہے کہ مستقبل میں نئے مواقع سامنے آئیں گے، جنہیں بروئے کار لا کر ہمدردی اور جدت کے ساتھ کمیونٹی کو سروس فراہم کی جائیں گی۔

اظہار تشکر

بورڈ ادارے کے کنسلٹنٹس، مینجمنٹ اور عملے کی انتھک کوششوں کو خراج تحسین پیش کرتا ہے جن کی بدولت ہر مشکل کے باوجود مریضوں کو معیاری اور تسلسل سے صحت کی سہولیات فراہم کرنا ممکن ہوا۔ بورڈ شیئر ہولڈرز، بینکرز، مریضوں اور ریگولیٹرز کا بھی شکریہ ادا ہے جنہوں نے ادارے پر اعتماد اور اس کی سرگرمیوں میں مسلسل تعاون فراہم کیا۔ بورڈ کی طرف سے


ڈاکٹر ذیشان بن اشتیاق
چیف ایگزیکٹو آفیسر


ڈاکٹر حبیب الرحمان
چیرمین

اسلام آباد

06 ستمبر، 2025

ڈائریکٹر رپورٹ

شفانیور سائنسز انسٹیٹیوٹ اسلام آباد (پرائیویٹ) لمیٹڈ (SNSI)

کمپنی کی حکمت عملی کے مطابق آپریشنل افادیت بڑھانے اور ہم آہنگی کو فروغ دینے کے لیے، شفانیور سائنسز انسٹیٹیوٹ اسلام آباد (پرائیویٹ) لمیٹڈ، جو کمپنی کی مکمل ملکیتی ذیلی کمپنی تھی، 25 مارچ 2025 سے شفانیور سائنسز انسٹیٹیوٹ میں ضم کر دی گئی۔

انضمام کی سکیم کی تمام ضروری دستاویزات سیکورٹیز اینڈ ایکسچینج کمیشن آف پاکستان (ایس ای سی پی) میں جمع کروائی گئیں، جس نے وصولی کی تصدیق کر دی۔ یہ سٹرٹیجک انضمام آپریشنز کو ہموار بنانے اور کمپنی کے طویل مدتی ترقی کے اہداف کے حصول میں مددگار ثابت ہوگا۔

آپریٹنگ اور مالیاتی ڈیٹا

گزشتہ چھ سالوں کے کلیدی عملی اور مالیاتی اعداد و شمار صفحہ نمبر 80 پر دیے گئے ہیں۔

کمپنی کی ویب سائٹ

کمپنی کی آفیشل ویب سائٹ درج ذیل ہے www.shifa.com.pk

کارپوریٹ ری سٹرکچرنگ، کاروباری توسیع، مستقبل کے امکانات، خدشات اور غیر یقینی عوامل

کمپنی اپنے بنیادی ڈھانچے کو مزید مستحکم بنانے کے لیے متوازن توسیع اور عملی مہارت پر مسلسل توجہ دے رہی ہے۔ اس کے ساتھ ساتھ ابھرتے ہوئے خطرات اور مواقع کو بھی پیش نظر رکھ رہی ہے۔

شفانیور سائنسز انسٹیٹیوٹ کی تعمیر جاری ہے اور اس مالی سال کے دوران اس کے فعال ہونے کی توقع ہے۔ یہ ملک بھر میں صحت کی معیاری سہولیات کو عام کرنے کی جانب سفر میں اہم سنگ میل ثابت ہوگا۔ اسی طرح شیئر ہولڈرز نے شفانیور سائنسز انسٹیٹیوٹ اسلام آباد کے حصول کی منظوری دے دی ہے۔ اس بات کی منصوبہ بندی جاری ہے کہ یہ اگلے چند سالوں میں مکمل طور پر فعال ہو جائے۔ اس سے وفاقی دارالحکومت میں ادارے کی موجودگی مزید نمایاں ہوگی۔

پیپر فیمل کلینکس پروگرام کے تحت، بحریہ ٹاؤن راولپنڈی میں کلینک آخری مراحل میں ہے اور جلد فعال ہو جائے گا۔ اس سے مریضوں کو سہولت اور ایجنڈا تک رسائی میں بہتری آئے گی۔

مزید برآں، پی ای ٹی سائنس سہولت کامیابی سے نصب اور فعال کر دی گئی ہے، جس کے ذریعے آنکولوجی کی مکمل سروسز فراہم کی جا رہی ہیں۔ یہ پیش رفت نہ صرف طبی سہولیات میں بہتری لائے گی بلکہ مریضوں کے رزلٹس اور کمپنی کی آمدنی پر بھی مثبت اثر ڈالے گی۔

آپریشنل سطح پر، آئی پی ڈی بیڈز کی از سر نو تقسیم باقاعدگی سے جاری ہے تاکہ جگہ کا بہترین استعمال ہو اور مریضوں کی بدلتی ضروریات کو مؤثر طریقے سے پورا کیا جاسکے۔ کمپنی نے انٹر پرائز ماڈل اپروچ بھی اختیار کیا ہے، جو توسیع کی حکمت عملی سے ہم آہنگ ہے۔ اس ماڈل کے تحت آپریشنز کا انضمام، ڈیجیٹل سسٹمز کو مضبوط کرنا اور کراس فنکشنل ہم آہنگی کو فروغ دینا بنیادی اہمیت کے حامل ہیں۔ اس سے ادارے کی مجموعی کارکردگی اور اثر میں اضافہ ہو رہا ہے۔

اگرچہ امکانات روشن ہیں، تاہم کمپنی تسلیم کرتی ہے کہ اسے کچھ خطرات اور چیلنجز بھی درپیش ہیں۔ فیک نیوز میں اضافے سے ادارے کی ساکھ کو خطرات لاحق ہیں۔ منظم اور منصوبہ بند طریقے سے ڈیجیٹل اور آن لائن موجودگی کے ذریعے انہیں کم کیا جا رہا ہے۔ اس کے ساتھ ادارہ اخلاقی اور ذمہ دار صحافت کے فروغ کے لیے بھی پرعزم ہے۔ اس کا مقصد ہیلتھ کیئر میں پریہیز کے نقطہ نظر موضوعات کو اجاگر کرنا اور سنسنی خیزی کی حوصلہ شکنی کرنا ہے۔

معاشی سطح پر موجودہ اشاریے اگرچہ حوصلہ افزا ہیں، تاہم سرحدی تنازعات اور افغان شہریوں کی واپسی جیسے عوامل مریضوں کے حجم اور ترقی کی رفتار پر اثر انداز ہو سکتے ہیں۔

ان غیر یقینی حالات کے باوجود مریضوں کا ادارے پر اعتماد قائم ہے، جس کی عکاسی ریٹل ٹائم فیڈ بیک سسٹمز سے ہوتی ہے۔ ادارہ عملی مہارت، مریضوں کی ضروریات سے ہم آہنگ ترقی اور اخلاقی اصولوں پر کاربند رہتے ہوئے مستقبل کے چیلنجز سے نمٹنے کی بھرپور صلاحیت رکھتا ہے۔

نمبر شمار	کمپنی کا نام	حیثیت	فیصد
1	شفائینٹل ہسپتال فیصل آباد (پرائیویٹ) لمیٹڈ	ذیلی کمپنی	60
2	شفامیڈیکل سینٹر اسلام آباد (پرائیویٹ) لمیٹڈ	ذیلی کمپنی	56
3	شفادوولپمنٹ سروسز (پرائیویٹ) لمیٹڈ	ذیلی کمپنی	55
4	شفاکیسر (پرائیویٹ) لمیٹڈ	ایسویٹ کمپنی	50
5	ایس آئی ایچ ٹی (پرائیویٹ) لمیٹڈ	ایسویٹ کمپنی	45.3

شفائینٹل ہسپتال فیصل آباد (پرائیویٹ) لمیٹڈ (SNHF)

کمپنی انٹرلوپ ہولڈنگز (پرائیویٹ) لمیٹڈ کے اشتراک سے فیصل آباد میں ایک جدید ہسپتال تعمیر کر رہی ہے۔ نظر ثانی شدہ فریٹیلٹی سٹڈی کی بنیاد پر کمپنی نے منصوبے کے لیے 1.6 ارب روپے کی سرمایہ کاری کا فیصلہ کیا ہے تاکہ نئے ترقیاتی اہداف حاصل کیے جاسکیں۔ رپورٹنگ کی تاریخ تک کمپنی 1.056 ارب روپے پہلے ہی فراہم کر چکی ہے، جو زیادہ تر فیڈرل کی تکمیل اور اسے فعال بنانے کے لیے استعمال ہوا۔ اس وقت آئی پی ڈی اور او پی ڈی ٹاورز کا گرے سٹرکچر مکمل ہو چکا ہے۔ وائرنگ، پلمبنگ اور فائر فائٹنگ کے کام جاری ہیں جو 2025 کے آخر تک مکمل ہونے کی توقع ہے۔ منصوبہ طے شدہ شیڈول کے مطابق آگے بڑھ رہا ہے اور توقع ہے کہ مقررہ وقت میں فعال ہو جائے گا۔

شفامیڈیکل سینٹر اسلام آباد (پرائیویٹ) لمیٹڈ (SMCI)

5 جون 2025 کو منعقدہ غیر معمولی جنرل میٹنگ میں منظور شدہ شراکت داری کے مطابق کمپنی نے شفامیڈیکل سینٹر اسلام آباد کے 103,349,961 شیئرز خریدے۔ اس کے نتیجے میں شفائینٹل ہسپتال لمیٹڈ کی ایس ایم سی آئی میں حصص داری بڑھ کر تقریباً 99 فیصد ہو گئی۔ حکمت عملی کا اگلا اقدام ایس ایم سی آئی کا شفائینٹل ہسپتال میں انضمام ہے، جو زرخور ہے اور متعلقہ قانونی و ریگولیٹری تقاضوں کے مطابق عمل میں لایا جائے گا۔

شفادوولپمنٹ سروسز (پرائیویٹ) لمیٹڈ (SDS)

رپورٹنگ کی تاریخ تک اس ذیلی کمپنی کے پاس کوئی جاری منصوبہ نہیں ہے۔ مزید یہ کہ اسے شدید مالی مشکلات کا سامنا ہے، جس سے اس کے مستقبل میں کاروبار جاری رکھنے کی صلاحیت پر خدشات ہیں۔

شفاکیسر (پرائیویٹ) لمیٹڈ (SCPL)

فی الحال اس کمپنی کے پاس کوئی جاری منصوبہ موجود نہیں۔ اسے سنگین مالی مشکلات درپیش ہیں، جس کی وجہ سے اس کا کاروبار جاری رہنا مشکل ہے۔

ایس آئی ایچ ٹی (پرائیویٹ) لمیٹڈ (SIHT)

مالی سال کے دوران کمپنی نے شفافاؤنڈیشن سے ایس آئی ایچ ٹی (پرائیویٹ) لمیٹڈ (جے سی آئی اے سے منظور شدہ ہوم ہیلتھ کمپنی) میں حصص کی خریداری کے لیے 300 ملین روپے ادا کیے، جس سے کمپنی کی ایس آئی ایچ ٹی میں ملکیت 45.30 فیصد تک بڑھ گئی۔

ڈائریکٹرز رپورٹ

کارپوریٹ بریفنگ سیشن

پاکستان اسٹاک ایکسچینج اچھی کارپوریٹ گورننس کے فروغ کی حوصلہ افزائی کرتا ہے۔ لسٹڈ کمپنیز کی لازمی ذمہ داری کے مطابق، 25 نومبر 2024 کو سرمایہ کاروں اور شیئرز ہولڈرز کے لیے ویڈیولنک کے ذریعے کارپوریٹ بریفنگ سیشن منعقد کیا گیا۔ اس دوران کمپنی کی کارکردگی اور مالی نتائج پر تفصیلی پریزنٹیشن دی گئی، اور کمپنی کی مینجمنٹ نے مستقبل کے منصوبوں کا مختصر جائزہ بھی پیش کیا۔ مینجمنٹ نے شرکاء کے تمام سوالات اور استفسارات کے تسلی بخش طریقے سے جواب دیے۔

ڈائریکٹرز کی ذمہ داری کا بیان

ڈائریکٹرز اس بات کی تصدیق کرتے ہیں کہ کمپنی نے سیکورٹیز اینڈ ایکسچینج کمیشن آف پاکستان کے کارپوریٹ اور مالی رپورٹنگ فریم ورک اور کوڈ کی مندرجہ ذیل شقوں کی تعمیل کی ہے:

- مالی بیانات کمپنی کی مینجمنٹ کی جانب سے تیار کیے گئے ہیں اور کمپنی کی مالی صورتحال، آپریشنز کے نتائج، کیش فلو اور ایکویٹی میں تبدیلیوں کو درست طریقے سے ظاہر کرتے ہیں
- کمپنی کے حسابات اور ریکارڈ کمپنیز ایکٹ 2017 کے مطابق برقرار رکھے گئے ہیں
- مالی بیانات کی تیاری میں مناسب اکاؤنٹنگ پالیسیوں کو مستقل طور پر اپنایا گیا اور حسابی تخمینے معقول اور محتاط فیصلے پر مبنی ہیں۔
- پاکستان میں قابل اطلاق بین الاقوامی اکاؤنٹنگ سٹینڈرڈز پر عمل کیا گیا
- داخلی کنٹرول کا نظام مضبوط اور مؤثر طور پر نافذ و مانع کیا گیا ہے
- کارپوریٹ گورننس کے بہترین طریقوں سے کوئی بڑا انحراف نہیں ہوا
- کمپنی کے جاری رہنے کی صلاحیت پر کوئی اہم شبہ نہیں ہے

متعلقہ پارٹی کے لین دین

متعلقہ پارٹی کے تمام لین دین بورڈ آف ڈائریکٹرز کی منظوری سے، کمپنی کی متعلقہ پالیسی کے مطابق کیے جاتے ہیں۔ کمپنی ان کا مکمل ریکارڈ، بشمول شرائط و ضوابط، برقرار رکھتی ہے۔ ان کی تفصیلات مالی بیانات کے نوٹ نمبر 36 میں فراہم کی گئی ہیں۔

اہم تبدیلیاں

مالی سال کے اختتام سے اس رپورٹ کی تاریخ تک کمپنی کی مالی حیثیت پر اثر انداز ہونے والی کوئی اہم تبدیلی یا کمٹمنٹ نہیں ہوئی ہے۔

کمپنی کے قانونی آڈیٹرز

آڈٹ کمپنی کی سفارش پر بورڈ آف ڈائریکٹرز نے 30 جون 2026 کو ختم ہونے والے مالی سال کے لیے، M/s BDO Ebrahim & Co. چارٹرڈ اکاؤنٹنٹس کو کمپنی کے بیرونی آڈیٹر کے طور پر نامزد کرنے کی سفارش کی ہے۔

ذیلی/ایسوسی ایٹ کمپنیاں

30 جون 2025 تک کمپنی کی ذیلی اور ایسوسی ایٹ کمپنیوں کی تفصیلات اور ہر ایک میں کمپنی کے شیئرز کی فیصد درج ذیل ہے:

ڈائریکٹرز کا معاوضہ

کمپنی کے بورڈ آف ڈائریکٹرز، کمپنی کے آرٹیکلز آف ایسوسی ایشن، ایکٹ اور کوڈ کے مطابق بورڈ کے ارکان کے معاوضے کی منظوری دیتا اور اسے مقرر کرتا ہے۔ ایگزیکٹو اور نان ایگزیکٹو ڈائریکٹرز کے معاوضے کی تفصیلات، بشمول تنخواہ/فیس، مراعات، فوائد اور کارکردگی سے منسلک ترغیبات وغیرہ، مالی بیانات کے نوٹ نمبر 37 میں ظاہر کی گئی ہیں۔

غیر ملکی ڈائریکٹر کی سکیورٹی کلیئرنس

بورڈ میں منتخب غیر ملکی ڈائریکٹر کو وزارت داخلہ سے سکیورٹی کلیئرنس درکار ہوتی ہے، جو سکیورٹی رٹیز اینڈ ایجنس کچھ میٹن آف پاکستان (SECP) کے ذریعے کی جاتی ہے۔ کمپنی کی جانب سے تمام قانونی تقاضے اور فارملٹیز مکمل طور پر پوری کی گئی ہیں۔

شیئرز کی خرید و فروخت

ڈائریکٹرز، چیف ایگزیکٹو، بڑے شیئرز ہولڈرز، ایگزیکٹو اور ان کے/کی شریک حیات کی کمپنی میں براہ راست یا بالواسطہ شیئرز کی خرید و فروخت اور موجودہ ہولڈنگز کمپنی سکریٹری کو تحریری طور پر رپورٹ کی جاتی ہیں۔ اس رپورٹ میں شیئرز کی تعداد، قیمت اور لین دین کی نوعیت شامل ہوتی ہے۔ کمپنی سکریٹری یہ معلومات بورڈ، ایس ای سی پی (جہاں ضروری ہو) اور پی ایس ایکس کو فراہم کرتا ہے۔ 30 جون 2025 تک شیئرز ہولڈنگ کے ریکارڈ میں ڈائریکٹرز، چیف ایگزیکٹو، بڑے شیئرز ہولڈرز اور ان کے شریک حیات کی موجودہ ہولڈنگز ظاہر کی گئی ہیں۔

شیئرز ہولڈنگ کا پیٹرن

30 جون 2025 تک کمپنی کے کل شیئرز ہولڈرز کی تعداد 2,834 تھی، جبکہ 30 جون 2024 کو یہ تعداد 2,431 تھی۔ شیئرز ہولڈنگ کا پیٹرن اس سالانہ رپورٹ میں شامل ہے۔

ڈائریکٹرز کا ٹریننگ پروگرام

11 میں سے 10 (90.90 فیصد) ڈائریکٹرز نے ڈائریکٹرز ٹریننگ پروگرام (ڈی ٹی پی) مکمل کیا، جیسا کہ کوڈ کے ریگولیشن 19(1) میں بیان کیا گیا ہے۔ تصدیق شدہ ڈائریکٹرز درج ذیل ہیں:

- 1- ڈاکٹر حبیب الرحمن
- 2- ڈاکٹر ذیشان بن اشتیاق
- 3- ڈاکٹر منظور ایچ قاضی
- 4- ڈاکٹر سمیعہ کوثر احمد
- 5- سید الیاس احمد
- 6- ڈاکٹر محمد نسیم انصاری
- 7- شاہ نوید سعید
- 8- ڈاکٹر محمد سلیم خان
- 9- ڈاکٹر ایوان پی کلین جوز*
- 10- جناب تیمور شاہ

* ڈاکٹر ایوان پی کلین جوز نے کوئٹہ ہسپتال سکول، نیویارک، یو ایس اے سے کارپوریٹ گورننس میں ایگزیکٹو ایجوکیشن پروگرام مکمل کیا۔

کوڈ کے سب ریگولیشن 19(2) کے تحت، قاسم فاروق احمد کم از کم 14 سالہ تعلیمی قابلیت کے حامل ہیں اور بورڈ میں 15 سال سے زائد مدت کے لیے ڈائریکٹر رہ چکے ہیں، اس لیے وہ ڈی ٹی پی سے مستثنیٰ ہیں۔ مزید برآں، کمپنی نے سب ریگولیشن 19(3)(i) کے تحت ایک مرد اور ایک خاتون ایگزیکٹو کے لیے ڈی ٹی پی کا انتظام بھی کیا۔

ڈائریکٹرز رپورٹ

رسک مینجمنٹ کمیٹی

کوڈ کے تحت بورڈ میں رسک مینجمنٹ کمیٹی (RMC) بھی شامل ہے، جس کے اراکین درج ذیل ہیں:

- 1۔ قاسم فاروق احمد
- 2۔ ڈاکٹر محمد نسیم انصاری
- 3۔ جناب تیمور شاہ
- 4۔ ڈاکٹر محمد سلیم خان

آراہیم سی کے ٹی اور آرز کے مطابق کمیٹی تمام اہم کنٹرولز بشمول مالی، آپریشنل اور تعمیلی (compliance) کنٹرولز کی نگرانی اور جائزہ لینے کی ذمہ دار ہے، اور اس بات کو یقینی بناتی ہے کہ خطرات کم کرنے کے اقدامات مضبوط اور مؤثر ہیں۔ مالی سال کے دوران آراہیم سی کا ایک اجلاس منعقد ہوا۔

بورڈ اور آڈٹ کمیٹی کے اجلاسوں کی تعداد اور حاضری

مالی سال کے دوران بورڈ آف ڈائریکٹرز کے چھ (06) اجلاس اور بی اے سی کے پانچ (05) اجلاس ویڈیو لنک کے ذریعے اور براہ راست منعقد کیے گئے۔ ان میں ڈائریکٹرز کی حاضری درج ذیل رہی:

ڈائریکٹر کا نام	بورڈ میٹنگز میں شرکت کی تعداد	آڈٹ کمیٹی میں شرکت کی تعداد
ڈاکٹر حبیب الرحمن *	6	1
ڈاکٹر ذیشان بن استیاق	6	لاگو نہیں
ڈاکٹر منظور ایچ قاضی *	6	3
جناب قاسم فاروق احمد	6	لاگو نہیں
ڈاکٹر سمیعہ کوثر احمد	6	5
سید الیاس احمد	6	5
ڈاکٹر محمد نسیم انصاری	6	لاگو نہیں
ڈاکٹر ایوان پی کلین جونز	6	لاگو نہیں
جناب شاہ نوید سعید	5	5
ڈاکٹر محمد سلیم خان	6	لاگو نہیں
جناب تیمور شاہ	6	لاگو نہیں

* ڈاکٹر حبیب الرحمن نے بی اے سی کے رکن کے طور پر استعفیٰ دے دیا۔ اپنی مدت کے دوران وہ بی اے سی کے ایک اجلاس میں شریک ہوئے۔ بعد ازاں ڈاکٹر منظور ایچ قاضی کو بی اے سی کا رکن مقرر کیا گیا۔

بورڈ کا جائزہ

ضابطے کی ضروریات کے مطابق، بورڈ ہر سال اپنی کارکردگی کا خود جائزہ لیتا ہے۔ اس میں بورڈ کا ڈھانچہ اور خصوصیات، کردار اور ذمہ داریاں، انتظامیہ کے ساتھ تعلقات اور ہسپتال سے متعلق مخصوص اقدامات شامل ہوتے ہیں۔

بورڈ کی مجموعی کارکردگی کو منظور شدہ معیار کی بنیاد پر اچھا قرار دیا گیا۔

امور پر بھی کام کرتی ہے تاکہ کمیٹی کے مفادات کا تحفظ یقینی بنایا جاسکے۔

بی اے سی کے چیئرمین کمیٹی کے مشاہدات اور سفارشات بورڈ کے سامنے پیش کرتے ہیں۔ بورڈ آڈٹ کمیٹی نے ایک اجلاس بیرونی آڈیٹرز کے ساتھ (ہیڈ آف انٹرنل آڈٹ اور سی ایف او کو خارج کر کے) اور ایک اجلاس ہیڈ آف انٹرنل آڈٹ کے ساتھ (سی ایف او اور بیرونی آڈیٹرز کو خارج کر کے) منعقد کیا۔ اس سال بی اے سی کی تشکیل میں ایک اہم تبدیلی ہوئی۔ بورڈ کے چیئرمین ڈاکٹر حبیب الرحمن، جو 2003 سے کمیٹی کے رکن تھے، نے اپنی مدت مکمل کی۔ ان کی جگہ ڈاکٹر منظور ایچ قاضی کو بطور ممبر نامزد کیا گیا۔ بی اے سی نے ڈاکٹر حبیب الرحمن کو ان کی طویل خدمات، قیمتی رہنمائی، اور پیشہ ورانہ بصیرت پر خراج تحسین پیش کیا۔

ہیومن ریسورس اینڈ ریمونزیشن کمیٹی

ہیومن ریسورس اینڈ ریمونزیشن (R&HR) کمیٹی کے اراکین درج ذیل ہیں:

- 1۔ ڈاکٹر محمد نسیم انصاری چیئرمین، آزاد ڈائریکٹر
- 2۔ ڈاکٹر حبیب الرحمن ممبر، نان ایگزیکٹو ڈائریکٹر
- 3۔ ڈاکٹر ذیشان بن اشتیاق ممبر، چیف ایگزیکٹو آفیسر
- 4۔ ڈاکٹر منظور ایچ قاضی ممبر، نان ایگزیکٹو ڈائریکٹر
- 5۔ سید الیاس احمد ممبر، نان ایگزیکٹو ڈائریکٹر
- 6۔ قاسم فاروق احمد ممبر، نان ایگزیکٹو ڈائریکٹر

ٹی اور آر کے مطابق "ایچ آر اینڈ آر" کمیٹی کا اہم مقصد ایگزیکٹو ڈائریکٹر اور سینئر عملے کے لیے موزوں معاوضے کے پیکج کا جائزہ لینا ہے تاکہ مارکیٹ کے معیار، قانونی تقاضوں اور سٹیک ہولڈرز کے مفادات کے مطابق عملہ برقرار رکھا جاسکے۔ ٹی اور آر کے تحت کمیٹی میں زیادہ تر اراکین نان ایگزیکٹو ڈائریکٹر ہونے چاہئیں، جن میں کم از کم ایک آزاد ڈائریکٹر شامل ہو، اور چیئرمین بھی آزاد ڈائریکٹر ہو۔

ایچ آر اینڈ آر کمیٹی منظور شدہ ٹی اور آر کے مطابق کام کرتی ہے۔ جائزہ سال کے دوران کمیٹی کا ایک اجلاس منعقد ہوا۔

کارپوریٹ گورننس اور نامزدگی کمیٹی

کارپوریٹ گورننس اور نامزدگی (N&CG) کمیٹی کے اراکین درج ذیل ہیں:

- 1۔ ڈاکٹر منظور ایچ قاضی چیئرمین، نان ایگزیکٹو ڈائریکٹر
- 2۔ ڈاکٹر ذیشان بن اشتیاق ممبر، چیف ایگزیکٹو آفیسر
- 3۔ ڈاکٹر سمیعہ کوثر احمد ممبر، نان ایگزیکٹو ڈائریکٹر
- 4۔ ڈاکٹر ایوان پی کلین جونیئر ممبر، نان ایگزیکٹو ڈائریکٹر

سی جی اینڈ این کمیٹی کے ٹی اور آر کوڈ کے مطابق تیار کیا گیا ہے۔ کمیٹی بنیادی طور پر بورڈ کی ساخت، حجم اور تشکیل کا جائزہ لینے کی ذمہ دار ہے۔ مالی سال کے دوران کمیٹی کا کوئی اجلاس نہیں ہوا۔

ڈائریکٹرز رپورٹ

بورڈ آف ڈائریکٹرز

(ا) مرد: دس (10)

(ب) خواتین: ایک (01)

بورڈ اپنے اختیارات اور فرائض کمپنی کے میمورینڈم اور آرٹیکلز آف ایسوسی ایشن کمپنیز ایکٹ 2017 ('دی ایکٹ')، لسٹڈ کمپنیز (کوڈ آف کارپوریٹ گورننس) ریگولیشنز 2019 ('دی کوڈ')، اور دیگر متعلقہ قوانین میں موجود نفعات سے حاصل کرتا ہے۔ بورڈ نے 30 جون 2025 کو مالی سال ختم ہونے تک کے عرصے میں چھ (06) اجلاس منعقد کیے۔ فی الحال بورڈ میں تین آزاد ڈائریکٹر، چھ نان ایگزیکٹو ڈائریکٹر (جن میں ایک خاتون شامل ہے) اور دو ایگزیکٹو ڈائریکٹر شامل ہیں، جو درج ذیل ہیں:

کیٹگری	نام
آزاد ڈائریکٹر	ڈاکٹر محمد نسیم انصاری ڈاکٹر محمد سلیم خان شاہ نوید سعید
غیر ایگزیکٹو ڈائریکٹر	ڈاکٹر حبیب الرحمان ڈاکٹر منظور ایچ قاضی جناب قاسم فاروق احمد ڈاکٹر سمیعہ کوثر احمد سید الیاس احمد ڈاکٹر ایون فیلیپ کلین جونز
ایگزیکٹو ڈائریکٹر	ڈاکٹر ذیشان بن اشتیاق (چیف ایگزیکٹو آفیسر) جناب تیمور شاہ

کمپنی کے بورڈ میں شامل افراد مختلف پیشہ ورانہ شعبوں سے تعلق رکھتے ہیں تاکہ بورڈ میں تنوع کو فروغ دیا جاسکے۔ ان میں چھ میڈیکل ڈاکٹرز، ایک آئی ٹی پروفیشنل، دو فارماسسٹ، ایک ہیلتھ کیئر مینجمنٹ پروفیشنل اور ایک چارٹرڈ اکاؤنٹنٹ شامل ہیں۔

بورڈ آڈٹ کمیٹی

بورڈ آڈٹ کمیٹی (BAC) میں تین نان ایگزیکٹو ڈائریکٹر اور ایک آزاد ڈائریکٹر شامل ہیں، جو درج ذیل ہیں:

- 1۔ جناب شاہ نوید سعید
چیئر مین، آزاد ڈائریکٹر
- 2۔ ڈاکٹر منظور ایچ قاضی
ممبر، نان ایگزیکٹو ڈائریکٹر
- 3۔ ڈاکٹر سمیعہ کوثر احمد
ممبر، نان ایگزیکٹو ڈائریکٹر
- 4۔ سید الیاس احمد
ممبر، نان ایگزیکٹو ڈائریکٹر

بی اے سی کے تمام اراکین اعلیٰ تعلیمی اور پیشہ ورانہ اہلیت کے حامل ہیں۔ بورڈ آڈٹ کمیٹی نے مالی سال کے دوران پانچ (05) اجلاس منعقد کیے۔

کمیٹی کے ٹرمز آف ریفرنس (ToRs) کوڈ کی ہدایات کے مطابق تیار کیے گئے ہیں اور بی اے سی انہی کے مطابق کام کرتی ہے۔ ٹی اور آر ز میں کمپنی کے اثاثوں کے تحفظ، اکاؤنٹنگ ریکارڈز کی مناسب دیکھ بھال، داخلی کنٹرولز اور رسک مینجمنٹ کی نگرانی، قانونی اور مضابطہ جاتی تعمیل، اور مالی بیانات کے جائزے سمیت دیگر ذمہ داریاں شامل ہیں۔ بی اے سی بورڈ کی طرف سے تفویض شدہ دیگر

1۔ اینٹی کرپشن پالیسی

شفا انٹرنیشنل ہسپتال کرپشن اور رشوت ستانی کے خلاف صفر برداشت کی پالیسی پر یقین رکھتا ہے۔ پالیسی ممنوعہ سرگرمیوں، رپورٹنگ کے طریقہ کار، اور خلاف ورزی کی صورت میں تادیبی اقدامات کو واضح کرتی ہے۔ غیر اخلاقی رویے کی رپورٹنگ کے لیے خفیہ و سل بلوٹنگ میکانزم بھی موجود ہے۔

2۔ ملازمین کی تربیت اور تھرڈ پارٹی جانچ

نئے ملازمین کو کوڈ آف کنڈکٹ کی مکمل تربیت دی جاتی ہے تاکہ وہ اخلاقی اصولوں اور بدعنوانی مخالف اقدامات کو بخوبی سمجھ سکیں۔ اسی طرح، تھرڈ پارٹی پارٹنرز، سپلائرز اور کنسٹرکٹرز کی بھی مکمل جانچ کی جاتی ہے۔

3۔ مانیٹرنگ اور تعمیل

غیر اخلاقی رویوں کی روک تھام کے لیے مضبوط نگرانی اور تعمیل کے اقدامات نافذ ہیں۔ باقاعدہ آڈٹس اور تعمیل کی نگرانی کی جاتی ہے تاکہ شفافیت، دیانتداری، اور اخلاقی اصولوں پر عمل کو یقینی بنایا جاسکے۔

خصوصی افراد کی ملازمت

کمپنی مختلف صلاحیتیں رکھنے والے افراد کے لیے مساوی مواقع فراہم کرنے کے لیے پرعزم ہے۔ اس وقت عملے میں ایسے 19 ارکان شامل ہیں، جو غیر امتیازی اور شمولیتی پالیسی کا عملی اظہار ہیں۔

صنف کی بنیاد پر تنوع میں فرق

خواتین کو مردوں کے مقابلے میں اوسط 11 فیصد اور درمیانی سطح پر 20 فیصد زیادہ تنوع دیا جاتا ہے۔

کوڈ آف کنڈکٹ

کمپنی نے ایک کوڈ آف کنڈکٹ اپنایا ہے جو تمام ملازمین سے کام کے ماحول میں انصاف، احترام اور دیانت برقرار رکھنے اور اخلاقی اصولوں کی تعمیل کا تقاضا کرتا ہے۔ اس میں قانونی تعمیل، سیاسی سرگرمیوں سے اجتناب، تحائف کی وصولی پر پابندی، تضاد مفادات سے بچاؤ، صنف، نسل، رنگ، عمر کی بنیاد پر امتیاز یا ہراسانی سے پرہیز، معلومات کی رازداری، اور ماحولیات کے قوانین کی تعمیل شامل ہیں۔ یہ کوڈ تمام ڈائریکٹرز، افسران، ملازمین، کنسلٹنٹس اور ایجنٹس پر لاگو ہوتا ہے۔

وسل بلوٹنگ پالیسی

کمپنی ایمانداری، دیانت، شفافیت اور جوابدہی کے ساتھ کاروبار کرنے کو اولین اہمیت دیتی ہے۔ اس مقصد کے لیے وسل بلوٹنگ پالیسی متعارف کرائی گئی، جو سٹیک ہولڈرز کو غیر قانونی سرگرمیوں، بدانتظامی، اختیار کے غلط استعمال یا کمپنی کی پالیسیوں سے متصادم امور رپورٹ کرنے کی سہولت دیتی ہے۔ اس پالیسی کے تحت رپورٹ کرنے والوں کو کسی بھی قسم کی سزا یا انتقام سے تحفظ فراہم کیا جاتا ہے۔

شکایات کے ازالے کی پالیسی

کمپنی اس بات کو یقینی بناتی ہے کہ ملازمین کی شکایات سنی جائیں، اور انہیں فوری حل کیا جائے۔ اس حوالے سے ملازمین کو پہلے اپنے سپروائزر سے رابطہ کرنے کی ترغیب دی جاتی ہے۔ تھرڈ پارٹی کے تحت کام کرنے والے ملازمین کی شکایات کو بھی متعلقہ سپروائزرز کے ذریعے وینڈر تک پہنچایا جاتا ہے۔ یہ کمپنی کی منصفانہ، ذمہ دار اور کام دوست ماحول کو فروغ دینے کی پالیسی کی عکاسی کرتا ہے۔

ڈائریکٹر رپورٹ

- تشدد کے شکار طلباء کو تعلیمی اور نفسیاتی معاونت فراہم کرنا
- 2025-2026 کی صنفی پالیسی کے تحت صنفی شمولیت کو فروغ دینا
- 235 طلباء اور اساتذہ کے بائیو مارکر سیمینٹ کے ڈیٹا کی بنیاد پر ذہنی صحت کے اقدامات

صارفین کے تحفظ کے اقدامات

شفا انٹرنیشنل ہسپتال نے مریضوں، وزیٹرز اور عملے کی حفاظت، اعتماد اور سہولت کو یقینی بنانے کے لیے متعدد اقدامات کیے، جن میں سیکورٹی کو بہتر کرنا، سروسز کی ہموار طریقے سے انجام دہی کو یقینی بنانا، اور جدید ٹیکنالوجیز کو شامل کرنا شامل ہیں۔

سیکیورٹی اور سروسز میں بہتری کے لیے اہم اقدامات

1۔ ایس ایس جی کمانڈ وز کی تعیناتی

ہسپتال کی سیکورٹی کو مضبوط بنانے کے لیے 10 تربیت یافتہ ایس ایس جی کمانڈ وز کی خدمات حاصل کی گئیں۔ اس سے ادارے کی ہنگامی صورت حال سے نمٹنے کے لیے تیاری اور رسپانس کی صلاحیت میں نمایاں اضافہ ہوا۔

2۔ گیٹ 1 پر نیا وزیٹر پارکنگ

گیٹ 1 کے قریب نیا پارکنگ ایریا فعال کیا گیا، جس سے ٹریفک بہاؤ بہتر ہوا، ہجوم کم ہوا اور مریضوں اور وزیٹرز کے لیے سہولت بڑھی۔

3۔ ویلیٹ سروسز کی توسیع

ویلیٹ سروسز کی گنجائش میں اضافہ کیا گیا۔ اب ٹیم روزانہ 350 گاڑیوں (پہلے 200) کو منیج کرتی ہے، جس سے پارکنگ کا عمل تیز اور مؤثر ہوا۔

4۔ لائسنس یافتہ اسلحہ اور ایس او پیز کا نفاذ

ہسپتال سیکورٹی ٹیم کو لائسنس یافتہ ہتھیار فراہم کیے گئے۔ ہتھیار کے ذمہ دارانہ استعمال کے لیے تفصیلی ایس او پیز تیار کیے گئے، تاکہ حفاظت کو یقینی بنایا جاسکے۔

جاری اور مستقبل کے منصوبے

5۔ اے ای کے حامل سی سی ٹی وی کے ذریعے نگرانی (ذریعہ تکمیل)

اے ای کے سافٹ ویئر کو موجودہ سی سی ٹی وی انفراسٹرکچر کے ساتھ شامل کیا جا رہا ہے۔ اے ای ٹی مشنوک افراد کی خود کار شناخت کر کے الرٹ فراہم کرے گا۔ وہ حقیقی وقت میں خطرات کی نشاندہی اور آگاہی میں اضافہ کرے گا۔

6۔ فیصل آباد سائٹ - سیکورٹی اور فائر سیفٹی سسٹمز (منصوبہ بندی)

سی سی ٹی وی، آرائف ای ڈی، واک تھر وگٹس اور فائر ڈیٹیکشن سسٹمز کے ساتھ مکمل سیکورٹی سیٹ اپ نصب کیا جا رہا ہے تاکہ فیصل آباد پروجیکٹ سائٹ محفوظ اور نگرانی کے تحت ہو۔

7۔ میڈیکل سینٹر - بحریہ سیوک سینٹر (منصوبہ بندی)

اسی طرح کی سیکورٹی انفراسٹرکچر، بشمول مانیٹرنگ کیمرے، رسائی کنٹرول اور فائر سیفٹی سسٹمز، نئے میڈیکل سینٹر میں نصب کیے جائیں گے۔

کاروباری اخلاقیات اور کرپشن کے خلاف اقدامات

شفا انٹرنیشنل ہسپتال اعلیٰ ترین کاروباری اخلاقیات اور کرپشن کے خلاف اقدامات پر یقین رکھتا ہے۔ ہمارے جامع کوڈ آف کنڈکٹ میں تمام ملازمین، ڈائریکٹرز، اورسٹیک ہولڈرز کے لیے اخلاقی اصول اور معیارات شامل ہیں۔ یہ اصول اور معیارات مفادات کے نگرانج، رازداری، اور منصفانہ رویے کو واضح طور پر بیان کرتے ہیں۔

کارپوریٹ فلاحی اقدامات

- پی سی پی اور ای اے ڈی سے منظور شدہ غیر منافع بخش ادارے کے طور پر، شفا فاؤنڈیشن نے گہرے اثرات کے حامل فلاحی پروگرام تشکیل دیے، جن میں درج ذیل شامل ہیں:
- فوڈ بینکر اور پینے کے محفوظ پانی کی تقسیم
- کم وسائل والے علاقوں میں جدید طبی علاج
- یونیورسٹیوں کے ساتھ فعال شراکت داری اور رضا کارانہ نیٹ ورک کی توسیع
- قدرتی آفات کے متاثرین کے لیے صحت اور حفظانِ صحت کے پروگرام
- فلاحی اقدامات فوری ضروریات کو پورا کرنے اور معاشرتی مساوات کو فروغ دینے میں بنیادی کردار ادا کرتے ہیں

کمیونٹی میں سرمایہ کاری اور فلاحی سکیمیں

- مالی سال 2024-25 میں، شفا انٹرنیشنل ہسپتال نے شفا فاؤنڈیشن کے ذریعے تعلیم، مہارتیں سکھانے، اور سماجی بہبود کے پروگراموں کے ذریعے کمیونٹی پر گہرے مثبت اثرات مرتب کیے۔
- سکوپ (Shifa Center of Professional Excellence) نے جاری طبی تعلیم، لائف سپورٹ ٹریننگ، اور تحقیقی اقدامات کے ذریعے پیشہ ورانہ صلاحیتوں کو بہتر کیا۔
- شفا فاؤنڈیشن نے اپنی رسائی کو وسیع کیا، جس سے ملک بھر میں ہزاروں افراد مستفید ہوئے۔ اس کے ذریعے سرکاری اداروں کے ساتھ قریبی تعاون کے ذریعے پائیدار نتائج یقینی بنائے گئے۔
- یونیسیف، ڈبلیو ایف پی، نیوٹریشن انٹرنیشنل، اور مقامی انتظامیہ بشمول بے نظیر انکم سپورٹ پروگرام کے ساتھ مضبوط شراکت داری نے پروگرام کی کامیابی اور مؤثر سروس کو مزید بہتر بنایا۔

ماں اور نوزائیدہ بچوں کے لیے نیوٹریشن پروگرام

8,317 حاملہ خواتین کو ملٹی مائیکرو نیوٹریشن سپلیمنٹس دیے گئے۔

SOPRAN انیشیٹیو

498 سکولوں میں 40,000 نو عمر لڑکیوں کو ہفتہ وار آئرن اور فولک ایسڈ سپلیمنٹ فراہم کیے گئے۔

دیہی ترقی کے پروگرام

- مالی سال 2024-25 میں شفا فاؤنڈیشن نے دیہی علاقوں میں صاف پانی، صفائی، اور فوڈ سیفٹی تک بہتر رسائی فراہم کی۔ بلوچستان میں پانی کے ذرائع اور صفائی کی سہولیات تعمیر اور بحال کی گئیں۔
- صحت و حفظانِ صحت کا شعور جاگ ر کرنے کے لیے سیشنز منعقد کیے گئے۔
- سیلاب سے متاثرہ سندھ میں مربوط اقدامات کے تحت محفوظ پینے کا پانی، روزگار کے لیے نقد امداد، اور کچن گارڈننگ ٹول کٹس فراہم کی گئیں۔ بچوں اور حاملہ خواتین میں غذائی کمی کی جانچ اور علاج کے ذریعے کمیونٹی کی صحت میں بہتری لائی گئی۔
- یہ اقدامات صرف فوری ضروریات کو پورا کرنے تک محدود نہیں تھے بلکہ ان کے اثرات کمیونٹی کی پائیدار ترقی اور مضبوطی پر بھی مرتب ہوئے۔

مستحق طبقات کے لیے فلاحی اخراجات

- شفا فاؤنڈیشن کے پروگراموں کا ہر حصہ کم وسائل والے افراد کی زندگیاں بہتر بنانے کی کوششوں کے لیے مختص کیا گیا۔ اس میں درج ذیل سرگرمیاں انجام دی گئیں:
- ایمرجنسی پرائمری کیئر سروسز جو 4,500 سے زائد افراد تک پہنچیں
- ماں اور بچے کی صحت کے لیے 140 کلین ڈیلیوری کٹس کی تقسیم
- کم وسائل والے صوبوں میں آریوٹی ایف اور ایس این ایف کے ذریعے غذا سے متعلق پیچیدگیوں سے نمٹنا

ڈائریکٹر رپورٹ

ایف ایم ایس (Facility Management & Safety) ٹریننگ

عمل کو ایف ایم ایس پروڈکٹوں کی باقاعدہ تربیت دی جاتی ہے، جس میں ذاتی سیشنز، آن لائن پریزنٹیشنز اور ویڈیو ماڈیولز شامل ہیں۔ آگاہی کی سطح کے جائزے کے ذریعے اس بات کو یقینی بنایا جاتا ہے کہ عملہ ہم حفاظتی ایریاز میں مکمل تیاری کے ساتھ فرائض انجام دینے کے قابل ہو، اور معلومات بروقت فراہم کی جائیں۔

جامع حفاظتی پروگرامز

شفا انٹرنیشنل ہسپتال نے افراد اور انفراسٹرکچر کے تحفظ کے لیے متعدد حفاظتی پروگرام لاگو کیے ہیں، جو مخصوص مینٹننس اور پالیسیز کے ذریعے عمل میں لائے جاتے ہیں۔ کلیدی پروگرامز میں شامل ہیں:

☆ فائر سیفٹی مینجمنٹ

☆ خطرناک مواد اور ویسٹ مینجمنٹ

☆ ملازمین کی صحت اور حفاظت

☆ ڈیزاسٹر مینجمنٹ

☆ ریڈی ایشن، لیزر اور لیبارٹری سیفٹی

انفیکشن سے بچاؤ اور کنٹرول

انفیکشن پریونشن اینڈ کنٹرول (آئی پی سی) ڈپارٹمنٹ نے 550 بیڈز پر مشتمل ہسپتال میں ہیلتھ کیئر سے متعلقہ انفیکشنز (ایچ اے آیز) کی مؤثر مانیٹرنگ کی۔ اگست 2024 میں ایک وقتی اضافے کے علاوہ ایچ اے آئی کی شرح 1000 ڈیوآس - دنوں کے لیے 5.2 کے بیچ مارک کے اندر رہی۔ ”ڈیوآس - دن“ میں ایک ڈیوآس کے ایک دن استعمال ہونے کو ایک دن شمار کیا جاتا ہے۔ اس اضافے کے رسپانس میں جو اقدامات کیے گئے، ان میں ہاتھوں کی صفائی کی ٹریننگ میں اضافہ، جوت پونی کیئر بنڈلز (سی اے یو ٹی آئی، سی ایل اے بی ایس آئی، وی اے پی) کا نفاذ، اپ ڈیٹڈ ڈس انفیکشن پروڈکٹوں اور ایچ اے آئی کے ڈیٹا کی حقیقی وقت میں مانیٹرنگ اور تجزیہ شامل تھے۔

آگاہی اور صلاحیت بڑھانے کے لیے ”گلوبل ہینڈ واشنگ ڈے“ اور ”انٹرنیشنل انفیکشن پریونشن ویک“ پر تعلیمی پروگراموں اور ویب ناز میں عملے کی شرکت کو یقینی بنایا گیا۔ عملے کی مہارت میں اضافہ کرنے کے لیے بین الاقوامی تربیتی تعاون بھی فراہم کیا گیا۔ اس میں سینٹ جیوڈ چلڈرنز ریسرچ ہسپتال کے ساتھ شراکت داری، قاہرہ میں عملی تربیت، اور آئی پی سی ڈپلومہ کی کامیاب تکمیل شامل ہیں۔

این آئی سی یو، ایمرجنسی، ایم آئی سی یو اور ایس آئی سی یو یونٹس میں اہم کواہٹی امپروومنٹ (کیو آئی) پروجیکٹس انجام دیے گئے۔ ان کا مقصد انفیکشن کی روک تھام، سپیس کی بروقت تشخیص، اور بلڈ کلچر میں آلودگی کو کم کرنا تھا۔

ڈپارٹمنٹ نے مینجمنٹ انفارمیشن سسٹم کے ذریعے ایک ڈیجیٹل ایچ اے آئی نگرانی اور رپورٹنگ نظام بھی تیار کیا اور فلیٹنگ فنڈ کے اے ایم آر سروسز پر وگرام میں قومی سطح پر حصہ لیا۔ آئی پی سی ڈپارٹمنٹ نے پرو ایکٹو مانیٹرنگ، سٹیک ہولڈر انگیجمنٹ، اور جدید طریقوں کے ذریعے ہسپتال میں مریضوں کی حفاظت اور دیکھ بھال کے معیار کو نمایاں طور پر بہتر بنایا۔

کارپوریٹ سماجی ذمہ داری کی سرگرمیاں

شفا انٹرنیشنل ہسپتال کی سی ایس ایس آر شاخ شفا فاؤنڈیشن صحت، تعلیم، غذائیت، WASH (پانی، صفائی اور حفظان صحت)، خوراک کی حفاظت، تحفظ، اور پائیدار ذریعہ معاش کے شعبوں میں سرگرمی سے کام کر رہی ہے۔ مالی سال 2024-2025 میں، فاؤنڈیشن نے پاکستان کے 60 سے زائد اضلاع میں لاکھوں افراد تک رسائی حاصل کی اور کئی ایس ڈی جیز (Sustainable Development Goals) کے حصول میں براہ راست کردار ادا کیا۔ ان اقدامات کا مقصد صحت کے بہتر نتائج، صاف پانی تک رسائی، تعلیمی مواقع، اور صنفی مساوات کو فروغ دینا تھا۔ ان کی تفصیل درج ذیل ہے:

- * شور کی نگرانی : اہم پلانٹ لوکیشنز میں اس کا جائزہ لیا جاتا ہے
- * راکھ کا تجزیہ : جدید تکنیک کے ذریعے معدنیاتی ساخت کا جائزہ لیا جاتا ہے
- * ان ہاؤس مانیٹرنگ : مختلف ماحولیاتی پیرامیٹرز کی نگرانی کرتا ہے

پانی کا ضیاع روکنا، اور اس کا دوبارہ استعمال

جدید میمبرین میڈیٹریڈ سسٹمز کے ذریعے شفا انٹرنیشنل ہسپتال روزانہ تقریباً 10,000 لیٹر ریجنیکٹ پانی ری سائیکل کرتا ہے، جو سالانہ 3 ملین لیٹر بنتا ہے۔ بوائمر کے ریجنیکٹ پانی کو لائڈری، فضلے کو جلانے اور آبپاشی کے لیے دوبارہ استعمال کیا جاتا ہے، جس سے 3,400 مکعب میٹر سے زائد پانی کی بچت ہوتی ہے۔ شفا انٹرنیشنل ہسپتال کا سپرنکسر سسٹم روایتی طریقوں کے مقابلے میں 40 فیصد زیادہ پانی بچاتا ہے، جس سے سالانہ صرف 55 ملین لیٹر پانی استعمال ہوتا ہے اور توانائی کے استعمال میں 500 کلو واٹ آور سے زائد کی آتی ہے۔

ملازمین کی حفاظت اور صحت

شفا انٹرنیشنل ہسپتال لمیٹڈ اپنے عملے، مریضوں، وینڈرز اور تیمارداروں کی صحت، حفاظت اور مامونیت پر خاص توجہ دیتا ہے۔ ہسپتال نے کام کی جگہ سے متعلق خطرات کو کم کرنے، محفوظ ماحول فراہم کرنے اور آپریشنل تسلسل کو یقینی بنانے کے لیے جامع نظام اور پروگرام نافذ کیے ہیں۔ ان کی تفصیل یہ ہے:

ISO 45001:2018 سرٹیفیکیشن

شفا انٹرنیشنل ہسپتال کا آپریشنل ہیلتھ اینڈ سیفٹی سسٹم ISO 45001:2018 کے تحت سرٹیفائیڈ ہے۔ اپریل 2025 میں ایس جی ایس کے ذریعے کیے گئے مانیٹرنگ نگرانی آڈٹ میں صرف چار اوپن آئیٹمز (Opportunities for Improvement) سامنے آئیں، اور کوئی غیر تعمیل نہیں پائی گئی۔ یہ ملازمین کی حفاظت کے عالمی معیارات کے ساتھ ہسپتال کی وابستگی کو ظاہر کرتی ہے۔

ایچ وی اے اینڈ آراے (Hazard Vulnerability Analysis & Risk Assessment)

سالانہ اور مخصوص صورتحال کے مطابق ایک کثیر الشعبہ ٹیم کے ذریعے HVA&RA انجام دی جاتی ہے تاکہ آگ، کیمیائی اثرات، حیاتیاتی خطرات، کام سے متعلق خطرات، شور اور دیگر ممکنہ خطرات کی نشاندہی اور ان کا سد باب کیا جاسکے۔ خطرات کو کنٹرول کرنے کے لیے مناسب اقدامات کیے جاتے ہیں تاکہ مریضوں، عملے اور انفراسٹرکچر کے لیے محفوظ اور صحت مند ماحول یقینی بنایا جاسکے۔

پی سی آراے اینڈ آئی سی آراے (Preconstruction & Infection Control Risk Assessments)

کسی بھی تعمیر، تزئین یا مرمت سے پہلے PCRA اور ICRA کی جاتی ہیں تاکہ مریضوں کی دیکھ بھال اور ماحولیاتی حفاظت کے ممکنہ خطرات کا اندازہ لگایا جاسکے۔ حفاظتی منصوبوں میں انفیکشن کنٹرول، ہوا کے معیار، آگ سے حفاظت، شور، وابہریشن (کمپن)، خطرناک مواد اور ایمرجنسی تیاری کو خاص طور پر مد نظر رکھا جاتا ہے۔

میڈیکل مانیٹرنگ پروگرام

ملازمین کو اپنے پیشہ ورانہ کام کی وجہ سے ہونے والی بیماریوں کا پتہ لگانے اور ان کی روک تھام کے لیے شفا انٹرنیشنل ہسپتال ان کا سالانہ بنیادوں پر طبی معائنہ کرتا ہے۔ ایسا خاص طور پر ان ملازمین میں کیا جاتا ہے جو براہ راست یا بالواسطہ مریضوں کی دیکھ بھال کے عمل میں شامل ہوں۔ اس حوالے سے اقدامات میں ویکسینیشن پروٹوکولز اور ٹیسٹنگ شامل ہیں۔

ایمرجنسی اور ڈیزاسٹر مینجمنٹ

شفا انٹرنیشنل ہسپتال ایک مضبوط ایچ آئی سی ایس (Hospital Incident Command System) کے تحت فوری رسپانس کو یقینی بناتا ہے۔ باقاعدہ ڈریل اور ٹیبل ٹاپ ایکسرسائز کی جاتی ہیں تاکہ بروقت تیاری کی جانچ ہو سکے۔ مئی 2025 میں ایک حقیقی جنگی منظر نامے کے دوران ادارہ جاتی ایچ آئی سی ایس کو فعال کیا گیا۔

ڈائریکٹرز رپورٹ

سولرانجی کے ذریعے قابل تجدید توانائی

شفا انٹرنیشنل ہسپتال نے KW 895 (DC) فوٹو وولٹائک سولر سسٹم نصب کیا ہے، جو نومبر 2022 سے فعال ہے۔ یہ نظام اسلام آباد کے ہائی سولر ریڈی ایشن پوٹنشل کو استعمال کرتے ہوئے ماحول دوست توانائی پیدا کرتا ہے۔ مالی سال 2024 میں اس سسٹم نے تقریباً 1.15 ملین کلو واٹ آور بجلی پیدا کی، جس سے تقریباً 599.4 میٹرک ٹن کاربن ڈائی آکسائیڈ کے اخراج سے بچا گیا۔ یہ اقدام فوسل فیوز پر انحصار کم کرنے اور ہسپتال کے طویل مدتی پائیداری کے اہداف کے حصول میں مددگار ہے۔

ویسٹ ہیٹ ریکوری (ڈبلیو ایچ آر) بوائلرز

شفا انٹرنیشنل ہسپتال نے ڈبلیو ایچ آر بوائلرز نصب کیے ہیں جن کی سٹیم جزیشن کی صلاحیت 2,400 hr/kg ہے۔ یہ بوائلرز فلو گیس کی حرارت کو سٹیم میں تبدیل کرتے ہیں، جو ہسپتال کی مختلف سرگرمیوں بشمول لائڈری اور کچن سروسز میں استعمال ہوتی ہے۔ اس اقدام کے دوران رپورٹنگ پیریڈ میں کاربن ڈائی آکسائیڈ کے تقریباً 192.32 میٹرک ٹن اخراج میں کمی ہوئی۔ یہ دونوں اقدامات شفا انٹرنیشنل ہسپتال کی ماحولیاتی ذمہ داری اور وسائل کے مؤثر استعمال کے عزم کو ظاہر کرتے ہیں۔

ماحولیاتی تحفظ کے اقدامات

شفا انٹرنیشنل ہسپتال نے ایک مضبوط اور حکمت عملی پر مبنی ماحولیاتی تحفظ کا فریم ورک نافذ کیا ہے تاکہ ہیلتھ کیئر کے پائیدار اہداف، قانونی تعمیل اور ماحولیاتی چک کو یقینی بنایا جاسکے۔ اہم اقدامات درج ذیل ہیں:

1۔ ای ایچ ایس اینڈ ایس پالیسی فریم ورک

ماحولیات، صحت، تحفظ اور پائیداری کی نظر ثانی شدہ پالیسی شفا انٹرنیشنل ہسپتال کے پائیدار آپریشنز، قانونی تعمیل، مضبوط انفراسٹرکچر اور ماحولیاتی شعور کے عزم کو ظاہر کرتی ہے۔

2۔ ماحولیاتی پائیداری پروگرام

ماحولیاتی تبدیلی کے تناظر میں شفا انٹرنیشنل ہسپتال نے ایک منظم پروگرام شروع کیا ہے، جو کم کاربن اخراج اور پائیدار ہیلتھ کیئر کے فروغ پر مرکوز ہے۔ یہ پروگرام JCI اور SDG 13 کے اہداف کے مطابق توانائی کی بچت، فضلے میں کمی اور عملے کی فعال شمولیت کو یقینی بناتا ہے۔

3۔ ماحولیاتی خطرات اور موسمیاتی اثرات کا جائزہ

شفا انٹرنیشنل ہسپتال منظم جائزوں کے ذریعے ماحولیاتی خطرات مثلاً سیلاب، ہیٹ ویوز اور فضائی آلودگی کی شناخت کے لیے ترجیحی بنیادوں پر اقدامات کرتا ہے۔ ان کے مدارک کے لیے موافقتی حکمت عملی کو ڈیزاسٹر پریپنرڈز میں اور ایمرجنسی ڈرلز میں شامل کیا گیا ہے تاکہ ہسپتال کی سروسز بلا تعطل جاری رہ سکیں۔

4۔ ماحولیاتی پائیداری منصوبہ

سالانہ منصوبہ گرین ہاؤس گیس کے اخراج کی نگرانی، کاربن میں کمی، پانی اور توانائی کی بچت، اور ویسٹ کے دوبارہ استعمال کے لیے اہداف متعین کرتا ہے۔ اس میں کارکردگی کے اشاریے شامل ہیں اور یہ ایس ڈی جیبر کے مطابق ترتیب دیا گیا ہے، جس سے مسلسل ماحولیاتی جوابدہی کو یقینی بنایا جاتا ہے۔

ماحولیاتی نگرانی اور قانونی تعمیل

شفا انٹرنیشنل ہسپتال قومی معیارات کی تعمیل کو SMART پروگرام کے تحت باقاعدہ نگرانی کے ذریعے یقینی بناتا ہے:

- * سٹیک اخراج : سٹیک اخراج وہ صنعتی گیس ہیں جو چھنی یا اخراج کے کسی اور ذریعے سے فضا میں شامل ہوتی ہیں۔ تمام کمیشن ذرائع کی سبہ ماہی بنیادوں پر مانیٹرنگ کی جاتی ہے
- * پانی کے معیار کی جانچ : پینے کے پانی، ڈسٹیلیٹر کے پانی اور بوتل بند پانی کو متعلقہ معیارات کے مطابق ٹیسٹ کیا جاتا ہے
- * لچو نیلا مانیٹرنگ : کولنگ ٹاورز میں HVAC کی حفاظت کو یقینی بنانے کے لیے نگرانی کی جاتی ہے
- * انڈور ایئر کوالٹی : جراثیم سے پاک ایریاز میں ذرات اور مائیکروبیل لوڈ کی نگرانی کی جاتی ہے

1۔ انٹرنیشنل سسٹین ایبلٹی پلیٹ فارم کی رکنیت

شفا انٹرنیشنل ہسپتال نے انٹرنیشنل ہسپتال فیڈریشن کے جیڈا سسٹین ایبلٹی سینٹر کی "سٹینڈالون ایسوسی ایٹ" ممبر شپ حاصل کی۔ اس سے ماحولیاتی شعور رکھنے والی ہیلتھ کیئر میں اس کا علاقائی قیادت کا کردار مزید مستحکم ہوا۔ یہ سینٹر ہیلتھ کیئر کے اداروں کو ماحول دوست، مساوی اور مضبوط نظام تشکیل دینے کے قابل بناتا ہے۔ اس سے شفا انٹرنیشنل ہسپتال کو جدید ٹولز، علم اور حکمت عملی تک رسائی حاصل ہوتی ہے۔

2۔ کاربن فٹ پرنٹ ٹریکنگ (گرین ہاؤس گیسوں کا اخراج)

شفا انٹرنیشنل ہسپتال کلائنٹ امپیکٹ چیک اپ ٹول کے ذریعے جی ایچ جی اخراج (اسکوپ 1، 2 اور 3) پر نظر رکھتا ہے۔
 اسکوپ 1: ایندھن کے جلنے، ہسپتال کی گاڑیوں اور آن سائٹ ویسٹ مینجمنٹ سے اخراج
 اسکوپ 2: بجلی کے استعمال سے اخراج
 اسکوپ 3: آمدورفت، کاروباری سفر اور بالواسطہ خدمات سے اخراج
 یہ اقدام کاربن کے اخراج کو کم کرنے کی حکمت عملی پر عمل درآمد کے لیے راہنمائی فراہم کرتا ہے۔

3۔ ہسپتال ویسٹ مینجمنٹ

ہسپتال ویسٹ مینجمنٹ رولز 2005 اور ڈبلیو ایچ او کے رہنما اصولوں کے مطابق، شفا انٹرنیشنل ہسپتال نے خطرناک فضلے کے انتظام کا ایک مضبوط اور جدید نظام نافذ کیا ہے۔ یہ نظام عالمی طور پر تسلیم شدہ بہترین پریکٹسز کے مطابق ہے تاکہ ماحولیاتی اثرات کم سے کم ہوں۔ خطرناک فضلہ ہائی ٹیمپرچر ٹرمل آکسیدیشن کے ذریعے تلف کیا جاتا ہے، اور اس کے اثرات کا سامنا بنیادوں پر جائزہ لیا جاتا ہے۔ اس کی راکھ کو مخصوص غیر آباد مقام پر دفن کیا جاتا ہے، جو اس کی تعمیر کے وقت کی انوائز و مینٹل اینڈسوشل سکریننگ رپورٹ کے مطابق ہے۔

4۔ خطرناک مواد پر کنٹرول

پاکستان کی عالمی ماحولیاتی معاہدوں (میناماتا، روٹریڈیم، باسل اور اشاک ہوم کنونشنز) سے وابستگی انسانی صحت اور ماحول کو خطرناک مادوں اور فضلے سے محفوظ رکھنے کے عزم کی عکاس ہے۔ انہی قومی کنونشنز کے مطابق، شفا انٹرنیشنل ہسپتال میں تمام خطرناک مواد کو "جی ایچ ایس" کے مطابق لیبل کیا جاتا ہے اور "ایم ایس ڈی ایس" رہنما اصولوں کے تحت ہینڈل اور ڈسپوز کیا جاتا ہے۔ اسی کے مطابق جامع انوینٹری برقرار رکھی جاتی ہے، اور عملے کو محفوظ استعمال کی باقاعدہ تربیت دی جاتی ہے۔

5۔ ویسٹ میں کمی

شفا انٹرنیشنل ہسپتال لمیٹڈ ویسٹ کو روک تھام، مؤثر علیحدگی اور ری سائیکلنگ کے ذریعے کم کرتا ہے۔ غیر خطرناک مواد کو شروع میں ہی الگ کر کے محفوظ رکھا جاتا ہے اور منظور شدہ وینڈرز کے ذریعے پراسیس کیا جاتا ہے۔ اس سے زمین میں دفن کیے جانے والے فضلے میں نمایاں کمی آتی ہے اور ماحولیاتی اثرات کم ہوتے ہیں۔

6۔ توانائی کی بچت کے اقدامات

پی وی سولر اور ویسٹ ہیٹ ریکوری سسٹمز کے ساتھ، شفا انٹرنیشنل ہسپتال نے توانائی کی کارکردگی بہتر بنانے کے لیے ٹیوب لائٹس کو ایل ای ڈیز سے تبدیل کیا، موٹروں کے سمارٹ کنٹرول کے لیے وی ایف ڈی بزنس کیے اور لفٹ آپریشنز کو مؤثر بنایا۔ ان اقدامات سے توانائی کے استعمال اور اخراج میں نمایاں کمی آئی۔

7۔ پانی کے تحفظ کے اقدامات

پانی کے بہتر انتظام کو فروغ دینے کے لیے شفا انٹرنیشنل ہسپتال نے اس کے استعمال میں کمی اور دوبارہ استعمال کے لیے مؤثر اقدامات کیے ہیں۔ ان میں اسپرینکلر ایلکیشن، لائڈری اور صفائی کے لیے آراور جیکٹس واٹر کا استعمال، ریکیکٹ والیوم میں کمی، اور ہائی سالیٹیٹی ٹریڈ واٹر کو پینے اور غیر پینے کے مقاصد کے لیے استعمال کرنے کی کوششیں شامل ہیں۔

توانائی کا تحفظ

پاکستان میں توانائی کے موجودہ چیلنجز کے پیش نظر، شفا انٹرنیشنل ہسپتال اس کے مؤثر اور ماحول دوست استعمال کو اولین ترجیح دیتا ہے۔ ہسپتال نے توانائی کی بچت اور پائیدار استعمال کے لیے دو بڑے اقدامات کیے ہیں:

ڈائریکٹر رپورٹ

1۔ نئے میڈیکل آئی سی پو (B-3 ونگ) کے ساتھ کیریٹیکل کیئر کی مضبوطی

زچہ و بچہ (Obs & Gynae) کے پرانے ونگ کو جدید ترین 8 بستروں پر مشتمل میڈیکل آئی سی یو میں تبدیل کیا گیا جس میں 3 وارڈ اور 5 پرائیویٹ بیڈز شامل ہیں۔ اس توسیع کے نتیجے میں شدید بیمار مریضوں کو جدید کیریٹیکل کیئر فراہم کرنے کی صلاحیت نمایاں طور پر بڑھ گئی۔

2۔ ون شاپ پلورل کلینک کا آغاز

پلمونالوجی ڈپارٹمنٹ کے تحت ایک ون شاپ پلورل کلینک قائم کیا گیا تاکہ پلورل امراض (پھیپھڑوں اور سینے کی جھلی کی بیماریاں) کی جامع تشخیص اور مؤثر علاج ایک ہی مقام پر فراہم کیا جاسکے۔ اس اقدام سے مریضوں کی سہولت میں اضافہ ہوا اور علاج کے معیار کو بین الاقوامی سطح سے ہم آہنگ کیا گیا۔

3۔ آکولوجی ڈائگنوسٹکس اپ گریڈ-CT-PET-ایچنگ

128-سلٹس CT کے ساتھ جدید CT-PET 40 سسٹم نصب کیا گیا۔ یہ سہولت کینسر کی جلد اور درست تشخیص، علاج کی مانیٹرنگ، اور فالو اپ میں نمایاں مدد فراہم کرے گی۔

4۔ ڈینٹل ایچنگ اور آپریٹری توسیع

پرانے "او پی جی سسٹمز" کی جگہ جدید بی سی ٹی (Cone Beam CT) ٹیکنالوجی نصب کی گئی، جو ڈینٹل اور میکسیلو فیشل پروسیجرز کے لیے اعلیٰ معیار کی 3D ایچنگ فراہم کرتی ہے۔ ساتھ ہی جدید ڈینٹل آپریٹری قائم کی گئی تاکہ علاج کی صلاحیت اور سہولت میں اضافہ ہو۔

5۔ 640-سلٹس سی ٹی سکن کے ساتھ ریڈیالوجی میں بہتری

ہائی اینڈ سی ٹی سکنز متعارف کرایا گیا۔ مریضوں کے لیے ایریا ز اور معاون سسٹم کی تزئین و آرائش بھی کی گئی، جس سے تشخیصی ماحول زیادہ جدید اور مریض دوست ہو گیا۔

6۔ دارالشفاء میں توسیع

چار بستروں پر مشتمل نیا ان پشمنٹ یونٹ شروع کیا گیا تاکہ مین کیمپس کے بوجھ کو کم کیا جاسکے، اور "ای آر" اور "او پی ڈی" مریضوں کی منتقلی کو آسان بنایا جاسکے۔

7۔ ڈراماٹولوجی کلینک اپ گریڈیشن

کلینک کو اس انداز میں از سر نو ترتیب دیا گیا کہ مریضوں کی آمدورفت اور سروس ڈیلیوری میں بہتری آئے۔ ایک علیحدہ ڈاکٹر زروم بھی شامل کیا گیا۔

8۔ یون میر وٹرانسپلانٹ یونٹ میں اضافہ

مریضوں کی ضرورت کو پورا کرنے کے لیے دو نئے بی ایم ٹی ان پشمنٹ رومز شامل کیے گئے، جس سے انتظار کے اوقات کم ہوئے اور معیاری علاج یقینی بنایا گیا۔

9۔ ای این ٹی کلینک کی توسیع۔ دوسری آراے روم

ایک اور وی آراے (Visual Reinforcement Audiometry) روم تعمیر کیا گیا تاکہ ڈیالوجیکل ٹیسٹنگ کی صلاحیت میں اضافہ کیا جاسکے اور بچوں و بالغوں، دونوں کو بہتر سہولیات فراہم ہو سکیں۔

10۔ ڈے کیئر انسٹیٹیوٹ یا کیئر، بہتری

ڈے کیئر انسٹیٹیوٹ یا یونٹ کو جدید بنایا گیا، جس میں ای سی جی، فلیکٹو می اور انسٹیٹیوٹ یا جانچ کے لیے علیحدہ کمرے شامل کیے گئے۔ اس سے پروسیجر سے پہلے مریضوں کی تیاری زیادہ مؤثر ہوئی، اور یہاں مریض کا تجربہ بہتر بنایا گیا۔

کمپنی کے کاروبار کا ماحولیاتی اثر

ایک ذمہ دار سہیتہ کیئر فراہم کنندہ کے طور پر شفا انٹرنیشنل ہسپتال لمیٹڈ اپنے کردار کو برقرار رکھے ہوئے ہے، اور ماحولیاتی تحفظ، وسائل کے مؤثر استعمال اور پائیدار ترقی پر بھرپور توجہ دیتا ہے۔ ہسپتال نے اپنے ماحولیاتی اثرات کو کم کرنے اور عالمی پائیداری کے معیارات کے مطابق کام کرنے کے لیے قابل پیمائش اقدامات نافذ کیے ہیں۔ ان کی تفصیل مندرجہ ذیل ہے:

آپریشنل خطرات

طبی غلطیاں، آلات کی خرابی اور سپلائی چین میں رکاوٹیں مریضوں کی حفاظت اور ادارے کی استعداد کار کو متاثر کر سکتی ہیں۔ شفا انٹرنیشنل ہسپتال ان خطرات کو جامع کلینیکل پروٹوکولز، آلات کی بروقت اور باقاعدہ دیکھ بھال، اور متبادل سپلائی چین منصوبہ بندی کے ذریعے کم کرتا ہے۔ یہ حکمت عملی سٹریٹجک سورسنگ اور سپلائرز کے ساتھ مضبوط تعلقات سے مزید مؤثر بنائی جاتی ہے۔

مالی خطرات

اخراجات میں اضافہ، انشورنس کلیمز میں تاخیر، مہنگائی اور سرمایہ کی محدود دستیابی ادارے پر مالی دباؤ ڈال سکتی ہے۔ شفا انٹرنیشنل ہسپتال ان خطرات کو مؤثر لاگت کنٹرول، کارکردگی میں بہتری، جامع مالی منصوبہ بندی اور انشورنس کمپنیوں کے ساتھ سازگار مذاکرات کے ذریعے کم کرتا ہے، تاکہ کیش فلو کو مستحکم رکھا جاسکے۔

مارکیٹ اور مسابقت

ہیلتھ کیئر کے مسابقتی ماحول میں کامیابی کے لیے جدت اور یکجہ ضروری ہیں۔ شفا انٹرنیشنل ہسپتال اپنی پوزیشن مستحکم کرنے اور مریضوں کے اطمینان کو بڑھانے کے لیے تحقیق، مارکیٹ تجزیے اور سروسز کے معیار میں مسلسل بہتری پر سرمایہ کاری کرتا ہے۔

سائبر سیکیورٹی خطرات

ڈیجیٹل سسٹم پر بڑھتے انحصار کے باعث ہسپتال سائبر خطرات کی زد میں آسکتا ہے۔ شفا انٹرنیشنل ہسپتال ڈیٹا کے تحفظ کو یقینی بنانے کے لیے جدید فائر وائلز، سخت ایکسیس کنٹرولز، ڈیٹا انکریپشن، مسلسل نگرانی اور تربیت یافتہ رسپانس ٹیم پر انحصار کرتا ہے۔

وبائی امراض کے خطرات

کووڈ-19 جیسے وبائی امراض اضافی اخراجات اور آپریشنز میں رکاوٹ کا سبب بن سکتے ہیں۔ شفا انٹرنیشنل ہسپتال نے اس چیلنج سے نمٹنے کے لیے تیاری کے منصوبے، پی پی ای ٹاک پائلز اور ٹیلی میڈیسن سروسز قائم کر رکھی ہیں تاکہ بحالی صورت حال کے دوران علاج کے تسلسل کو یقینی بنایا جاسکے۔

ماحولیاتی اور جغرافیائی خطرات

قدرتی آفات یا دہائی ہسپتال کے انفراسٹرکچر اور سپلائی چین کو نقصان پہنچا سکتی ہیں۔ شفا انٹرنیشنل ہسپتال ان خطرات کا تجزیہ کرتا ہے، ڈیزاسٹر رزلٹ منعقد کرتا ہے، بزنس کنٹینیوٹی پروٹوکولز برقرار رکھتا ہے، اہم سسٹمز کو مضبوط کرتا ہے اور متعلقہ حکام کے ساتھ قریبی رابطے میں رہ کر مؤثر رسپانس دیتا ہے۔

کمپنی کا ریسک مینجمنٹ فریم ورک اور اندرونی کنٹرولز

شفا انٹرنیشنل ہسپتال کے پاس ایک مربوط ریسک مینجمنٹ فریم ورک موجود ہے جو آپریشنز، مالیات اور ساکھ پر اثر انداز ہونے والے خطرات کی نشاندہی، ان کی جانچ اور ان میں ہر ممکن حد تک کمی کو یقینی بناتا ہے۔ اس فریم ورک کو اندرونی کنٹرول سسٹم سپورٹ کرتا ہے، جس کے تحت کارکردگی، تعمیل اور درست مالی رپورٹنگ کو یقینی بنایا جاتا ہے۔ ان کنٹرولز میں واضح پالیسیاں، منظوری کے نظام، اندرونی آڈٹ اور سسٹم مانیٹرنگ شامل ہیں۔ شفا انٹرنیشنل ہسپتال ان اقدامات پر مسلسل نظر ثانی کرتا رہتا ہے تاکہ اثاثوں کے تحفظ، ادارے کی یکجہ اور پائیدار ترقی کو مزید تقویت دی جاسکے۔

سال کے دوران توسیعی سرگرمیاں

زیر جائزہ سال کے دوران شفا انٹرنیشنل ہسپتالوں میں کلینیکل انفراسٹرکچر اور تشخیصی سہولیات کو بہتر بنانے کے لیے بڑے پیمانے پر ترقیاتی منصوبے شروع کیے۔ ان توسیعی اقدامات کا مقصد مریضوں کی نگہداشت کو بلند معیار پر لانا، آپریشنل کارکردگی کو بہتر بنانا اور سہولیات کو بین الاقوامی معیار سے ہم آہنگ کرنا ہے۔ ان کی تفصیل درج ذیل ہے:

ڈائریکٹر رپورٹ

ڈیجیٹل تبدیلی اور استعداد کار

آئندہ سال کے کلیدی اقدامات میں محفوظ ڈیجیٹل ادائیگی کے ذرائع متعارف کرانا شامل ہے۔ ان میں موبائل والٹس، آن لائن بینک ٹرانسفر اور پی او ایس بیسڈ سلوشنز نمایاں ہیں۔ یہ اقدامات نقد لین دین میں کمی، انتظار کے اوقات گھٹانے اور مریضوں کے لواحقین کے لیے سہولت میں اضافہ یقینی بنائیں گے۔ مزید برآں، آئی ٹی ڈیپارٹمنٹ کے اشتراک سے ویب بیسڈ پورٹلز متعارف کرائے جائیں گے، جن کے ذریعے ای انوائسنگ، انشورنس کلیم سمیشن اور ری ایمر سمٹ ٹریکنگ ممکن ہوگی۔ اس سے ادارے کے کلائنٹس اور انشورنس پارٹنرز کے ساتھ شفافیت اور بروقت رسپانس کو مزید تقویت حاصل ہوگی۔

مالی اور سروس کی بہتری

مسابقت اور مالیاتی پائیداری برقرار رکھنے کے لیے مارکیٹ کے حالات اور استعمال کے رجحانات کے مطابق پینل ریٹ ریویو جاری رہیں۔ اس کے ساتھ ساتھ، پراسیس آٹومیشن اور لاگت میں کمی اہم ترجیحات رہیں گی، جن سے وسائل کے بہتر استعمال اور ڈیپارٹمنٹس کی کارکردگی میں اضافہ ہوگا۔

مریضوں کی کیئر اور کلینیکل توسیع

گزشتہ پیش رفت کی بنیاد پر آئندہ منصوبوں میں خصوصی سروسز تک رسائی کو مزید بڑھایا جائے گا۔ شام اور اختتام ہفتہ پر کونسلٹنٹس کی دستیابی کو یقینی بنایا جائے گا۔ مریضوں کی سہولت کے لیے ایڈمیشن اور ڈسچارج کے عمل کو مزید موثر بنایا جائے گا۔ اس کے ساتھ ساتھ بستروں میں اضافے اور آؤٹ پیسٹ سپیسز کی نئی ترتیب سے مریضوں کی آمدورفت اور سروسز کے معیار کو بہتر بنایا جائے گا۔

اسٹریٹجک ترقی اور آؤٹ ریچ

ہسپتال کے دائرہ اثر میں آؤٹ ریچ اوپن ڈی کلینکس کو بڑے شہروں تک توسیع دی جائے گی تاکہ مریض اپنے گھروں کے قریب ماہرین کی مشاورت سے فائدہ اٹھاسکیں اور ہسپتال کے لیے ریفرنز میں اضافہ ہو۔ اس کے ساتھ ساتھ eShifa، جو ہمارا ہوم ہیلتھ اور ڈیجیٹل کیئر پارٹنر ہے، ٹیلی میڈیسن اور ہوم سروسز کے ذریعے نگہداشت تک رسائی اور تسلسل کو مزید موثر بناتا رہے گا۔

ایکسی لینس کے ساتھ وابستگی

حالیہ برسوں کی پیش رفت کے تسلسل میں ہسپتال اپنے عملے، جدید ٹیکنالوجی اور معیاری اقدامات میں مسلسل سرمایہ کاری کے لیے پرعزم ہے۔ یہ حکمت عملی نہ صرف آپریشنل کارکردگی اور مریضوں کے تجربے کو بہتر بنائے گی بلکہ پائیدار ترقی کو بھی یقینی بنائے گی۔ اس طرح ہسپتال خطے میں جدید طبی سہولیات فراہم کرنے والے ایک معتبر ادارے کے طور پر اپنا مقام مزید مضبوط کرے گا۔

اہم خطرات اور غیر یقینی صورتحال کی تفصیل

شفا انٹرنیشنل ہسپتال تیزی سے تغیر پذیر ہیلتھ کیئر ماحول میں اپنا کام جاری رکھے ہوئے ہے، جہاں اندرونی اور بیرونی خطرات کارکردگی اور پائیداری کو متاثر کر سکتے ہیں۔ اہم خطرات اور ان سے بچاؤ کے لیے اقدامات درج ذیل ہیں:

ریگولیٹری ضروریات کی تعمیل

ہیلتھ کیئر کا شعبہ سخت ریگولیٹری مانیٹرنگ کے تحت ہے۔ قوانین پر عدم عمل درآمد کی صورت میں جرمانے، مالی نقصانات یا ادارے کی ساکھ کو نقصان پہنچ سکتا ہے۔ اس تناظر میں، شفا انٹرنیشنل ہسپتال نے خصوصی کمپلائنس ٹیم قائم کر رکھی ہے۔ یہ ٹیم باقاعدگی سے آڈٹ کرتی ہے اور بدلتے ہوئے قوانین کے مطابق پالیسیوں اور پروسیجرز کو اپ ڈیٹ کرتی ہے تاکہ قوانین پر ان کی روح کے مطابق عمل درآمد کو یقینی بنایا جاسکے۔

قومی خزانے میں کنٹری بیوشن

موجودہ سال کے دوران کمپنی کا قومی خزانے میں کنٹری بیوشن درج ذیل ہے:

تفصیل	(000' روپوں میں)
براہ راست ٹیکسز	1,555,745
بالواسطہ ٹیکسز	1,221,022
سپلائرز، ملازمین وغیرہ سے ٹیکس کٹوتی	1,794,720
ٹوٹل	4,571,487

اہم سرگرمیاں، ترقی اور کارکردگی

زیر جائزہ سال کے دوران، ایڈمیشن اینڈ ڈسچارج (A&D) اور کارپوریٹ بلنگ ڈیپارٹمنٹ (CBD) نے ہسپتال میں مریضوں کی آمدورفت کے عمل اور سروسز کی بروقت فراہمی کو یقینی بنانے میں کلیدی کردار ادا کیا۔ گزشتہ سالوں کی پیش رفت کو بنیاد بناتے ہوئے، دونوں ڈیپارٹمنٹس نے پراسیس کو مزید موثر بنانے، رکاوٹوں کو کم کرنے اور مریضوں اور ان کے لواحقین کے لیے علاج کے دوران سہولت فراہم کرنے پر توجہ مرکوز رکھی۔

گزشتہ اقدامات کے تسلسل میں، مریضوں کے لیے سروسز میں ہم آہنگی اور درستی کو بہتر بنانے کے لیے ٹیکنالوجی اور پراسیس میں جدت پر خاص توجہ دی گئی۔ ڈیجیٹل ٹولز کے تدریجی استعمال، ورک فلو کی آٹومیشن، اور آسان کمیونٹی کیشن چینلز نے آپریشنل استعداد کار میں اضافہ کیا اور سروسز کو مریض کے نقطہ نظر سے ہم آہنگ رکھنے میں کردار ادا کیا۔

گزشتہ سال کی طرح، اس سال بھی ادارے کی کلائنٹ سروسز کو بہتر بنانے پر توجہ دی گئی۔ سی بی ڈی نے اکاؤنٹس کی شفاف اور بروقت کلیئرنس کو یقینی بنایا، اور کارپوریٹ پارٹنرز کے ساتھ تعلقات کو مضبوط کیا تاکہ مالی لین دین آسان اور کلائنٹ کا شفا انٹرنیشنل کے ساتھ تجربہ بہتر ہو۔ ان اقدامات نے نہ صرف ادارے پر اعتماد کو بڑھایا بلکہ ہسپتال کی ساکھ کو ایک معتبر ہیلتھ کیئر پارٹنر کے طور پر مستحکم کیا۔

مستقبل کی حکمت عملی کے تحت یہ ڈیپارٹمنٹس ہسپتال کے وسیع تر تبدیلی کے اہداف سے ہم آہنگ ہو رہے ہیں۔ آئندہ سال جدید ٹیکنالوجی پلیٹ فارمز کے استعمال، ایس او پیز کی مزید بہتری اور عملے کی تربیت پر خصوصی توجہ دی جائے گی۔ اس حکمت عملی کے نتیجے میں زیادہ درستی کے ساتھ، کم وقت میں اور بہتر سروسز کی فراہمی ممکن ہو سکے گی۔ اس سے مریض، ان کے لواحقین اور کارپوریٹ کلائنٹس، سب کو براہ راست فائدہ پہنچے گا۔

بحیثیت مجموعی، جائزہ سال کی کارکردگی علاج میں تسلسل، اعلیٰ آپریشنل کارکردگی اور مریضوں کے اطمینان کو یقینی بنانے کے لیے ہسپتال کے غیر متزلزل عزم کی عکاس ہے۔ گزشتہ کامیابیوں کی بنیاد پر آگے بڑھنے اور جدت کے مسلسل امتزاج نے ادارے کی آپریشنل مضبوطی کو برقرار رکھنے کے ساتھ ساتھ مریضوں کے اعتماد کو مزید مستحکم بنانے میں بھی بنیادی کردار ادا کیا ہے۔

اگلے مالی سال کے لیے سٹریٹجک منصوبے

مستقبل میں ہسپتال اپنی توجہ مریضوں، ان کے لواحقین اور کلائنٹس کے تجربے کو مزید بہتر بنانے کے لیے ٹیکنالوجی اور پراسیس میں بہتری پر مرکوز رکھے گا۔ ساتھ ہی، گزشتہ سالوں میں متعارف کرائے گئے اقدامات کو مزید موثر بنانے کا عمل بھی جاری رہے گا۔

ڈائریکٹر رپورٹ

آپ کی کمپنی کے ڈائریکٹر 30 جون 2025 کو ختم ہونے والے مالی سال کے لیے کمپنی کے آڈٹ شدہ مالیاتی گوشواروں کے ساتھ سالانہ رپورٹ پیش کرتے ہوئے خوشی محسوس کر رہے ہیں۔

مالیاتی کارکردگی

مختصر مالیاتی تجزیہ پیش خدمت ہے:

30 جون کو ختم ہونے والے سال کے مالیاتی نتائج (روپے '000 میں)			
تبدیلی (فیصد)	2024	2025	کاروباری کارکردگی کے نتائج
18.7	23,563,840	27,967,661	خالص آمدن
111.9	190,123	402,822	دیگر آمدن
13.3	(20,944,954)	(23,737,514)	آپریٹنگ لاگت
83.3	2,256,177	4,134,716	منافع قبل از ٹیکس
71.0	1,362,074	2,328,980	رواں سال کا منافع
71.0	21.55	36.84	آمدن فی شیئر (روپوں میں)

زیر جائزہ سال کے دوران کمپنی نے پائیدار اور مستحکم کارکردگی کا مظاہرہ کیا، جو اس کی آپریٹنگ پیک اور ڈسپلن پرمیٹریٹجی کے مؤثر نفاذ کی عکاسی کرتی ہے۔ اس سال آمدنی میں 18.7 فیصد اضافہ ریکارڈ کیا گیا جبکہ خالص منافع 71 فیصد بڑھ گیا۔ اس کے نتیجے میں فی شیئر آمدنی 36.84 روپے رہی، جو پچھلے سال کے 21.55 روپے کے مقابلے میں نمایاں اضافہ ہے۔

منافع میں اس غیر معمولی اضافہ کی بنیاد مسلسل ریونیو میں توسیع، اخراجات پر مؤثر کنٹرول اور مختلط مالیاتی نگرانی تھی۔ آمدنی کے مقابلے میں آپریٹنگ اخراجات کی شرح معتدل رہی، جس سے بہتر آپریٹنگ لیوریج کا اظہار ہوا۔ مزید برآں مالیاتی اخراجات میں 19.8 فیصد کمی واقع ہوئی، جو بنیادی طور پر مالی ذمہ داریوں کی بروقت ادائیگی کے نتیجے میں ممکن ہوئی۔ دیگر آمدن میں بھی قابل ذکر اضافہ ہوا، جس نے مجموعی مالیاتی کارکردگی پر مثبت اثر ڈالا۔

یہ شاندار کارکردگی کمپنی کی مضبوط کارپوریٹ گورننس، آپریٹنگ ڈسپلن اور سٹریٹجک اہداف کے کامیاب نفاذ کا مظہر ہے۔ صحت مند لیکویڈیٹی اور مستحکم کیپٹل اسٹرکچر کی بدولت کمپنی ترقی کے سفر کو جاری رکھنے اور اپنے شیئر ہولڈرز کے لیے پائیدار طویل مدتی قدر پیدا کرنے کے لیے پوری طرح تیار ہے۔

شیئر ہولڈرز کو منافع کی تقسیم

بورڈ آف ڈائریکٹر نے 30 جون 2025 کو اختتام پذیر ہونے والے مالی سال کے لیے فی شیئر پانچ (5) روپے (50 فیصد) کے حتمی نقد ڈیویڈنڈ کی سفارش کی ہے۔



NOTICE OF THE 39TH ANNUAL GENERAL MEETING

Notice is hereby given that the 39th Annual General Meeting (AGM) of the members of Shifa International Hospitals Limited (the "Company") will be held at the Company's registered office (C-0 Auditorium) situated at Sector H-8/4, Islamabad, which may also be attended through video-link (Zoom Application) on Saturday, October 25, 2025 at 1100 hours to transact the following business:

Ordinary Business

1. To confirm the minutes of the Extraordinary General Meeting of the Company held on June 05, 2025.
2. To receive, consider and adopt the Audited Financial Statements (consolidated and unconsolidated) of the Company for the year ended June 30, 2025 together with the Directors' and Auditors' Report thereon.
3. To consider, approve and authorise the payment of final cash dividend of 50% i.e. Rs. 5 per share of Rs. 10/- each, as recommended by the Board of Directors.
4. To appoint auditors for the year ending June 30, 2026 and to fix their remuneration.

ISLAMABAD
October 02, 2025

By Order of the Board



MUHAMMAD NAEEM
Company Secretary

Notes

i) Participation in the Annual General Meeting (AGM) through video link:

In order to attend the AGM through electronic facility, shareholders are requested to get themselves registered by providing the requisite details at their earliest but not later than 48 hours before the time of the AGM (i.e. by 1100 hours on October 23, 2025) through e-mail to be sent at muhammad.naeem@shifa.com.pk

Shareholders are advised to provide the following particulars, along with the scanned copy of their CNIC and that of their proxies, if so appointed. Moreover, in the case of a corporate member, the scanned copy of the resolution of the Board of Directors/Power of Attorney with a specimen signature of the nominee must also be provided.

NOTICE OF THE 39TH ANNUAL GENERAL MEETING

Name of Shareholder*	CNIC No.	Folio No./ CDC Account No.	Mobile No.**	Email Address**

*Where applicable please also give the above particulars of the proxy-holder or nominee of the shareholder

**Shareholders are requested to provide their active mobile number and email address to ensure timely communication.

Members who are registered on or before October 23, 2025, after the necessary verification, will be provided a Zoom video-link by the Company via return email. The login facility will be opened on the date of AGM from 1055 hours till the end of the meeting.

ii) Closure of Share Transfer Books:

The share transfer books of the Company will remain closed from October 17, 2025 to October 25, 2025 (both days inclusive). No transfer will be accepted for registration during this period. Transfers received in order at the share registrar's office of the Company i.e. M/s Corplink (Pvt.) Limited, Wings Arcade, 1-K, Commercial, Model Town, Lahore, by the close of business on October 16, 2025 will be considered as being in time for the purpose to attend and vote at the meeting.

iii) Appointment of Proxy:

A member entitled to attend and vote at this meeting is entitled to appoint another member as his/ her proxy to attend and vote for him/her. Proxies in order to be effective must be received at the registered office of the Company at Sector H-8/4, Islamabad, not less than 48 hours before the time of holding the meeting. Proxy form is attached with the notice.

CDC Account holders will further have to follow the under mentioned guidelines as laid down in Circular 1 dated January 26, 2000 issued by the Securities and Exchange Commission of Pakistan.

Guidelines for Central Depository Company of Pakistan ('CDC') Investor Account Holders

For appointing proxies

- In case of individuals, the account holders or sub account holders whose registration details are uploaded as per regulations, shall submit the proxy form as per the above requirements. The proxy form shall be witnessed by two persons whose names, addresses and CNIC numbers shall be mentioned on the proxy form. Copies of CNIC or the passport of the beneficial owners and the proxy shall be furnished with the proxy form.
- In case of corporate entities, the Board of Directors' resolution/ power of attorney with specimen signature of the person nominated to represent and vote on behalf of the corporate entity, shall be submitted (unless it has not been provided earlier) along with proxy form to the Company.

iv) Payment of dividend through bank account of the shareholder:

Pursuant to the requirement of Section 242 of the Companies Act, 2017, shareholders are MANDATORILY required to provide their International Bank Account Number (IBAN) to receive their cash dividend directly in their bank accounts instead of dividend warrants. In this regard and in pursuance of the directives of the SECP vide Circular No. 18 of 2017 dated August 01, 2017, shareholders are requested to submit their written request (if not already provided) to the Company's registered address, giving particulars of

their bank account. In the absence of shareholder's valid bank account details by October 16, 2025, the Company will be constrained to withhold dividend of such members.

CDC account holders are requested to submit their mandate instruction to the relevant member stock exchange or to CDC if maintaining CDC investor account.

v) Submission of computerized national identity card (CNIC) /National Tax Number (NTN) for payment of Final Cash Dividend:

Pursuant to the directive of the Securities & Exchange Commission of Pakistan, CNIC numbers of members are mandatorily required for the payment of dividend. Members are, therefore, requested to submit a copy of their CNIC and/or NTN (if not already provided) to the Company to its registered address/ Share Registrar.

Shareholders maintaining their shareholdings under Central Depository System (CDS) are requested to submit the above information directly to relevant Participant/CDC Investor Account Service.

vi) Confirmation of "Filer" Status for Income Tax Withholding on Cash Dividend:

For cash dividend, the rates of deduction of income tax, under section 150 of the Income Tax Ordinance, 2001 are as follows:

a.	Rate of tax deduction for filer of income tax returns	15%
b.	Rate of tax deduction for non-filer of income tax returns	30%

The FBR vide its clarification letter No. I (54) Exp/2014-132872-R of 25 September, 2014 has clarified that holders of shares held in joint names or joint accounts will be treated individually as filers or non-filers and tax will be deducted according to the proportionate holding of each shareholder. Joint shareholders should intimate the proportion of their respective joint holding to the share registrar latest by October 16, 2025, in the following form:

CDC Account Number	Folio No.	Total Shares	Principle Shareholder		Joint Shareholder	
			Name & CNIC	Shareholding Proportion	Name & CNIC	Shareholding Proportion

If no notification is received, each joint holder shall be assumed to have an equal number of shares.

The CNIC number / NTN detail is now mandatory and is required for checking the tax status as per the Active Taxpayers List (ATL) issued by the Federal Board of Revenue (FBR) from time to time.

vii) Exemption from deduction of Income Tax / Zakat:

Members seeking exemption from deduction of income tax or are eligible for deduction at a reduced rate are requested to submit a valid tax withholding exemption certificate or necessary documentary evidence for this purpose. Members desiring non-deduction of zakat are also requested to submit a valid declaration for non-deduction of zakat.

CDC account holders are requested to submit their declaration for non-deduction of zakat to the relevant member stock exchange or to CDC if maintaining CDC investor account.

NOTICE OF THE 39TH ANNUAL GENERAL MEETING

viii) Unclaimed Dividend/ shares U/s 244 of the Companies Act, 2017:


As per the provisions of Section 244 of the Companies Act, 2017, any shares issued or dividend declared by the Company which have remained unclaimed/unpaid for a period of three years from the date on which it was due and payable, are required to be deposited with the SECP for the credit of Federal Government after issuance of notices to the shareholders to file their claim. Shareholders are requested to ensure that their claims for unclaimed dividend and shares are lodged promptly. In case no claim is lodged, the Company shall proceed to deposit the unclaimed/unpaid amount and shares with the Federal Government pursuant to the provision under Section 244(2) of the Companies Act, 2017 as and when notified by the SECP.

ix) Transmission of Audited Financial Statements/Notices:

Members are hereby informed that Securities and Exchange Commission of Pakistan (SECP) vide SRO 389(I)/2023 dated March 21, 2023 has allowed Companies for transmission of the annual balance sheet, profit and loss account, auditor's report and directors' report, etc. (annual audited financial statements or the annual report) to the members/ shareholders through QR-enabled code and web-link, instead of transmitting the same through CD/ DVD/USB, the same was approved by the shareholders in Company's Annual General Meeting held on October 27, 2023.

The Annual Audited Financial Statements/Annual Report and the Notice of Annual General Meeting for the year ended June 30, 2025, have been placed on the Company's Website, which can be accessed/ downloaded from the following link and QR code:

Website: <https://www.shifa.com.pk/annual-report/>



The Annual Audited Financial Statements / Annual Report along with the Notice of Annual General Meeting are being emailed to the members having opted to receive such communication in electronic format. Other members who wish to receive the Annual Report 2025 in electronic form are requested to fill the standard request form (available on the Company's website <https://www.shifa.com.pk/wp-content/uploads/2019/12/Financial-Statements-Request-Form.pdf>) and send it to the Company's registered address.

For printed copy of the Annual Report of the Company any member can send request on a standard request form which is available at Company's website (<https://www.shifa.com.pk/wp-content/uploads/2014/05/Request-Form-2018.pdf>) duly signed along with copy of CNIC/PoA to the Company's Share Registrar.

Members are also requested to intimate any change in their registered email addresses in a timely manner, to ensure effective communication by the Company.

x) Change of Address:

Members are requested to notify any change in their registered addresses immediately.

xi) Video Conference Facility

In accordance with Section 132(2) of the Companies Act, 2017 if the Company receives consent from members holding in aggregate 10% or more shareholding residing in a geographical location, other than the registered office of the Company, to participate in the meeting through video conference at least 7 days prior to the date of AGM, the Company will arrange video conference facility in that city subject to availability of such facility in that city.

To avail this facility please submit such request to the Company Secretary at:

Shifa International Hospitals Limited, Sector H-8/4, Islamabad

xii) Statutory Code of Conduct at AGM

Section 215 of the Companies Act, 2017 and Regulation 55 of the Companies Regulations 2024, state the Code of Conduct of Shareholders, as follows:

Shareholders are not permitted to exert influence or approach the management directly for decisions which may lead to creation of hurdles in the smooth functioning of management. The law states that Shareholders shall not bring material that may cause threat to participants or premises where the AGM is being held, confine themselves to the agenda items covered in the notice of AGM and shall not conduct themselves in a manner to disclose any political affiliation or offend religious susceptibility of other members. Additionally, the Company is not permitted to distribute gifts in any form to its shareholders in its meetings as per Section 185 of Companies Act, 2017.

xiii) Deposit of Physical Shares into Central Depository

Pursuant to Section 72 of the Companies Act, 2017 and directive issued by SECP vide its letter No. CSD/ED/Misc./2016-639-640 dated March 26, 2021, every existing listed company shall be required to replace its physical shares with book-entry form in a manner as may be specified and from the date notified by the SECP, within a period not exceeding four years from the commencement of the Act i.e. May 30, 2017.

In view of the aforesaid requirement, the shareholders having physical shares are requested to open their CDC sub-account with any of the brokers or investors account directly with CDC to convert their physical shares into book entry form as soon as possible.

xiv) Prohibition on grant of gifts to Shareholders

The Securities and Exchange Commission of Pakistan (the "SECP"), through its Circular 2 of 2018, dated February 9, 2018 read with SRO 452(I) of 2025, has strictly prohibited companies from providing gifts or incentives, in lieu of gifts (tokens / coupons / lunches / takeaway packages) in any form or manner, to shareholders at or in connection with general meetings. Under Section 185 of the Act, any violation of this directive is considered an offense, and companies failing to comply may face penalties.

For any query/information, the shareholders may contact the Company and/or the Share Registrar at the following addresses/contact numbers:

Company's Registered Office

M/s Shifa International Hospitals Limited

Pitras Bukhari Road, Sector H-8/4,
Islamabad.

Phone # 051-8464227

Share Registrar's Office

M/s Corplink (Pvt.) Limited

Wings Arcade, 1-K, Commercial,
Model Town, Lahore.

Phone # 0423-5839182

STATEMENT OF COMPLIANCE WITH LISTED COMPANIES

(CODE OF CORPORATE GOVERNANCE) REGULATIONS, 2019

The Company has complied with the requirements of the Regulations in the following manner:

1. The total number of directors are Eleven (11) (including CEO) as per the following:
 - a. Male: Ten (10)
 - b. Female: One (01)
2. The composition of the Board is as follows:

Category	Names
Independent Directors*	Dr. Mohammad Naseem Ansari Mr. Shah Naveed Saeed Dr. Mohammad Salim Khan
Non-Executive Directors	Dr. Habib Ur Rahman (Chairman) Dr. Manzoor H. Qazi Mr. Qasim Farooq Ahmad Dr. Samea Kauser Ahmad (Female Director) Syed Ilyas Ahmed Dr. Ioan Philippe Cleaton-Jones
Executive Directors	Dr. Zeeshan Bin Ishtiaque (Chief Executive Officer) Mr. Taimoor Shah (Chief Operating Officer)

* The total number of elected directors of the Company are ten (10) and one third of the same is equal to 3.33. As decimal digit is less than 0.50, therefore, the figure 3.33 has been rounded off to 3.

3. The directors have confirmed that none of them is serving as a director on more than seven listed companies, including this Company.
4. The Company has prepared a Code of Conduct and has ensured that appropriate steps have been taken to disseminate it throughout the Company along with its supporting policies and procedures.
5. The Board has developed a vision/mission statement, overall corporate strategy and significant policies of the Company. The Board has ensured that complete record of particulars of the significant policies along with their date of approval or updating is maintained by the Company.
6. All the powers of the Board have been duly exercised and decisions on relevant matters have been taken by the Board/shareholders as empowered by the relevant provisions of the Act and these Regulations.
7. The meetings of the Board were presided over by the Chairman. The Board has complied with the requirements of the Act and the Regulations with respect to frequency, recording and circulating minutes of meeting of the Board.
8. The Board has a formal policy and transparent procedures for remuneration of directors in accordance with the Act and these Regulations.

9. As at June 30, 2025 Nine of the existing Board members (including the CEO) have completed the Director's Training Program (DTP). Out of the two remaining Directors, one has completed the Executive Education Program in Corporate Governance from the Columbia Business School at Columbia University, New York, USA. The other Director, as per the criteria set under sub regulation 19 (2) of the Code, has a minimum education of 14 years and has remained a director on the Board of the Company for over 15 years, thereby being exempt from the DTP. The Company also arranged DTP for a male and female executive, during the year.
10. The Board had approved appointment of Chief Financial Officer, Company Secretary and Head of Internal Audit, as and when made, including their remuneration and terms and conditions of employment and complied with relevant requirements of the Regulations.
11. Chief Financial Officer and Chief Executive Officer duly endorsed the financial statements before approval of the Board.
12. The Board has formed committees comprising of members given below:

a) Audit Committee

Shah Naveed Saeed

Chairman

Dr. Manzoor H. Qazi

Member

Dr. Samea Kauser Ahmad

Member

Syed Ilyas Ahmed

Member

b) HR & Remuneration Committee

Dr. Mohammad Naseem Ansari

Chairman

Dr. Habib Ur Rahman

Member

Dr. Zeeshan Bin Ishtiaque

Member

Dr. Manzoor H. Qazi

Member

Syed Ilyas Ahmed

Member

Mr. Qasim Farooq Ahmad

Member

c) Corporate Governance & Nominations Committee

Dr. Manzoor H. Qazi

Chairman

Dr. Zeeshan Bin Ishtiaque

Member

Dr. Samea Kauser Ahmad

Member

Dr. Ioan P. Cleaton-Jones

Member

d) Risk Management Committee

Mr. Qasim Farooq Ahmad

Chairman

Dr. Mohammad Naseem Ansari

Member

Mr. Taimoor Shah

Member

Dr. Mohammad Salim Khan

Member

STATEMENT OF COMPLIANCE WITH LISTED COMPANIES

(CODE OF CORPORATE GOVERNANCE) REGULATIONS, 2019

13. The terms of reference of the aforesaid committees have been formed, documented and advised to the committees for compliance.
14. The yearly frequency of meetings of the committees were as per following:
 - a. Audit Committee: 5
 - b. Human Resource and Remuneration Committee: 1
 - c. Corporate Governance & Nominations Committee: None
 - d. Risk Management Committee: 1
15. The Board has set up an effective internal audit function.
16. The statutory auditors of the Company have confirmed that they have been given a satisfactory rating under the Quality Control Review program of the Institute of Chartered Accountants of Pakistan and are registered with Audit Oversight Board of Pakistan, that they and all their partners are in compliance with International Federation of Accountants (IFAC) guidelines on code of ethics as adopted by the Institute of Chartered Accountants of Pakistan and that they and the partners of the firm involved in the audit are not a close relative (spouse, parent, dependent and non-dependent children) of the Chief Executive Officer, Chief Financial Officer, Head of Internal Audit, Company Secretary or Director of the Company.
17. The statutory auditors or the persons associated with them have not been appointed to provide other services except in accordance with the Act, these Regulations or any other regulatory requirement and the auditors have confirmed that they have observed IFAC guidelines in this regard.
18. We confirm that all requirements of regulations 3, 6, 7, 8, 27, 32, 33 and 36 of the Regulations have been complied with.



DR. ZEESHAN BIN ISHTIAQUE
Chief Executive Officer

ISLAMABAD
September 06, 2025



DR. MANZOOR H. QAZI
Director




SIX YEARS AT A GLANCE

		2025	2024	2023	2022	2021	2020
PROFITABILITY							
Operating profit margin	%	16.0	11.4	12.2	12.2	9.3	10.5
Net profit margin	%	8.3	5.8	6.0	7.2	4.9	4.2
Return on equity	%	17.8	12.0	11.5	12.8	8.6	7.5
Return on assets	%	20.9	14.7	13.0	11.5	7.9	8.4
Asset turnover	Times	1.3	1.3	1.1	0.9	0.9	0.8
INVESTMENT							
Market value per share (year end)	Rs.	475.13	146.61	122.49	179.14	219.15	233.36
Breakup value per share	Rs.	226.32	188.50	171.16	152.66	136.97	125.33
Earnings per share	Rs.	36.84	21.55	18.69	18.39	11.07	8.18
Dividend - Cash (per share)	Rs.	5.00	4.00	1.50	3.00	-	-
Dividend - Bonus Shares	%	-	-	-	-	2.00	-
Dividend yield / effective dividend rate	%	1.1	2.7	1.2	1.7	-	-
Market price to breakup value	Times	2.1	0.8	0.7	1.2	1.6	1.9
Price earning ratio	Times	12.9	6.8	6.6	9.7	19.8	28.5
Interest cover	Times	12.7	6.1	5.2	5.2	3.7	2.7
Debt : equity	Ratio	11:89	14:86	19:81	27:73	35:65	34:66
LIQUIDITY							
Current ratio	Ratio	1.4	1.1	1.0	1.1	1.2	1.3
Quick ratio	Ratio	1.2	0.9	0.8	0.9	1.1	1.1
HISTORICAL TRENDS							
UNCONSOLIDATED STATEMENT OF FINANCIAL POSITION		(Rupees in '000')					
Authorised share capital		1,000,000	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
Issued, subscribed and paid up capital		632,144	632,144	632,144	632,144	619,749	619,749
Share premium		2,738,888	2,738,888	2,738,888	2,738,888	2,751,283	2,751,283
Surplus on revaluation of property, plant and equipment		1,104,985	920,827	936,615	867,283	792,396	760,346
Unappropriated profit		9,830,602	7,624,157	6,511,963	5,411,656	4,325,259	3,636,170
Shareholders' equity		14,306,619	11,916,016	10,819,610	9,649,971	8,488,687	7,767,548
Non-current liabilities		1,649,211	1,496,057	1,750,801	2,310,214	3,317,760	3,962,551
Current liabilities		5,475,152	4,874,579	5,892,382	5,251,868	4,886,521	3,529,154
Total equity and liabilities		21,430,982	18,286,652	18,462,793	17,212,053	16,692,968	15,259,253
Property, plant and equipment		8,618,241	6,837,904	7,017,740	7,134,172	6,791,843	6,991,936
Intangible assets		43,052	40,780	41,834	53,365	31,343	57,414
Investment property - at cost		624,872	720,292	748,450	-	-	-
Long term investments - at cost		4,522,553	5,060,970	4,714,217	3,918,618	3,178,758	2,933,524
Long term deposits		105,003	113,937	91,616	85,324	96,260	111,740
Non-current assets		13,913,721	12,773,883	12,613,857	11,191,479	10,098,204	10,094,614
Current assets		7,517,261	5,512,769	5,848,936	5,699,621	5,996,707	4,669,661
Non-current assets held for sale		-	-	-	320,953	598,057	494,978
Total assets		21,430,982	18,286,652	18,462,793	17,212,053	16,692,968	15,259,253
UNCONSOLIDATED STATEMENT OF PROFIT OR LOSS		(Rupees in '000')					
Revenue - net		27,967,661	23,563,840	19,721,425	16,197,551	14,219,718	12,151,762
Other income		402,822	190,123	617,015	637,429	107,479	637,219
Operating costs		(23,737,514)	(20,944,954)	(17,872,504)	(14,791,977)	(12,899,400)	(11,480,652)
Expected credit losses		(144,421)	(111,778)	(57,105)	(69,069)	(103,529)	(32,278)
Operating profit		4,488,548	2,697,231	2,408,831	1,973,934	1,324,268	1,276,051
Finance costs		(353,832)	(441,054)	(462,630)	(382,432)	(360,375)	(478,598)
Income tax expense / levies		(1,805,736)	(894,103)	(764,795)	(428,953)	(263,969)	(292,262)
Profit for the year		2,328,980	1,362,074	1,181,406	1,162,549	699,924	505,191
UNCONSOLIDATED STATEMENT OF CASH FLOWS		(Rupees in '000')					
Net cash generated from operating activities		4,307,612	1,899,249	2,409,213	1,601,920	1,549,681	321,405
Net cash used in investing activities		(2,766,332)	(794,676)	(1,625,200)	(992,875)	(1,117,057)	(1,180,120)
Net cash (used in) / generated from financing activities		(449,945)	(1,165,160)	(1,260,718)	(1,517,527)	98,357	2,348,331
Changes in cash & cash equivalents (C&CE)		1,091,335	(60,587)	(476,705)	(908,482)	530,981	1,489,616
Cash & cash equivalents at beginning of the year		2,132,377	2,219,433	2,320,432	2,812,697	2,398,052	794,696
Cash & cash equivalents of amalgamated company		283,903	-	-	-	-	-
Effect of exchange rate change on C&CE		7,199	(26,469)	375,706	416,217	(116,336)	113,740
Cash & cash equivalents at end of year		3,514,814	2,132,377	2,219,433	2,320,432	2,812,697	2,398,052

SIX YEARS AT A GLANCE


Revenue - net

(Rupees in Million)




Shareholders' equity

(Rupees in Million)




Debt equity ratio

(%)




Current assets & current liabilities

(Rupees in Million)




Earnings per share

(Rupees)



Profit for the year

(Rupees in Million)






HORIZONTAL & VERTICAL ANALYSIS

	2025	2024	2023	2022	2021	2020
HORIZONTAL ANALYSIS						
UNCONSOLIDATED STATEMENT OF FINANCIAL POSITION						
	%					
Non-current assets	8.9	1.3	12.7	10.8	-	15.5
Current assets	36.4	(5.7)	2.6	(5.0)	28.4	61.5
Non-current asset held for sale	-	-	(100)	(46.3)	20.8	61.1
Total assets	17.2	(1.0)	7.3	3.1	9.4	27.8
Share capital and reserves	20.1	10.1	12.1	13.7	9.3	37.6
Non-current liabilities	10.2	(14.6)	(24.2)	(30.4)	(16.3)	45.8
Current liabilities	12.3	(17.3)	12.2	7.5	38.5	(1.2)
Total equity and liabilities	17.2	(1.0)	7.3	3.1	9.4	27.8
UNCONSOLIDATED STATEMENT OF PROFIT OR LOSS						
	%					
Revenue - net	18.7	19.5	21.8	13.9	17.0	3.4
Other income	111.9	(69.2)	(3.2)	493.1	(83.1)	1,338.7
Operating costs	13.3	17.2	20.8	14.7	12.4	7.9
Finance costs	(19.8)	(4.7)	21.0	6.1	(24.7)	403.3
Expected credit losses	29.2	95.7	(17.3)	(33.3)	220.7	(372.3)
Profit before levies and income tax	83.3	15.9	22.3	65.1	20.9	(25.7)
Income tax expense / levies	102.0	16.9	78.3	62.5	(9.7)	(1.2)
Profit for the year	71.0	15.3	1.6	66.1	38.5	(35.0)
VERTICAL ANALYSIS						
UNCONSOLIDATED STATEMENT OF FINANCIAL POSITION						
	%					
Non-current assets	64.9	69.9	68.3	65.0	60.5	66.2
Current assets	35.1	30.1	31.7	33.1	35.9	30.6
Non-current asset held for sale	-	-	-	1.9	3.6	3.2
Total assets	100	100	100	100	100	100
Share capital and reserves	66.8	65.1	58.6	56.1	50.8	50.9
Non-current liabilities	7.7	8.2	9.5	13.4	19.9	26.0
Current liabilities	25.5	26.7	31.9	30.5	29.3	23.1
Total equity and liabilities	100	100	100	100	100	100
UNCONSOLIDATED STATEMENT OF PROFIT OR LOSS						
	%					
Revenue - net	100	100	100	100	100	100
Other income	1.4	0.8	3.1	3.9	0.8	5.2
Operating costs	(84.9)	(88.8)	(90.6)	(91.3)	(90.8)	(94.4)
Finance costs	(1.3)	(1.9)	(2.3)	(2.4)	(2.5)	(3.9)
Expected credit losses	(0.5)	(0.5)	(0.3)	(0.4)	(0.7)	(0.3)
Profit before levies and income tax	14.7	9.6	9.9	9.8	6.8	6.6
Income tax expense / levies	(6.5)	(3.8)	(3.9)	(2.6)	(1.9)	(2.4)
Profit for the year	8.2	5.8	6.0	7.2	4.9	4.2

STATEMENT OF VALUE ADDITION

	2025		2024	
	(Rupees in '000')	%	(Rupees in '000')	%
Wealth Generated				
Revenue - net	27,967,661	98.6	23,563,840	99.2
Other income	402,822	1.4	190,123	0.8
	28,370,483	100	23,753,963	100
Wealth Distributed				
Supplies and other operating costs	12,905,764	45.5	11,443,657	48.2
To Employees				
Salaries, wages and benefits	8,869,196	31.2	7,800,352	32.8
To Government				
Taxes	3,026,758	10.7	1,817,727	7.7
To Providers of Capital				
Dividend to shareholders	316,072	1.1	252,858	1.1
Finance costs	145,775	0.5	249,397	1.0
	461,847	1.6	502,255	2.1
Retained in the Business				
Depreciation, amortization and retained profits	3,106,918	11.0	2,189,972	9.2
	28,370,483	100	23,753,963	100







UNCONSOLIDATED **FINANCIAL STATEMENTS**

FOR THE YEAR ENDED JUNE 30, 2025

REVIEW REPORT TO THE MEMBERS ON THE STATEMENT OF COMPLIANCE CONTAINED IN LISTED COMPANIES (CODE OF CORPORATE GOVERNANCE) REGULATIONS, 2019

We have reviewed the enclosed Statement of Compliance with the Listed Companies (Code of Corporate Governance) Regulations, 2019 (the Regulations) prepared by the Board of Directors of **SHIFA INTERNATIONAL HOSPITALS LIMITED** for the year ended June 30, 2025 in accordance with the requirements of regulation 36 of the Regulations.

The responsibility for compliance with the Regulations is that of the Board of Directors of the Company. Our responsibility is to review whether the Statement of Compliance reflects the status of the Company's compliance with the provisions of the Regulations and report if it does not and to highlight any non-compliance with the requirements of the Regulations. A review is limited primarily to inquiries of the Company's personnel and review of various documents prepared by the Company to comply with the Regulations.

As a part of our audit of the financial statements, we are required to obtain an understanding of the accounting and internal control systems sufficient to plan the audit and develop an effective audit approach. We are not required to consider whether the Board of Directors' statement on internal control covers all risks and controls or to form an opinion on the effectiveness of such internal controls, the Company's corporate governance procedures and risks.

The Regulations require the Company to place before the Audit Committee, and upon recommendation of the Audit Committee, place before the Board of Directors for their review and approval, its related party transactions and also ensure compliance with requirements of section 208 of the Companies Act, 2017. We are only required and have ensured compliance of this requirement to the extent of the approval of the related party transactions by the Board of Directors upon recommendation of the Audit Committee. We have not carried out any procedures to assess and determine the Company's process for identification of related parties and that whether the related party transactions were undertaken at arm's length price or not.

Based on our review, nothing has come to our attention which causes us to believe that the Statement of Compliance does not appropriately reflect the Company's compliance, in all material respects, with the requirements contained in the Regulations as applicable to the Company for the year ended June 30, 2025.

ISLAMABAD
DATED: 16 SEP 2025
UDIN : CR202510060gxijARO8X



BDO EBRAHIM & CO
CHARTERED ACCOUNTANTS
Engagement Partner: Atif Riaz

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHIFA INTERNATIONAL HOSPITALS LIMITED

Report on the Audit of the Unconsolidated Financial Statements

Opinion

We have audited the annexed unconsolidated financial statements of **SHIFA INTERNATIONAL HOSPITALS LIMITED** (the Company), which comprise the unconsolidated statement of financial position as at June 30, 2025, and the unconsolidated statement of profit or loss, the unconsolidated statement of comprehensive income, the unconsolidated statement of changes in equity and the unconsolidated statement of cash flows for the year then ended, and notes to the unconsolidated financial statements, including a summary of material accounting policies and other explanatory information, and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of the audit.

In our opinion and to the best of our information and according to the explanations given to us, the unconsolidated statement of financial position, the unconsolidated statement of profit or loss, the unconsolidated statement of comprehensive income, the unconsolidated statement of changes in equity, the unconsolidated statement of cash flows, together with the notes forming part thereof conform with the accounting and reporting standards as applicable in Pakistan and give the information required by the Companies Act, 2017 (XIX of 2017), in the manner so required and respectively give a true and fair view of the state of the Company's affairs as at June 30, 2025 and of the profit and comprehensive income, the changes in equity and its cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) as applicable in Pakistan. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the unconsolidated financial statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants as adopted by the Institute of Chartered Accountants of Pakistan (the Code) and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of unconsolidated financial statements of the current period. These matters are addressed in the context of our audit of the unconsolidated financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

Following are the key audit matters:

Sr. No.	Key audit matters	How the matter was addressed in our audit
1.	<p>Revenue Recognition</p> <p>(Refer note 27 to the unconsolidated financial statements)</p> <p>Revenue consists of inpatient revenue, outpatient revenue, pharmacy, cafeteria, rent of building and other services.</p> <p>During the year ended June 30, 2025, the Company recognised aggregate revenue of Rs. 27,967.661 million from rendering of services to inpatients, outpatients, external pharmacy outlets, cafeteria sales and operating leases to related parties/ other parties.</p> <p>We identified recognition of revenue as an area of higher risk as it includes large number of revenue transactions with a large number of customers in various geographical locations and revenue being one of the key performance indicators of the Company. Accordingly, it was considered as a key audit matter.</p>	<p>Our procedures in relation to revenue recognition, amongst others, included:</p> <ul style="list-style-type: none"> • Understood and evaluated management controls over revenue and verified their validations; • Performed test of controls and evaluation of Information Technology General Controls (ITGC) with the assistance of our IT expert to assess the operating effectiveness of controls related to the automation of revenue recognition; • Verified that revenue has been recognised in accordance with the Company's accounting policy and the applicable reporting framework; • Performed verification of sample of revenue transactions with underlying documentation including invoices, agreements, charge-sheets and other relevant underlying documents; • Verified receipts from customers on sample basis against the revenue booked during the year; • Performed cut-off procedures on sample basis to ensure revenue has been recognised in the correct period; • Tested journal entries relating to revenue recognised during the year based on identified risk criteria; and • Assessed the appropriateness of disclosures made in the financial statements related to revenue as required under the applicable reporting framework.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

Sr. No.	Key audit matters	How the matter was addressed in our audit
2.	<p>Expected credit loss allowance on trade debts</p> <p>(Refer note 22 to the unconsolidated financial statements)</p> <p>The Company has recognised balance of an expected credit loss allowance of Rs. 293.877 million on gross amount of trade debts of Rs. 1,755.333 million as at June 30, 2025.</p> <p>Under IFRS 9, the Company is required to recognise expected credit loss allowance for financial assets using Expected Credit Loss (ECL) model. Determination of ECL provision for trade debts requires significant judgment and assumptions including consideration of factors such as historical credit loss experience, time value of money and forward-looking macroeconomic information etc. We have considered the expected credit loss assessment as a key audit matter due to the significance of estimates and judgments involved.</p>	<p>Our audit procedures in relation to expected credit loss assessment of trade debts, amongst others, included the following:</p> <ul style="list-style-type: none"> • Understood the management's process for estimating the ECL in relation to trade debts. Assessed and evaluated the assumptions used by the management in determining impairment loss under the ECL model; • Verified appropriateness of ageing, on sample basis, by comparing individual balances with underlying documentation; • Reviewed the appropriateness of assumptions used for ECL computation from relevant external and internal sources; • Circularised balance confirmation for trade debtors on sample basis and evaluated responses received; • Verified subsequent clearance of balances due as of June 30, 2025 on sample basis; and • Assessed the appropriateness of disclosures related to impairment assessment of trade debts as required under the applicable reporting framework.

Information Other than the Unconsolidated Financial Statements and Auditor's Report Thereon

Management is responsible for the other information. The other information comprises the information included in the annual report but does not include the unconsolidated financial statements and our auditor's report thereon.

Our opinion on the unconsolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the unconsolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the unconsolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

Responsibilities of Management and Board of Directors for the Unconsolidated Financial Statements

Management is responsible for the preparation and fair presentation of the unconsolidated financial statements in accordance with the accounting and reporting standards as applicable in Pakistan and the requirements of Companies Act, 2017 (XIX of 2017) and for such internal control as management determines is necessary to enable the preparation of unconsolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the unconsolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Unconsolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the unconsolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs as applicable in Pakistan will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these unconsolidated financial statements.

As part of an audit in accordance with ISAs as applicable in Pakistan, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the unconsolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the unconsolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

- Evaluate the overall presentation, structure and content of the unconsolidated financial statements, including the disclosures, and whether the unconsolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the board of directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the board of directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Based on our audit, we further report that in our opinion:

- a) proper books of account have been kept by the Company as required by the Companies Act, 2017 (XIX of 2017);
- b) the unconsolidated statement of financial position, the unconsolidated statement of profit or loss, the unconsolidated statement of comprehensive income, the unconsolidated statement of changes in equity, the unconsolidated statement of cash flows together with the notes thereon have been drawn up in conformity with the Companies Act, 2017 (XIX of 2017) and are in agreement with the books of account and returns;
- c) investments made, expenditure incurred and guarantees extended during the year were for the purpose of the Company's business; and
- d) Zakat deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980), was deducted by the Company and deposited in the Central Zakat Fund established under section 7 of that Ordinance.

The engagement partner on the audit resulting in this independent auditor's report is Atif Riaz.

ISLAMABAD

DATED: 16 SEP 2025

UDIN : AR202510060Lvq8Jxr7c



BDO EBRAHIM & CO
CHARTERED ACCOUNTANTS

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

UNCONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2025


		2025	2024
	Note	(Rupees in '000')	
SHARE CAPITAL AND RESERVES			
Authorised share capital 100,000,000 (2024: 100,000,000) ordinary shares of Rs. 10 each		1,000,000	1,000,000
Issued, subscribed and paid up capital	5	632,144	632,144
Capital reserves			
Share premium	6	2,738,888	2,738,888
Surplus on revaluation of property, plant and equipment	7	1,104,985	920,827
Revenue reserves			
Unappropriated profit		9,830,602	7,624,157
		14,306,619	11,916,016
NON - CURRENT LIABILITIES			
Long term financing - secured	8	853,419	579,756
Deferred liabilities	9	289,268	389,394
Lease liabilities	10	506,524	526,907
		1,649,211	1,496,057
CURRENT LIABILITIES			
Trade and other payables	11	4,865,657	4,044,057
Unclaimed dividend		48,935	44,730
Markup accrued	12	7,974	23,858
Taxation - net	13	104,501	-
Current portion of long term financing - secured	8	255,190	495,195
Current portion of lease liabilities	10	192,895	266,739
		5,475,152	4,874,579
		21,430,982	18,286,652
CONTINGENCIES AND COMMITMENTS			
	14		

The annexed notes from 1 to 48 form an integral part of these unconsolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE

		2025	2024
	Note	(Rupees in '000')	
NON - CURRENT ASSETS			
Property, plant and equipment	15	8,618,241	6,837,904
Intangible assets	16	43,052	40,780
Investment property - at cost	17	624,872	720,292
Long term investments - at cost	18	4,522,553	5,060,970
Long term deposits	19	105,003	113,937
		13,913,721	12,773,883
CURRENT ASSETS			
Stores, spare parts and loose tools	20	224,161	243,579
Stock in trade	21	959,987	1,018,321
Trade debts	22	1,461,456	1,346,189
Loans and advances	23	138,025	157,457
Deposits, prepayments and other receivables	24	196,244	185,398
Markup accrued		19,219	4,102
Other financial assets	25	1,006,355	202,566
Taxation - net		-	225,780
Cash and bank balances	26	3,511,814	2,129,377
		7,517,261	5,512,769
		21,430,982	18,286,652



CHIEF FINANCIAL OFFICER

UNCONSOLIDATED STATEMENT OF PROFIT OR LOSS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Revenue - net	27	27,967,661	23,563,840
Other income	28	402,822	190,123
Operating costs	29	(23,737,514)	(20,944,954)
Finance costs	30	(353,832)	(441,054)
Expected credit losses	24.2 & 41.1.3	(144,421)	(111,778)
Profit before levies and income tax		4,134,716	2,256,177
Levies	31	(6,923)	(7,288)
Profit before income tax		4,127,793	2,248,889
Income tax expense	31	(1,798,813)	(886,815)
Profit for the year		2,328,980	1,362,074
Earnings per share - basic and diluted (Rupees)	32	36.84	21.55

The annexed notes from 1 to 48 form an integral part of these unconsolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

UNCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Profit for the year		2,328,980	1,362,074
Other comprehensive income			
Items that will not be subsequently reclassified to the unconsolidated statement of profit or loss:			
Loss on remeasurement of staff gratuity fund benefit plan (net of tax)	11.5.4	(50,820)	(76,024)
Surplus on revaluation of land	15	181,216	-
		130,396	(76,024)
Total comprehensive income for the year		2,459,376	1,286,050

The annexed notes from 1 to 48 form an integral part of these unconsolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

UNCONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED JUNE 30, 2025

	Share capital	Share premium	Surplus on revaluation of property, plant and equipment	Un-appropriated profit	Total
(Rupees in '000')					
Balance as at July 01, 2023	632,144	2,738,888	936,615	6,511,963	10,819,610
Total comprehensive income					
Profit for the year	-	-	-	1,362,074	1,362,074
Other comprehensive loss - net of tax	-	-	-	(76,024)	(76,024)
	-	-	-	1,286,050	1,286,050
Realisation of revaluation surplus on disposal of assets	-	-	(4,284)	4,284	-
Transfer of revaluation surplus on property, plant and equipment in respect of incremental depreciation / amortisation	-	-	(11,504)	11,504	-
Distribution to owners					
Dividend - final 2023 @ Rs. 1.5 per share	-	-	-	(94,822)	(94,822)
Dividend - interim 2024 @ Rs. 1.5 per share	-	-	-	(94,822)	(94,822)
Balance as at June 30, 2024	632,144	2,738,888	920,827	7,624,157	11,916,016
Total comprehensive income					
Profit for the year	-	-	-	2,328,980	2,328,980
Other comprehensive income / (loss) - net of tax	-	-	181,216	(50,820)	130,396
	-	-	181,216	2,278,160	2,459,376
Transfer upon merger (refer note 1.1)	-	-	28,730	60,533	89,263
Realisation of revaluation surplus on disposal of assets	-	-	(14,517)	14,517	-
Transfer of revaluation surplus on property, plant and equipment in respect of incremental depreciation / amortisation	-	-	(11,271)	11,271	-
Distribution to owners					
Dividend - final 2024 @ Rs. 2.5 per share	-	-	-	(158,036)	(158,036)
Balance as at June 30, 2025	632,144	2,738,888	1,104,985	9,830,602	14,306,619

The annexed notes from 1 to 48 form an integral part of these unconsolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

UNCONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before levies and income tax		4,134,716	2,256,177
Adjustment of non-cash income and expense	40	2,019,813	2,070,835
Operating cash flows before changes in working capital		6,154,529	4,327,012
Changes in working capital:			
(Increase) / decrease in current assets:			
Stores, spare parts and loose tools		16,746	33,556
Stock-in-trade		58,334	(59,368)
Trade debts		(167,997)	(73,340)
Loans and advances		19,432	(12,227)
Deposits, prepayments and other receivables		(34,735)	85,381
Increase / (decrease) in current liabilities:			
Trade and other payables		483,989	(779,810)
		375,769	(805,808)
Cash generated from operations		6,530,298	3,521,204
Finance costs paid		(258,570)	(395,644)
Income tax paid		(1,555,738)	(827,215)
Payment to SIHL Employees' Gratuity Fund Trust		(215,360)	(242,112)
Compensated absences paid		(89,047)	(72,684)
Payment to defined contribution plan		(103,971)	(84,300)
Net cash generated from operating activities		4,307,612	1,899,249
CASH FLOWS FROM INVESTING ACTIVITIES			
Addition to property, plant and equipment (PPE)		(1,083,951)	(616,043)
Addition to intangible assets		(5,787)	-
Addition to long term investments		(1,159,104)	(425,000)
(Investment) / encashment of other financial assets - net		(750,296)	155,377
Proceeds from disposal of PPE		5,317	4,662
Proceeds on derecognition of investment		-	2,265
Proceeds from disposal of investment property		-	26,000
Markup received		170,255	64,889
Dividend received		50,926	16,975
Decrease / (increase) in long term deposits		6,308	(23,801)
Net cash used in investing activities		(2,766,332)	(794,676)

UNCONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
CASH FLOWS FROM FINANCING ACTIVITIES			
Long term financing - repayments		(504,047)	(881,581)
Proceeds from long term financing		537,704	216,122
Payment of lease liabilities		(329,771)	(317,832)
Dividend paid		(153,831)	(181,869)
Net cash used in financing activities		(449,945)	(1,165,160)
Net increase / (decrease) in cash and cash equivalents		1,091,335	(60,587)
Cash and cash equivalents at beginning of the year		2,132,377	2,219,433
Cash and cash equivalents of amalgamated company		283,903	-
Effect of exchange rate changes on cash and cash equivalents		7,199	(26,469)
Cash and cash equivalents at end of the year	38	3,514,814	2,132,377

The annexed notes from 1 to 48 form an integral part of these unconsolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

1 STATUS AND NATURE OF BUSINESS

Shifa International Hospitals Limited (the Company / SIHL) was incorporated in Pakistan on September 29, 1987 as a private limited company under the Companies Ordinance, 1984 (repealed with the enactment of the Companies Act, 2017 on May 30, 2017) and converted into a public limited company on October 12, 1989. The shares of the Company are quoted on Pakistan Stock Exchange Limited. The registered office of the Company is situated at Sector H-8/4, Islamabad.

The principal activity of the Company is to establish and run medical centers and hospitals in Pakistan. The Company has established its first hospital in 1993 in H-8/4 Islamabad, second hospital in 2011 in Faisalabad and another in 2014 in G-10/4 Islamabad. The Company is also running medical centers, lab collection points and pharmacies in different cities of Pakistan.

Geographical locations of business units of the Company are as follows:

H-8 Hospital, Pitras Bukhari Road, Sector H-8/4, Islamabad

Neuro Sciences Institute, Pitras Bukhari Road, Sector H-8/4, Islamabad

G-10 Hospital, G-10 Markaz, Islamabad

Shifa Medical Center, Gulberg Greens, Islamabad

Faisalabad Hospital, Main Jaranwala Road, Faisalabad

	2025	2024
Percentage share of total revenue given in note 27 is as follows:		
Islamabad	97%	97%
Faisalabad	3%	3%
	100%	100%

1.1 Merger / amalgamation of Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNS Islamabad) with and into the Company

The board of directors of the Company and SNS Islamabad, in their respective meetings held on February 22, 2025, and February 24, 2025, approved the merger / amalgamation of SNS Islamabad with and into the Company in accordance with the provisions of section 284 of the Companies Act, 2017. The Company has filed scheme of amalgamation along with requisite documentation to the Securities and Exchange Commission of Pakistan (SECP) on March 25, 2025, effective date of amalgamation, which has been acknowledged by SECP on May 9, 2025. The Company has adopted the predecessor method of accounting for the merger of SNS Islamabad as per the S.R.O 52 (I) 2022 issued by SECP to account for common control transactions. As it was business combination under common control and therefore, scoped out of IFRS 3 'Business Combinations'.

Accordingly, on March 25, 2025, the Company recorded in its books the assets and liabilities transferred from SNS Islamabad at their respective carrying values, after eliminating all intercompany balances and transactions without paying any consideration. The difference between the value of net assets acquired as a result of the merger and the cost of investment was fully adjusted through recognition in accumulated profit and transfer to

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

the surplus on revaluation of property, plant and equipment. Accordingly, no amount has been recognised as a "Merger reserve" in the financial statements. Furthermore, the items appearing in the statement of profit or loss and the statement of comprehensive income of SNS Islamabad are incorporated prospectively from the effective date of merger / amalgamation into the financial statements of the Company. Consequently, these financial statements do not reflect the results of SNS Islamabad for the period before the merger transaction occurred and the corresponding amounts for the previous year presented are not restated.

Following the amalgamation, the Company is pursuing title transfer of land through a registered sale deed with the CDA. The initial suit filed by CDA was dismissed on January 29, 2024, and is now under appeal before the Islamabad High Court. The Company's management, based on advice from legal counsel, remains confident of favorable resolution in the aforementioned matter.

Detail of carrying amount of amalgamated SNS Islamabad's assets and liabilities as on merger date are as follows:

	(Rupees in '000')
Assets	
Non-current assets	
Property	1,024,115
Investment property	503,681
	1,527,796
Current assets	
Investment - at amortised cost	259,563
Markup accrued	110
Cash and bank balances	24,339
	284,012
Total assets	1,811,808
Liabilities	
Security deposit	20,278
Accrued liabilities	2,509
Taxation - net	2,237
	25,024
Total liabilities	25,024
Net assets	1,786,784
Adjusted against cost of investment in amalgamated company	1,697,521
	89,263
Accumulated profit recognised by the Company till date of merger	60,533
Transfer to surplus on revaluation of property, plant and equipment	28,730
Merger reserve	-

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

2 BASIS OF PREPARATION

2.1 Statement of compliance

These unconsolidated financial statements of the Company have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan. The accounting and reporting standards as applicable in Pakistan comprise of:

- International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and Islamic Financial Accounting Standards (IFASs) issued by the Institute of Chartered Accountants of Pakistan as are notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ from the IFRS or IFASs, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.2 Basis of measurement

These unconsolidated financial statements have been prepared under the historical cost convention, except for certain items as disclosed in relevant accounting policies.

In these unconsolidated financial statements, being the separate financial statements of the Company, investment in subsidiaries and associates are stated at cost rather than on the basis of reporting results of the investee. Consolidated financial statements are prepared separately.

2.3 Functional and presentation currency

These unconsolidated financial statements are presented in Pak Rupees, which is the Company's functional currency.

2.4 Use of estimates and judgments

The preparation of unconsolidated financial statements in conformity with accounting and reporting standards requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgment about carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The areas where various assumptions and estimates are significant to the Company's unconsolidated financial statements or where judgment was exercised in application of accounting policies are as follows:

Notes 4.2, 4.3, 4.16.4 and 8	Estimate of fair value of financial liabilities at initial recognition
Notes 4.4, 4.5, 9, 13 and 31	Provision for taxation
Notes 4.6, 10 and 15	Right of use asset and corresponding lease liability
Notes 4.8, 11.4 and 11.5	Employee benefits
Notes 4.9, 4.10 and 14	Provisions and contingencies
Notes 4.11 and 15	Estimate of useful life of property, plant and equipment
Notes 4.12 and 16	Estimate of useful life of intangible assets
Note 4.14	Impairment of non-financial assets
Notes 4.15 and 18	Estimate of recoverable amount of investment in subsidiaries and associates
Notes 4.16.2, 24.2 and 41.1.3	Expected credit loss allowance
Notes 4.17 and 20	Provision for slow moving stores, spares and loose tools

3 STANDARDS, INTERPRETATIONS AND AMENDMENTS TO THE APPROVED ACCOUNTING STANDARDS

3.1 New accounting standards, amendments and IFRS interpretations that are effective for the year ended June 30, 2025

The following standards, amendments and interpretations are effective for the year ended June 30, 2025. These standards, amendments and interpretations are either not relevant to the Company's operations or did not have significant impact on the unconsolidated financial statements other than certain additional disclosures.

3.2 New accounting standards, amendments and interpretations that are not yet effective

	Effective date (annual periods beginning on or after)
Amendments to IAS 21 'The Effects of Changes in Foreign Exchange Rates' - Lack of Exchangeability	January 01, 2025
Amendments to IFRS 7 'Financial Instruments: Disclosures' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026
Amendments to IFRS 9 'Financial Instruments' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

**Effective date
(annual periods
beginning on or
after)**

IFRS 17 Insurance Contracts

January 01, 2026

Certain annual improvements have also been made to a number of IFRSs and IASs.

IFRS 1 'First-time Adoption of International Financial Reporting Standards' has been issued by IASB effective from July 01, 2009. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRS 18 'Presentation and Disclosures in Financial Statements' has been issued by IASB effective from January 01, 2027. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRS 19 'Subsidiaries without Public Accountability: Disclosures' has been issued by IASB effective from January 01, 2027. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRIC 12 'Service Concession Arrangement' has been issued by IASB effective from January 01, 2008. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

4 MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies set out below have been applied consistently to all periods presented in these unconsolidated financial statements.

4.1 Share capital and dividend

Dividend is recognised as a liability in the period in which it is declared. Movement in reserves is recognised in the year in which it is approved.

4.2 Financing and finance cost

Financing is recognised initially at fair value, less attributable transaction costs. Subsequent to initial recognition, financing is stated at amortised cost with any difference between cost and redemption value being recognised in the unconsolidated statement of profit or loss over the period of the financing on an effective interest basis. Finance cost is recognised as an expense in the period in which it is incurred.

4.3 Government grants

Government grants are transfer of resources to an entity by a government entity in return for compliance with certain past or future conditions related to the entity's operating activities e.g. a government subsidy.

Government grants are recognised at fair value, as deferred income, when there is reasonable assurance that the grants will be received and the Company will be able to comply with the conditions associated with the grants.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Grants that compensate the Company for expenses incurred, are recognised on a systematic basis in the income for the year in which the finance cost is recognised and reported net of grant in note 30.

A loan is initially recognised and subsequently measured in accordance with IFRS 9. IFRS 9 requires loans at below-market rates to be initially measured at their fair value - e.g. the present value of the expected future cash flows discounted at a market-related interest rate. The benefit that is the government grant is measured as the difference between the fair value of the loan on initial recognition and the amount received, which is accounted for according to the nature of the grant.

4.4 Taxation

Taxation for the year comprises current and deferred tax. Taxation is recognised in the unconsolidated statement of profit or loss except to the extent that it relates to items recognised directly in the unconsolidated statement of changes in equity and unconsolidated statement of comprehensive income.

Current

Provision for current taxation is based on taxable income at the current rates of tax after taking into account applicable tax credits, rebates, losses and exemptions available, if any.

Deferred

Deferred tax is accounted for using balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the unconsolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences, unused tax losses and tax credits can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that is no longer probable that the related tax benefit will be realised.

Deferred tax is calculated at the rates that are expected to apply to the period when the differences reverse, based on tax rates that have been enacted. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets and they relate to income taxes levied by the same tax authority on the same taxable entity or on different tax entities but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

The Company takes into account the current income tax law and decisions taken by appellate authorities. Instances where the Company's view differs from the view taken by the income tax department at the assessment stage and where the Company considers that its view on items of material nature is in accordance with law, the amounts are shown as contingent liabilities.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.5 Levies

Minimum tax, final tax and super tax not based on taxable profits are recognised as a levy in the unconsolidated statement of profit or loss. The amount calculated on taxable income using the notified tax rate is recognised as current income tax expense for the year in the statement of profit or loss under the scope of IAS 12. Any excess of expected income tax paid or payable for the year under the Income Tax Ordinance, 2001 ("the Ordinance") over the amount designated as current income tax for the year, is then recognised as a levy falling under the scope of IFRIC 21 / IAS 37.

4.6 Leases

4.6.1 Right of use assets (ROUs)

The Company recognises right of use assets and a lease liability at the lease commencement date. The right of use assets is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right of use assets is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right of use assets or the end of the lease term. The estimated useful lives of right of use assets are determined as those of similar assets or the lease term as specified in contract. In addition, the right of use assets is periodically reduced by impairment loss, if any, and adjusted for certain remeasurements of the lease liability.

The Company has not elected to recognise right of use assets and lease liabilities for short-term leases of properties that have a lease term of 12 months or less and leases of low value assets. The Company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

4.6.2 Lease liability

The lease liability is initially measured at the present value of the future lease payments discounted using the Company's incremental borrowing rate. Lease payments in the measurement of the lease liability comprise the following:

- Fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- Variable lease payments that are based on an index or a rate;
- Amounts expected to be payable by the lessee under residual value guarantees;
- The exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
- Payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use assets, or is recorded in consolidated statement of profit or loss if the carrying amount of the right of use asset has been reduced to zero.

4.7 Trade and other payable

Liabilities for trade and other payables are carried at amortised cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Company.

4.8 Employee benefits

Defined benefit plan

The Company operates approved funded gratuity scheme for all its non management employees who have completed the minimum qualifying period of service as defined in the scheme. Provision is made annually to cover obligations under the scheme on the basis of actuarial valuation and is charged to the consolidated statement of profit or loss. The actuarial gain or loss at each evaluation date are charged to consolidated statement of comprehensive income.

The amount recognised in the consolidated statement of financial position represents the present value of defined benefit obligations as reduced by the fair value of plan assets.

Calculation of gratuity asset requires assumptions to be made of future outcomes which mainly include increase in remuneration, expected long term return on plan assets and the discount rate used to convert future cash flows to current values. Calculations are sensitive to changes in the underlying assumptions and determined by actuary.

Defined contribution plan

A defined contribution plan is a post-employment benefit plan where monthly contribution equal to 1/12th of eligible salary is made by the Company in employees' pension fund account maintained with designated asset management company and recognised as expense in the consolidated statement of profit or loss as and when they become due. Employees will be eligible for pension fund on the completion of minimum qualifying period. On fulfilment of criteria accumulated contribution against qualifying period of services from the date of joining classified as deferred liability and will be transferred to employees' pension fund account.

Compensated absences

The Company provides for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. Accrual to cover the obligations is made using the current salary levels of the employees.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.9 Provisions

Provisions are recognised when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount can be made. However, provisions are reviewed at each reporting date and adjusted prospectively to reflect the current best estimates.

4.10 Contingencies

A contingent liability is disclosed when the Company has a possible obligation as a result of past events, whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or the Company has a present legal or constructive obligation that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

The Company discloses significant contingent liabilities for the pending litigations and claims against the Company based on its judgment and the advice of the legal advisors for the estimated financial outcome. The actual outcome of these litigations and claims can have an effect on the carrying amounts of the liabilities recognised at the reporting date. However, based on the best judgment of the Company and its legal advisors, the likely outcome of these litigations and claims is remote and there is no need to recognise any liability at the reporting date.

4.11 Property, plant and equipment

Property, plant and equipment except freehold and leasehold land and capital work in progress are stated at cost less accumulated depreciation and impairment in value, if any. Leasehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent accumulated amortisation and impairment loss while freehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent impairment loss, if any.

Any revaluation increase arising on the revaluation of land is recognised in unconsolidated statement of comprehensive income and presented as a separate component of equity as "Revaluation surplus on property, plant and equipment", except to the extent that it reverses a revaluation decrease for the same asset previously recognised in the unconsolidated statement of profit or loss, in which case the increase is credited to the unconsolidated statement of profit or loss to the extent of the decrease previously charged. Any decrease in carrying amount arising on the revaluation of land is charged to the unconsolidated statement of profit or loss to the extent that it exceeds the balance, if any, held in the revaluation surplus on property, plant and equipment relating to a previous revaluation of that asset. The surplus on leasehold land to the extent of incremental depreciation charged is transferred to unappropriated profit.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Capital work in progress and stores held for capital expenditure are stated at cost less impairment loss recognised, if any. All expenditures connected with specific assets incurred during installation and construction period are carried under capital work in progress. These are transferred to specific items of property, plant and equipment when available for intended use.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repair and maintenance costs that do not meet the recognition criteria are charged to the unconsolidated statement of profit or loss as and when incurred.

Depreciation / amortisation is charged to the unconsolidated statement of profit or loss commencing when the asset is ready for its intended use, applying the straight-line method over the estimated useful life.

In respect of additions and disposals during the year, depreciation / amortisation is charged when the asset is available for use and up to the month preceding the asset's classified as held for sale or derecognised, whichever is earlier.

Assets are derecognised when disposed off or when no future economic benefits are expected to flow from its use. Gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and is recognised on net basis in the unconsolidated statement of profit or loss.

The Company reviews the useful lives of property, plant and equipment on a regular basis. Similarly revaluation of lands are made with sufficient regularity. Any change in estimates in future years might affect the carrying amounts of the respective items of property, plant and equipment with a corresponding effect on the depreciation / amortisation charge and impairment.

4.12 Intangible assets

Intangible assets are stated at cost less accumulated amortisation and impairment loss, if any. Subsequent cost on intangible assets is capitalised only when it increases the future economic benefits embodied in the specific assets to which it relates. All other expenditure is expensed as incurred.

Amortisation is charged to the unconsolidated statement of profit or loss on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Amortisation on additions to intangible assets is charged from the month in which an item is acquired or capitalised while no amortisation is charged for the month in which the item is disposed off.

The Company reviews the useful lives of intangible assets on a regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of intangibles with the corresponding effect on the amortisation charge and impairment.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.13 Investment property - at cost

Investment property, principally comprising of land, is held for long term capital appreciation and is valued using the cost method i.e. at cost less impairment loss, if any.

Cost includes expenditure that is directly attributable to the acquisition of the investment property. The cost of self-constructed investment property includes the cost of materials and direct labour, any other costs directly attributable to bringing the investment property to a working condition for their intended use and capitalised borrowing costs, if any.

The gain or loss on disposal of investment property, represented by the difference between the sale proceeds and the carrying amount of the asset is recognised as income or expense in the unconsolidated statement of profit or loss.

4.14 Impairment of non - financial assets

The Company assesses at each reporting date whether there is any indication that assets except deferred tax assets and inventory may be impaired. If such indication exists, the carrying amounts of such assets are reviewed to assess whether they are recorded in excess of their recoverable amounts. Where carrying values exceed the respective recoverable amounts, assets are written down to their recoverable amounts and the resulting impairment loss is recognised in the unconsolidated statement of profit or loss except for the impairment loss on revalued assets, which is adjusted against the related revaluation surplus to the extent that the impairment loss does not exceed the surplus on revaluation of that asset. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use.

Where impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised recoverable amount but limited to the extent of the carrying amount that would have been determined (net of depreciation / amortisation) had no impairment loss been recognised for the asset in prior years. Reversal of impairment loss is recognised in the unconsolidated statement of profit or loss.

4.15 Investments

All purchases and sales of investments are recognised using settlement date accounting. Settlement date is the date on which the investments are delivered to or by the Company. All investments are derecognised when the rights to receive cash flows from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

4.15.1 Investment in subsidiary

Investment in subsidiary is initially recognised at cost. At subsequent reporting date, recoverable amounts are estimated to determine the extent of impairment loss, if any, and carrying amount of investment is adjusted accordingly. Impairment loss is recognised as expense in the unconsolidated statement of profit or loss. Where impairment loss is subsequently reversed, the carrying amount of investment are increased to its revised recoverable amount, limited to the extent of initial cost of investment. Reversal of impairment loss is recognised in the unconsolidated statement of profit or loss.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The profit or loss of subsidiary is carried forward in their financial statements and is not dealt within these unconsolidated financial statements except to the extent of dividend declared by the subsidiaries. Gain or loss on disposal of investment is included in unconsolidated statement of profit or loss. When the disposal of investment in subsidiary results in loss of control such that it becomes an associate, the retained investment is carried at cost.

4.15.2 Investment in associate

Investment in associate is initially recognised at cost. At subsequent reporting date, the recoverable amounts are estimated to determine the extent of impairment loss, if any, and carrying amount of investments are adjusted accordingly. Impairment loss is recognised as expense in the unconsolidated statement of profit or loss. Where impairment loss is subsequently reversed, the carrying amount of investment is increased to the revised recoverable amounts but limited to the extent of initial cost of investments. A reversal of impairment loss is recognised in the unconsolidated statement of profit or loss. The profit or loss of associate is carried forward in their financial statements and is not dealt within these unconsolidated financial statements except to the extent of dividend declared by the associate. Gain or loss on disposal of investments is included in the unconsolidated statement of profit or loss.

4.16 Financial assets

Initial measurement

A financial asset is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition.

The Company classifies its financial assets into following three categories:

- fair value through other comprehensive income (FVOCI);
- fair value through profit or loss (FVTPL); and
- amortised cost.

Subsequent measurement

i) Debt instrument at FVOCI

These assets are subsequently measured at fair value. Interest / markup income calculated using the effective interest method, foreign exchange gain or loss and impairment are recognised in the unconsolidated statement of profit or loss. Other net gain or loss is recognised in the unconsolidated statement of comprehensive income. On derecognition, gain or loss accumulated in the unconsolidated statement of comprehensive income are reclassified to the unconsolidated statement of profit or loss.

ii) Equity instrument at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in the unconsolidated statement of profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gain or loss is recognised in the unconsolidated statement of comprehensive income and is never reclassified to the unconsolidated statement of profit or loss.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

iii) Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gain or loss, including any interest / markup and dividend income, are recognised in the unconsolidated statement of profit or loss.

iv) Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment loss. Interest / markup income, foreign exchange gain or loss and impairment are recognised in the unconsolidated statement of profit or loss.

4.16.1 Other financial assets

Investment in units of mutual funds are classified at fair value through profit or loss and is initially measured at fair value and subsequently is measured at fair value determined using the net assets value of the funds at each reporting date. Net gain or loss is recognised in the unconsolidated statement of profit or loss.

Investment in term deposit receipts is classified as amortised cost and is initially measured at fair value. Transaction costs directly attributable to the acquisition are included in the carrying amount. Subsequently, these investments are measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment loss, if any. Interest / markup income, loss and impairment are recognised in the unconsolidated statement of profit or loss.

4.16.2 Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses (ECL) associated with its financial assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

The Company applies the simplified approach for trade debts which requires expected life time losses to be recognised from initial recognition of the receivables.

The Company recognises life time ECL for trade debts, using the simplified approach. The ECL on trade debts is estimated using a provision matrix based on the Company's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of current as well as the forecast direction of conditions at the reporting date. Life time ECL against other receivables is also recognised due to significant increase in credit risk since initial recognition.

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forward-looking information as described above. As for the exposure at default for financial assets, this is represented by the assets' gross carrying amount at the reporting date reduced by security deposit held. For other financial assets, the ECL is based on the 12 month ECL. The 12 month ECL is the portion of life time ECL that results from default events on a financial instrument that are possible within 12 months after the reporting date. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The Company recognises an impairment loss in the unconsolidated statement of profit or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account.

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering of a financial asset in its entirety or a portion thereof. The Company individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery.

The Company writes off financial assets that are still subject to enforcement activities. Subsequent recoveries of amounts previously written off will result in impairment gain.

4.16.3 Derecognition

Financial assets are derecognised when the contractual rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

4.16.4 Financial liabilities

Financial liabilities are classified as measured at amortised cost or at fair value through profit or loss (FVTPL). A financial liability is classified at FVTPL if it is held for trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gain or loss, including any interest expense, are recognised in the unconsolidated statement of profit or loss.

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gain or loss is recognised in the unconsolidated statement of profit or loss. Any gain or loss on derecognition is also recognised in the unconsolidated statement of profit or loss.

Financial liabilities are derecognised when the contractual obligations are discharged or cancelled or have expired or when the financial liabilities' cash flows have been substantially modified.

4.16.5 Off-setting financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount is reported in the unconsolidated statement of financial position, if the Company has a legally enforceable right to set off the recognised amounts, and the Company either intends to settle on a net basis, or realise the asset and settle the liability simultaneously. Legally enforceable right must not be contingent on future events and must be enforceable in normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

4.17 Stores, spare parts and loose tools

These are valued at cost, determined on moving average cost basis or net realisable value, whichever is lower. For items which are slow moving or identified as surplus to the Company's requirement, a provision is made for excess of book value over estimated net realisable value.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The Company reviews the carrying amount of stores, spare parts and loose tools on a regular basis. Any change in the estimates in future years might affect the carrying amounts of the respective items of stores and spares with a corresponding affect on the provision.

4.18 Stock in trade

Stock in trade is valued at lower of cost, determined on moving average basis or net realisable value. The cost includes expenditure incurred in acquiring the stock items and other cost incurred in bringing them to their present location and condition.

The Company reviews the carrying amount of stock in trade on a regular basis. Any change in the estimates in future years might affect the carrying amounts of the respective items of stock in trade with a corresponding affect on the provision.

4.19 Trade debts, loans, deposits, interest accrued and other receivables

These are classified at amortised cost and are initially recognised when they are originated and measured at fair value of consideration receivable. These assets are written off when there is no reasonable expectation of recovery. Past years experience of credit loss is used to base the calculation of credit loss.

4.20 Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, cheques in hand, balances with banks and highly liquid short term investments that are readily convertible to known amount of cash and which are subject to insignificant risk of change in value with maturity of three months or less from the date of acquisition.

4.21 Foreign currencies

Transactions in currencies other than Pak Rupees are recorded at the rates of exchange prevailing on the dates of transactions. At each reporting date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the reporting date. Gain or loss arising on retranslation is included in the unconsolidated statement of profit or loss.

4.22 Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the board of directors that makes strategic decisions. The management has determined that the Company has a single reportable segment as the board of directors view the Company's operations as one reportable segment.

4.23 Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer. Revenue from operations of the Company is recognised when the services are provided, and thereby the performance obligations are satisfied.

Revenue consists of inpatient revenue, outpatient revenue, pharmacy, cafeteria, rent of building and other services. Company's contract performance obligations are fulfilled at point in time when the services are provided to customer in case of inpatient, outpatient

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

and other services and goods are delivered to customer in case of pharmacy and cafeteria revenue. Revenue is recognised at that point in time, as the control has been transferred to the customers.

Receivable is recognised when the services are provided and goods are delivered to customers as this is the point in time that the consideration is unconditional because only passage of time is required before the payment is due. The Company recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as 'advances from customers' in the unconsolidated statement of financial position.

Interest income is accrued on time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount.

Rental income is recognised on a straight-line basis over the term of the rent agreement.

Scrap sales and miscellaneous receipts are recognised on realised amounts.

4.24 Earnings per share

The Company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, adjusted for the effects of all dilutive potential ordinary shares.

4.25 Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market is accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their best economic interest.

A fair value measurement of a non financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. The carrying values of all financial assets and liabilities reflected in the financial statements approximate their fair values.

All assets and liabilities for which fair value is measured or disclosed in the unconsolidated financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level of input that is significant to the fair value measurement as a whole:

- Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 - Valuation techniques for which the lowest level of input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the unconsolidated financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level of input that is significant to the fair value measurement as a whole) at the end of each reporting period.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

5 ISSUED, SUBSCRIBED AND PAID UP CAPITAL

	2025	2024		2025	2024
	Number			(Rupees in '000')	
	61,974,886	61,974,886	Ordinary shares of Rs.10 each issued for cash	619,749	619,749
	1,239,497	1,239,497	Ordinary shares of Rs.10 each issued as fully paid bonus shares	12,395	12,395
	63,214,383	63,214,383		632,144	632,144

5.1 The Company has only one class of ordinary shares which carries no right to fixed income. The shareholders are entitled to receive dividend as declared from time to time and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

5.2 7,585,725 ordinary shares representing 12% shareholding in the Company are owned by International Finance Corporation (IFC). IFC has the right to nominate one director at the board of directors of the Company as long as IFC holds ordinary shares representing 5% of total issued share capital of the Company. Further, the Company if intends to amend or repeal the memorandum and articles of association, affects the rights of IFC on its shares issuance of preference shares ranking senior to the equity securities held by IFC, incur any financial debt to any shareholder, change the nature of the business of the Company etc. shall seek consent of IFC.

5.3 The Company has no reserved shares for issuance under options and sales contracts.

5.4 Capital management

The Company's objectives when managing capital are to ensure the Company's ability not only to continue as a going concern but also to meet its requirements for expansion and enhancement of its business, maximise return of shareholders and optimise benefits for other stakeholders to maintain an optimal capital structure and to reduce the cost of capital. There were no changes to the Company's approach to capital management during the year.

	2025	2024
Equity (Rupees in '000')	14,306,619	11,916,016
Debt including lease liabilities (Rupees in '000')	1,808,028	1,868,597
Debt to equity ratio (Percentage)	11	14

In order to achieve the above objectives, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares through bonus or right issue or sell assets to reduce debts or raise debts, if required.

6 SHARE PREMIUM

This comprises of share premium of Rs. 5, Rs. 250 and Rs. 229.29 per share received on issue of 8,000,000, 4,024,100 and 7,436,986 ordinary shares of Rs. 10 each in the years 1994, 2016 and 2020, respectively. Out of the above, the Company during the year ended June 30, 2022 has issued bonus shares at the rate of 2% (total 1,239,497 bonus shares

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

having face value of Rs. 10 each) as approved in Annual General Meeting held on October 28, 2021. The balance reserve cannot be utilised except for the purposes mentioned in section 81 of the Companies Act, 2017.

		2025	2024
		(Rupees in '000')	
7	SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT		
	Balance at beginning of the year	920,827	936,615
	Revaluation surplus during the year	181,216	-
	Transfer of revaluation surplus on property (note 1.1)	28,730	-
	Realisation of revaluation surplus on disposal of assets	(14,517)	(4,284)
	Transferred to unappropriated profit in respect of incremental depreciation / amortisation charged during the year	(11,271)	(11,504)
	Balance at end of the year	1,104,985	920,827

7.1 Surplus on revaluation of property, plant and equipment in respect of leasehold and freehold land is not available for distribution of dividend to the shareholders of the Company in accordance with section 241 of the Companies Act, 2017.

		2025	2024
	Note	(Rupees in '000')	
8	LONG TERM FINANCING - SECURED		
	From banking companies and non-banking financial institutions		
	Syndicated Islamic Finance Facility	8.1	-
	Diminishing Musharakah Facility-1	8.2	105,964
	Diminishing Musharakah Facility-2	8.3	-
	Diminishing Musharakah Facility-3	8.4	433,043
	Diminishing Musharakah Facility-4	8.5	475,986
	Islamic Refinance Facility to Combat COVID -19 (IRFCC)	8.6	28,003
	Deferred income - Government grant		861
			28,864
	Islamic Refinance Facility to Combat COVID-19 (IRFCC)	8.7	13,249
	Deferred income - Government grant		1,516
			14,765
	Refinance Facility to Combat COVID-19 (RFCC)	8.8	45,339
	Deferred income - Government grant		4,648
			49,987
			1,108,609
	Less: current portion		255,190
			853,419
			142,857
			78,250
			83,333
			577,390
			-
			69,647
			5,341
			74,988
			22,245
			4,073
			26,318
			78,486
			13,329
			91,815
			1,074,951
			495,195
			579,756

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 8.1 This represented the syndicated islamic finance facility, arranged and lead by Meezan Bank Limited, obtained on profit rate basis at 3 months KIBOR plus 0.85% per annum. The facility with sanctioned limit of Rs. 2,000 million has been fully repaid on August 22, 2024. The financing was secured by pari passu charge of Rs. 2,667 million on all present and future Company's movable fixed assets and land / building located at H-8/4, Islamabad. Meezan Bank Limited has the custody of original ownership documents of the Company's land located at H-8/4 Islamabad.
- 8.2 This represents the outstanding balance of long term islamic finance facility obtained under Diminishing Musharakah basis from First Habib Modaraba of Rs. 161.90 million (2024: Rs. 119.10 million). Principal amount is repayable in 60 equal monthly instalments carrying profit rate at 3 months KIBOR plus 0.70% (2024: 3 months KIBOR plus 0.70%) per annum. The unavailed limit of this facility is nil (2024: nil). This also represented the long term islamic finance facility obtained from Al Baraka Bank (Pakistan) Limited, carrying profit rate basis at 3 months KIBOR plus 0.80% per annum. The facility with sanctioned limit of Rs. 470.20 million has been fully repaid on September 30, 2024. The financing was secured by first exclusive charge of Rs. 781.30 million against equipment / machinery.
- 8.3 This represented the long term islamic finance facility obtained from Meezan Bank Limited, carrying profit rate at 3 months KIBOR plus 0.85% per annum. The facility with sanctioned limit of Rs. 500 million has been fully repaid on October 01, 2024. The financing was secured by first pari passu charge of Rs. 667 million on all present and future fixed assets of the Company.
- 8.4 This represents the outstanding balance of long term islamic finance facility obtained from Bank Alfalah Limited of Rs. 577.40 million (2024: Rs. 577.40 million). Principal amount is repayable in 16 equal quarterly instalments carrying profit rate at 3 months KIBOR plus 0.70% (2024: 3 months KIBOR plus 0.70%) per annum. The financing is initially secured by a ranking charge of Rs. 800 million, which has been upgraded to a first exclusive charge on the plant and machinery being financed under the Diminishing Musharakah facility to be installed at the hospital located at H-8/4, Islamabad. The unavailed limit of this facility is nil (2024: nil).
- 8.5 This represents the outstanding balance of long term islamic finance facility obtained from Meezan Bank Limited of Rs. 475.9 million (2024: nil). Principal amount is repayable in 16 equal quarterly instalments carrying profit rate at 3 months KIBOR plus 0.50% per annum. The financing is secured by existing first pari passu charge of Rs. 800 million on all present and future fixed assets of the Company. The unavailed limit of this facility is Rs. 124.10 million (2024: nil).
- 8.6 This represents the outstanding balance of long term islamic finance facility obtained from Meezan Bank Limited of Rs. 200 million (2024: Rs. 200 million) for the purpose of import / purchase of medical equipment / machinery to combat COVID-19 under State Bank of Pakistan IRFCC scheme. Principal amount shall be repaid by January 27, 2026 in 18 equal quarterly instalments with no profit rate. The financing is secured by first pari passu hypothecation charge of Rs. 267 million on all present and future fixed assets of the Company (excluding land and building). The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries no profit rate, the loan has been recognised at present value using the Company's effective profit rate along with the recognition of government grant.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	5,341	13,313
Amortisation during the year	(4,480)	(7,972)
Balance at end of the year	861	5,341

- 8.7 This represents the outstanding balance of long term islamic finance facility obtained from Al Baraka Bank (Pakistan) Limited of Rs. 45.90 million (2024: Rs. 45.90 million) for the purpose of import / purchase of medical equipment / machinery to combat COVID-19 under State Bank of Pakistan IRFCC scheme. Principal amount shall be repaid in 9 equal half yearly instalments with profit rate of 1% per annum. The facility is secured by exclusive charge of Rs. 55 million over equipment / machinery against DM IRFCC. The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries the profit rate below the market rate, the loan has been recognised at present value using the Company's effective profit rate along with the recognition of government grant.

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	4,073	7,447
Amortisation during the year	(2,557)	(3,374)
Balance at end of the year	1,516	4,073

- 8.8 This represents the outstanding balance of long term finance facility obtained from United Bank Limited of Rs. 185.20 million (2024: Rs. 185.20 million). Principal amount shall be repaid by September 14, 2026 in 18 equal quarterly instalments carrying profit at 1% per annum. The financing is secured by first pari passu charge of Rs. 267 million over fixed assets (excluding land and building) of the Company. The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries the markup rate below the market rate, the loan has been recognised at present value using the Company's effective profit rate along with the recognition of government grant.

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	13,329	27,830
Amortisation during the year	(8,681)	(14,501)
Balance at end of the year	4,648	13,329

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

			2025	2024
	Note		(Rupees in '000')	
9	DEFERRED LIABILITIES			
	Deferred taxation	9.1	244,422	354,960
	Defined contribution plan		44,846	34,434
			289,268	389,394
9.1	Deferred taxation:			
	Deferred tax liability	9.1.1	530,575	604,045
	Deferred tax asset	9.1.2	(286,153)	(249,085)
	Net deferred tax liability		244,422	354,960
9.1.1	Deferred tax liability on taxable temporary differences:			
	Accelerated depreciation / amortisation allowance		530,575	604,045
9.1.2	Deferred tax asset on deductible temporary differences:			
	Right of use assets net of lease liabilities		(57,984)	(66,580)
	Specific provisions		(188,105)	(130,739)
	Retirement benefit obligation		(40,064)	(51,766)
			(286,153)	(249,085)

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

9.1.3 Breakup and movement of deferred tax balances is as follows:

Deferred tax liabilities / (assets)	Opening balance	Statement of profit or loss	Other comprehensive income	Closing balance
(Rupees in '000')				
2025				
Effect of taxable temporary differences				
Accelerated depreciation / amortisation allowance	604,045	(73,470)	-	530,575
Effect of deductible temporary differences				
Right of use assets net of lease liabilities	(66,580)	8,596	-	(57,984)
Specific provisions	(130,739)	(57,366)	-	(188,105)
Retirement benefit obligation	(51,766)	44,193	(32,491)	(40,064)
	354,960	(78,047)	(32,491)	244,422
2024				
Effect of taxable temporary differences				
Accelerated depreciation / amortisation allowance	642,947	(38,902)	-	604,045
Effect of deductible temporary differences				
Right of use assets net of lease liabilities	(59,669)	(6,911)	-	(66,580)
Specific provisions	(118,572)	(12,167)	-	(130,739)
Retirement benefit obligation	(66,133)	62,972	(48,605)	(51,766)
	398,573	4,992	(48,605)	354,960

9.1.4 Deferred tax assets and liabilities on temporary differences are measured at the rate of 39% (2024: 39%).

		2025	2024
		(Rupees in '000')	
	Note		
10 LEASE LIABILITIES			
Balance at beginning of the year		793,646	727,642
Addition during the year		207,615	291,807
Interest expense during the year	30	111,146	92,428
Termination during the year	10.1	(83,217)	(399)
Payment during the year		(329,771)	(317,832)
Balance at end of the year	10.2	699,419	793,646
Less: current portion		192,895	266,739
		506,524	526,907

10.1 Pursuant to the merger / amalgamation disclosed in note 1.1, the ROU asset amounting to Rs. 49.80 million and the corresponding lease liability of Rs. 77.90 million, related to a building leased from SNS Islamabad, have been derecognised. Consequently, a net gain of Rs. 28.10 million has been recorded in other income (note 28).

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

10.2 Lease liabilities are payable as follows:

	Minimum lease payments	Interest	Present value of minimum lease payments
(Rupees in '000')			
2025			
Less than one year	242,874	49,979	192,895
Between one and five years	528,383	142,038	386,345
More than five years	218,502	98,323	120,179
	989,759	290,340	699,419
2024			
Less than one year	303,062	36,323	266,739
Between one and five years	585,023	189,059	395,964
More than five years	250,177	119,234	130,943
	1,138,262	344,616	793,646

		2025	2024
	Note	(Rupees in '000')	
10.3	Amounts recognised in the unconsolidated statement of profit or loss		
Interest expense on lease liabilities	30	111,146	92,428
Expense relating to short term / low value lease	29	26,218	15,754
		137,364	108,182
11	TRADE AND OTHER PAYABLES		
Creditors	11.1	2,456,297	2,097,474
Accrued liabilities		749,818	616,962
Advances from customers - contract liability	11.2	422,014	384,383
Medical consultants' charges		726,226	476,006
Security deposits	11.3	144,573	132,451
Compensated absences	11.4	223,374	175,903
Defined contribution plan		31,027	16,185
Retention money		9,600	11,959
Shifa International Hospitals Limited (SIHL) Employees' Gratuity Fund Trust (the Fund)	11.5	102,728	132,734
		4,865,657	4,044,057

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
		(Rupees in '000')	
11.1	This includes payable to related parties (unsecured) as detailed below:		
	Tameer-e-Millat Foundation (TMF)	4,186	7,285
	Shifa Tameer-e-Millat University (STMU)	42,798	31,566
		46,984	38,851
11.2	Advances from customers - contract liability		
	Balance at beginning of the year	384,383	276,239
	Revenue recognised during the year	(71,099)	(88,650)
	Advance refund during the year	(64,797)	-
	Advance received during the year	173,527	196,794
	Balance at end of the year	422,014	384,383
11.3	This includes security deposits retained from employees of Rs. 54.44 million (2024: Rs. 47.53 million) held in separate bank account and balances obtained from customers of Rs. 90.14 million (2024: Rs. 84.92 million) that are utilisable for the purpose of the business in accordance with agreement with customers.		
		2025	2024
	Note	(Rupees in '000')	
11.4	Compensated absences		
	Balance at beginning of the year	175,903	145,524
	Provision made for the year	136,518	103,063
		312,421	248,587
	Payments made during the year	(89,047)	(72,684)
	Balance at end of the year 11.4.1	223,374	175,903
11.4.1	Actuarial valuation of un-availed leaves has not been carried out since management believes that the effect of actuarial valuation would not be material.		
		2025	2024
	Note	(Rupees in '000')	
11.5	The amount recognised in the unconsolidated statement of financial position:		
	Present value of defined benefit obligation 11.5.1	769,150	556,506
	Fair value of plan assets 11.5.2	(666,422)	(423,772)
		102,728	132,734

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	2025	2024
	(Rupees in '000')	
11.5.1 Movement in the present value of defined benefit obligation:		
Balance at beginning of the year	556,506	387,539
Interest cost	77,364	56,442
Current service cost	98,635	72,974
Benefits paid	(60,107)	(78,839)
Benefits payable	(3,895)	(2,635)
Remeasurement loss on defined benefit obligation	100,647	121,025
Balance at end of the year	769,150	556,506
11.5.2 Movement in the fair value of plan assets:		
Balance at beginning of the year	423,772	217,966
Interest income on plan assets	73,956	48,772
Contributions	215,360	242,112
Benefits paid	(60,107)	(78,839)
Benefits payable	(3,895)	(2,635)
Return on plan assets, excluding interest income	17,336	(3,604)
Balance at end of the year	666,422	423,772
11.5.3 Charge for the year:		
Current service cost	98,635	72,974
Interest cost on defined benefit obligation	77,364	56,442
Interest income on plan assets	(73,956)	(48,772)
	102,043	80,644
11.5.4 Remeasurements recognised in the unconsolidated statement of comprehensive income (OCI):		
Remeasurement loss on defined benefit obligation	100,647	121,025
Return on plan assets, excluding interest income	(17,336)	3,604
Remeasurement loss recognised in OCI	83,311	124,629
Deferred tax relating to remeasurement of staff gratuity fund benefit plan	(32,491)	(48,605)
	50,820	76,024

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
11.5.5	Movement in liability recognised in unconsolidated statement of financial position:		
Balance at beginning of the year		132,734	169,573
Charge for the year		102,043	80,644
Remeasurement recognised in OCI during the year		83,311	124,629
Contributions during the year		(215,360)	(242,112)
Balance at end of the year		102,728	132,734
11.5.6	Plan assets comprise of:		
Term deposit receipts		559,671	306,190
Ordinary shares of SIHL	11.5.6.1	37,279	11,503
Cash and bank balances		89,616	122,328
Payable to outgoing members		(20,144)	(16,249)
		666,422	423,772

11.5.6.1 Number of ordinary shares held by the Fund at year end were 78,461 shares (2024: 78,461 shares) with market value of Rs. 475.13 (2024: Rs. 146.61) per share.

11.5.7 Latest actuarial valuation was carried out by an independent actuary on June 30, 2025 using the Projected Unit Credit Method.

		2025	2024
11.5.8	Principal actuarial assumptions used in the actuarial valuation:		
Discount rate used for interest cost in profit or loss		14.75%	16.25%
Discount rate used for year end obligation		11.75%	14.75%
Expected rate of salary growth			
- Salary increase FY 2025		N/A	13.75%
- Salary increase FY 2026 onward		11.75%	13.75%
Mortality rate		SLIC 2001-2005 set back 1 year	SLIC 2001-2005 set back 1 year
Withdrawal rates		Age based	Age based
Retirement assumption		Age 60	Age 60

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

11.5.9 Sensitivity analysis

The calculation of the defined benefit obligation is sensitive to assumptions set out above. The following table summarises how the impact on the defined benefit obligation at the end of the reporting period would have increased / decreased as a result of a change in respective assumptions by one percent.

	2025		2024	
	Defined benefit obligation		Defined benefit obligation	
	Effect of 1% increase	Effect of 1% decrease	Effect of 1% increase	Effect of 1% decrease
(Rupees in '000')				
Discount rate	714,039	833,098	519,684	598,872
Future salary increase	832,486	713,577	598,872	519,075

11.5.10 The average duration of the defined benefit obligation as at June 30, 2025 is 8 years (2024: 7 years).

11.5.11 The expected expenses for the next year amount to Rs. 141.06 million.

11.5.12 Risks associated with the scheme

Final salary risk

The risk that the final salary at the time of cessation of service is greater than what we assumed. Since the benefit is calculated on the final salary (which will closely reflect inflation and other macroeconomic factors), the benefit amount increases as salary increases.

Demographic risks

a) Mortality risk

The risk that the actual mortality experience is different than the assumed mortality. This effect is more pronounced in schemes where the age and service distribution is on the higher side.

b) Withdrawal risk

The risk of actual withdrawals experience is different from assumed withdrawal probability. The significance of the withdrawal risk varies with the age, service and the entitled benefits of the beneficiary.

c) Investment risk

The risk of the investment under performing and being not sufficient to meet the liabilities.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
12	MARKUP ACCRUED		
	Long term financing	7,974	23,858
13	TAXATION - NET		
	Tax refundable at beginning of the year	(225,780)	(287,675)
	Income tax paid / deducted at source during the year	(1,553,502)	(827,215)
		(1,779,282)	(1,114,890)
	Income tax expense / levies 31	1,883,783	889,110
	Tax payable / (refund) at end of the year	104,501	(225,780)

14 CONTINGENCIES AND COMMITMENTS

14.1 Contingencies

14.1.1 The guarantees issued by bank in favour of Sui Northern Gas Pipelines Limited (SNGPL) and Imtiaz Group (SMC-Private) Limited of aggregate sum of Rs. 36.60 million (2024: Rs. 33.10 million) on behalf of the Company in its ordinary course of business.

14.1.2 The Company is facing claims and penalties amounting to Rs. 5.9 million (2024: Rs. 22.25 million). Against these claims the Company has made payments under protest amounting to Rs. 2.4 million (2024: Rs. 1.4 million). In compliance with the directions of the Islamabad High Court (IHC), the Company has furnished a bank guarantee for Rs. 0.5 million (2024: Rs. 1.5 million) and, submitted a pay order of Rs. 2 million to the IHC. These claims and penalties originated from ongoing legal proceedings and complaints currently under litigation before the Islamabad, Peshawar and Lahore High Courts and the Supreme Court of Pakistan.

Furthermore, on June 06, 2012, the Competition Commission of Pakistan (CCP) imposed a penalty of Rs. 20 million against each Gulf Cooperation Council's (GCC) Approved Medical Center (GAMC), including the Company, on the allegations of engaging in non-competitive practices involving territorial division and equal allocation of customers among GAMCs. The Company, in conjunction with other GAMCs, is actively contesting this matter which is presently pending adjudication before the Competition Appellate Tribunal (CAT) and the Supreme Court of Pakistan.

Subsequently, the CAT has adjudicated the matter and through order dated August 11, 2025, reduced the penalty from Rs. 20 million to Rs. 2 million. The Company, in conjunction with other GAMCs, will contest the order of the CAT by preferring an appeal before the Supreme Court of Pakistan.

Following the CAT's order, the CCP, without serving any notice on the Company and in deviation from the procedure prescribed under the Competition Act, 2010, initiated coercive recovery proceedings. On August 12, 2025, the CCP proceeded to attach the Company's accounts and recovered an aggregate amount of Rs. 4.01 million, i.e. twice the penalty determined by the CAT. Consequently, the Company is in the process of filing a writ petition before the IHC seeking, inter alia, a declaration that the recovery is illegal and the refund of the unlawfully recovered amount of Rs. 4.01 million.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The Company's management, based on advice from respective legal counsels, remains confident of favorable resolutions in the aforementioned matters.

- 14.1.3 During the year, the Company has received a demand notice from the Capital Development Authority (CDA) regarding the payment of regularisation charges. As per the notice dated March 21, 2025, CDA has demanded payment of Rs. 790.76 million as regularisation charges, out of which Rs. 384.92 million has already been paid by the Company. The balance amount of Rs. 405.84 million is being contested vehemently as the same is beyond the scope of legal charges / rates invoked at the time of demand. The Company intends to pursue rigorously and avail all appropriate legal remedy before competent forum. The Company has also expressed its protest in clear terms to the CDA against said excessive demand. No provision has been made in these financial statements as the Company's management as per advice of the legal counsel, is confident that a favorable outcome will be achieved.

14.1.4 Contingencies related to income tax and sales tax are as follows:

- 14.1.4.1 The tax authorities amended the assessments for the tax years 2012 to 2016, 2019, 2021 and 2023 under section 122(5A) of the Income Tax Ordinance, 2001 (the Ordinance). They raised total tax demands of Rs. 648.70 million against these years. The Company, being aggrieved, appealed these amended assessments before the Commissioner Inland Revenue (Appeals) [CIR(A)] or the Appellate Tribunal Inland Revenue (ATIR), as applicable, on various dates from September 2018 to February 2025. These appeals are currently pending adjudication.
- 14.1.4.2 The tax authorities imposed taxes of Rs. 109.60 million, Rs. 178.40 million, Rs. 27.40 million, and Rs. 29.20 million under section 161/205 of the Ordinance for the tax years 2016, 2014, 2013, and 2012 respectively, based on alleged non-deduction of tax on payments. The Company, being aggrieved, appealed these assessments before the CIR(A). Regarding the tax year 2012, the CIR(A) deleted the assessment, while for the tax years 2013 and 2016, the assessment was set aside, and for the tax year 2014, the assessment was confirmed. The Company, still aggrieved, filed appeals for the tax years 2013, 2014, and 2016 before the ATIR. The appeals for the tax years 2013 and 2016 were filed on November 26, 2019 and June 06, 2023 respectively, and they are currently pending adjudication. Additionally, the ATIR has set aside the assessment for the tax year 2014 for denovo consideration.
- 14.1.4.3 The tax authorities amended the assessments for the tax years 2012 to 2018 under section 122(1)/(5) of the Ordinance. They raised an aggregate tax demand of Rs. 2,537.10 million. Being aggrieved, the Company appealed these assessments before the CIR(A) except tax year 2018. The CIR(A) annulled all the assessment orders from October 15, 2018 to October 23, 2018 resulting in the deletion of the tax demands. Dissatisfied with the CIR(A)'s decision, the tax department filed an appeal before the ATIR from November 15, 2018 to November 27, 2019. These appeals are currently pending adjudication. For the tax year 2018, the Company appealed the assessment before the ATIR on July 24, 2024.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

14.1.4.4 The tax authorities imposed sales tax under section 11 of the Sales Tax Act, 1990, on the alleged non-payment of sales tax on sales of scrap, fixed assets, and cafeteria services for the tax years 2016 to 2020, raising total tax demands of Rs. 225.20 million for these years. Upon appeal, the ATIR through orders from February 16, 2021 to July 30, 2024 deleted the sales tax charged on cafeteria services and fixed assets but confirmed the sales tax on scrap. Furthermore, for the tax years 2016 and 2020, the department has filed sales tax references before the High Court, which are currently pending adjudication.

14.1.4.5 In the case of amalgamated entity, SNS Islamabad, the tax authorities amended the assessment for tax year 2021 under section 122(5A) of the Ordinance, through an order dated August 31, 2022, creating a demand of Rs. 8.50 million by disallowing a refund adjustment from tax year 2020. The CIR(A) annulled the order on February 10, 2023. However, a fresh notice for reassessment was issued on May 27, 2025, and a revised order was passed on the same grounds, alleging the refund of Rs. 8.50 million as unverified. Being aggrieved, the Company filed an appeal before CIR(A) on July 24, 2025 which is pending adjudication.

Management is confident that the above disallowances and levies do not hold merit and the related amounts have been lawfully claimed in the income and sales tax returns as per the applicable tax laws and these matters will ultimately be decided in favour of the Company. Accordingly, no provision has been made in respect of above in these unconsolidated financial statements.

		2025	2024
		(Rupees in '000')	
14.2	Commitments		
14.2.1	Capital expenditure contracted	160,117	294,233
14.2.2	Letter of credit	-	521,187

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

15 PROPERTY, PLANT AND EQUIPMENT

Particulars		Owned assets										Right of use assets					
		Freehold land	Leasehold land	Building on freehold land	Building on leasehold land	Leasehold improvements	Biomedical equipment	Air conditioning equipment and machinery	Electrical and other equipment	Furniture and fittings	Construction equipment	Computer installations	Vehicles	Capital work in progress (note 15.7)	Office premises	Electrical equipment	Total
(Rupees in '000')																	
Cost / revalued amount																	
Balance as at July 01, 2023																	
	40,656	1,009,761	58,898	2,678,563	397,281	5,190,647	568,275	871,895	255,561	3,163	691,131	167,190	636,751	1,362,677	57,000	13,989,449	
Additions	-	-	-	-	-	252,903	3,623	68,274	16,845	607	161,665	66,369	45,757	293,287	-	909,330	
Disposals	-	-	-	-	-	-	-	-	-	-	(1,303)	(7,421)	-	(8,724)	-	(324)	
Termination of lease	-	-	-	-	-	-	-	-	-	-	-	-	-	(324)	-	(76,154)	
Write offs	-	-	-	-	-	(58,243)	(2,048)	(10,025)	(456)	(122)	(5,260)	-	-	-	-	-	
Transfers	-	-	-	41,844	120,026	125,162	-	-	-	-	58,887	-	(345,919)	-	-	-	
Balance as at June 30, 2024																	
	40,656	1,009,761	58,898	2,720,407	517,307	5,510,469	569,850	930,144	271,950	3,648	905,120	226,138	336,589	1,655,640	57,000	14,813,577	
Balance as at July 01, 2024																	
Additions	-	-	-	-	517,307	5,510,469	569,850	930,144	271,950	3,648	905,120	226,138	336,589	1,655,640	57,000	14,813,577	
On merger (refer note 1.1)	-	1,024,115	-	503,681	-	308,008	11,847	29,067	8,698	-	59,224	87,058	580,049	210,241	-	1,294,192	
Revaluation	19,344	161,872	-	-	-	-	-	-	-	-	-	-	-	-	-	1,527,796	
Disposals	-	-	-	-	-	-	-	-	-	-	(1,942)	(13,980)	-	-	-	181,216	
Termination of lease (refer note 10.1)	-	-	-	-	-	(239,714)	(19,937)	(96,522)	(39,086)	(862)	(80,720)	-	(60,443)	(516,767)	-	(516,767)	
Write offs	-	-	-	-	-	359,037	-	-	-	-	6,529	-	(391,838)	-	-	(537,284)	
Transfers	-	-	-	206,393	(180,121)	-	-	-	-	-	-	-	-	-	-	-	
Balance as at June 30, 2025																	
	60,000	2,195,748	58,898	3,430,481	337,186	5,937,800	561,760	862,689	241,562	2,786	888,211	299,216	464,357	1,349,114	57,000	16,746,808	
Depreciation / amortisation																	
Balance as at July 01, 2023																	
Charge for the year	-	128,116	9,816	937,036	96,983	3,053,967	403,146	636,448	176,148	2,439	567,383	115,194	-	788,033	57,000	6,971,709	
On disposals	-	14,254	2,945	75,818	86,488	405,567	54,266	69,163	16,795	337	84,761	24,605	-	244,703	-	1,079,702	
Termination of lease	-	-	-	-	-	-	-	-	-	-	(1,176)	(5,551)	-	-	-	(6,727)	
On write offs	-	-	-	-	-	(52,427)	(2,048)	(8,800)	(395)	(122)	(5,194)	-	-	(25)	-	(25)	
Balance as at June 30, 2024																	
	-	142,370	12,761	1,012,854	183,471	3,407,107	455,364	696,811	192,548	2,654	645,774	134,248	-	1,032,711	57,000	7,975,673	
Balance as at July 01, 2024																	
Charge for the year	-	142,370	12,761	1,012,854	183,471	3,407,107	455,364	696,811	192,548	2,654	645,774	134,248	-	1,032,711	57,000	7,975,673	
On disposals	-	18,463	2,945	97,264	79,223	412,206	42,064	59,646	15,624	279	100,884	33,314	-	228,583	-	1,090,495	
Termination of lease	-	-	-	-	-	-	-	-	-	-	(1,828)	(11,277)	-	-	-	(13,105)	
On write offs	-	-	-	-	-	(226,341)	(19,914)	(96,092)	(37,772)	(802)	(80,654)	-	-	(462,921)	-	(462,921)	
Balance as at June 30, 2025																	
	-	160,833	15,706	1,110,118	262,694	3,592,972	477,514	660,365	170,400	2,131	664,176	156,285	-	798,373	57,000	8,128,567	
Carrying value as at June 30, 2024																	
	40,656	867,391	46,137	1,707,553	333,836	2,103,362	114,486	233,333	79,402	994	259,346	91,890	336,589	622,929	-	6,837,904	
Carrying value as at June 30, 2025																	
	60,000	2,034,915	43,192	2,320,363	74,492	2,344,828	84,246	202,324	71,162	655	224,035	142,931	464,357	550,741	-	8,618,241	
Annual rate of depreciation (%)																	
	-	1.58	5	2.5-4.0	20	10	10-15	10-20	10	10-20	25	20	-	5.85-33	-	33.3	

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

15.1 The Company's leasehold and freehold lands were revalued as at June 30, 2025, by an independent valuer on a fair market value basis.

15.2 Had there been no revaluation, the carrying value would have been as under:

	Cost	Accumulated amortisation	Carrying value
	(Rupees in '000')		
Freehold land			
June 30, 2025	14,483	-	14,483
June 30, 2024	14,483	-	14,483
Leasehold land			
June 30, 2025	1,221,761	20,883	1,200,878
June 30, 2024	197,646	13,805	183,841

15.3 Particulars of Company's freehold and leasehold land are as follows:

		2025	2024
Location	Nature	Area	
Shifa Cooperative Housing Society, Islamabad Expressway - Sq. yds	Freehold land	1003	1003
SIHL H-8/4, Islamabad * - Kanal	Leasehold land	87.8	87.8
Neuro Sciences Institute H-8/4, Islamabad * - Sq. yds	Leasehold land	7100	-

*The covered area includes multi-storey buildings.

15.4 Property, plant and equipment include items with aggregate cost of Rs. 3,484.01 million (2024: Rs. 3,165.68 million) representing fully depreciated assets that are still in use of the Company.

15.5 Property, plant and equipment of the Company are encumbered under an aggregate charge of Rs. 7,665.59 million (2024: Rs. 8,116.83 million) in favor of lenders under various financing arrangements as disclosed in note 8.

15.6 The Forced Sale Value (FSV) of the revalued leasehold and freehold land has been assessed at Rs. 1,627.93 million (2024: Rs. 716.78 million) and Rs. 51 million (2024: Rs. 32.53 million) respectively.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
		(Rupees in '000')	
	Note		
15.7 Capital work in progress			
Civil work		212,638	243,714
Installation of equipment		251,719	92,875
		464,357	336,589
16 INTANGIBLE ASSETS			
Softwares in use	16.1	37,265	1,405
Software under development / deployment	16.2	5,787	39,375
		43,052	40,780
16.1 Softwares in use			
Cost			
Balance at beginning of the year		109,400	109,400
Addition during the year		39,375	-
Balance at end of the year		148,775	109,400
Accumulated amortisation			
Balance at beginning of the year		107,995	106,941
Charged during the year		3,515	1,054
Balance at end of the year		111,510	107,995
Carrying value		37,265	1,405
16.2 Software under development / deployment			
Balance at beginning of the year		39,375	39,375
Addition during the year	16.2.1	5,787	-
Capitalised during the year		(39,375)	-
Balance at end of the year		5,787	39,375
Annual amortisation rate (percentage)		25	25

16.2.1 This represents advance paid for implementation of Oracle Fusion software.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
17	INVESTMENT PROPERTY - AT COST		
	Balance at beginning of the year	720,292	748,450
	Disposed off during the year	(95,420)	(28,158)
	Balance at end of the year	17.1	624,872

17.1 This represents freehold land comprising of 11 plots at Shifa Cooperative Housing Society, Islamabad Expressway (SCHS), 48K-3M-182 Sqft at Chak No. 4, near Sargodha Road, Faisalabad of which 20K-14M-181 Sqft are subject to possession proceedings and 105.02 kanal at Motorway, Mouza Noon, Islamabad. An independent valuation was conducted to determine the fair value of the investment property. The prices were assessed through a market survey of comparable properties in the vicinity. The fair value was based on the independent valuer's professional judgment, using openly available information and inquiries made in the market. Valuation was carried out by an independent valuer who holds a recognised and relevant professional qualification and has recent experience in the location and category of the investment property being valued. The fair value and forced sale value of the land located at SCHS, Sargodha Road Faisalabad and Motorway, Mouza Noon, Islamabad are Rs. 430 million, Rs. 146.24 million, Rs. 315.06 million (2024: Rs. 360.12 million, Rs. 136.89 million, Rs. 425.02 million) and Rs. 365.50 million, Rs. 116.99 million, Rs. 252.05 million (2024: Rs. 288.09 million, Rs. 109.51 million, Rs. 340.02 million) respectively.

During the previous year, the Company was informed by its former property dealer about the sale of 49 kanal of land located at Mouza Noon, Islamabad; however, the Company was provided with the sale proceeds of only 10.83 kanal. Further, in coordination with land revenue authorities based on the Company's verification of land title against official record through an independent source, the authorities, in their latest assessment to date, have confirmed the Company's ownership of 105.02 kanal, of which 6.5 kanal remain under review. Accordingly, the sales proceeds of 36.7 kanal land were recorded in other receivables. The matter is being pursued, and the final outcome of the assessment will form the basis for determining the appropriate course of action.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
18	LONG TERM INVESTMENTS - AT COST		
	In subsidiary companies (unquoted):		
Shifa Development Services (Private) Limited (SDSPL)	18.2	9,966	9,966
Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNS Islamabad)	18.3	-	1,697,521
Shifa National Hospital Faisalabad (Private) Limited (SNH Faisalabad)	18.4	2,137,373	1,582,279
Shifa Medical Centre Islamabad (Private) Limited (SMC Islamabad)	18.5	1,660,180	1,356,170
	In associated companies (unquoted):		
Shifa CARE (Private) Limited (SCPL)	18.6	45,001	45,001
SIHT (Private) Limited (SIHT)	18.7	725,000	425,000
		4,577,520	5,115,937
	Less: Impairment loss		
Shifa Development Services (Private) Limited (SDSPL)		9,966	9,966
Shifa CARE (Private) Limited (SCPL)		45,001	45,001
		54,967	54,967
		4,522,553	5,060,970

18.1 Per share breakup values of these investments are given below:

	2025	2024
	(Rupees)	
Shifa Development Services (Private) Limited (SDSPL)	(8.70)	(8.02)
Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNS Islamabad)	-	10.54
Shifa National Hospital Faisalabad (Private) Limited (SNH Faisalabad)	11.16	11.06
Shifa Medical Centre Islamabad (Private) Limited (SMC Islamabad)	13.29	12.90
Shifa Care (Private) Limited (SCPL)	(0.60)	0.16
SIHT (Private) Limited	68.63	54.34

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 18.2 This represents investment in 1,650,000 (2024: 1,650,000) fully paid ordinary shares of Rs. 10 each of SDSPL. The above investment in ordinary shares represents 55% (2024: 55%) shareholding in SDSPL held by the Company. During the last year the investment has been fully impaired in view of financial difficulties faced by SDSPL due to which it might not be able to continue its business.
- 18.3 Prior to the merger as disclosed in note 1.1, the Company held 169,752,100 fully paid ordinary shares of Rs. 10 each, representing 100% of SNS Islamabad's share capital. Post-merger, the investment of Rs. 1,697.52 million has been fully adjusted against SNS Islamabad's net assets.
- 18.4 This represents investment in 213,737,338 (2024: 158,227,912) fully paid ordinary shares of Rs. 10 each of SNH Faisalabad. The above investment in ordinary shares represents 60% (2024: 61%) shareholding in SNH Faisalabad held by the Company.

			2025	2024
		Note	(Rupees in '000')	
18.5	Investment in equity shares	18.5.1	1,356,170	1,356,170
	Advance paid for acquisition of shares	18.5.2	304,010	-
			1,660,180	1,356,170

- 18.5.1 This represents investment in 135,617,001 (2024: 135,617,001) fully paid ordinary shares of Rs. 10 each of SMC Islamabad. The above investment in ordinary shares represents 56% (2024: 56%) shareholding in SMC Islamabad held by the Company.

- 18.5.2 This represents the first instalment paid to Interloop Holdings (Private) Limited (ILHPL) under a tripartite Share Purchase Agreement (SPA) dated July 10, 2025 for the acquisition of 96,572,500 shares (40% equity interest) in SMC Islamabad, with total consideration of Rs. 1,520.05 million payable in five quarterly instalments. Subsequent to year-end, the referred shares were transferred to the Company in accordance with the SPA, secured through four post-dated cheques issued by the Company and a pending share pledge agreement over SNH Faisalabad shares worth Rs. 1,216.04 million, owned by the Company.

In addition to above Rs. 106.68 million was paid post year-end to minority shareholders for a 2.81% stake, increasing the Company's ownership in SMC Islamabad to approximately 99%.

The above acquisition was approved by shareholders in the Extraordinary General Meeting held on June 5, 2025.

- 18.6 This represents investment in 4,500,050 (2024: 4,500,050) fully paid ordinary shares of Rs. 10 each of SCPL. The above investment in ordinary shares represents 50% (2024: 50%) shareholding in SCPL held by the Company. During the last year, the investment has been fully impaired in view of the financial difficulties faced by SCPL due to which it might not be able to continue its business.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Summary of results of SCPL are as under:

	2025	2024
	(Rupees in '000')	
Summarised statement of financial position		
Non-current assets	-	-
Current assets	2,609	2,921
Current liabilities	(7,997)	(1,437)
Net assets	(5,388)	1,484
Reconciliation to carrying amount		
Opening net assets	1,484	90,157
Total comprehensive loss for the year	(6,872)	(88,673)
Closing net assets	(5,388)	1,484
Company's share in carrying value of net assets	(2,694)	742
Company's share in total comprehensive loss	(3,436)	(44,336)
Summarised statement of profit or loss and comprehensive income		
Revenue for the year – gross	-	-
Depreciation and amortisation	(174)	(4,008)
Finance cost	-	(256)
Provision for taxation	-	-
Loss for the year	(6,872)	(88,673)
Total comprehensive loss for the year	(6,872)	(88,673)

18.6.1 The above information is based on management financial statements of SCPL.

18.7 In line with the decision of board of directors of the Company in its meeting held on April 12, 2023, on September 23, 2023, the Company entered into a tripartite Shares Purchase Agreement (SPA) with Shifa Foundation and its wholly owned subsidiary SIHT (Private) Limited (SIHT) for acquiring 50% shareholding in SIHT from Shifa Foundation.

The SPA provides that the paid up share capital of SIHT shall be increased from Rs. 100.10 million to Rs. 500.10 million representing 5,001,000 ordinary shares of Rs. 100 each over the arrangement period. The SPA further provides that the referred acquisition of equity interest in SIHT to be made in 9 quarterly instalments shall be completed by September 30, 2025. Accordingly, by the end of the current year a sum of Rs. 300 million (2024: Rs. 425 million) has been paid to Shifa Foundation to acquire further 937,680 shares (2024: 1,328,397 shares).

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

At year end the Company has investment in 2,266,077 (2024: 1,328,397) fully paid ordinary shares of Rs. 100 each of SIHT representing 45.30% (2024: 29.50%) shareholding.

Summary of results of SIHT are as under:

	2025	2024
	(Rupees in '000')	
Summarised statement of financial position		
Non-current assets	181,806	179,734
Current assets	415,707	285,698
Non-current liabilities	(88,558)	(100,482)
Current liabilities	(165,714)	(120,376)
Net assets	343,241	244,574
Reconciliation to carrying amount		
Opening net assets	244,574	(84,443)
Total comprehensive income / (loss) for the year	48,668	(20,983)
Equity	50,000	350,000
Closing net assets	343,242	244,574
Company's share in carrying value of net assets	72,941	42,073
Company's share in total comprehensive income / (loss)	16,112	(955)
Summarised statement of profit or loss and comprehensive income		
Revenue for the year – gross	717,519	597,996
Depreciation and amortisation	(39,814)	(45,827)
Finance cost	(13,182)	(17,398)
Provision for taxation	(15,646)	(10,065)
Profit / (loss) for the year	48,668	(20,983)
Total comprehensive income / (loss) for the year	48,668	(20,983)

18.7.1 The above information is based on initialled financial statements of SIHT.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

19 LONG TERM DEPOSITS

This represents security deposits given to various institutions / persons and are refundable on termination of relevant services / arrangements. These are unsecured and considered good.

		2025	2024
	Note	(Rupees in '000')	
20	STORES, SPARE PARTS AND LOOSE TOOLS		
Stores		229,584	252,158
Spare parts		13,710	7,806
Loose tools		1,303	1,380
		244,597	261,344
Less: provision for slow moving items	20.1	20,436	17,765
		224,161	243,579
20.1	Movement of provision for slow moving items		
Balance at beginning of the year		17,765	19,657
Charged / (reversal) during the year		2,671	(1,892)
Balance at end of the year		20,436	17,765

21 STOCK IN TRADE

This represents medicines being carried at moving average cost.

		2025	2024
	Note	(Rupees in '000')	
22	TRADE DEBTS		
Unsecured - considered good			
Related party - Shifa Foundation	22.1	14,422	7,137
Others		1,740,911	1,580,199
		1,755,333	1,587,336
Less: allowance for expected credit losses (ECL)	41.1.3	293,877	241,147
		1,461,456	1,346,189

22.1 Maximum amount due from Shifa Foundation at the end of any month during the year was Rs. 24.58 million (2024: Rs. 15.80 million).

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
23	LOANS AND ADVANCES		
Secured - considered good			
Executives		12,281	10,641
Other employees		16,420	23,239
	23.1	28,701	33,880
Unsecured - consultants		7,123	13,870
Unsecured - suppliers / contractors		102,201	109,707
		109,324	123,577
		138,025	157,457

23.1 These advances are secured against employee terminal benefits.

		2025	2024
	Note	(Rupees in '000')	
24	DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES		
Unsecured - considered good			
Short term prepayments		52,998	48,561
Security deposit (refer note 1.1)		-	20,278
Other receivables	24.1	311,254	192,876
		364,252	261,715
Less: allowance for expected credit losses against other receivables	24.2	168,008	76,317
		196,244	185,398

24.1 This includes Rs. 59.90 million (2024: Rs. 30.33 million) due from SIHT (Private) Limited. Maximum amount due from SIHT (Private) Limited at the end of any month during the year was Rs. 148.88 million (2024: Rs. 133.80 million).

		2025	2024
	Note	(Rupees in '000')	
24.2	Allowance for expected credit losses against other receivables (unrelated parties)		
Balance at beginning of the year		76,317	57,812
Charged during the year	24.2.1	91,691	18,505
Balance at end of the year		168,008	76,317

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

24.2.1 This represents an amount whose recovery is considered doubtful.

		2025	2024
	Note	(Rupees in '000')	
25	OTHER FINANCIAL ASSETS		
Investment in Term Deposit Receipt - at amortised cost	25.1	3,000	3,000
Investment in Mutual Fund - at fair value through profit or loss	25.2	1,003,355	199,566
		1,006,355	202,566

25.1 This represents term deposit receipt (TDR) having face value of Rs. 3 million (2024: Rs. 3 million) with three months maturity. Profit payable on monthly basis at the weighted average rate of 11.17% (2024: 18.98%).

25.2 This represents investment in 2,175,860 (2024: 1,973,327) and 76,983,043 (2024: nil) units of UBL Al-Ameen Islamic Cash Fund and NBP Islamic Money Market Fund, respectively. Fair value of the investment was determined using quoted repurchase price at year end.

		2025	2024
	Note	(Rupees in '000')	
26	CASH AND BANK BALANCES		
Cash at bank in:			
Current accounts:			
Local currency		570,771	396,855
Foreign currency		365,160	913,410
		935,931	1,310,265
Saving accounts:			
Local currency		2,561,048	792,779
Foreign currency		284	278
	26.1	2,561,332	793,057
	26.2	3,497,263	2,103,322
Cash in hand		14,551	26,055
		3,511,814	2,129,377

26.1 Balances with saving accounts earned profit / mark-up at weighted average rate of 13.43% per annum (2024: 16.52% per annum).

26.2 Balances with banks includes Rs. 144.58 million (2024: Rs. 132.45 million) in respect of security deposits (note 11.3).

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
27	REVENUE - NET		
Inpatients		17,581,470	14,796,234
Outpatients		9,780,501	8,194,000
Other services	27.1	810,716	773,422
		28,172,687	23,763,656
Less: discount		112,414	116,591
Less: sales tax		92,612	83,225
		205,026	199,816
		27,967,661	23,563,840

27.1 This represents revenue from external pharmacy outlets, cafeteria sales and operating leases to related parties / other parties.

27.2 The revenue-net is excluding of physician share of Rs. 2,910.43 million (2024: Rs. 1,930.07 million).

		2025	2024
	Note	(Rupees in '000')	
28	OTHER INCOME		
	Income from financial assets:		
Profit on bank balances		185,262	66,914
Dividend income from mutual fund - investments at fair value through profit or loss		27,690	35,844
Un-realised gain on investments at fair value through profit or loss		25,803	14,180
Dividend income from subsidiary	28.1	50,926	16,975
		289,681	133,913
	Income from other than financial assets:		
Gain on disposal of property, plant and equipment		2,500	2,664
Exchange gain on foreign currency translation		7,199	-
Sale of scrap - net of sales tax		13,147	23,222
Miscellaneous	28.2	90,295	30,324
		113,141	56,210
		402,822	190,123

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 28.1 This represents the dividend at the rate of Re. 0.30 (2024: Re. 0.10) per share received from former subsidiary, SNS Islamabad.
- 28.2 This includes an amount of Rs. 28.27 million (2024: nil) [net of sales tax] received from DAI Pakistan (Private) Limited under the Fleming Fund Country Grant – Pakistan, to support the implementation of the Clinical Engagement Program for Antimicrobial Resistance (AMR) related interventions. Further, all relevant expenses of this project have been recorded under the respective operating expense heads.

		2025	2024
		(Rupees in '000')	
	Note		
29	OPERATING COSTS		
Salaries, wages and benefits	29.1	8,869,196	7,800,352
Medicines consumed	29.2	6,700,403	6,083,422
Supplies consumed		3,023,211	2,429,431
Utilities		1,352,916	1,327,372
Depreciation / amortisation	15	1,090,495	1,079,702
Repairs and maintenance		1,251,342	1,123,554
Rates and taxes	29.3	395,357	23,832
Cleaning and washing		271,309	271,911
Printing and stationery		198,154	223,406
Fee, subscription and membership		142,784	141,466
Travelling and conveyance		60,432	47,785
Communication		59,956	70,189
Advertising and sales promotion		41,358	50,956
Legal and professional		39,511	32,400
Rent		26,218	15,754
Insurance		23,327	20,704
Property, plant and equipment written off	29.4	75,709	7,168
Loss on disposal of investment property		7,340	2,708
Auditors' remuneration	29.5	4,498	4,218
Amortisation on intangible assets	16	3,515	1,054
Charged / (reversal) of provision for slow moving stores		2,671	(1,892)
Impairment loss on long term investments- at cost		-	54,967
Exchange loss on foreign currency translation		-	26,469
Loss on derecognition of investment		-	21,015
Miscellaneous		97,812	87,011
		23,737,514	20,944,954

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 29.1 This includes charge for employee gratuity of Rs. 102.04 million (2024: Rs. 80.64 million), defined contribution plan (pension) of Rs. 129.23 million (2024: Rs. 109.03 million), compensated absences of Rs. 136.52 million (2024: Rs. 103.06 million) and bonus of Rs. 302.79 million (2024: Rs. 170.73 million).
- 29.2 This includes stock-in-trade amounting to Rs. 6.44 million (2024: nil) written off during the year.
- 29.3 This includes an amount of Rs. 384.92 million paid to the Capital Development Authority (CDA) for building regularisation charges (note 14.1.3).
- 29.4 This represents property, plant and equipment written off that were determined to be irreparable after carrying out detailed reassessment / physical verification exercise by the management.

		2025	2024
	Note	(Rupees in '000')	
29.5	Auditors' remuneration		
	Annual audit fee	1,881	1,710
	Half yearly review fee	990	900
	Statutory certifications	745	850
	Out of pocket expenses	340	239
		3,956	3,699
	Sales tax	542	519
		4,498	4,218
30	FINANCE COSTS		
	Markup on long term loans - secured	145,775	249,397
	Interest on lease liabilities 10	111,146	92,428
	Credit card payment collection and bank charges	96,911	99,229
		353,832	441,054
31	INCOME TAX EXPENSE / LEVIES		
	Current tax		
	- for the year	1,736,264	889,110
	- prior year	147,519	-
		1,883,783	889,110
	Deferred tax (expense) / income 13 & 31.1	(78,047)	4,993
		1,805,736	894,103

- 31.1 Reconciliation between current tax charged under the Ordinance with current tax recognised in the unconsolidated statement of profit or loss, is as follows:

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Current tax liability for the year as per the Ordinance			
Portion of current tax liability as per tax law, representing income tax under IAS 12		1,876,860	881,822
Portion of current tax liability as per tax law, representing levy in term of requirement of IFRIC 21 / IAS 37	31.2	6,923	7,288
		1,883,783	889,110

31.2 This represents portion of final tax paid as per the Ordinance, representing levy in terms of requirements of IFRIC 21 / IAS 37.

		2025	2024
31.3	Reconciliation of tax charge for the year:		
	Profit before levies and income tax (Rupees in '000')	4,134,716	2,256,177
	Income tax expense / levies (Rupees in '000')	1,805,736	894,103
	Effective tax rate (Percentage)	43.67	39.63
	Reconciliation of effective tax rate (percentage)		
	Applicable tax rate	29.00	29.00
	Add: super tax	10.00	10.00
	Add: net tax effects of amounts that are inadmissible for tax purposes / others	20.75	27.16
	Less: net tax effect of amounts that are deductible for tax purposes / others	16.08	26.53
	Average effective tax rate charged on income	43.67	39.63
32	EARNINGS PER SHARE - BASIC AND DILUTED		
	Profit for the year (Rupees in '000')	2,328,980	1,362,074
	Weighted average number of ordinary shares outstanding during the year (Number in '000')	63,214	63,214
	Earnings per share - basic and diluted (Rupees)	36.84	21.55

32.1 There is no dilutive effect on the basic earnings per share of the Company.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

33 CAPACITY UTILISATION

The actual inpatient available bed days, occupied bed days and room occupancy ratio of the Company are given below:

	2025	2024	2025	2024	2025	2024
	Available bed days		Occupied bed days		Occupancy ratio	
H-8 Hospital Islamabad	180,196	183,301	114,543	113,642	63.57%	62.00%
Faisalabad Hospital	20,805	20,630	6,957	7,583	33.44%	36.76%

33.1 Reported utilisation is a result of pattern of patient turnover under different specialties.

34 UNAVAILED CREDIT FACILITIES

Unavailed credit facilities at year end other than those disclosed in note 8 of the unconsolidated financial statements are as under:

	2025	2024
	(Rupees in '000')	
Letter of credit	193,485	200,000
Diminishing musharakah	310,482	240,561
Ijarah financing	51,709	51,709
Running musharakah	500,000	500,000
Letter of guarantee	30,368	32,416
	1,086,044	1,024,686
	Number	
35 NUMBER OF EMPLOYEES		
Number of employees	5,627	5,329
Average number of employees	5,490	5,296

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

36 RELATED PARTIES TRANSACTIONS

The related parties comprise of subsidiaries, associates, directors, major shareholders, key management personnel, SIHL Employees' Gratuity Fund Trust and the entities over which directors are able to exercise influence.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Company considers its chief executive officer, chief financial officer, company secretary, directors and departmental heads to be its key management personnel. There are no transactions with key management personnel other than their terms of employment / entitlement.

Related party transactions are based on arm's length between the parties as per pricing policy approved by the board of directors of the SIHL. Transactions and balances with the related parties are given below:

		2025	2024
	Note	(Rupees in '000')	
Shifa Foundation:			
Transactions			
Revenue from medical and other services earned by the Company		24,062	13,997
Rent expense paid by and reimbursed to the Company		1,373	1,215
Acquisition of 937,680 (2024: 1,328,397) ordinary shares of SIHT (Private) Limited		300,000	425,000
Balance			
Receivable - unsecured at the year end		14,422	7,137
Tameer-e-Millat Foundation:			
Transactions			
Supplies provided to the Company		81,787	102,662
Other services provided to the Company	36.1	28,755	35,904
Rental services received / earned by the Company		14,418	6,353
Balance			
Payable - unsecured at the year end		4,186	7,285
Shifa Tameer-e-Millat University:			
Transactions			
Revenue from medical and other services earned by the Company		26,063	28,402
Revenue from rent earned by the Company		4,256	3,869
Other services provided to the Company	36.1	84,924	113,015
Expenses paid and reimbursed to the Company		20,487	21,160
Expenses paid and reimbursed by the Company		29,788	33,410
Balance			
Payable - unsecured at the year end		42,798	31,566

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
SIHT (Private) Limited:			
Transactions			
Revenue from medical services earned by the Company		770,121	568,496
Expenses paid by and reimbursed to the Company		4,534	5,724
Other services provided to the Company	36.1	3,544	26,267
Balance			
Receivable - unsecured at the year end		59,898	30,329
Shifa Development Services (Private) Limited:			
Transactions			
Revenue from rent earned by the Company		-	1,096
Balance			
Receivable / (payable) - unsecured at the year end		-	-
Shifa Cooperative Housing Society Limited:			
Transactions			
Plot maintenance charges paid by the Company		2,571	3,112
Balance			
Receivable / (payable) - unsecured at the year end		-	-
Shifa Medical Centre Islamabad (Private) Limited:			
Transactions			
Corporate shared services provided by the Company		-	5,131
Balance			
Receivable / (payable) - unsecured at the year end		-	-
Shifa National Hospital Faisalabad (Private) Limited:			
Transactions			
Investment made by the Company in 55,509,426 (2024: nil) ordinary shares		555,094	-
Corporate shared services provided by the Company		-	5,131
Balance			
Receivable / (payable) - unsecured at the year end		-	-

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Shifa Neuro Sciences Institute Islamabad (Private) Limited:			
Transactions			
Rent paid by the Company		93,690	117,390
Dividend income received by the Company		50,926	16,975
Balance			
Receivable - unsecured at the year end		-	20,278
Shifa International DWC - LLC:			
Transactions			
Patient referral services provided to the Company		-	14,677
Balance			
Receivable / (payable) - unsecured at the year end		-	-
Shifa CARE (Private) Limited:			
Transactions			
Corporate shared services provided by the Company		-	1,924
Balance			
Receivable / (payable) - unsecured at the year end		-	-
International Finance Corporation:			
Transactions			
Dividend paid by the Company		18,964	22,757
Balance			
Receivable / (payable) - unsecured at the year end		-	-
SIHL Employees' Gratuity Fund Trust:			
Transactions			
Payments made by the Company		215,360	242,112
Dividend paid by the Company		196	235
Balance			
Payable - unsecured at the year end		102,728	132,734
Remuneration including benefits and perquisites of key management personnel	36.2	523,268	389,359

36.1 This represents services of nursing education, employees' children education and media services.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

36.2 This includes employee retirement benefits amounting to Rs. 19.09 million (2024: Rs. 14.68 million).

36.3 Following is the list of related parties and their shareholding for the year ended June 30, 2025;

Sr #	Name of related party (RP)	Basis of relationship	Percentage of	
			Company's shareholding in RP	RP's shareholding in the Company
1	Shifa Foundation	Common Directorship	N/A*	6.57%
2	Tameer-e-Millat Foundation	Common Directorship	N/A	12.44%
3	SIHL Employees' Gratuity Fund Trust	Benefit Plan	N/A	0.12%
4	Shifa Tameer-e-Millat University	Common Directorship	N/A	0.27%
5	Shifa Development Services (Private) Limited	Subsidiary & Common Directorship	55%	Nil
6	Shifa Cooperative Housing Society Limited	Common Directorship	N/A	Nil
7	Shifa National Hospital Faisalabad (Private) Limited	Subsidiary & Common Directorship	60%	Nil
8	Shifa Medical Centre Islamabad (Private) Limited	Subsidiary & Common Directorship	56%	Nil
9	Shifa CARE (Private) Limited	Associate & Common Directorship	50%	Nil
10	SIHT (Private) Limited	Associate & Common Directorship	45.3%	Nil
11	International Finance Corporation (IFC)	Associate	Nil	12.00%
12	Ahmed E.H. Jaffer Foundation	Common Directorship	N/A	Nil

*N/A stands for not applicable.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

37 REMUNERATION OF CHIEF EXECUTIVE, DIRECTORS AND EXECUTIVES

The aggregate amount charged in these unconsolidated financial statements in respect of remuneration and benefits, to the chief executive, directors and executives of the Company is given below:

	Chief Executive		Executive Director		Non Executive Directors			Executives	
	2025	2024	2025	2024	2025	2024	2024	2025	2024
	(Rupees in '000')								
Managerial remuneration	45,167	40,816	30,195	6,324	14,412	12,500		759,047	474,811
Annual bonus	2,145	1,815	1,221	-	331	260		26,703	14,090
Defined contribution plan	2,598	2,368	1,532	-	-	-		35,586	23,661
Medical insurance	125	120	94	146	277	394		6,684	4,553
Leave encashment	1,969	-	1,112	-	-	-		17,421	11,136
	52,004	45,119	34,154	6,470	15,020	13,154		845,441	528,251
Number of persons	1	1	1	1	9	11		147	91

37.1 The chief executive, executive director and eligible executives are provided with Company maintained vehicle.

37.2 Managerial remuneration includes Rs. 8.70 million (2024: Rs. 5.02 million) paid to directors in respect of meeting fee.

37.3 Executive means an employee, other than the chief executive and directors, whose basic salary exceeds Rs. 1.20 million (2024: Rs. 1.20 million) during the year.

37.4 Travelling and other expenses of Rs. 20.28 million (2024: Rs. 26.50 million) for official purposes are reimbursed by the Company to directors.

38 CASH AND CASH EQUIVALENTS

	Note	2025	2024
		(Rupees in '000')	
Investment in Term Deposit Receipt - at amortised cost	25	3,000	3,000
Cash and bank balances	26	3,511,814	2,129,377
		3,514,814	2,132,377

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

39 RECONCILIATION OF MOVEMENT OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

	(Rupees in '000')					
2025	Liabilities		Equity		Total	
	Long term financing	Government grant	Lease liabilities	Share capital	Share premium	Un-appropriated profit
Balance at beginning of the year	1,052,208	22,743	793,646	632,144	2,738,888	7,624,157
Changes from financing cash flows						
Proceeds from long term financing	537,704	-	-	-	-	-
Repayments of long term financing	(504,047)	-	-	-	-	-
Payment of lease liabilities	-	-	(329,771)	-	-	-
Dividend paid	-	-	-	-	-	(153,831)
Total changes from financing cash flows	33,657	-	(329,771)	-	-	(153,831)
Other changes						
Liability related	15,718	-	235,544	-	-	-
Amortisation of government grant	-	(15,718)	-	-	-	-
Equity related	-	-	-	-	-	-
Total comprehensive changes	-	-	-	-	-	-
Transfer upon merger (refer note 1.1)	-	-	-	-	-	-
Other changes	-	-	-	-	-	-
Changes in unclaimed dividend	-	-	-	-	-	-
Total of equity related changes	-	-	-	-	-	-
Balance at end of the year	1,101,583	7,025	699,419	632,144	2,738,888	9,830,602
						2,360,276
						15,009,660

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	Liabilities			Equity			Total
	Long term financing	Government grant	Lease liabilities	Share capital	Share premium	Un-appropriated profit	
2024	(Rupees in '000')						
Balance at beginning of the year	1,691,820	48,590	727,642	632,144	2,738,888	6,511,963	12,351,047
Changes from financing cash flows							
Proceeds from long term financing	216,122	-	-	-	-	-	216,122
Repayments of long term financing	(881,581)	-	-	-	-	-	(881,581)
Payment of lease liabilities	-	-	(317,832)	-	-	-	(317,832)
Dividend paid	-	-	-	-	-	(181,869)	(181,869)
Total changes from financing cash flows	(665,459)	-	(317,832)	-	-	(181,869)	(1,165,160)
Other changes							
Liability related	25,847	-	383,836	-	-	-	409,683
Amortisation of government grant	-	(25,847)	-	-	-	-	(25,847)
Equity related							
Total comprehensive changes	-	-	-	-	-	1,286,050	1,286,050
Other changes	-	-	-	-	-	15,787	15,787
Changes in unclaimed dividend	-	-	-	-	-	(7,775)	(7,775)
Total of equity related changes	-	-	-	-	-	1,294,062	1,294,062
Balance at end of the year	1,052,208	22,743	793,646	632,144	2,738,888	7,624,157	12,863,785

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
40	ADJUSTMENT OF NON-CASH INCOME AND EXPENSE		
Depreciation / amortisation	29	1,090,495	1,079,702
Amortisation on intangible assets	29	3,515	1,054
Expected credit losses	24.2 & 41.1.3	144,421	111,778
Property, plant and equipment written off	29	75,709	7,168
Gain on disposal of property, plant and equipment	28	(2,500)	(2,664)
Loss on disposal of investment property	29	7,340	2,708
Gain on termination of right of use assets		(29,371)	(75)
Provision for compensated absences	29	136,518	103,063
Provision for defined contribution plan	29	129,225	109,027
Provision for bonus for employees	29	302,795	170,730
Provision for gratuity	29	102,043	80,644
Charged / (reversal) of provision for slow moving stores	29	2,671	(1,892)
Gain on investments and bank deposits	28	(289,681)	(133,913)
Impairment loss on long term investment		-	54,967
Impairment loss on derecognition of investment		-	21,015
(Gain) / loss on foreign currency translation	28 & 29	(7,199)	26,469
Finance costs	30	353,832	441,054
		2,019,813	2,070,835

41 FINANCIAL RISK MANAGEMENT

The Company has exposure to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

Risk management framework

The Board meets frequently throughout the year for developing and monitoring the Company's risk management policies. The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

the Company's activities. The Company, through its standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Audit Committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

41.1 Credit risk

Credit risk represents the financial loss that would be recognised at the reporting date if counterparties failed completely to perform as contracted. The Company does not have significant exposure to any individual counter-party. To reduce exposure to credit risk, the Company has developed a formal approval process whereby credit limits are applied to its customers. The management also regularly monitors the credit exposure towards the customers and makes allowance for ECL for those credit exposure. Furthermore, the Company has credit control in place to ensure that services are rendered to customers with an appropriate credit history.

41.1.1 Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	2025	2024
	(Rupees in '000')	
Long term deposits	105,003	113,937
Trade debts	1,461,456	1,346,189
Deposits and other receivables	143,246	136,837
Markup accrued	19,219	4,102
Other financial assets	1,006,355	202,566
Bank balances	3,497,263	2,103,322
	6,232,542	3,906,953

The Company is exposed to credit risk from its operating and short term investing activities. The Company's credit risk exposures are categorised under the following headings:

41.1.2 Counterparties

The Company conducts transactions with the following major types of counterparties:

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Trade debts

Trade debts are essentially due from government companies / institutions, private companies (panel companies) and individuals to whom the Company is providing medical services. Normally the services are rendered to the panel companies on agreed rates and limits from whom the Company does not expect any inability to meet their obligations. The Company manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Company has credit control in place to ensure that services are rendered to customers with an appropriate credit history and makes allowance for ECL against those balances considered doubtful of recovery.

Bank balances and investments

The Company limits its exposure to credit risk by investing in liquid securities and maintaining bank accounts only with counterparties that have a high credit ratings and therefore management does not expect any counterparty to fail to meet its obligations.

The maximum exposure to credit risk for trade debts at the reporting date by type of customer was:

	2025	2024
	(Rupees in '000')	
Government companies	1,004,186	845,715
Private companies	396,193	444,325
Individuals	340,532	290,159
Related parties	14,422	7,137
	1,755,333	1,587,336

41.1.3 Impairment losses

The ageing of trade debts at the reporting date was:

	2025		2024	
	Gross debts	Allowance for ECL	Gross debts	Allowance for ECL
	(Rupees in '000')			
Not past due	592,897	4,566	498,244	3,178
1 - 2 months	463,688	13,068	357,017	12,967
3 - 4 months	139,545	7,889	218,635	30,316
5 - 7 months	123,122	17,642	148,772	24,285
8 - 12 months	110,930	46,906	98,670	31,039
Above 12 months	325,151	203,806	265,998	139,362
	1,755,333	293,877	1,587,336	241,147

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The movement in the allowance for impairment in respect of trade debts during the year was as follows:

	Note	2025 (Rupees in '000')	2024
Balance at beginning of the year		241,147	226,563
Expected credit losses		52,730	93,273
Bad debts written off		-	(78,689)
Balance at end of the year	22	293,877	241,147

41.1.4 The ageing of Shifa Foundation (SF) and SIHT (Private) Limited at the reporting date was:

	Note	2025 (Rupees in '000')		2024 (Rupees in '000')	
		Gross debts / Other receivables	Allowance for ECL	Gross debts / Other receivables	Allowance for ECL
Shifa Foundation					
1 - 6 months	22	14,422	-	7,137	-
SIHT (Private) Limited					
1 - 3 months	24.1	59,898	-	30,329	-

41.1.5 The Company maintained balances of Rs. 3,497.26 million (2024: Rs. 2,103.32 million) with Banks and Rs. 1,003.36 million (2024: Rs. 199.57 million) with Asset Management Companies as at June 30, 2025. Management has assessed the credit quality of the counterparties as satisfactory. Geographical analysis and credit rating information is given below:

Banks / financial institutions	Credit Rating	Rating		2025	2024
	Agency	Short term	Long term	(Rupees in '000')	
Pakistan:					
Habib Bank Limited	JCR - VIS	A1+	AAA	637,091	1,041,268
Meezan Bank Limited	JCR - VIS	A1+	AAA	281,707	500,902
Al - Baraka Bank (Pakistan) Limited	JCR - VIS	A1	AA-	1,970,854	284,198
United Bank Limited (UBL)	JCR - VIS	A1+	AAA	21,062	57,686
MCB Bank Limited	PACRA	A1+	AAA	19,260	13,854
Dubai Islamic Bank Pakistan Limited	JCR - VIS	A1+	AA	83,241	13,603
Askari Bank Limited	PACRA	A1+	AA+	14	14
Faysal Bank Limited	JCR - VIS	A1+	AA+	37,032	53,778
Bank Alfalah Limited	PACRA	A1+	AAA	48,196	6,030
Bank Al Habib Limited	PACRA	A1+	AAA	384,791	122,398
National Bank of Pakistan (NBP)	JCR - VIS	A1+	AAA	13,890	9,592
Habib Metropolitan Bank Limited	PACRA	A1+	AA+	126	-
UBL - Al Ameen Islamic Cash Fund	JCR - VIS	-	AA+(f)	220,283	199,566
NBP Islamic Money Market Fund	PACRA	-	AA(f)	783,072	-

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

41.2 Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to manage liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. For this purpose the Company has credit facilities as mentioned in notes 8 and 34 to the financial statements. Further liquidity position of the Company is monitored by the Board through budgets, cash flow projections and comparison with actual results.

Following is the maturity analysis of financial liabilities:

	Carrying amount	Six months or less	Six to twelve months	One to two years	Two to five years	Above five years
(Rupees in '000')						
2025						
Long term financing- secured	1,108,609	136,369	118,795	276,752	546,986	29,707
Deferred liabilities	44,846	-	-	44,846	-	-
Trade and other payables	3,932,341	3,932,341	-	-	-	-
Unclaimed dividend	48,935	48,935	-	-	-	-
Mark up accrued	7,974	7,974	-	-	-	-
	5,142,705	4,125,619	118,795	321,598	546,986	29,707
2024						
Long term financing-secured	1,074,951	361,803	133,392	243,370	336,386	-
Deferred liabilities	34,434	-	-	34,434	-	-
Trade and other payables	3,516,285	3,516,285	-	-	-	-
Unclaimed dividend	44,730	44,730	-	-	-	-
Mark up accrued	23,858	23,858	-	-	-	-
	4,694,258	3,946,676	133,392	277,804	336,386	-

Maturity analysis of lease liabilities is given in note 10.

41.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, markup rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk. The Company is exposed to currency, mark up rate and market price risk.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

41.3.1 Foreign currency risk

Exposure to foreign currency risk

Foreign currency risk arises mainly where receivables and payables exist due to transactions with foreign undertakings and cash in foreign currency bank account. The Company's exposure to foreign currency risk is as follows:

	2025		2024	
	(Amount in '000')			
	Euro	USD	Euro	USD
Bank balances	-	1,289	-	3,285
Letter of credit	-	-	(555)	(1,460)
	-	1,289	(555)	1,825

	2025		2024	
	(Rupees in '000')			
Bank balances	-	365,444	-	913,689
Letter of credit	-	-	(165,397)	(406,837)
	-	365,444	(165,397)	506,852

Following are significant exchange rates applied during the year:

	Average rate		Closing rate	
	2025	2024	2025	2024
	(Rupees)			
USD 1 - Buying	279.14	283.02	283.53	278.15
USD 1 - Selling	279.57	283.45	283.97	278.59
Euro 1 - Buying	-	306.25	-	297.45
Euro 1 - Selling	-	306.72	-	297.92

Foreign currency sensitivity analysis

A 10 percent variation of PKR against USD at June 30 would have effected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular markup rates, remains constant.

	Change in Foreign Exchange Rates	Effect on Profit	Effect on Equity
2025	%	(Rupees in '000')	
Foreign currencies	+10%	22,292	22,292
Foreign currencies	-10%	(22,292)	(22,292)

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	Change in Foreign Exchange Rates	Effect on Profit	Effect on Equity
2024	%	(Rupees in '000')	
Foreign currencies	+10%	20,829	20,829
Foreign currencies	-10%	(20,829)	(20,829)

41.3.2 Markup rate risk

The markup rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Majority of the interest rate exposure arises from long term financing, short term investments and deposits with banks which are variable rate financial instruments. At the reporting date the markup rate profile of the Company's markup-bearing financial instruments are:

	Note	2025	2024
		(Rupees in '000')	
Financial assets			
Investment - at amortised cost	25.1	3,000	3,000
Bank balances	26	2,561,332	793,057
		2,564,332	796,057
Financial liabilities			
Financing - secured	8	(1,108,609)	(1,074,951)
		1,455,723	(278,894)

The effective markup rates for the financial assets and liabilities are mentioned in respective notes to the financial statements.

Markup rate sensitivity analysis

If markup rates had been 50 basis points higher / lower and all other variables were held constant, the Company's profit for the year ended June 30, 2025 would decrease / increase by Rs. 0.40 million (2024: Rs. 1.11 million). This is mainly attributable to the Company's exposure to markup rates on its variable rate borrowings.

41.3.3 Price risk

The Company's price risk arises from investments in units as disclosed in note 25.2 which are designated at fair value through profit or loss, however, in accordance with the investment strategy the performance of units is actively monitored and they are managed on a fair value basis.

Price risk sensitivity analysis

If the fair value of mutual fund investments at the year end had fluctuated by 1% higher or lower, with all other variables held constant, the profit for the year would have been higher or lower by Rs. 6.12 million (2024: Rs. 1.22 million), primarily due to changes in the fair value of investments.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

41.4 Financial instrument by category

	Amortised cost	Fair value through profit or loss	Total
2025	(Rupees in '000')		
Financial assets			
Maturity upto one year			
Trade debts	1,461,456	-	1,461,456
Deposits and other receivables	143,246	-	143,246
Markup accrued	19,219	-	19,219
Other financial assets	3,000	1,003,355	1,006,355
Cash and bank balances	3,511,814	-	3,511,814
Maturity after one year			
Long term deposits	105,003	-	105,003
	5,243,738	1,003,355	6,247,093
Financial liabilities			
Maturity upto one year			
Trade and other payables	3,932,341	-	3,932,341
Unclaimed dividend	48,935	-	48,935
Markup accrued	7,974	-	7,974
Current portion of long term financing - secured	255,190	-	255,190
Current portion of lease liabilities	192,895	-	192,895
Maturity after one year			
Long term financing - secured	853,419	-	853,419
Deferred liabilities	44,846	-	44,846
Lease liabilities	506,524	-	506,524
	5,842,124	-	5,842,124

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	Amortised cost	Fair value through profit or loss (Rupees in '000')	Total
2024			
Financial assets			
Maturity upto one year			
Trade debts	1,346,189	-	1,346,189
Deposits and other receivables	136,837	-	136,837
Markup accrued	4,102	-	4,102
Other financial assets	3,000	199,566	202,566
Cash and bank balances	2,129,377	-	2,129,377
Maturity after one year			
Long term deposits	113,937	-	113,937
	3,733,442	199,566	3,933,008
Financial liabilities			
Maturity upto one year			
Trade and other payables	3,516,285	-	3,516,285
Unclaimed dividend	44,730	-	44,730
Markup accrued	23,858	-	23,858
Current portion of long term financing - secured	495,195	-	495,195
Current portion of lease liabilities	266,739	-	266,739
Maturity after one year			
Long term financing - secured	579,756	-	579,756
Deferred liabilities	34,434	-	34,434
Lease liabilities	526,907	-	526,907
	5,487,904	-	5,487,904

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

41.5 Fair value

Fair value versus carrying amounts

The fair value of financial assets and liabilities, together with the carrying amounts shown in the unconsolidated statement of financial position are as follows:

	2025		2024	
	Carrying value	Fair value	Carrying value	Fair value
(Rupees in '000')				
Assets carried at amortised cost				
Long term deposits	105,003	105,003	113,937	113,937
Trade debts	1,461,456	1,461,456	1,346,189	1,346,189
Deposits and other receivables	143,246	143,246	136,837	136,837
Markup accrued	19,219	19,219	4,102	4,102
Other financial assets	3,000	3,000	3,000	3,000
Cash and bank balances	3,511,814	3,511,814	2,129,377	2,129,377
	5,243,738	5,243,738	3,733,442	3,733,442
Assets carried at fair value				
Other financial assets	1,003,355	1,003,355	199,566	199,566
Liabilities carried at amortised cost				
Long term financing - secured	853,419	853,419	579,756	579,756
Deferred Liabilities	44,846	44,846	34,434	34,434
Lease liabilities	506,524	506,524	526,907	526,907
Trade and other payables	3,932,341	3,932,341	3,516,285	3,516,285
Unclaimed dividend	48,935	48,935	44,730	44,730
Markup accrued	7,974	7,974	23,858	23,858
Current portion of long term financing - secured	255,190	255,190	495,195	495,195
Current portion of lease liabilities	192,895	192,895	266,739	266,739
	5,842,124	5,842,124	5,487,904	5,487,904

The basis for determining fair values is as follows:

The interest rates used to discount estimated cash flows, when applicable, are based on the government yield curve at the reporting date plus an adequate credit spread. For instruments carried at amortised cost, since the majority of the interest bearing investments are variable rate based instruments, there is no difference in carrying amount and the fair value. Further, for fixed rate instruments, since there is no significant difference in market rate and the rate of instrument and therefore most of the fixed rate instruments are short term in nature, fair value significantly approximates to carrying value.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

42 FAIR VALUE HIERARCHY

Other financial assets

Fair value of investment in mutual funds (note 25.2) has been determined using quoted repurchase price at reporting date and categorised under level 1 of fair value hierarchy.

Fair value of land

Lands owned by the Company are valued by independent valuer to determine the fair values of lands as at reporting date. The fair value of lands subject to revaluation model fall under level 2 of fair value hierarchy.

There were no transfer amongst the levels during the year. Further, there were no changes in the valuation techniques during the year.

43 DISCLOSURE REQUIREMENT FOR COMPANIES NOT ENGAGED IN SHARIAH NON-PERMISSIBLE BUSINESS ACTIVITIES

Following information has been disclosed as required under amended part I clause VII of Fourth Schedule to the Companies Act, 2017 as amended via S.R.O 1278(I)/2024 dated August 15, 2024:

		2025	2024
	Note	(Rupees in '000')	
Financing as per islamic mode			
Long term financing (including current portion)	8	1,058,622	983,136
Short term shariah compliant investments			
Investment in Mutual Fund - at fair value through profit or loss	25	1,003,355	199,566
Shariah compliant bank balances			
Bank balances	26	2,442,121	607,812
Shariah compliant revenue			
Revenue - net	27	27,967,661	23,563,840
Dividend earned on shariah compliant investments			
Dividend income from mutual fund - investments at fair value through profit or loss	28	27,690	35,844
Dividend income from subsidiary	28	50,926	16,975
Profit earned from shariah compliant bank balances			
Profit on bank balances	28	177,098	40,389

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Exchange gain earned from actual currency			
Exchange gain / (loss)	28 & 29	7,199	(26,469)
Profit paid on islamic mode of financing			
Long term financing	30	145,023	248,179
Source and detailed breakup of other income			
Shariah compliant			
Un-realised gain on investments at fair value through profit or loss	28	25,803	14,180
Others	28	332,195	148,193
Non-Shariah compliant			
Profit on bank balances	28	8,164	26,525
Others	28	36,660	1,225
Relationship with sharia compliant financial institutions / takaful operators			
Name	Relationship		
Al-Baraka Bank (Pakistan) Limited	Funded facility and Bank balance		
Meezan Bank Limited	Funded / Non-funded facility and Bank balance		
Habib Bank Limited	Funded / Non-funded facility and Bank balance		
Dubai Islamic Bank Pakistan Limited	Bank balance		
Faysal Bank Limited	Bank balance		
Bank Alfalah Limited	Funded facility and Bank balance		
First Habib Modaraba	Funded facility		
EFU General Insurance Limited	Takaful		
Jubilee General Insurance Company Limited	Takaful		

44 OPERATING SEGMENTS

The financial statements have been prepared on the basis of single reportable segment. All revenue of the Company is earned in Pakistan. All non-current assets of the Company at June 30, 2025 are located in Pakistan. There is no other segment with more than 10% of total revenue of the Company for the year.

NOTES TO THE UNCONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

45 NON-ADJUSTING EVENT AFTER THE REPORTING DATE

The board of directors of the Company in its meeting held on September 06, 2025 has proposed a final cash dividend for the year ended June 30, 2025 @ Rs. 5 per share, amounting to Rs. 316.07 million for approval of the members in the Annual General Meeting to be held on October 25, 2025. The unconsolidated financial statements for the year ended June 30, 2025 do not include the effect of the final dividend which will be accounted for in the year in which it is approved.

46 CORRESPONDING FIGURES

Corresponding figures have been rearranged and reclassified, wherever considered necessary, for better presentation. However, following reclassification has been made during the year.

2024		
Description	Note	(Rupees in '000')
Reclassification from Stock in trade to Stores, spare parts and loose tools	20 & 21	23,545

47 DATE OF AUTHORISATION FOR ISSUE

These unconsolidated financial statements were approved and authorised for issue by the board of directors of the Company on September 06, 2025.

48 GENERAL

Figures have been rounded off to the nearest one thousand Pak Rupees unless otherwise stated.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER





CONSOLIDATED **FINANCIAL STATEMENTS**

FOR THE YEAR ENDED JUNE 30, 2025

This page is intentionally left blank

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHIFA INTERNATIONAL HOSPITALS LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the annexed consolidated financial statements of **Shifa International Hospitals Limited** (the Group), which comprise the consolidated statement of financial position as at June 30, 2025, and the consolidated statement of profit or loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at June 30, 2025 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with the accounting and reporting standards as applicable in Pakistan.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) as applicable in Pakistan. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants as adopted by the Institute of Chartered Accountants of Pakistan (the Code) and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of consolidated financial statements of the current period. These matters are addressed in the context of our audit of the consolidated financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

Following are the key audit matters:

Sr. No.	Key audit matters	How the matter was addressed in our audit
1.	<p>Revenue Recognition</p> <p>(Refer note 29 to the consolidated financial statements)</p> <p>The Group's revenue consists of inpatient revenue, outpatient revenue, pharmacy, cafeteria, rent of building and other services.</p> <p>During the year ended June 30, 2025, the Group recognised aggregate revenue of Rs. 27,967.661 million from rendering of services to inpatients, outpatients, external pharmacy outlets, cafeteria sales and operating leases to related parties/ other parties.</p> <p>We identified recognition of revenue as an area of higher risk as it includes large number of revenue transactions with a large number of customers in various geographical locations and revenue being one of the key performance indicators of the Group. Accordingly, it was considered as a key audit matter.</p>	<p>Our procedures in relation to revenue recognition, amongst others, included:</p> <ul style="list-style-type: none"> • Understood and evaluated management controls over revenue and verified their validations; • Performed test of controls and evaluation of Information Technology General Controls (ITGC) with the assistance of our IT expert to assess the operating effectiveness of controls related to the automation of revenue recognition; • Verified that revenue has been recognised in accordance with the Group's accounting policy and the applicable reporting framework; • Performed verification of sample of revenue transactions with underlying documentation including invoices, agreements, charge-sheets and other relevant underlying documents; • Verified receipts from customers on sample basis against the revenue booked during the year; • Performed cut-off procedures on sample basis to ensure revenue has been recognised in the correct period; • Tested journal entries relating to revenue recognised during the year based on identified risk criteria; and • Assessed the appropriateness of disclosures made in the financial statements related to revenue as required under the applicable reporting framework.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

Sr. No.	Key audit matters	How the matter was addressed in our audit
2.	<p>Expected credit loss allowance on trade debts</p> <p>(Refer note 24 to the consolidated financial statements)</p> <p>The Group has recognised balance of an expected credit loss allowance of Rs. 295.676 million on gross amount of trade debts of Rs. 1,757.132 million as at June 30, 2025.</p> <p>Under IFRS 9, the Group is required to recognise expected credit loss allowance for financial assets using Expected Credit Loss (ECL) model. Determination of ECL provision for trade debts requires significant judgment and assumptions including consideration of factors such as historical credit loss experience, time value of money and forward-looking macroeconomic information etc. We have considered the expected credit loss assessment as a key audit matter due to the significance of estimates and judgments involved.</p>	<p>Our audit procedures in relation to expected credit loss assessment of trade debts, amongst others, included the following:</p> <ul style="list-style-type: none"> • Understood the management's process for estimating the ECL in relation to trade debts. Assessed and evaluated the assumptions used by the management in determining impairment loss under the ECL model; • Verified appropriateness of ageing, on sample basis, by comparing individual balances with underlying documentation; • Reviewed the appropriateness of assumptions used for ECL computation from relevant external and internal sources; • Circularised balance confirmation for trade debtors on sample basis and evaluated responses received; • Verified subsequent clearance of balances due as of June 30, 2025 on sample basis; and • Assessed the appropriateness of disclosures related to impairment assessment of trade debts as required under the applicable reporting framework.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

Management is responsible for the other information. The other information comprises the information included in the annual report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.



In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the accounting and reporting standards as applicable in Pakistan and the requirements of Companies Act, 2017 (XIX of 2017) and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Board of directors is responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs as applicable in Pakistan will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs as applicable in Pakistan, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the board of directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the board of directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Atif Riaz.

ISLAMABAD

DATED: 16 SEP 2025

UDIN : AR202510060m7yJx9IUa



BDO EBRAHIM & CO
CHARTERED ACCOUNTANTS

BDO Ebrahim & Co. Chartered Accountants

BDO Ebrahim & Co., a Pakistan registered partnership firm, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the International BDO network of independent member firms.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
SHARE CAPITAL AND RESERVES			
Authorised share capital 100,000,000 (2024: 100,000,000) ordinary shares of Rs. 10 each		1,000,000	1,000,000
Issued, subscribed and paid up capital	5	632,144	632,144
Capital reserves			
Share premium	6	2,738,888	2,738,888
Surplus on revaluation of property, plant and equipment	7	2,355,123	2,021,310
Revenue reserves			
Unappropriated profit		9,203,864	7,118,684
		14,930,019	12,511,026
NON - CONTROLLING INTEREST	8	2,967,066	2,470,891
NON - CURRENT LIABILITIES			
Long term financing - secured	9	853,419	579,756
Deferred liabilities	10	289,268	389,394
Lease liabilities	11	506,524	483,396
		1,649,211	1,452,546
CURRENT LIABILITIES			
Trade and other payables	12	4,895,138	4,168,270
Unclaimed dividend		48,935	44,730
Markup accrued	13	7,974	23,858
Taxation - net	14	62,833	-
Current portion of long term financing - secured	9	255,190	495,195
Current portion of lease liabilities	11	192,895	146,911
		5,462,965	4,878,964
		25,009,261	21,313,427

CONTINGENCIES AND COMMITMENTS

15

The annexed notes 1 to 50 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE

		2025	2024
	Note	(Rupees in '000')	
NON - CURRENT ASSETS			
Property, plant and equipment	16	14,992,071	13,860,258
Intangible assets	17	42,701	39,375
Investment property - at cost	18	624,872	720,292
Long term investments	19	740,157	424,045
Long term advances to suppliers and contractors	20	324,174	-
Long term deposits	21	117,961	126,050
		16,841,936	15,170,020
CURRENT ASSETS			
Stores, spare parts and loose tools	22	224,161	243,579
Stock in trade	23	959,987	1,018,321
Trade debts	24	1,461,456	1,346,189
Loans and advances	25	451,924	454,495
Deposits, prepayments and other receivables	26	213,445	175,459
Markup accrued		19,219	4,383
Other financial assets	27	1,075,513	484,991
Taxation - net		-	258,787
Cash and bank balances	28	3,761,620	2,157,203
		8,167,325	6,143,407
		25,009,261	21,313,427



CHIEF FINANCIAL OFFICER

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Revenue - net	29	27,967,661	23,553,578
Other income	30	383,202	233,279
Operating costs	31	(23,813,756)	(20,981,597)
Finance costs	32	(345,724)	(421,091)
Expected credit losses	26.2 & 43.1.3	(141,016)	(116,289)
Share of profit / (loss) of associates	19	16,112	(4,506)
Profit before levies and income tax		4,066,479	2,263,374
Levies	33	(7,717)	(15,224)
Profit before income tax		4,058,762	2,248,150
Income tax expense	33	(1,826,928)	(918,524)
Profit for the year - continuing operations		2,231,834	1,329,626
Profit for the year - discontinued operations - net of tax		-	2,466
Profit for the year		2,231,834	1,332,092
Attributable to:			
Equity holders of SIHL			
Continuing operations		2,257,919	1,368,030
Discontinued operations		-	2,466
		2,257,919	1,370,496
Non-controlling interest			
Continuing operations		(26,085)	(38,404)
Discontinued operations		-	-
		(26,085)	(38,404)
		2,231,834	1,332,092
Earnings per share - basic and diluted (Rupees)			
Continuing operations		35.72	21.64
Discontinued operations		-	0.04
	34	35.72	21.68

The annexed notes 1 to 50 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Profit for the year		2,231,834	1,332,092
Other comprehensive income			
Items that will not be subsequently reclassified to the consolidated statement of profit or loss:			
Loss on remeasurement of staff gratuity fund benefit plan (net of tax)	12.5.4	(50,820)	(76,024)
Surplus on revaluation of land	16	506,447	20,321
		455,627	(55,703)
Total comprehensive income for the year		2,687,461	1,276,389
Attributable to:			
Equity holders of SIHL			
Continuing operations		2,577,029	1,303,420
Discontinued operations		-	2,466
		2,577,029	1,305,886
Non-controlling interest			
Continuing operations		110,432	(29,497)
Discontinued operations		-	-
		110,432	(29,497)
		2,687,461	1,276,389

The annexed notes from 1 to 50 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED JUNE 30, 2025

	Share capital	Share premium	Surplus on revaluation of property, plant and equipment	Un - appropriated profit	Non - controlling interest (NCI)	Total
(Rupees in '000')						
Balance as at July 01, 2023	632,144	2,738,888	2,032,194	5,991,558	2,500,388	13,895,172
Total comprehensive income						
Profit / (loss) for the year	-	-	-	1,370,496	(38,404)	1,332,092
Other comprehensive income / (loss) - net of tax	-	-	11,414	(76,024)	8,907	(55,703)
	-	-	11,414	1,294,472	(29,497)	1,276,389
Realisation of revaluation surplus on disposal of assets	-	-	(4,284)	4,284	-	-
Transfer of revaluation surplus on property, plant and equipment in respect of incremental depreciation / amortisation	-	-	(18,014)	18,014	-	-
Distribution to owners						
Dividend - final 2023 @ Rs. 1.5 per share	-	-	-	(94,822)	-	(94,822)
Dividend - interim 2024 @ Rs. 1.5 per share	-	-	-	(94,822)	-	(94,822)
Balance as at June 30, 2024	632,144	2,738,888	2,021,310	7,118,684	2,470,891	14,981,917
Total comprehensive income						
Profit / (loss) for the year	-	-	-	2,257,919	(26,085)	2,231,834
Other comprehensive income / (loss) - net of tax	-	-	369,930	(50,820)	136,517	455,627
	-	-	369,930	2,207,099	110,432	2,687,461
Realisation of revaluation surplus on disposal of assets	-	-	(14,517)	14,517	-	-
Transfer of revaluation surplus on property, plant and equipment in respect of incremental depreciation / amortisation	-	-	(21,600)	21,600	-	-
NCI recognised during the year	-	-	-	-	385,743	385,743
Distribution to owners						
Dividend - final 2024 @ Rs. 2.5 per share	-	-	-	(158,036)	-	(158,036)
Balance as at June 30, 2025	632,144	2,738,888	2,355,123	9,203,864	2,967,066	17,897,085

The annexed notes from 1 to 50 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before levies and income tax - continuing operations		4,066,479	2,263,374
Profit before levies and income tax - discontinued operations		-	2,466
Adjustment of non-cash income and expense	42	2,004,281	1,970,762
Operating cash flows before changes in working capital		6,070,760	4,236,602
Changes in working capital:			
(Increase) / decrease in current assets:			
Stores, spare parts and loose tools		16,746	33,556
Stock in trade		58,334	(59,368)
Trade debts		(167,997)	(73,340)
Loans and advances		2,571	(19,594)
Deposits, prepayments and other receivables		(41,598)	105,166
Discontinued operations		-	(37,148)
Increase / (decrease) in current liabilities:			
Trade and other payables		395,174	(807,279)
		263,230	(858,007)
Cash generated from operations		6,333,990	3,378,595
Finance costs paid		(258,807)	(395,670)
Income tax paid		(1,591,071)	(866,606)
Payment to SIHL Employees' Gratuity Fund Trust		(215,360)	(242,112)
Compensated absences paid		(89,047)	(72,684)
Payment to defined contribution plan		(103,971)	(84,300)
Net cash generated from operating activities		4,075,734	1,717,223
CASH FLOWS FROM INVESTING ACTIVITIES			
Addition to property, plant and equipment (PPE)		(1,581,347)	(646,079)
Addition to intangible assets		(5,787)	-
Addition to long term investments		(300,000)	(425,000)
(Investment) / encashment of other financial assets - net		(710,537)	241,331
Proceeds from disposal of PPE		5,317	18,826
Proceeds from derecognition of investment		-	2,265
Proceeds from disposal of investment property		-	26,000
Markup received		224,479	100,145
Increase in advances to suppliers and contractors		(324,174)	-
Decrease / (increase) in long term deposits		5,463	(23,200)
Net cash used in investing activities		(2,686,586)	(705,712)

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
CASH FLOWS FROM FINANCING ACTIVITIES			
Non-controlling interest		385,743	-
Long term financing - repayments		(504,047)	(881,581)
Proceeds from long term financing		537,704	216,122
Payment of lease liabilities		(236,081)	(200,524)
Dividend paid		(153,831)	(181,869)
Net cash generated from / (used in) financing activities		29,488	(1,047,852)
Net increase / (decrease) in cash and cash equivalents		1,418,636	(36,341)
Cash and cash equivalents at beginning of the year		2,383,305	2,446,115
Effect of exchange rate changes on cash and cash equivalents		7,199	(26,469)
Cash and cash equivalents at end of the year	40	3,809,140	2,383,305

The annexed notes from 1 to 50 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

1 STATUS AND NATURE OF BUSINESS

Shifa International Hospitals Limited ("the Group") comprises of Shifa International Hospitals Limited (SIHL / parent company) and its subsidiaries, Shifa Development Services (Private) Limited, Shifa National Hospital Faisalabad (Private) Limited and Shifa Medical Center Islamabad (Private) Limited.

SIHL was incorporated in Pakistan on September 29, 1987 as a private limited company under the Companies Ordinance, 1984 (repealed with the enactment of the Companies Act, 2017 on May 30, 2017) and converted into a public limited company on October 12, 1989. The shares of the SIHL are quoted on Pakistan Stock Exchange Limited. The registered office of the SIHL is situated at Sector H-8/4, Islamabad. The principal activity of SIHL is to establish and run medical centers and hospitals in Pakistan. The SIHL has established its first hospital in 1993 in H-8/4 Islamabad, second hospital in 2011 in Faisalabad and another in 2014 in G-10/4 Islamabad. The SIHL is also running medical centers, lab collection points and pharmacies in different cities of Pakistan.

Shifa Development Services (Private) Limited (SDSPL) was incorporated in Pakistan on December 18, 2014. The principal activity of SDSPL is to provide consulting services relating to healthcare facility, medical staff, human resource, architectural designing, procurement, hospital quality and project management services. The registered office of SDSPL is situated at Shifa International Hospitals Limited, Sector H-8/4, Islamabad. During the last year, the investment has been fully impaired in view of financial difficulties faced by SDSPL due to which it might not be able to continue its business.

Shifa National Hospital Faisalabad (Private) Limited (SNH Faisalabad) was incorporated in Pakistan on February 28, 2019. The principal line of business of the SNH Faisalabad is to establish, run, control, manage and operate tertiary / quaternary care hospitals including diagnostic centers, clinics, laboratories, operation theaters, dental clinics, healthcare centers and provide all healthcare and surgical related facilities of different diseases, inpatient and outpatient services and treatment of viral, bacterial and chronic diseases and all other related services thereof, subject to permission from relevant authorities, if required. The registered office of the SNH Faisalabad is situated at Shifa International Hospitals Limited, Sector H-8/4, Islamabad.

Shifa Medical Center Islamabad (Private) Limited (SMC Islamabad) was incorporated in Pakistan on February 28, 2019. The principal line of business of the SMC Islamabad is to establish, run, control, manage and operate facilities providing ambulatory services including day care surgeries, diagnostic centers, clinics, laboratories, operation theaters, dental clinics, healthcare centers and provide healthcare and surgical related facilities of different various, inpatient and outpatient services and treatment of viral, bacterial and chronic diseases and all other related services thereof, subject to permission from relevant authorities, if required. The registered office of the SMC Islamabad is situated at Shifa International Hospitals Limited, Sector H-8/4, Islamabad.

The shareholders of the SIHL in the Extraordinary General Meeting dated June 05, 2025 have approved the purchase of 105,814,336 ordinary shares having face value of Rs. 10/- per share held in SMC Islamabad from all the other existing shareholders (the "Minority Shareholders") of SMC Islamabad for an aggregate amount of approximately Rs. 1,666 million.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Geographical locations of business units of the Group are as follows:

H-8 Hospital, Pitras Bukhari Road, Sector H-8/4, Islamabad

Neuro Sciences Institute, Pitras Bukhari Road, Sector H-8/4, Islamabad

G-10 Hospital, G-10 Markaz, Islamabad

Shifa Medical Center, Gulberg Greens, Islamabad

SMCI Hospital, F-11, Islamabad

Faisalabad Hospital, Main Jaranwala Road, Faisalabad

SNHF Hospital, Sheikhpura Road, Faisalabad

	2025	2024
Percentage share of total revenue given in note 29 is as follows:		
Islamabad	97%	97%
Faisalabad	3%	3%
	100%	100%

The consolidated financial statements of the Group have been prepared based upon initialled accounts for Shifa Medical Center Islamabad (Private) Limited, Shifa National Hospital Faisalabad (Private) Limited and Shifa Development Services (Private) Limited, as at June 30, 2025.

1.1 Merger / amalgamation of Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNS Islamabad) with and into the SIHL

The board of directors of the SIHL and SNS Islamabad, in their respective meetings held on February 22, 2025, and February 24, 2025, approved the merger / amalgamation of SNS Islamabad with and into the SIHL in accordance with the provisions of section 284 of the Companies Act, 2017. The SIHL has filed a scheme of amalgamation along with requisite documentation to the Securities and Exchange Commission of Pakistan (SECP) on March 25, 2025 (effective date of amalgamation), which has been acknowledged by SECP on May 9, 2025. Accordingly, SNS Islamabad stands merged into the SIHL with effect from March 25, 2025.

2 BASIS OF PREPARATION

2.1 Statement of compliance

These consolidated financial statements of the Group have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan. The accounting and reporting standards as applicable in Pakistan comprise of:

- International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and Islamic Financial Accounting Standards (IFASs) issued by the Institute of Chartered Accountants of Pakistan as are notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Where provisions of and directives issued under the Companies Act, 2017 differ from the IFRS or IFASs, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.2 Basis of measurement

These consolidated financial statements have been prepared under the historical cost convention, except for certain items as disclosed in relevant accounting policies.

2.3 Functional and presentation currency

These consolidated financial statements are presented in Pak Rupees, which is the Group's functional currency.

2.4 Use of estimates and judgments

The preparation of consolidated financial statements in conformity with accounting and reporting standards requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgment about carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

The areas where various assumptions and estimates are significant to the Group's consolidated financial statements or where judgment was exercised in application of accounting policies are as follows:

Notes 4.1 and 19	Estimate of recoverable amount of investment in associated company
Notes 4.3, 4.4, 4.17.4 and 9	Estimate of fair value of financial liabilities at initial recognition
Notes 4.5, 4.6, 10, 14 and 33	Provision for taxation
Notes 4.7, 11 and 16	Right of use assets and corresponding lease liability
Notes 4.9, 12.4 and 12.5	Employee benefits
Notes 4.10, 4.11 and 15	Provisions and contingencies
Notes 4.12 and 16	Estimate of useful life of property, plant and equipment
Notes 4.13 and 17	Estimate of useful life of intangible assets
Note 4.15	Impairment of non-financial assets
Notes 4.17.2, 26.2 and 43.1.3	Expected credit loss allowance
Notes 4.18 and 22	Provision for slow moving stores, spares and loose tools

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

3 STANDARDS, INTERPRETATIONS AND AMENDMENTS TO THE APPROVED ACCOUNTING STANDARDS

3.1 New accounting standards, amendments and IFRS interpretations that are effective for the year ended June 30, 2025

The following standards, amendments and interpretations are effective for the year ended June 30, 2025. These standards, amendments and interpretations are either not relevant to the Group's operations or did not have significant impact on the consolidated financial statements other than certain additional disclosures.

3.2 New accounting standards, amendments and interpretations that are not yet effective

**Effective date
(annual reporting
periods beginning
on or after)**

Amendments to IAS 21 'The Effects of Changes in Foreign Exchange Rates' - Lack of Exchangeability	January 01, 2025
Amendments to IFRS 7 'Financial Instruments: Disclosures' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026
Amendments to IFRS 9 'Financial Instruments' - Amendments regarding the classification and measurement of financial instruments	January 01, 2026
IFRS 17 Insurance Contracts	January 01, 2026

Certain annual improvements have also been made to a number of IFRSs and IASs.

IFRS 1 'First-time Adoption of International Financial Reporting Standards' has been issued by IASB effective from July 01, 2009. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRS 18 'Presentation and Disclosures in Financial Statements' has been issued by IASB effective from January 01, 2027. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRS 19 'Subsidiaries without Public Accountability: Disclosures' has been issued by IASB effective from January 01, 2027. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

IFRIC 12 Service Concession Arrangement has been issued by IASB effective from January 01, 2008. However, it has not been adopted yet locally by Securities and Exchange Commission of Pakistan (SECP).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4 MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements unless otherwise stated.

4.1 Basis of consolidation

These consolidated financial statements includes the financial statements of Shifa International Hospitals Limited and its subsidiaries, SDSPL 55% owned (2024: 55% owned), SMC Islamabad 56% owned (2024: 56% owned), SNH Faisalabad 60% owned (2024: 61% owned) and SNS Islamabad (2024: 100% owned) which has been merged into parent company as disclosed in note 1.1.

Subsidiaries

Subsidiaries are all entities over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are derecognised from the date the control ceases.

The Group uses the acquisition method of accounting to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities (including contingent liabilities) assumed in a business combination are measured initially at their fair values at the acquisition date. On an acquisition by acquisition basis, the Group recognises any non-controlling interest in the acquiree at the non-controlling interest's proportionate share of the acquiree's identifiable net assets.

Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

Associates (equity accounted investee)

Entities over which the Group has significant influence directly or indirectly (through subsidiaries) but not control and which are neither subsidiaries nor joint ventures of the members of the Group, are associates and are accounted for under the equity method of accounting (equity accounted investees). These investments are initially recognised at cost. The consolidated financial statements include the associates' share of profit or loss and movements in other comprehensive income, after adjustments, if any, to align the accounting policies with those of the Group, from the date that significant influence

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

commences until the date it ceases. Share of post acquisition profit / loss of associates is recognised in the consolidated statement of profit or loss and the consolidated statement of comprehensive income. Distributions received from associates reduce the carrying amount of investment.

When the Group's share of losses exceeds its interest in an equity accounted investee, the carrying amount of that investment (including any long-term interests that, in substance, form part of the Group's net investment in the associate) is reduced to nil and the recognition of further losses is discontinued except to the extent that the Group has an obligation or has made payments on behalf of the investee.

Non controlling interest (NCI)

NCI is measured at their proportionate share of the acquiree's identifiable net assets at the date of acquisition.

Loss of control

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any related NCI and other components of equity. Any resulting gain or loss is recognised in the consolidated statement of profit or loss. Any interest retained in the former subsidiary is measured at fair value when the control is lost.

4.2 Share capital and dividend

Dividend is recognised as a liability in the period in which it is declared. Movement in reserves is recognised in the year in which it is approved.

4.3 Financing and finance cost

Financing is recognised initially at fair value, less attributable transaction costs. Subsequent to initial recognition, financing is stated at amortised cost with any difference between cost and redemption value being recognised in the consolidated statement of profit or loss over the period of the financing on an effective interest basis. Finance cost is recognised as an expense in the period in which these are incurred.

4.4 Government grants

Government grants are transfer of resources to an entity by a government entity in return for compliance with certain past or future conditions related to the entity's operating activities e.g. a government subsidy.

Government grants are recognised at fair value, as deferred income, when there is reasonable assurance that the grants will be received and the Group will be able to comply with the conditions associated with the grants.

Grants that compensate the Group for expenses incurred, are recognised on a systematic basis in the income for the year in which the finance cost is recognised and finance cost is reported net of grant in note 32.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

A loan is initially recognised and subsequently measured in accordance with IFRS 9. IFRS 9 requires loans at below-market rates to be initially measured at their fair value. e.g. the present value of the expected future cash flows discounted at a market-related interest rate. The benefit that is the government grant is measured as the difference between the fair value of the loan on initial recognition and the amount received, which is accounted for according to the nature of the grant.

4.5 Taxation

Taxation for the year comprises of current and deferred tax. Taxation is recognised in the consolidated statement of profit or loss except to the extent that it relates to items recognised directly in the consolidated statement of changes in equity and consolidated statement of comprehensive income.

Current

Provision for current taxation is based on taxable income at the current rates of tax after taking into account applicable tax credits, rebates, losses and exemptions available, if any.

Deferred

Deferred tax is accounted for using balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences, unused tax losses and tax credits can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that is no longer probable that the related tax benefit will be realised.

Deferred tax is calculated at the rates that are expected to apply to the period when the differences reverse, based on tax rates that have been enacted. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets and they relate to income taxes levied by the same tax authority on the same taxable entity or on different tax entities but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

The Group takes into account the current income tax law and decisions taken by appellate authorities. Instances where the Group's view differs from the view taken by the income tax department at the assessment stage and where the Group considers that its view on items of material nature is in accordance with law, the amounts are shown as contingent liabilities.

Deferred tax asset of Rs. 111.93 million (2024: Rs. 86.48 million) on deductible temporary difference of Rs. 384.95 million (2024: Rs. 298.20 million) has not been recorded in respect of subsidiaries.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.6 Levies

Minimum tax, final tax and super tax not based on taxable profits are recognised as a levy in the consolidated statement of profit or loss. The amount calculated on taxable income using the notified tax rate is recognised as current income tax expense for the year in consolidated statement of profit or loss under the scope of IAS 12. Any excess of expected income tax paid or payable for the year under the Income Tax Ordinance, 2001 ("the Ordinance") over the amount designated as current income tax for the year, is then recognised as a levy falling under the scope of IFRIC 21 / IAS 37.

4.7 Leases

4.7.1 Right of use assets (ROUs)

The SIHL recognises right of use assets and a lease liability at the lease commencement date. The right of use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right of use assets are subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right of use assets or the end of the lease term. The estimated useful lives of right of use assets are determined as those of similar assets or the lease term as specified in contract. In addition, the right of use assets is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The Group has not elected to recognise right of use assets and lease liabilities for short-term leases of properties that have a lease term of 12 months or less and leases of low-value assets. The Group recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

4.7.2 Lease liability

The lease liability is initially measured at the present value of the future lease payments discounted using the SIHL's incremental borrowing rate. Lease payments in the measurement of the lease liability comprise the following:

- Fixed payments (including in-substance fixed payments) less any lease incentives receivable;
- Variable lease payments that are based on an index or a rate;
- Amounts expected to be payable by the lessee under residual value guarantees;
- The exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
- Payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the SIHL's estimate of the amount expected to be payable under a residual value guarantee, or if the SIHL changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right of use assets, or is recorded in the consolidated statement of profit or loss if the carrying amount of the right of use assets has been reduced to zero.

4.8 Trade and other payables

Liabilities for trade and other payables are carried at amortised cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Group.

4.9 Employee benefits

Defined benefit plan

The SIHL operates approved funded gratuity scheme for all its non management employees who have completed the minimum qualifying period of service as defined in the scheme. Provision is made annually to cover obligations under the scheme on the basis of actuarial valuation and is charged to the consolidated statement of profit or loss. The actuarial gain or loss at each evaluation date is charged to consolidated statement of comprehensive income.

The amount recognised in the consolidated statement of financial position represents the present value of defined benefit obligations as reduced by the fair value of plan assets.

Calculation of gratuity asset requires assumptions to be made of future outcomes which mainly include increase in remuneration, expected long term return on plan assets and the discount rate used to convert future cash flows to current values. Calculations are sensitive to changes in the underlying assumptions and determined by actuary.

Defined contribution plan

A defined contribution plan is a post-employment benefit plan where monthly contribution equal to 1/12th of eligible salary are made by the SIHL in employees' pension fund account maintained with designated asset management company and recognised as expense in the consolidated statement of profit or loss as and when they become due. Employees will be eligible for pension fund on the completion of minimum qualifying period. On fulfilment of criteria, accumulated contribution against qualifying period of services from the date of joining classified as deferred liability and will be transferred to employees' pension fund account.

Compensated absences

The Group provides for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. Accrual to cover the obligations is made using the current salary levels of the employees.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.10 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount can be made. However, provisions are reviewed at each reporting date and adjusted prospectively to reflect the current best estimates.

4.11 Contingencies

A contingent liability is disclosed when the Group has a possible obligation as a result of past events, whose existence will be confirmed only by the occurrence or non-occurrence, of one or more uncertain future events not wholly within the control of the Group; or the Group has a present legal or constructive obligation that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

The Group discloses significant contingent liabilities for the pending litigations and claims against the Group based on its judgment and the advice of the legal advisors for the estimated financial outcome. The actual outcome of these litigations and claims can have an effect on the carrying amounts of the liabilities recognised at the reporting date. However, based on the best judgment of the Group and its legal advisors, the likely outcome of these litigations and claims is remote and there is no need to recognise any liability at the reporting date.

4.12 Property, plant and equipment

Property, plant and equipment except freehold and leasehold land and capital work in progress are stated at cost less accumulated depreciation and impairment in value, if any. Leasehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent accumulated amortisation and impairment losses while freehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent impairment losses, if any.

Any revaluation increase arising on the revaluation of land is recognised in consolidated statement of comprehensive income and presented as a separate component of equity as "Revaluation surplus on property, plant and equipment", except to the extent that it reverses a revaluation decrease for the same asset previously recognised in the consolidated statement of profit or loss, in which case the increase is credited to the consolidated statement of profit or loss to the extent of the decrease previously charged. Any decrease in carrying amount arising on the revaluation of land is charged to the consolidated statement of profit or loss to the extent that it exceeds the balance, if any, held in the revaluation surplus on property, plant and equipment relating to a previous revaluation of that asset. The surplus on leasehold land to the extent of incremental depreciation charged is transferred to unappropriated profit.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Capital work in progress and stores held for capital expenditure are stated at cost less impairment loss recognised, if any. All expenditures connected with specific assets incurred during installation and construction period are carried under capital work in progress. These are transferred to specific items of property, plant and equipment when available for intended use.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance costs that do not meet the recognition criteria are charged to the consolidated statement of profit or loss as and when incurred.

Depreciation / amortisation is charged to the consolidated statement of profit or loss commencing when the asset is ready for its intended use, applying the straight-line method over the estimated useful life.

In respect of additions and disposals during the year, depreciation / amortisation is charged when the asset is available for use and up to the month preceding the asset's classified as held for sale or derecognised, whichever is earlier.

Assets are derecognised when disposed off or when no future economic benefits are expected to flow from its use. Gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and is recognised on net basis in the consolidated statement of profit or loss.

The Group reviews the useful lives of property, plant and equipment on a regular basis. Similarly revaluation of land is made with sufficient regularity. Any change in estimates in future years might affect the carrying amounts of the respective items of property, plant and equipment with a corresponding effect on the depreciation / amortisation charge and impairment.

4.13 Intangible assets

Intangible assets are stated at cost less accumulated amortisation and impairment losses, if any. Subsequent cost on intangible assets is capitalised only when it increases the future economic benefits embodied in the specific assets to which it relates. All other expenditure is expensed as incurred.

Amortisation is charged to the consolidated statement of profit or loss on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Amortisation on additions to intangible assets is charged from the month in which an item is acquired or capitalised while no amortisation is charged for the month in which the item is disposed off.

The Group reviews the useful lives of intangible assets on a regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of intangibles with the corresponding effect on the amortisation charge and impairment.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.14 Investment property - at cost

Investment property, principally comprising of land, is held for long term capital appreciation and is valued using the cost method i.e. at cost less impairment losses, if any.

Cost includes expenditure that is directly attributable to the acquisition of the investment property. The cost of self-constructed investment property includes the cost of materials and direct labor, any other costs directly attributable to bringing the investment property to a working condition for their intended use and capitalised borrowing costs, if any.

The gain or loss on disposal of investment property, represented by the difference between the sale proceeds and the carrying amount of the asset is recognised as income or expense in the consolidated statement of profit or loss.

4.15 Impairment of non - financial assets

The Group assesses at each reporting date whether there is any indication that assets except deferred tax assets and inventory may be impaired. If such indication exists, the carrying amounts of such assets are reviewed to assess whether they are recorded in excess of their recoverable amounts. Where carrying values exceed the respective recoverable amounts, assets are written down to their recoverable amounts and the resulting impairment loss is recognised in the consolidated statement of profit or loss except for the impairment loss on revalued assets, which is adjusted against the related revaluation surplus to the extent that the impairment loss does not exceed the surplus on revaluation of that asset. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use.

Where impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised recoverable amount but limited to the extent of the carrying amount that would have been determined (net of depreciation / amortisation) had no impairment loss been recognised for the asset in prior years. Reversal of impairment loss is recognised in the consolidated statement of profit or loss.

4.16 Investments

All purchases and sales of investments are recognised using settlement date accounting. Settlement date is the date on which that investments are delivered to or by the Group. All investments are derecognised when the rights to receive cash flows from the investments have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership.

4.17 Financial assets

Initial measurement

A financial asset is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

The Group classifies its financial assets into following three categories:

- fair value through other comprehensive income (FVOCI);
- fair value through profit or loss (FVTPL); and
- amortised cost.

Subsequent measurement

i) Debt instrument at FVOCI

These assets are subsequently measured at fair value. Interest / markup income calculated using the effective interest method, foreign exchange gains or losses and impairment are recognised in the consolidated statement of profit or loss. Other net gains or losses are recognised in consolidated statement of comprehensive income. On de-recognition, gains or losses accumulated in consolidated statement of comprehensive income are reclassified to the consolidated statement of profit or loss.

ii) Equity instrument at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in the consolidated statement of profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains or losses are recognised in consolidated statement of comprehensive income and are never reclassified to the consolidated statement of profit or loss.

iii) Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains or losses, including any interest / markup or dividend income, are recognised in the consolidated statement of profit or loss.

iv) Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest / markup income, foreign exchange gains or losses and impairment are recognised in the consolidated statement of profit or loss.

4.17.1 Other financial assets

Investment in units of mutual funds are classified at fair value through profit or loss and is initially measured at fair value and subsequently is measured at fair value determined using the net assets value of the funds at each reporting date. Net gain or loss is recognised in the consolidated statement of profit or loss.

Investments in term deposit receipts are classified as amortised cost and are initially measured at fair value. Transaction costs directly attributable to the acquisition are included in the carrying amount. Subsequently these investments are measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses, if any. Interest/markup income, losses and impairment are recognised in the consolidated statement of profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.17.2 Impairment of financial assets

The Group assesses on a forward-looking basis the expected credit losses (ECL) associated with its financial asset carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

The Group applies the simplified approach for trade debts which requires expected lifetime losses to be recognised from initial recognition of the receivables.

The Group recognises life time ECL for trade debts, using the simplified approach. The ECL on trade debts are estimated using a provision matrix based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date. Life time expected credit losses against other receivables are also recognised due to significant increase in credit risk since initial recognition.

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forward-looking information as described above. As for the exposure at default for financial assets, this is represented by the assets' gross carrying amounts at the reporting date reduced by security deposit held. For other financial assets, the ECL is based on the 12 month ECL. The 12 month ECL is the portion of lifetime ECL that results from default events on a financial instrument that are possible within 12 months after the reporting date. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECL.

The Group recognises an impairment loss in the consolidated statement of profit or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account.

The gross carrying amount of a financial asset is written off when the Group has no reasonable expectations of recovering of a financial asset in its entirety or a portion thereof. The Group individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery.

The Group writes off financial assets that are still subject to enforcement activities. Subsequent recoveries of amounts previously written off will result in impairment gain.

4.17.3 Derecognition

Financial assets are derecognised when the contractual rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.17.4 Financial liabilities

Financial liabilities are classified as measured at amortised cost or at fair value through profit or loss (FVTPL). A financial liability is classified at FVTPL if it is classified as held for trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in the consolidated statement of profit or loss.

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in the consolidated statement of profit or loss. Any gain or loss on derecognition is also recognised in the consolidated statement of profit or loss.

Financial liabilities are derecognised when the contractual obligations are discharged or cancelled or have expired or when the financial liabilities' cash flows have been substantially modified.

4.17.5 Off-setting financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount is reported in the consolidated statement of financial position, if the Group has a legally enforceable right to set off the recognised amounts, and the Group either intends to settle on a net basis, or realise the asset and settle the liability simultaneously. Legally enforceable right must not be contingent on future events and must be enforceable in normal course of business and in the event of default, insolvency or bankruptcy of the Group or the counterparty.

4.18 Stores, spare parts and loose tools

These are valued at cost, determined on moving average cost basis or net realisable value, whichever is lower. For items which are slow moving or identified as surplus to the SIHL's requirement, a provision is made for excess of book value over estimated net realisable value.

The SIHL reviews the carrying amount of stores, spare parts and loose tools on a regular basis. Any change in the estimates in future years might affect the carrying amounts of the respective items of stores and spares with a corresponding affect on the provision.

4.19 Stock in trade

Stock in trade is valued at lower of cost, determined on moving average basis or net realisable value. The cost includes expenditure incurred in acquiring the stock items and other cost incurred in bringing them to their present location and condition.

The SIHL reviews the carrying amount of stock in trade on a regular basis. Any change in the estimates in future years might effect the carrying amounts of the respective items of stock in trade with a corresponding affect on the provision.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

4.20 Trade debts, loans, deposits, interest accrued and other receivables

These are classified at amortised cost and are initially recognised when they are originated and measured at fair value of consideration receivable. These assets are written off when there is no reasonable expectation of recovery. Past years experience of credit loss is used to base the calculation of credit loss.

4.21 Cash and cash equivalents

Cash and cash equivalents comprises of cash in hand, cheques in hand, balances with banks and highly liquid short term investments that are readily convertible to known amounts of cash and which are subject to insignificant risk of change in value with maturity of three months or less from the date of acquisition.

4.22 Foreign currencies

Transactions in currencies other than Pak Rupees are recorded at the rates of exchange prevailing on the dates of transactions. At each reporting date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the reporting date. Gain or loss arising on retranslation is included in the consolidated statement of profit or loss.

4.23 Operating segment

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the board of directors that makes strategic decisions. The Group's management has determined that the Group has a single reportable segment as the board of directors views the Group's operations as one reportable segment.

4.24 Revenue recognition

Revenue is measured based on the consideration specified in a contract with a customer. Revenue from operations of the Group are recognised when the services are provided, and thereby the performance obligations are satisfied.

Revenue consists of inpatient revenue, outpatient revenue, pharmacy, cafeteria, rent of building and other services. Group's contract performance obligations are fulfilled at point in time when the services are provided to customer in case of inpatient, outpatient and other services and goods are delivered to customer in case of pharmacy and cafeteria revenue. Revenue is recognised at that point in time, as the control has been transferred to the customers.

Receivable is recognised when the services are provided and goods are delivered to customers as this is the point in time that the consideration is unconditional because only passage of time is required before the payment is due. The Group recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as advances from customers' in the consolidated statement of financial position.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Interest income is accrued on time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount.

Rental income is recognised on a straight-line basis over the term of the rent agreement.

Scrap sales and miscellaneous receipts are recognised on realised amounts.

4.25 Earnings per share

The Group presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding during the year. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, adjusted for the effects of all dilutive potential ordinary shares.

4.26 Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market is accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. The carrying values of all financial assets and liabilities reflected in the consolidated financial statements approximate their fair values.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities;
- Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable; and
- Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

5 ISSUED, SUBSCRIBED AND PAID UP CAPITAL

	2025	2024		2025	2024
	Number			(Rupees in '000')	
	61,974,886	61,974,886	Ordinary shares of Rs.10 each issued for cash	619,749	619,749
	1,239,497	1,239,497	Ordinary shares of Rs.10 each issued as fully paid bonus shares	12,395	12,395
	63,214,383	63,214,383		632,144	632,144

5.1 The SIHL has only one class of ordinary shares which carries no right to fixed income. The shareholders are entitled to receive dividend as declared from time to time and are entitled to one vote per share at meetings of the SIHL. All shares rank equally with regard to the SIHL's residual assets.

5.2 7,585,725 ordinary shares representing 12% shareholding in the SIHL are owned by International Finance Corporation (IFC). IFC has the right to nominate one director at the board of directors of the SIHL as long as IFC holds ordinary shares representing 5% of total issued share capital of the SIHL. Further, the SIHL if intends to amend or repeal the memorandum and articles of association, affects the rights of IFC on its shares issuance of preference shares ranking senior to the equity securities held by IFC, incur any financial debt to any shareholder, change the nature of the business of the SIHL etc. shall seek consent of IFC.

5.3 The SIHL has no reserved shares for issuance under options and sales contracts.

5.4 Capital management

The Group's objectives when managing capital are to ensure the Group's ability not only to continue as a going concern but also to meet its requirements for expansion and enhancement of its business, maximise return of shareholders and optimise benefits for other stakeholders to maintain an optimal capital structure and to reduce the cost of capital. There were no changes to the Group's approach to capital management during the year.

	2025	2024
Equity (Rupees in '000')	14,930,019	12,511,026
Debt including lease liabilities (Rupees in '000')	1,808,028	1,705,258
Debt to equity ratio (Percentage)	11	12

In order to achieve the above objectives, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares through bonus or right issue or sell assets to reduce debts or raise debts, if required.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

6 SHARE PREMIUM

This comprises of share premium of Rs. 5, Rs. 250 and Rs. 229.29 per share received on issue of 8,000,000, 4,024,100 and 7,436,986 ordinary shares of Rs. 10 each in the years 1994, 2016 and 2020, respectively. Out of the above the SIHL, during the year ended June 30, 2022 has issued bonus shares at the rate of 2% (total 1,239,497 bonus shares having face value of Rs. 10 each) as approved in Annual General Meeting held on October 28, 2021. The balance reserve cannot be utilised except for the purposes mentioned in section 81 of the Companies Act, 2017.

		2025	2024
		(Rupees in '000')	
7	SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT		
	Balance at beginning of the year	2,021,310	2,032,194
	Revaluation surplus during the year	506,447	20,321
	Transfer to non-controlling interest	(136,517)	(8,907)
	Realisation of revaluation surplus on disposal of assets	(14,517)	(4,284)
	Transferred to unappropriated profit in respect of incremental depreciation / amortisation charged during the year	(21,600)	(18,014)
	Balance at end of the year	2,355,123	2,021,310

- 7.1 Surplus on revaluation of property, plant and equipment in respect of leasehold and freehold land is not available for distribution of dividend to the shareholders of the Group in accordance with section 241 of the Companies Act, 2017.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

8 NON - CONTROLLING INTEREST (NCI)

Following is the summarised financial information of SDSPL, SNH Faisalabad and SMC Islamabad:

NCI percentage	SDSPL				SNH Faisalabad				SMC Islamabad				Total	
	45%		45%		40%		39%		44%		44%			
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024		
(Rupees in '000')														
Summarised statement of financial position														
Current assets	24,354	37,675	259,111	125,419	99,596	327,811	383,061	490,905						
Non-current assets	3,302	4,599	3,705,582	2,883,782	3,112,640	2,798,103	6,821,524	5,686,484						
Current liabilities	53,767	66,325	15,258	93,356	4,217	11,502	73,242	171,183						
Non-current liabilities	-	-	11,357	31,189	-	-	11,357	31,189						
Net assets	(26,111)	(24,051)	3,938,078	2,884,656	3,208,019	3,114,412	7,119,986	5,975,017						
Accumulated NCI	(58,051)	(57,248)	1,590,788	1,148,104	1,434,329	1,380,035	2,967,066	2,470,891						
Summarised statement of comprehensive income														
Revenue-net	-	-	-	-	-	-	-	-						
Other income	115	5,514	28,831	26,309	3,514	26,101	32,460	57,924						
Loss for the year	(2,058)	(86,627)	(36,156)	(61)	(82,883)	(10,318)	(121,097)	(97,006)						
Other comprehensive income	-	-	148,740	-	176,491	20,321	325,231	20,321						
Total comprehensive income / (loss)	(2,058)	(86,627)	112,584	(61)	93,608	10,003	204,134	(76,685)						
Profit / (Loss) attributable to NCI	(926)	(38,982)	(2,098)	1,994	(23,061)	(2,274)	(26,085)	(39,262)						
Comprehensive income for the year attributable to NCI	-	-	59,161	-	77,356	8,907	136,517	8,907						
Total comprehensive income / (loss) for the year attributable to NCI	(926)	(38,982)	57,063	1,994	54,294	6,633	110,432	(30,355)						
Summarised statement of cash flows														
Cash flows from operating activities	(1,252)	(30,551)	(81,104)	(43,795)	125,816	(59,300)	43,460	(133,646)						
Cash flows from investing activities	-	16,590	(640,759)	38,876	(97,138)	56,297	(737,897)	111,763						
Cash flows from financing activities	-	(2,515)	940,838	-	-	-	940,838	(2,515)						
Net increase / (decrease) in cash and cash equivalents	(1,252)	(16,476)	218,975	(4,919)	28,678	(3,003)	246,401	(24,398)						

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
9	LONG TERM FINANCING - SECURED		
	From banking companies and non-banking financial institutions		
Syndicated Islamic Finance Facility	9.1	-	142,857
Diminishing Musharakah Facility-1	9.2	105,964	78,250
Diminishing Musharakah Facility-2	9.3	-	83,333
Diminishing Musharakah Facility-3	9.4	433,043	577,390
Diminishing Musharakah Facility-4	9.5	475,986	-
Islamic Refinance Facility to Combat COVID -19 (IRFCC)	9.6	28,003	69,647
Deferred income - Government grant		861	5,341
		28,864	74,988
Islamic Refinance Facility to Combat COVID-19 (IRFCC)	9.7	13,249	22,245
Deferred income - Government grant		1,516	4,073
		14,765	26,318
Refinance Facility to Combat COVID-19 (RFCC)	9.8	45,339	78,486
Deferred income - Government grant		4,648	13,329
		49,987	91,815
		1,108,609	1,074,951
Less: current portion		255,190	495,195
		853,419	579,756

- 9.1 This represented the syndicated islamic finance facility, arranged and lead by Meezan Bank Limited, obtained on profit rate basis at 3 months KIBOR plus 0.85% per annum. The facility with sanctioned limit of Rs. 2,000 million has been fully repaid on August 22, 2024. The financing was secured by pari passu charge of Rs. 2,667 million on all present and future SIHL's movable fixed assets and land / building located at H-8/4, Islamabad. Meezan Bank Limited has the custody of original ownership documents of the SIHL's land located at H-8/4 Islamabad.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 9.2 This represents the outstanding balance of long term islamic finance facility obtained under Diminishing Musharakah basis from First Habib Modaraba of Rs. 161.90 million (2024: Rs. 119.10 million). Principal amount is repayable in 60 equal monthly instalments carrying profit rate at 3 months KIBOR plus 0.70% (2024: 3 months KIBOR plus 0.70%) per annum. The unavailed limit of this facility is nil (2024: nil). This also represented the long term islamic finance facility obtained from Al Baraka Bank (Pakistan) Limited, obtained on profit rate basis at 3 months KIBOR plus 0.80% per annum. The facility with sanctioned limit of Rs. 470.20 million has been fully repaid on September 30, 2024. The financing was secured by first exclusive charge of Rs. 781.30 million against equipment / machinery.
- 9.3 This represented the long term islamic finance facility obtained from Meezan Bank Limited, carrying profit rate at 3 months KIBOR plus 0.85% per annum. The facility with sanctioned limit of Rs. 500 million has been fully repaid on October 01, 2024. The financing was secured by first pari passu charge of Rs. 667 million on all present and future fixed assets of the SIHL.
- 9.4 This represents the outstanding balance of long term islamic finance facility obtained from Bank Alfalah Limited of Rs. 577.40 million (2024: Rs. 577.40 million). Principal amount is repayable in 16 equal quarterly instalments carrying profit rate at 3 months KIBOR plus 0.70% (2024: 3 months KIBOR plus 0.70%) per annum. The financing is initially secured by a ranking charge of Rs. 800 million, which has been upgraded to a first exclusive charge on the plant and machinery being financed under the DM facility to be installed at the hospital located at H-8/4, Islamabad. The unavailed limit of this facility is nil (2024: nil).
- 9.5 This represents the outstanding balance of long term islamic finance facility obtained from Meezan Bank Limited of Rs. 475.90 million (2024: nil). Principal amount is repayable in 16 equal quarterly instalments carrying profit rate at 3 months KIBOR plus 0.50% per annum. The financing is secured by existing first pari passu charge of Rs. 800 million on all present and future fixed assets of the SIHL. The unavailed limit of this facility is Rs. 124.10 million (2024: nil).
- 9.6 This represents the outstanding balance of long term islamic finance facility obtained from Meezan Bank Limited of Rs. 200 million (2024: Rs. 200 million) for the purpose of import / purchase of medical equipment / machinery to combat COVID-19 under State Bank of Pakistan IRFCC scheme. Principal amount shall be repaid by January 27, 2026 in 18 equal quarterly instalments with no profit rate. The financing is secured by first pari passu hypothecation charge of Rs. 267 million on all present and future fixed assets of the SIHL (excluding land and building). The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries no profit rate, the loan has been recognised at present value using the SIHL's effective profit rate along with the recognition of government grant.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	5,341	13,313
Amortisation during the year	(4,480)	(7,972)
Balance at end of the year	861	5,341

- 9.7 This represents the outstanding balance of long term islamic finance facility obtained from Al Baraka Bank (Pakistan) Limited of Rs. 45.90 million (2024: Rs. 45.90 million) for the purpose of import / purchase of medical equipment / machinery to combat COVID-19 under State Bank of Pakistan IRFCC scheme. Principal amount shall be repaid in 9 equal half yearly instalments with profit rate of 1% per annum. The facility is secured by exclusive charge of Rs. 55 million over equipment / machinery against DM IRFCC. The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries the profit rate below the market rate, the loan has been recognised at present value using the SIHL's effective profit rate along with the recognition of government grant.

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	4,073	7,447
Amortisation during the year	(2,557)	(3,374)
Balance at end of the year	1,516	4,073

- 9.8 This represents the outstanding balance of long term finance facility obtained from United Bank Limited of Rs. 185.20 million (2024: Rs. 185.20 million). Principal amount shall be repaid by September 14, 2026 in 18 equal quarterly instalments carrying profit at 1% per annum. The financing is secured by first pari passu charge of Rs. 267 million over fixed assets (excluding land and building) of the SIHL. The unavailed limit of this facility is nil (2024: nil). Since the financing under SBP refinance scheme carries the markup rate below the market rate, the loan has been recognised at present value using the SIHL's effective profit rate along with the recognition of government grant.

	2025	2024
	(Rupees in '000')	
Balance at beginning of the year	13,329	27,830
Amortisation during the year	(8,681)	(14,501)
Balance at end of the year	4,648	13,329

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
10	DEFERRED LIABILITIES		
	Deferred taxation	244,422	354,960
	Defined contribution plan	44,846	34,434
		289,268	389,394
10.1	Deferred taxation		
	Deferred tax liability	530,575	604,045
	Deferred tax asset	(286,153)	(249,085)
	Net deferred tax liability	244,422	354,960
10.1.1	Deferred tax liability on taxable temporary differences:		
	Accelerated depreciation / amortisation allowance	530,575	604,045
10.1.2	Deferred tax asset on deductible temporary differences:		
	Right of use assets net of lease liabilities	(57,984)	(66,580)
	Specific provisions	(188,105)	(130,739)
	Retirement benefit obligation	(40,064)	(51,766)
		(286,153)	(249,085)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

10.1.3 Breakup and movement of deferred tax balances is as follows:

Deferred tax liabilities / (assets)	Opening balance	Statement of profit or loss	Other comprehensive income	Closing balance
(Rupees in '000')				
2025				
Effect of taxable temporary differences				
Accelerated depreciation / amortisation allowance	604,045	(73,470)	-	530,575
Effect of deductible temporary differences				
Right of use assets net of lease liabilities	(66,580)	8,596	-	(57,984)
Specific provisions	(130,739)	(57,366)	-	(188,105)
Retirement benefit obligation	(51,766)	44,193	(32,491)	(40,064)
	354,960	(78,047)	(32,491)	244,422
2024				
Effect of taxable temporary differences				
Accelerated depreciation / amortisation allowance	643,508	(39,463)	-	604,045
Effect of deductible temporary differences				
Right of use assets net of lease liabilities	(59,683)	(6,897)	-	(66,580)
Specific provisions	(119,119)	(11,620)	-	(130,739)
Retirement benefit obligation	(66,133)	62,972	(48,605)	(51,766)
	398,573	4,992	(48,605)	354,960

10.1.4 Deferred tax assets and liabilities on temporary differences are measured at the rate of 39% (2024: 39%).

FOR THE YEAR ENDED JUNE 30, 2025

11.1 Lease liabilities are payable as follows:

207

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
11.2	Amounts recognised in the consolidated statement of profit or loss		
	Interest expense on lease liabilities	32	102,801
	Expense relating to short term / low value lease	31	26,218
		129,019	88,836
12	TRADE AND OTHER PAYABLES		
	Creditors	12.1	2,469,714
	Accrued liabilities		752,488
	Advances from customers - contract liability	12.2	422,014
	Medical consultants' charges		726,226
	Security deposits	12.3	144,573
	Compensated absences	12.4	223,374
	Defined contribution plan		31,027
	Retention money		22,994
	Shifa International Hospitals Limited (SIHL)		
	Employees' Gratuity Fund Trust (the Fund)	12.5	102,728
		4,895,138	4,168,270
12.1	This includes payables to related parties (unsecured) as detailed below:		
	Tameer-e-Millat Foundation (TMF)		4,186
	Shifa Tameer-e-Millat University (STMU)		42,798
		46,984	38,851
12.2	Advances from customers - contract liability		
	Balance at beginning of the year		384,383
	Revenue recognised during the year		(71,099)
	Advance refund during the year		(64,797)
	Advance received during the year		173,527
	Balance at end of the year		422,014
12.3	This includes security deposits retained from employees of Rs. 54.44 million (2024: Rs. 47.53 million) held in separate bank account and balances obtained from customers of Rs. 90.14 million (2024: Rs. 84.92 million) that are utilisable for the purpose of the business in accordance with agreements with customers.		

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
12.4	Compensated absences		
	Balance at beginning of the year	175,903	145,524
	Provision made for the year	136,518	103,063
		312,421	248,587
	Payments made during the year	(89,047)	(72,684)
	Balance at end of the year 12.4.1	223,374	175,903

12.4.1 Actuarial valuation of compensated absences has not been carried out since SIHL management believes that the effect of actuarial valuation would not be material.

		2025	2024
	Note	(Rupees in '000')	
12.5	The amounts recognised in the consolidated statement of financial position:		
	Present value of defined benefit obligation 12.5.1	769,150	556,506
	Fair value of plan assets 12.5.2	(666,422)	(423,772)
		102,728	132,734
12.5.1	Movement in the present value of defined benefit obligation:		
	Balance at beginning of the year	556,506	387,539
	Interest cost	77,364	56,442
	Current service cost	98,635	72,974
	Benefits paid	(60,107)	(78,839)
	Benefits payable	(3,895)	(2,635)
	Remeasurement loss on defined benefit obligation	100,647	121,025
	Balance at end of the year	769,150	556,506
12.5.2	Movement in the fair value of plan assets:		
	Balance at beginning of the year	423,772	217,966
	Interest income on plan assets	73,956	48,772
	Contributions	215,360	242,112
	Benefits paid	(60,107)	(78,839)
	Benefits payable	(3,895)	(2,635)
	Return on plan assets, excluding interest income	17,336	(3,604)
	Balance at end of the year	666,422	423,772

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
12.5.3	Charge for the year:		
	Current service cost	98,635	72,974
	Interest cost on defined benefit obligation	77,364	56,442
	Interest income on plan assets	(73,956)	(48,772)
		102,043	80,644
12.5.4	Remeasurement recognised in consolidated statement of other comprehensive income (OCI):		
	Remeasurement loss on defined benefit obligation	100,647	121,025
	Return on plan assets, excluding interest income	(17,336)	3,604
	Remeasurement loss recognised in OCI	83,311	124,629
	Deferred tax relating to remeasurement of staff gratuity fund benefit plan	(32,491)	(48,605)
		50,820	76,024
12.5.5	Movement in liability recognised in consolidated statement of financial position:		
	Balance at beginning of the year	132,734	169,573
	Charge for the year	102,043	80,644
	Remeasurement recognised in OCI during the year	83,311	124,629
	Contributions during the year	(215,360)	(242,112)
	Balance at end of the year	102,728	132,734
12.5.6	Plan assets comprise of:		
	Term deposit receipts	559,671	306,190
	Ordinary shares of SIHL	37,279	11,503
	Cash and bank balances	89,616	122,328
	Payable to outgoing members	(20,144)	(16,249)
		666,422	423,772
12.5.6.1	Number of ordinary shares of SIHL held by the Fund at year end were 78,461 shares (2024: 78,461 shares) with market value of Rs. 475.13 (2024: Rs. 146.61) per share.		
12.5.7	Latest actuarial valuation was carried out by an independent actuary on June 30, 2025 using the Projected Unit Credit Method.		

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	2025	2024
12.5.8 Principal actuarial assumptions used in the actuarial valuation:		
Discount rate used for interest cost in profit or loss	14.75%	16.25%
Discount rate used for year end obligation	11.75%	14.75%
Expected rate of salary growth		
- Salary increase FY 2025	N/A	13.75%
- Salary increase FY 2026 onward	11.75%	13.75%
Mortality rate	SLIC 2001-2005 set back 1 year	SLIC 2001-2005 set back 1 year
Withdrawal rates	Age based	Age based
Retirement assumption	Age 60	Age 60

12.5.9 Sensitivity analysis

The calculation of the defined benefit obligation is sensitive to assumptions set out above. The following table summarises how the impact on the defined benefit obligation at the end of the reporting period would have increased / decreased as a result of a change in respective assumptions by one percent.

	2025		2024	
	Defined benefit obligation		Defined benefit obligation	
	Effect of 1% increase	Effect of 1% decrease	Effect of 1% increase	Effect of 1% decrease
(Rupees in '000')				
Discount rate	714,039	833,098	519,684	598,872
Future salary increase	832,486	713,577	598,872	519,075

12.5.10 The average duration of the defined benefit obligation as at June 30, 2025 is 8 years (2024: 7 years).

12.5.11 The expected expenses for the next year amounting to Rs. 141.06 million.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

12.5.12 Risks associated with the scheme

Final salary risk

The risk that the final salary at the time of cessation of service is greater than what is assumed. Since the benefit is calculated on the final salary (which will closely reflect inflation and other macroeconomic factors), the benefit amount increases as salary increases.

Demographic risks

a) Mortality risk

The risk that the actual mortality experience is different than the assumed mortality. This effect is more pronounced in schemes where the age and service distribution is on the higher side.

b) Withdrawal risk

The risk of actual withdrawals experience is different from assumed withdrawal probability. The significance of the withdrawal risk varies with the age, service and the entitled benefits of the beneficiary.

c) Investment risk

The risk of the investment under performing and being not sufficient to meet the liabilities.

		2025	2024
	Note	(Rupees in '000')	
13	MARKUP ACCRUED		
	Long term financing	7,974	23,858
14	TAXATION - NET		
	Tax refund at beginning of the year	(258,787)	(320,936)
	Income tax paid / deducted at source during the year	(1,591,071)	(866,606)
		(1,849,858)	(1,187,542)
	Income tax expense / levies 33	1,912,691	928,755
	Tax payable / (refund) at end of the year	62,833	(258,787)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

15 CONTINGENCIES AND COMMITMENTS

15.1 Contingencies

15.1.1 The guarantees issued by bank in favour of Sui Northern Gas Pipelines Limited (SNGPL) and Imtiaz Group (SMC-Private) Limited of aggregate sum of Rs. 36.60 million (2024: Rs. 33.10 million) on behalf of the SIHL in its ordinary course of business. Additionally, a bank guarantee amounting to Rs. 44.50 million (2024: nil) has been issued in favour of the Capital Development Authority (CDA) to secure obligations under the ICT Building Control Regulations - 2020 (Amended 2023) on behalf of SMC Islamabad. Further, a letter of guarantee amounted to Rs. 78.30 million issued in favor of CDA by insurance company on behalf of the SMC Islamabad to cover its obligations under the Islamabad Capital Territory (ICT) Building Control Regulations - 2020 (Amended 2023). This guarantee stands expired during the current year.

15.1.2 The SIHL is facing claims and penalties amounting to Rs. 5.9 million (2024: Rs. 22.25 million). Against these claims the SIHL has made payments under protest amounting to Rs. 2.4 million (2024: Rs. 1.4 million). In compliance with the directions of the Islamabad High Court (IHC), the SIHL has furnished a bank guarantee for Rs. 0.5 million (2024: Rs. 1.5 million) and, submitted a pay order of Rs. 2 million to the IHC. These claims and penalties originated from ongoing legal proceedings and complaints currently under litigation before the Islamabad, Peshawar and Lahore High Courts and the Supreme Court of Pakistan.

Furthermore, on June 06, 2012, the Competition Commission of Pakistan (CCP) imposed a penalty of Rs. 20 million against each Gulf Cooperation Council's (GCC) Approved Medical Center (GAMC), including the SIHL, on the allegations of engaging in non-competitive practices involving territorial division and equal allocation of customers among GAMCs. The SIHL, in conjunction with other GAMCs, is actively contesting this matter which is presently pending adjudication before the Competition Appellate Tribunal (CAT) and the Supreme Court of Pakistan.

Subsequently, the CAT has adjudicated the matter and through order dated August 11, 2025, reduced the penalty from Rs. 20 million to Rs. 2 million. The SIHL, in conjunction with other GAMCs, will contest the order of the CAT by preferring an appeal before the Supreme Court of Pakistan.

Following the CAT's order, the CCP, without serving any notice to the SIHL and in deviation from the procedure prescribed under the Competition Act, 2010, initiated coercive recovery proceedings. On August 12, 2025, the CCP proceeded to attach the SIHL's accounts and recovered an aggregate amount of Rs. 4.01 million, i.e., twice the penalty determined by the CAT. Consequently, the SIHL is in the process of filing a Writ Petition before the IHC seeking, inter alia, a declaration that the recovery is illegal and the refund of the unlawfully recovered amount of Rs. 4.01 million.

The SIHL's management, based on advice from respective legal counsels, remains confident of favourable resolutions in the aforementioned matters.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

15.1.3 During the year the SIHL has received a demand notice from the Capital Development Authority (CDA) regarding the payment of regularisation charges. As per the notice dated March 21, 2025, CDA has demanded payment of Rs. 790.76 million as regularisation charges, out of which Rs. 384.92 million has already been paid by the SIHL. The balance amount of Rs. 405.84 million is being contested vehemently as the same is beyond the scope of legal charges / rates invoked at the time of demand. The SIHL intends to pursue rigorously and avail all appropriate legal remedy before competent forum. The SIHL has also expressed its protest in clear terms to the CDA against said excessive demand. No provision has been made in these consolidated financial statements as the SIHL's management as per advice of the legal counsel, is confident that a favorable outcome will be achieved.

15.1.4 Contingencies related to income tax and sales tax are as follows:

15.1.4.1 The tax authorities amended the assessments for the tax years 2012 to 2016, 2019, 2021 and 2023 under section 122(5A) of the Income Tax Ordinance, 2001 (the Ordinance). They raised total tax demands of Rs. 648.70 million against these years. The SIHL, being aggrieved, appealed these amended assessments before the Commissioner Inland Revenue (Appeals) [CIR(A)] or the Appellate Tribunal Inland Revenue [ATIR], as applicable, on various dates from September 2018 to February 2025. These appeals are currently pending adjudication.

15.1.4.2 The tax authorities imposed taxes of Rs. 109.60 million, Rs. 178.40 million, Rs. 27.40 million, and Rs. 29.20 million under section 161/205 of the Ordinance for the tax years 2016, 2014, 2013, and 2012 respectively, based on alleged non-deduction of tax on payments. The SIHL, being aggrieved, appealed these assessments before the CIR(A). Regarding the tax year 2012, the CIR(A) deleted the assessment, while for the tax years 2013 and 2016, the assessment was set aside, and for the tax year 2014, the assessment was confirmed. The SIHL, still aggrieved, filed appeals for the tax years 2013, 2014, and 2016 before the ATIR. The appeals for the tax years 2013 and 2016 were filed on November 26, 2019 and June 06, 2023 respectively, and they are currently pending adjudication. Additionally, the ATIR has set aside the assessment for the tax year 2014 for denovo consideration.

15.1.4.3 The tax authorities amended the assessments for the tax years 2012 to 2018 under section 122(1)/(5) of the Ordinance. They raised an aggregate tax demand of Rs. 2,537.10 million. Being aggrieved, the SIHL appealed these assessments before the CIR(A) except tax year 2018. The CIR(A) annulled all the assessment orders from October 15, 2018 to October 23, 2018, resulting in the deletion of the tax demands. Dissatisfied with the CIR(A)'s decision, the tax department filed an appeal before the ATIR from November 15, 2018 to November 27, 2019. These appeals are currently pending adjudication. For the tax year 2018, the SIHL appealed the assessment before the ATIR on July 24, 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

15.1.4.4 The tax authorities imposed sales tax under section 11 of the Sales Tax Act, 1990, on the alleged non-payment of sales tax on sales of scrap, fixed assets, and cafeteria services for the tax years 2016 to 2020, raising total tax demands of Rs. 225.20 million for these years. Upon appeal, the ATIR through orders from February 16, 2021 to July 30, 2024 deleted the sales tax charged on cafeteria services and fixed assets but confirmed the sales tax on scrap. Furthermore, for the tax years 2016 and 2020, the department has filed sales tax references before the High Court, which are currently pending adjudication.

15.1.4.5 In the case of amalgamated entity, SNS Islamabad, the tax authorities amended the assessment for tax year 2021 under section 122(5A) of the Ordinance, through an order dated August 31, 2022, creating a demand of Rs. 8.50 million by disallowing a refund adjustment from tax year 2020. The CIR(A) annulled the order on February 10, 2023. However, a fresh notice for reassessment was issued on May 27, 2025, and a revised order was passed on the same grounds, alleging the refund of Rs. 8.50 million as unverified. Being aggrieved SIHL filed an appeal before CIR(A) on July 24, 2025 which is pending adjudication.

Management is confident that the above disallowances and levies do not hold merit and the related amounts have been lawfully claimed in the income and sales tax returns as per the applicable tax laws and these matters will ultimately be decided in favour of the SIHL. Accordingly, no provision has been made in respect of above in these consolidated financial statements.

		2025	2024
		(Rupees in '000')	
15.2	Commitments		
15.2.1	Capital expenditure contracted	160,117	294,233
15.2.2	Letters of credit	-	521,187

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

16 PROPERTY, PLANT AND EQUIPMENT

Particulars	Owned assets										Right of use assets					
	Freehold land	Leasehold land	Building on freehold land	Building on leasehold land	Leasehold Improvements	Biomedical equipment	Air conditioning equipment and machinery	Electrical and other equipment	Furniture and fittings	Construction equipment	Computer installations	Vehicles	Capital work in progress (note 16.8)	Office premises	Electrical equipment	Total
(Rupees in '000')																
Cost / revalued amount																
Balance as at July 01, 2023	1,032,257	3,597,281	58,898	3,364,188	397,281	5,190,647	568,275	932,194	264,201	3,163	700,240	177,666	3,721,132	856,020	57,000	20,920,443
Additions	-	-	-	-	-	252,903	3,623	68,275	16,845	607	161,601	66,369	104,827	293,287	-	968,337
Revaluation	-	20,321	-	-	-	-	-	-	-	-	-	-	-	-	-	20,321
Disposals	-	-	-	-	-	-	-	-	-	-	(5,674)	(15,853)	-	-	-	(21,527)
Termination of lease	-	-	-	-	-	-	-	-	-	-	-	-	-	(324)	-	(324)
Write offs	-	-	-	-	-	(58,243)	(2,048)	(10,025)	(456)	(122)	(5,260)	-	-	-	-	(76,154)
Impairment	-	-	-	-	-	-	-	(621)	(3,102)	-	-	-	-	-	(314)	(4,037)
Transfers	-	-	-	41,844	120,026	125,162	-	-	-	-	58,887	-	(345,919)	-	-	-
Balance as at June 30, 2024	1,032,257	3,617,602	58,898	3,406,032	517,307	5,510,469	569,850	989,823	277,488	3,648	909,480	228,182	3,480,040	1,148,983	57,000	21,807,060
Balance as at July 01, 2024	1,032,257	3,617,602	58,898	3,406,032	517,307	5,510,469	569,850	989,823	277,488	3,648	909,480	228,182	3,480,040	1,148,983	57,000	21,807,060
Additions	-	-	-	-	-	308,008	11,847	29,067	8,698	-	59,459	87,058	1,077,210	210,241	-	1,791,588
Revaluation	168,084	338,363	-	-	-	-	-	-	-	-	-	-	-	-	-	506,447
Disposals	-	-	-	-	-	-	-	-	-	-	(1,942)	(13,980)	-	-	-	(15,922)
Termination of lease	-	-	-	-	-	-	-	-	-	-	-	-	-	(10,109)	-	(10,109)
Write offs	-	-	-	-	-	(239,714)	(19,937)	(96,522)	(39,086)	(862)	(80,720)	-	(60,443)	-	-	(537,284)
Transfers	-	-	-	206,393	(180,121)	359,037	-	-	-	-	6,529	-	(391,838)	-	-	-
Balance as at June 30, 2025	1,200,341	3,955,965	58,898	3,612,425	337,186	5,937,800	561,760	922,368	247,100	2,786	892,806	301,260	4,104,969	1,349,115	57,000	23,541,780
Depreciation / amortisation																
Balance as at July 01, 2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Charge for the year	-	232,815	9,816	1,063,536	96,983	3,053,967	403,146	664,796	178,485	2,443	571,581	117,865	-	480,535	57,000	6,932,968
On disposals	-	47,544	2,945	110,318	86,488	405,567	54,266	98,228	17,680	333	85,625	25,144	-	159,375	-	1,093,513
Termination of lease	-	-	-	-	-	-	-	-	-	-	(2,856)	(7,812)	-	-	-	(10,668)
On write offs	-	-	-	-	-	(52,427)	(2,048)	(8,800)	(395)	(122)	(5,194)	-	-	(25)	-	(25)
Balance as at June 30, 2024	-	280,359	12,761	1,173,854	183,471	3,407,107	455,364	754,224	195,770	2,654	649,156	135,197	-	639,885	57,000	7,946,802
Balance as at July 01, 2024	-	280,359	12,761	1,173,854	183,471	3,407,107	455,364	754,224	195,770	2,654	649,156	135,197	-	639,885	57,000	7,946,802
Charge for the year	-	47,454	2,945	122,583	79,223	412,206	42,064	61,253	15,916	279	101,462	33,714	-	164,553	-	1,083,652
On disposals	-	-	-	-	-	-	-	-	-	-	(1,828)	(11,277)	-	-	-	(13,105)
Termination of lease	-	-	-	-	-	-	-	-	-	-	-	-	-	(6,045)	-	(6,045)
On write offs	-	-	-	-	-	(226,341)	(19,914)	(96,092)	(37,772)	(802)	(80,654)	-	-	-	-	(461,575)
Balance as at June 30, 2025	-	327,813	15,706	1,296,437	262,694	3,592,972	477,514	719,385	173,914	2,131	668,136	157,634	-	798,373	57,000	8,549,709
Carrying value as at June 30, 2024	1,032,257	3,337,243	46,137	2,232,178	333,836	2,103,362	114,486	235,599	81,718	994	260,324	92,985	3,480,040	509,098	-	13,860,258
Carrying value as at June 30, 2025	1,200,341	3,628,152	43,992	2,315,988	74,492	2,344,828	84,246	202,983	73,186	655	224,670	143,626	4,104,969	550,742	-	14,992,071
Annual rate of depreciation %	-	1.37	5	2.5-40	20	10	10-15	10-20	10	10-20	25	20	-	5.85-33	33.33	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

16.1 The Group's leasehold and freehold lands were revalued as at June 30, 2025, by an independent valuer on a fair market value basis.

16.2 Had there been no revaluation the carrying value would have been as under:

	Cost	Accumulated amortisation	Carrying value
(Rupees in '000')			
Freehold land			
June 30, 2025	658,928	-	658,928
June 30, 2024	658,928	-	658,928
Leasehold land			
June 30, 2025	1,621,716	215,258	1,406,458
June 30, 2024	1,621,716	190,700	1,431,016

16.3 Particulars of Group's freehold and leasehold land are as follows:

		2025	2024
Location	Nature	Area	
Shifa Cooperative Housing Society, Islamabad Expressway - Sq. yds	Freehold land	1003	1003
SNHF Hospital, Sheikhpura Road, Faisalabad - Kanal	Freehold land	49.6	49.6
SMCI Hospital, F-11, Islamabad - Kanal	Leasehold land	6.7	6.7
SIHL H-8/4, Islamabad* - Kanal	Leasehold land	87.8	87.8
Neuro Sciences Institute, H-8/4, Islamabad* - Sq. yds	Leasehold land	7100	7100

*The covered area includes multi-storey buildings.

16.4 Property, plant and equipment include items with aggregate cost of Rs. 3,541.89 million (2024: Rs. 3,200.02 million) representing fully depreciated assets that are still in use of the Group.

16.5 Property, plant and equipment of the SIHL are encumbered under an aggregate charge of Rs. 7,665.59 million (2024: Rs. 8,116.83 million) in favour of banking companies under various financing arrangements as disclosed in note 9.

16.6 The Forced Sale Value (FSV) of the revalued leasehold and freehold land has been assessed at Rs. 2,902.60 million (2024: Rs. 2,739.98 million) and Rs. 963.27 million (2024: Rs. 825.81 million) respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 16.7 Immediately after acquisition, the sale deed for the land and building of the SNS Islamabad was duly registered with the sub-registrar in Islamabad, in accordance with the provisions outlined in the allotment letter / indenture of lease deed. Subsequently, the SNS Islamabad initiated formal proceedings with the Capital Development Authority (CDA) to effectuate the change of title through the registered sale deed. However, the CDA raised objections to the transfer, leading to the initiation of a legal suit by CDA. The aforementioned suit was dismissed by the relevant learned district judge on January 29, 2024. The CDA have filed appeal against the judgment and Decree of the District Judge before the honourable Islamabad High Court and the SNS Islamabad has filed cross objections against the said appeal. The matter is currently pending adjudication before the Islamabad High Court and there are reasonable grounds to believe that the case will be decided in favour of the SNS Islamabad. After merger (as explained in note 1.1), the parent company as successor will be impleaded, in the place of the SNS Islamabad, in the pending civil appeal led by the CDA before the honourable Islamabad High Court against the order of dismissal of earlier suit led by CDA wherein objections were raised on the transfer of said property in the name of SNS Islamabad via registered sale deed.

		2025	2024
	Note	(Rupees in '000')	
16.8	Capital work in progress		
	Civil work	3,853,250	3,387,165
	Installation of equipment	251,719	92,875
		4,104,969	3,480,040

16.8.1 Civil work

This represents the cost of civil work mainly comprising of cost of materials, payments to contractors and pre construction activities cost etc. as detailed below:

	2025	2024
	(Rupees in '000')	
SMC Islamabad Hospital	1,375,763	1,291,867
SNH Faisalabad Hospital	2,252,863	1,839,590
Others	224,624	255,708
	3,853,250	3,387,165

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
17	INTANGIBLE ASSETS		
	Softwares in use	17.1	36,914
	Software under development / deployment	17.2	5,787
			42,701
17.1	Softwares in use		
	Cost		
	Balance at beginning of the year	106,468	106,882
	Addition during the year	39,375	-
	Impairment loss during the year	-	(414)
	Balance at end of the year	145,843	106,468
	Accumulated amortisation		
	Balance at beginning of the year	106,468	106,222
	Charged during the year	2,461	246
	Balance at end of the year	108,929	106,468
	Carrying value	36,914	-
17.2	Software under development / deployment		
	Balance at beginning of the year	39,375	39,375
	Addition during the year	17.2.1	5,787
	Capitalised during the year	(39,375)	-
	Balance at end of the year	5,787	39,375
	Annual amortisation rate (percentage)	25	25

17.2.1 This represents advance paid for implementation of Oracle Fusion software.

		2025	2024
	Note	(Rupees in '000')	
18	INVESTMENT PROPERTY - AT COST		
	Balance at beginning of the year	720,292	748,450
	Disposed off during the year	(95,420)	(28,158)
	Balance at end of the year	18.1	624,872

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 18.1 This represents freehold land comprising of 11 plots at Shifa Cooperative Housing Society, Islamabad Expressway (SCHS), 48K-3M-182 Sq ft at Chak No. 4, near Sargodha Road, Faisalabad of which 20K-14M-181 Sq ft are subject to possession proceedings and 105.02 kanal at Motorway, Mouza Noon, Islamabad. An independent valuation was conducted to determine the fair value of the investment property. The prices were assessed through a market survey of comparable properties in the vicinity. The fair value was based on the independent valuer's professional judgment, using openly available information and inquiries made in the market. Valuation was carried out by an independent valuer who holds a recognised and relevant professional qualification and has recent experience in the location and category of the investment property being valued. The fair value and forced sale value of the land located at SCHS, Sargodha Road Faisalabad and Motorway, Mouza Noon, Islamabad are Rs. 430 million, Rs. 146.24 million, Rs. 315.06 million (2024: Rs. 360.12 million, Rs.136.89 million, Rs. 425.02 million) and Rs. 365.50 million, Rs. 116.99 million, Rs. 252.05 million (2024: Rs. 288.09 million, Rs. 109.51 million, Rs. 340.02 million) respectively.

During the previous year, the SIHL was informed by its former property dealer about the sale of 49 kanal of land located at Mouza Noon, Islamabad; however, the SIHL was provided with the sale proceeds of only 10.83 kanal. Further, in coordination with land revenue authorities based on the SIHL's verification of land title against official record through an independent source, the authorities, in their latest assessment to date, have confirmed the SIHL's ownership of 105.02 kanal, of which 6.5 kanal remain under review. Accordingly, the sales proceeds of 36.7 kanal land were recorded in other receivables. The matter is being pursued, and the final outcome of the assessment will form the basis for determining the appropriate course of action.

		2025	2024
Note		(Rupees in '000')	
19	LONG TERM INVESTMENTS		
	Associated Companies (unquoted)		
	Shifa CARE (Private) Limited (SCPL)	19.1	-
	SIHT (Private) Limited (SIHT)	19.2	424,045
		740,157	424,045
19.1	Shifa CARE (Private) Limited (SCPL)		
	Balance at beginning of the year	-	45,079
	Impairment loss on investment	-	(41,528)
	Share in (loss) / profit for the year	-	(3,551)
	Balance at end of the year	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

This represents investment in 4,500,050 (2024: 4,500,050) fully paid ordinary shares of Rs. 10 each of SCPL. The above investment in ordinary shares represents 50% (2024: 50%) shareholding in SCPL held by the SIHL. The share of loss in SCPL for the year amounting to Rs. 3.44 million is not recognised as the carrying amount of investment has been reduced to zero due to recognition of impairment loss during the last year.

Summary of results of SCPL are as under:

	2025	2024
	(Rupees in '000')	
Summarised statement of financial position		
Non-current assets	-	-
Current assets	2,609	2,921
Current liabilities	(7,997)	(1,437)
Net assets	(5,388)	1,484
Reconciliation to carrying amount		
Opening net assets	1,484	90,157
Total comprehensive loss for the year	(6,872)	(88,673)
Closing net assets	(5,388)	1,484
Group's share in carrying value of net assets	(2,694)	742
Group's share in total comprehensive loss	(3,436)	(44,336)
Summarised statement of profit or loss and comprehensive income		
Revenue for the year - gross	-	-
Depreciation and amortisation	(174)	(4,008)
Finance costs	-	(256)
Provision for taxation	-	-
Loss for the year	(6,872)	(88,673)
Total comprehensive loss for the year	(6,872)	(88,673)

19.1.1 The above information is based on management financial statements of SCPL.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
		(Rupees in '000')	
19.2	SIHT (Private) Limited (SIHT)		
	Balance at beginning of the year	424,045	-
	Investment made during the year	300,000	425,000
	Share in profit / (loss) for the year	16,112	(955)
	Balance at end of the year	740,157	424,045

19.2.1 In line with the decision of board of directors of the SIHL in its meeting held on April 12, 2023, and on September 23, 2023, the SIHL entered into a tripartite Shares Purchase Agreement (SPA) with Shifa Foundation and its wholly owned subsidiary SIHT (Private) Limited (SIHT) for acquiring 50% shareholding in SIHT from Shifa Foundation.

The SPA provides that the paid up share capital of SIHT shall be increased from Rs. 100.10 million to Rs. 500.10 million representing 5,001,000 ordinary shares of Rs. 100 each over the arrangement period. The SPA further provides that the referred acquisition of equity interest in SIHT to be made in 9 quarterly instalments shall be completed by September 30, 2025. Accordingly, by the end of the current year a sum of Rs. 300 million (2024: Rs. 425 million) has been paid to Shifa Foundation to acquire further 937,680 shares (2024: 1,328,397 shares).

At year end the SIHL has investment in 2,266,077 (2024: 1,328,397) fully paid ordinary shares of Rs. 100 each of SIHT representing 45.30% (2024: 29.50%) shareholding.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Summary of results of SIHT are as under:

	2025	2024
	(Rupees in '000')	
Summarised statement of financial position		
Non-current assets	181,806	179,734
Current assets	415,707	285,698
Non-current liabilities	(88,558)	(100,482)
Current liabilities	(165,714)	(120,376)
Net assets	343,241	244,574
Reconciliation to carrying amount		
Opening net assets	244,574	(84,443)
Total comprehensive income / (loss) for the year	48,668	(20,983)
Equity	50,000	350,000
Closing net assets	343,242	244,574
Group's share in carrying value of net assets	72,941	42,073
Group's share in total comprehensive income / (loss)	16,112	(955)
Summarised statement of profit or loss and comprehensive income		
Revenue for the year - gross	717,519	597,996
Depreciation and amortisation	(39,814)	(45,827)
Finance costs	(13,182)	(17,398)
Provision for taxation	(15,646)	(10,065)
Profit / (loss) for the year	48,668	(20,983)
Total comprehensive income / (loss) for the year	48,668	(20,983)

19.2.2 The above information is based on initialled financial statements of SIHT.

20 LONG TERM ADVANCES TO SUPPLIERS AND CONTRACTORS

This represents advance paid to suppliers and contractors for the services and procurement of capital nature items for the construction of the hospital in Islamabad and Faisalabad.

21 LONG TERM DEPOSITS

This represents security deposits given to various institutions / persons and are refundable on termination of relevant services / arrangements. These are unsecured and considered good.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
22	STORES, SPARE PARTS AND LOOSE TOOLS		
	Stores	229,584	252,158
	Spare parts	13,710	7,806
	Loose tools	1,303	1,380
		244,597	261,344
	Less: provision for slow moving items 22.1	20,436	17,765
		224,161	243,579
22.1	Movement of provision for slow moving items		
	Balance at beginning of the year	17,765	19,657
	Charged / (reversal) during the year	2,671	(1,892)
	Balance at end of the year	20,436	17,765
23	STOCK IN TRADE		
	This represents medicines being carried at moving average cost.		
		2025	2024
	Note	(Rupees in '000')	
24	TRADE DEBTS		
	Unsecured - considered good		
	Related party - Shifa Foundation 24.1	14,422	7,137
	Others	1,742,710	1,581,998
		1,757,132	1,589,135
	Less: allowance for expected credit losses (ECL) 43.1.3	295,676	242,946
		1,461,456	1,346,189
24.1	Maximum amount due from Shifa Foundation at the end of any month during the year was Rs. 24.58 million (2024: Rs. 15.80 million).		

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
25	LOANS AND ADVANCES		
Secured - considered good			
Executives		12,281	10,641
Other employees		16,420	23,239
	25.1	28,701	33,880
Unsecured - consultants		7,123	13,870
Advance paid for acquisition of shares	25.2	304,010	-
Unsecured - suppliers / contractors		112,090	406,745
		423,223	420,615
		451,924	454,495

25.1 These advances are secured against employee terminal benefits.

25.2 This represents the first instalment paid by SIHL to Interloop Holdings (Private) Limited (ILHPL) under a tripartite Share Purchase Agreement (SPA) dated July 10, 2025 for the acquisition of 96,572,500 shares (40% equity interest) in SMC Islamabad, with total consideration of Rs. 1,520.05 million payable in 5 quarterly instalments.

The above arrangement was approved by shareholders of SIHL in the Extraordinary General Meeting held on June 5, 2025.

		2025	2024
	Note	(Rupees in '000')	
26	DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES		
Unsecured - considered good			
Short term prepayments		60,329	51,511
Other receivables	26.1	322,796	205,342
		383,125	256,853
Less: allowance for expected credit losses against other receivables	26.2	169,680	81,394
		213,445	175,459

26.1 This includes Rs. 59.90 million (2024: Rs. 30.33 million) due from SIHT (Private) Limited. Maximum amount due from SIHT (Private) Limited at the end of any month during the year was Rs. 148.88 million (2024: Rs. 133.80 million).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
26.2	Allowance for expected credit losses against other receivables (unrelated parties)		
	Balance at beginning of the year	81,394	58,377
	Charged during the year	88,286	23,017
	Balance at end of the year	169,680	81,394
27	OTHER FINANCIAL ASSETS		
	Investment - at amortised cost	27.1	47,520
	Investment in Mutual Funds - at fair value through profit or loss	27.2	1,027,993
		1,075,513	484,991

27.1 This represents term deposit receipt (TDR) having face value of Rs. 3 million (2024: Rs. 3 million) with three months maturity and Rs. 44.50 million with one month maturity (2024: nil). Profit payable on monthly basis at the weighted average rate of 11.17% and 5.50% per annum respectively (2024: 18.98% per annum).

27.2 This represents investment in 2,175,860 (2024: 1,973,327), 76,983,043 (2024: nil), 227,898 (2024: 266,892), 10,467 (2024: nil) and 6,003 (2024: 307,880) units of UBL Al-Ameen Islamic Cash Fund, NBP Islamic Money Market Fund, HBL Cash Fund and HBL Money Market Fund respectively. Fair value of investments was determined using quoted repurchase price at year end.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
28 CASH AND BANK BALANCES			
Cash at bank in:			
Current accounts:			
Local currency		820,414	403,709
Foreign currency		365,160	913,410
		1,185,574	1,317,119
Saving accounts:			
Local currency		2,561,048	813,619
Foreign currency		284	278
	28.1	2,561,332	813,897
	28.2	3,746,906	2,131,016
Cash in hand		14,714	26,187
		3,761,620	2,157,203

28.1 Balance with saving account earned profit / markup at weighted average rate of 13.43% per annum (2024: 16.52% per annum).

28.2 Balances with banks include Rs. 144.58 million (2024: Rs. 132.45 million) in respect of security deposits (note 12.3).

		2025	2024
	Note	(Rupees in '000')	
29 REVENUE - NET			
Inpatients		17,581,470	14,796,234
Outpatients		9,780,501	8,194,000
Other services	29.1	810,716	761,822
		28,172,687	23,752,056
Less: discount		112,414	116,591
Less: sales tax		92,612	81,887
		205,026	198,478
		27,967,661	23,553,578

29.1 This represents revenue from external pharmacy outlets, cafeteria sales, operating leases to related parties / other parties.

29.2 The revenue-net is excluding physician share of Rs. 2,910.43 million (2024: Rs. 1,930.07 million).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
30	OTHER INCOME		
	Income from financial assets:		
	Profit on bank deposits	188,369	67,878
	Dividend income from mutual fund - investment at fair value through profit or loss	30,867	54,172
	Un-realised gain on investments at fair value through profit or loss	27,700	15,145
	Interest income on treasury bills	50,946	34,573
		297,882	171,768
	Income from other than financial assets:		
	Gain on disposal of property, plant and equipment	2,500	7,965
	Exchange gain on foreign currency translation	7,199	-
	Sale of scrap - net of sales tax	13,147	23,222
	Miscellaneous 30.1	62,474	30,324
		85,320	61,511
		383,202	233,279

30.1 This includes an amount of Rs. 28.27 million (2024: nil) [net of sales tax] received from DAI Pakistan (Private) Limited under the Fleming Fund Country Grant – Pakistan, to support the implementation of the Clinical Engagement Program for Antimicrobial Resistance (AMR) related interventions. Further, all relevant expenses of this project have been recorded under the respective operating expense heads.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
31	OPERATING COSTS		
Salaries, wages and benefits	31.1	8,885,561	7,825,621
Medicines consumed	31.2	6,700,403	6,083,422
Supplies consumed		3,023,211	2,429,431
Utilities		1,353,224	1,329,745
Depreciation / amortisation	16	1,083,652	1,064,542
Repairs and maintenance		1,251,572	1,124,550
Printing and stationery		198,330	223,548
Cleaning and washing		271,309	271,966
Fee, subscription and membership		143,085	141,693
Advertising and sales promotion		41,378	51,070
Communication		60,282	70,615
Travelling and conveyance		60,484	49,356
Legal and professional		44,912	43,771
Rent		26,218	16,400
Rates and taxes	31.3	396,262	24,701
Insurance		30,623	27,555
Amortisation on intangible assets	17	2,461	246
Property, plant and equipment written off	31.4	75,709	7,168
Auditors' remuneration	31.5	7,794	5,812
Charged / (reversal) of provision for slow moving stores		2,671	(1,892)
Loss on disposal of investment property		7,340	2,708
Exchange loss on foreign currency translation		-	26,469
Impairment loss on tangible / intangible assets		-	4,450
Impairment loss on investment		-	41,528
Project cost		-	27,660
Miscellaneous		147,275	89,462
		23,813,756	20,981,597

- 31.1 This includes charge for employee gratuity of Rs. 102.04 million (2024: Rs. 80.64 million), defined contribution plan (pension) of Rs. 129.23 million (2024: Rs. 109.03 million), compensated absences of Rs. 136.52 million (2024: Rs. 103.06 million) and bonus of Rs. 302.79 million (2024: Rs. 170.73 million).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 31.2 This includes stock in trade amounting to Rs. 6.44 million (2024: nil) written off during the year.
- 31.3 This includes an amount of Rs. 384.92 million paid to the Capital Development Authority (CDA) for building regularisation charges (note 15.1.3).
- 31.4 This represents property, plant and equipment written off that were determined to be irreparable after carrying out detailed reassessment / physical verification exercise by the management.

		2025	2024
	Note	(Rupees in '000')	
31.5	Auditors' remuneration		
	Annual audit fee	3,521	2,380
	Half yearly review fee	1,840	1,570
	Statutory certifications	745	850
	Group reporting	450	-
	Out of pocket expenses	482	344
		7,038	5,144
	Sales tax	756	668
		7,794	5,812
32	FINANCE COSTS		
	Markup on long term loans - secured	145,775	249,397
	Interest on lease liabilities 11	102,801	72,436
	Credit card payment collection and bank charges	97,148	99,258
		345,724	421,091
33	INCOME TAX EXPENSE / LEVIES		
	Current tax		
	- for the year	1,765,172	928,755
	- prior year	147,519	-
	14 & 33.1	1,912,691	928,755
	Deferred tax (expense) / income	(78,046)	4,993
		1,834,645	933,748

- 33.1 Reconciliation between current tax charged under the Ordinance with current tax recognised in the consolidated statement of profit or loss, is as follows:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Current tax liability for the year as per the Ordinance			
Portion of current tax liability as per tax law, representing income tax under IAS 12		1,904,974	913,531
Portion of current tax liability as per tax law, representing levy in term of requirement of IFRIC 21 / IAS 37	33.2	7,717	15,224
		1,912,691	928,755

33.2 This represents portion of final tax paid as per the Ordinance, representing levy in terms of requirements of IFRIC 21 / IAS 37.

		2025	2024
34	EARNINGS PER SHARE - BASIC AND DILUTED		
	Profit for the year - continuing operations (Rupees in '000')	2,257,919	1,368,030
	Profit for the year - discontinued operations (Rupees in '000')	-	2,466
	Weighted average number of ordinary shares outstanding during the year (Number in '000')	63,214	63,214
	Earnings per share - basic and diluted (Rupees)		
	- Continuing operations	35.72	21.64
	- Discontinued operations	-	0.04

34.1 There is no dilutive effect on the basic earnings per share of the Group.

35 CAPACITY UTILISATION

The actual inpatient available bed days, occupied bed days and room occupancy ratio of SIHL are given below:

	2025	2024	2025	2024	2025	2024
	Available bed days		Occupied bed days		Occupancy ratio	
H-8 Hospital Islamabad	180,196	183,301	114,543	113,642	63.57%	62.00%
Faisalabad Hospital	20,805	20,630	6,957	7,583	33.44%	36.76%

35.1 Reported utilisation is a result of pattern of patient turnover under different specialties.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

36 UNAVAILED CREDIT FACILITIES

Unavailed credit facilities at year end other than those disclosed in note 9 of the consolidated financial statements are as under:

	2025	2024
	(Rupees in '000')	
Letters of credit	193,485	200,000
Diminishing musharakah	310,482	240,561
Ijarah financing	51,709	51,709
Running musharkah	500,000	500,000
Letter of guarantee	30,368	32,416
	1,086,044	1,024,686
	Number	
37 NUMBER OF EMPLOYEES		
Group's number of employees	5,665	5,348
Group's average number of employees	5,515	5,332

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

38 RELATED PARTIES TRANSACTIONS

The related parties comprise of associates, directors, major shareholders, key management personnel, SIHL Employees' Gratuity Fund Trust and the entities over which directors are able to exercise influence.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group. The Group considers its chief executive officer, chief financial officer, company secretary, directors and departmental heads to be its key management personnel. There are no transactions with key management personnel other than their terms of employment / entitlement.

Related party transactions are based on arm's length between the parties as per pricing policy approved by the board of directors of the SIHL. Transactions and balances with the related parties are given below:

		2025	2024
	Note	(Rupees in '000')	
Shifa Foundation:			
Transactions			
Revenue from medical and other services earned by the SIHL		24,062	13,997
Rent expense paid by and reimbursed to the SIHL		1,373	1,215
Acquisition of 937,680 (2024: 1,328,397) ordinary shares of SIHT (Private) Limited		300,000	425,000
Balance			
Receivable - unsecured at the year end		14,422	7,137
Tameer-e-Millat Foundation:			
Tranactions			
Supplies provided to the SIHL		81,787	102,662
Other services provided to the SIHL	38.1	28,755	35,904
Rental services received / earned by the SIHL		14,418	6,353
Balance			
Payable - unsecured at the year end		4,186	7,285

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Shifa Tameer-e-Millat University:			
Transactions			
Revenue from medical and other services earned by the SIHL		26,063	28,402
Revenue from rent earned by the SIHL		4,256	3,869
Other services provided to the SIHL	38.1	84,924	113,015
Expenses paid and reimbursed to the SIHL		20,487	21,160
Expenses paid and reimbursed by the SIHL		29,788	33,410
Balance			
Payable - unsecured at the year end		42,798	31,566
SIHT (Private) Limited:			
Transactions			
Revenue from medical services earned by the SIHL		770,121	568,496
Expenses paid by and reimbursed to the SIHL		4,534	5,724
Other services provided to the SIHL	38.1	3,544	26,267
Balance			
Receivable - unsecured at year end		59,898	30,329
Shifa Cooperative Housing Society Limited:			
Transactions			
Plot maintenance charges paid by the SIHL		2,571	3,112
Balance			
Receivable / (payable) - unsecured at year end		-	-
Shifa CARE (Private) Limited:			
Transactions			
Corporate shared services provided by the SIHL		-	1,924
Balance			
Receivable / (payable) - unsecured at year end		-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
International Finance Corporation:			
Transactions			
Dividend paid by the SIHL		18,964	22,757
Balance			
Receivable / (payable) - unsecured at year end		-	-
SIHL Employees' Gratuity Fund Trust:			
Transactions			
Payment made by the SIHL		215,360	242,112
Dividend paid by the SIHL		196	235
Balance			
Payable - unsecured at year end		102,728	132,734
Remuneration including benefits and perquisites of key management personnel	38.2	529,349	396,517

- 38.1 This represents services of nursing education, employees' children education and media services.
- 38.2 This includes employee retirement benefits amounting to Rs. 19.09 million (2024: Rs. 14.68 million).
- 38.3 Following is the list of related parties and their shareholding for the year ended June 30, 2025.

Sr #	Name of related party (RP)	Basis of relationship	Percentage of	
			SIHL's shareholding in RP	RP's shareholding in the SIHL
1	Shifa Foundation	Common Directorship	N/A*	6.57%
2	Tameer-e-Millat Foundation	Common Directorship	N/A	12.44%
3	SIHL Employees' Gratuity Fund Trust	Benefit plan	N/A	0.12%
4	Shifa Tameer-e-Millat University	Common Directorship	N/A	0.27%
5	Shifa CARE (Private) Limited	Associate and Common Directorship	50%	Nil
6	SIHT (Private) Limited	Associate and Common Directorship	45.3%	Nil
7	Shifa Cooperative Housing Society Limited	Common Directorship	N/A	Nil
8	International Finance Corporation (IFC)	Associate	Nil	12.00%
9	Ahmed E.H. Jaffer Foundation	Common Directorship	N/A	Nil

*N/A stands for not applicable.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

39 REMUNERATION OF CHIEF EXECUTIVE, DIRECTORS AND EXECUTIVES

The aggregate amount charged in these consolidated financial statements in respect of remuneration and benefits, to chief executive, directors and executives of the Group are given below:

	Chief Executive		Executive Directors		Non Executive Directors		Executives	
	2025	2024	2025	2024	2025	2024	2025	2024
	(Rupees in '000')							
Managerial remuneration	45,167	40,816	30,195	6,824	14,412	12,500	765,128	481,470
Annual bonus	2,145	1,815	1,221	-	331	260	26,703	14,090
Defined contribution plan	2,598	2,368	1,532	-	-	-	35,586	23,661
Medical insurance	125	120	94	146	277	394	6,684	4,553
Leave encashment	1,969	-	1,112	-	-	-	17,421	11,136
	52,004	45,119	34,154	6,970	15,020	13,154	851,522	534,910
Number of persons	1	1	1	2	9	11	147	94

39.1 The chief executive, executive director and eligible executives are provided with SIHL maintained vehicles.

39.2 Managerial remuneration includes Rs. 8.70 million (2024: Rs. 5.02 million) paid to directors in respect of meeting fee.

39.3 Executive means an employee, other than the chief executive and directors, whose basic salary exceeds Rs. 1.20 million (2024: Rs. 1.20 million) during the year.

39.4 Travelling and other expenses of Rs. 20.28 million (2024: Rs. 26.50 million) for official purposes are reimbursed by the SIHL to directors.

40 CASH AND CASH EQUIVALENTS

	Note	2025	2024
		(Rupees in '000')	
Investment - at amortised cost	27	47,520	226,102
Cash and bank balances	28	3,761,620	2,157,203
		3,809,140	2,383,305

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

41 RECONCILIATION OF MOVEMENT OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

	Liabilities		Equity				Total
	Long term financing	Government grant	Lease liabilities	Share capital	Share premium	Non-controlling Interest	Un-appropriated profit
2025	(Rupees in '000')						
Balance at beginning of the year	1,052,208	22,743	630,306	632,144	2,738,888	2,470,891	7,118,684
Changes from financing cash flows							
Proceeds from long term financing	537,704	-	-	-	-	-	-
Repayments of long term financing	(504,047)	-	-	-	-	-	-
Payments of lease liabilities	-	-	(236,081)	-	-	-	-
NCI recognised during the year	-	-	-	-	-	385,743	-
Dividend paid	-	-	-	-	-	-	(153,831)
Total changes from financing cash flows	33,657	-	(236,081)	-	-	385,743	(153,831)
Other changes							
Liability related	15,718	-	305,194	-	-	-	-
Amortisation of government grant	-	(15,718)	-	-	-	-	-
Equity related							
Total comprehensive changes	-	-	-	-	-	110,432	2,207,099
Other changes	-	-	-	-	-	-	36,117
Changes in unclaimed dividend	-	-	-	-	-	-	(4,205)
Total of equity related changes	-	-	-	-	-	110,432	2,239,011
Balance at end of the year	1,101,583	7,025	699,419	632,144	2,738,888	2,967,066	9,203,864
							17,349,989

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	Liabilities		Equity				Total
	Long term financing	Government grant	Lease liabilities	Share capital	Share premium	Non-controlling Interest	Un-appropriated profit
2024	(Rupees in '000')						
Balance at beginning of the year	1,691,820	48,590	466,986	632,144	2,738,888	2,500,388	5,991,558
Changes from financing cash flows							
Proceeds from long term financing	216,122	-	-	-	-	-	-
Repayments of long term financing	(881,581)	-	-	-	-	-	-
Payments of lease liabilities	-	-	(200,524)	-	-	-	-
Dividend paid	-	-	-	-	-	-	-
Total changes from financing cash flows	(665,459)	-	(200,524)	-	-	-	(181,869)
Other changes							
Liability related	25,847	-	363,844	-	-	-	-
Amortisation of government grant	-	(25,847)	-	-	-	-	-
Equity related							
Total comprehensive changes	-	-	-	-	-	(29,497)	1,294,471
Other changes	-	-	-	-	-	-	22,299
Changes in unclaimed dividend	-	-	-	-	-	-	(7,775)
Total of equity related changes	-	-	-	-	-	(29,497)	1,308,995
Balance at end of the year	1,052,208	22,743	630,306	632,144	2,738,888	2,470,891	7,118,684
							14,665,864

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
42	ADJUSTMENT OF NON-CASH INCOME AND EXPENSE		
Depreciation / amortisation	31	1,083,652	1,064,542
Amortisation on intangible assets	31	2,461	246
Impairment loss on tangible / intangible assets	31	-	4,450
Expected credit losses	26.2 & 43.1.3	141,016	116,289
Property, plant and equipment written off	31	75,709	7,168
Gain on disposal of property, plant and equipment	30	(2,500)	(7,965)
Gain on termination of right of use assets		(1,180)	(75)
Loss on disposal of investment property	31	7,340	2,708
Provision for compensated absences	31	136,518	103,063
Provision for defined contribution plan	31	129,225	109,027
Provision for bonus for employees	31	302,795	170,730
Provision for gratuity	31	102,043	80,644
Charged / (reversal) of provision for slow moving stores	31	2,671	(1,892)
Share of (profit) / loss of associates	19	(16,112)	4,506
Impairment loss on long term investment	31	-	41,528
Gain on investments and bank deposits	30	(297,882)	(171,768)
(Gain) / loss on foreign currency translation	30 & 31	(7,199)	26,469
Finance costs	32	345,724	421,092
		2,004,281	1,970,762

43 FINANCIAL RISK MANAGEMENT

The Group has exposure to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

Risk management framework

The Board meets frequently throughout the year for developing and monitoring the Group's risk management policies. The Group's risk management policies are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

systems are reviewed regularly to reflect changes in market conditions and the Group's activities. The Group, through its standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Audit Committee oversees how management monitors compliance with the Group's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group.

43.1 Credit risk

Credit risk represents the financial loss that would be recognised at the reporting date if counterparties failed completely to perform as contracted. The Group does not have significant exposure to any individual counter-party. To reduce exposure to credit risk, the Group has developed a formal approval process whereby credit limits are applied to its customers. The management also regularly monitors the credit exposure towards the customers and makes allowance for ECL for those credit exposure. Furthermore, the Group has credit control in place to ensure that services are rendered to customers with an appropriate credit history.

43.1.1 Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	2025	2024
	(Rupees in '000')	
Long term deposits	117,961	126,050
Trade debts	1,461,456	1,346,189
Other receivables	153,116	123,948
Markup accrued	19,219	4,383
Other financial assets	1,075,513	484,991
Bank balances	3,746,906	2,131,016
	6,574,171	4,216,577

The Group is also exposed to credit risk from its operating and short term investing activities. The Group's credit risk exposures are categorised under the following headings:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

43.1.2 Counterparties

The Group conducts transactions with the following major types of counterparties:

Trade debts

Trade debts are essentially due from government companies / institutions, private companies and individuals to whom the Group is providing medical services. Normally the services are rendered to the panel companies on agreed rates and limits from whom the Group does not expect any inability to meet their obligations. The Group manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Group has credit control in place to ensure that services are rendered to customers with an appropriate credit history and makes allowance for ECL against those balances considered doubtful of recovery.

Bank balances and investments

The Group limits its exposure to credit risk by investing in liquid securities and maintaining bank accounts only with counterparties that have a high credit ratings and therefore management does not expect any counterparty to fail to meet its obligations.

The maximum exposure to credit risk for trade debts at the reporting date by type of customer was:

	2025	2024
	(Rupees in '000')	
Government companies	1,004,186	845,715
Private companies	397,992	446,124
Individuals	340,532	290,159
Related parties	14,422	7,137
	1,757,132	1,589,135

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

43.1.3 Impairment losses

The ageing of trade debts at the reporting date was:

	2025		2024	
	Gross debts	Allowance for ECL	Gross debts	Allowance for ECL
(Rupees in '000')				
Not past due	592,897	4,566	498,244	3,178
1 - 2 months	463,688	13,068	357,017	12,967
3 - 4 months	139,545	7,889	218,635	30,316
5 - 7 months	123,122	17,642	148,772	24,285
8 - 12 months	110,930	46,906	98,670	31,039
Above 12 months	326,950	205,605	267,797	141,161
	1,757,132	295,676	1,589,135	242,946

The movement in the allowance for impairment in respect of trade debts during the year was as follows:

	Note	2025	2024
		(Rupees in '000')	
Balance at beginning of the year		242,946	228,362
Expected credit losses		52,730	93,273
Bad debts written off		-	(78,689)
Balance at end of the year	24	295,676	242,946

43.1.4 The ageing of Shifa Foundation (SF) and SIHT (Private) Limited at the reporting date was:

		2025		2024	
		Gross debts / Other receivables	Allowance for ECL	Gross debts / Other receivables	Allowance for ECL
Note		(Rupees in '000')			
Shifa Foundation					
1 - 6 months	24	14,422	-	7,137	-
SIHT (Private) Limited					
1 - 3 months	26.1	59,898	-	30,329	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

- 43.1.5 The Group maintained balances of Rs. 3,746.91 million (2024: Rs. 2,131.02 million) with Banks and Rs. 1,027.99 million (2024: Rs. 258.89 million) with Asset Management Companies as at June 30, 2025. Management has assessed the credit quality of the counterparties as satisfactory. Geographical analysis and credit rating information is given below:

Banks / financial institutions	Credit Rating Agency	Rating		2025	2024
		Short term	Long term	(Rupees in '000')	
Pakistan:					
Habib Bank Limited (HBL)	JCR - VIS	A1+	AAA	886,697	1,046,878
Meezan Bank Limited	JCR - VIS	A1+	AAA	281,711	500,902
Al - Baraka Bank (Pakistan) Limited	JCR - VIS	A1	AA-	1,970,886	285,440
United Bank Limited (UBL)	JCR - VIS	A1+	AAA	21,062	57,686
MCB Bank Limited	PACRA	A1+	AAA	19,260	13,854
Dubai Islamic Bank Pakistan Limited	JCR - VIS	A1+	AA	83,241	34,444
Askari Bank Limited	PACRA	A1+	AA+	14	14
Faysal Bank Limited	JCR - VIS	A1+	AA+	37,032	53,778
Bank Alfalah Limited	PACRA	A1+	AAA	48,196	6,030
Bank Al Habib Limited	PACRA	A1+	AAA	384,791	122,398
National Bank of Pakistan (NBP)	JCR - VIS	A1+	AAA	13,890	9,592
Habib Metropolitan Bank Limited	PACRA	A1+	AA+	126	-
UBL - Al Ameen Islamic Cash Fund	JCR - VIS	-	AA+(f)	220,283	199,566
NBP Islamic Money Market Fund	PACRA	-	AA(f)	783,072	-
HBL Cash Fund	JCR - VIS	-	AA+(f)	24,636	59,323
HBL Money Market Fund	JCR - VIS	-	AA+(f)	2	-

43.2 Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group's approach to manage liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. For this purpose, the Group has credit facilities as mentioned in notes 9 and 36 to these consolidated financial statements. Further, liquidity position of the Group is monitored by the Board through budgets, cash flow projections and comparison with actual results.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

Following is the maturity analysis of financial liabilities:

	Carrying amount	Six months or less	Six to twelve months	One to two years	Two to five years	Above five years
(Rupees in '000')						
2025						
Long term financing- secured	1,108,609	136,369	118,795	276,752	546,986	29,707
Deferred liabilities	44,846	-	-	44,846	-	-
Trade and other payables	3,948,428	3,948,428	-	-	-	-
Unclaimed dividend	48,935	48,935	-	-	-	-
Mark up accrued	7,974	7,974	-	-	-	-
	5,158,792	4,141,706	118,795	321,598	546,986	29,707
2024						
Long term financing-secured	1,074,951	361,803	133,392	243,370	336,386	-
Deferred liabilities	34,434	-	-	34,434	-	-
Trade and other payables	3,662,078	3,662,078	-	-	-	-
Unclaimed dividend	44,730	44,730	-	-	-	-
Mark up accrued	23,858	23,858	-	-	-	-
	4,840,051	4,092,469	133,392	277,804	336,386	-

Maturity analysis of lease liabilities is given in note 11.

43.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, markup rates and equity prices will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk. The Group is exposed to currency, mark up rate and market price risk.

43.3.1 Foreign currency risk

Exposure to foreign currency risk

Foreign currency risk arises mainly where receivables and payables exist due to transactions with foreign undertakings and cash in foreign currency bank account. The Group's exposure to foreign currency risk is as follows:

	2025		2024	
	(Amount in '000')			
	Euro	USD	Euro	USD
Bank balances	-	1,289	-	3,285
Letter of credit	-	-	(555)	(1,460)
	-	1,289	(555)	1,825

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	2025	2024
	(Rupees in '000')	
Bank balances	- 365,444	- 913,689
Letter of credit	- -	(165,397) (406,837)
	- 365,444	(165,397) 506,852

Following are significant exchange rates applied during the year:

	Average rate		Closing rate	
	2025	2024	2025	2024
	(Rupees)			
USD 1 - Buying	279.14	283.02	283.53	278.15
USD 1 - Selling	279.57	283.45	283.97	278.59
Euro 1 - Buying	-	306.25	-	297.45
Euro 1 - Selling	-	306.72	-	297.92

Foreign currency sensitivity analysis

A 10 percent variation of PKR against USD at June 30 would have effected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular markup rates, remains constant.

	Change in Foreign Exchange Rates	Effect on Profit	Effect on Equity
	%	(Rupees in '000')	
2025			
Foreign currencies	+10%	22,292	22,292
Foreign currencies	-10%	(22,292)	(22,292)
2024			
Foreign currencies	+10%	20,829	20,829
Foreign currencies	-10%	(20,829)	(20,829)

43.3.2 Markup rate risk

The markup rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Majority of the interest rate exposure arises from long term financing, short term investments and deposits with banks. At the reporting date, the markup rate profile of the Group's markup bearing financial instruments are:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Financial assets			
Investment - at amortised cost	27.1	47,520	226,102
Bank balances	28	2,561,332	813,897
		2,608,852	1,039,999
Financial liabilities			
Financing - secured	9	(1,108,609)	(1,074,951)
		1,500,243	(34,952)

The effective markup rates for the financial assets and liabilities are mentioned in respective notes to the financial statements.

Markup rate sensitivity analysis

If markup rates had been 50 basis points higher / lower and all other variables were held constant, the Group's profit for the year ended June 30, 2025 would decrease / increase by Rs. 0.43 million (2024: Rs. 1.11 million). This is mainly attributable to the Group's exposure to markup rates on its variable rate borrowings.

43.3.3 Price risk

The Group's price risk arises from investments in units as disclosed in note 27.2 which are designated at fair value through profit or loss, however, in accordance with the investment strategy, the performance of units is actively monitored and they are managed on a fair value basis.

Price risk sensitivity analysis

If the fair value of mutual fund investments at the year end had fluctuated by 1% higher or lower, with all other variables held constant, the profit for the year would have been higher or lower by Rs. 6.27 million (2024: Rs. 1.58 million), primarily due to changes in the fair value of investments.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

43.4 Financial instrument by category

	Amortised cost	Fair value through profit or loss	Total
2025	(Rupees in '000')		
Financial assets			
Maturity upto one year			
Trade debts	1,461,456	-	1,461,456
Deposits and other receivables	153,116	-	153,116
Markup accrued	19,219	-	19,219
Other financial assets	47,520	1,027,993	1,075,513
Cash and bank balances	3,761,620	-	3,761,620
Maturity after one year			
Long term deposits	117,961	-	117,961
	5,560,892	1,027,993	6,588,885
Financial liabilities			
Maturity upto one year			
Trade and other payables	3,948,428	-	3,948,428
Unclaimed dividend	48,935	-	48,935
Markup accrued	7,974	-	7,974
Current portion of long term financing - secured	255,190	-	255,190
Current portion of lease liabilities	192,895	-	192,895
Maturity after one year			
Long term financing - secured	853,419	-	853,419
Deferred liabilities	44,846	-	44,846
Lease liabilities	506,524	-	506,524
	5,858,211	-	5,858,211

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

	Amortised cost	Fair value through profit or loss (Rupees in '000')	Total
2024			
Financial assets			
Maturity upto one year			
Trade debts	1,346,189	-	1,346,189
Deposits and other receivables	123,948	-	123,948
Markup accrued	4,383	-	4,383
Other financial assets	226,102	258,889	484,991
Cash and bank balances	2,157,203	-	2,157,203
Maturity after one year			
Long term deposits	126,050	-	126,050
	3,983,875	258,889	4,242,764
Financial liabilities			
Maturity upto one year			
Trade and other payables	3,662,078	-	3,662,078
Unclaimed dividend	44,730	-	44,730
Markup accrued	23,858	-	23,858
Current portion of long term financing - secured	495,195	-	495,195
Current portion of lease liabilities	146,911	-	146,911
Maturity after one year			
Long term financing - secured	579,756	-	579,756
Deferred liabilities	34,434	-	34,434
Lease liabilities	483,396	-	483,396
	5,470,358	-	5,470,358

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

43.5 Fair value

Fair value versus carrying amounts

The fair values of financial assets and liabilities, together with the carrying amounts shown in the consolidated statement of financial position, are as follows:

	2025		2024	
	Carrying value	Fair value	Carrying value	Fair value
(Rupees in '000')				
Assets carried at amortised cost				
Long term deposits	117,961	117,961	126,050	126,050
Trade debts	1,461,456	1,461,456	1,346,189	1,346,189
Deposits and other receivables	153,116	153,116	123,948	123,948
Markup accrued	19,219	19,219	4,383	4,383
Other financial assets	47,520	47,520	226,102	226,102
Cash and bank balances	3,761,620	3,761,620	2,157,203	2,157,203
	5,560,892	5,560,892	3,983,875	3,983,875
Assets carried at fair value				
Other financial assets	1,027,993	1,027,993	258,889	258,889
Liabilities carried at amortised cost				
Long term financing - secured	853,419	853,419	579,756	579,756
Deferred Liabilities	44,846	44,846	34,434	34,434
Lease liabilities	506,524	506,524	483,396	483,396
Trade and other payables	3,948,428	3,948,428	3,662,078	3,662,078
Unclaimed dividend	48,935	48,935	44,730	44,730
Markup accrued	7,974	7,974	23,858	23,858
Current portion of long term financing - secured	255,190	255,190	495,195	495,195
Current portion of lease liabilities	192,895	192,895	146,911	146,911
	5,858,211	5,858,211	5,470,358	5,470,358

The basis for determining fair values is as follows:

The interest rates used to discount estimated cash flows, when applicable, are based on the government yield curve at the reporting date plus an adequate credit spread. For instruments carried at amortised cost, since the majority of the interest bearing investments are variable rate based instruments, there is no difference in carrying amount and the fair value. Further, for fixed rate instruments, since there is no significant difference in market rate and the rate of instrument and therefore most of the fixed rate instruments are short term in nature, fair value significantly approximates to carrying value.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

44 FAIR VALUE HIERARCHY

Other financial assets

Fair value of investment in mutual funds (note 27.2) has been determined using quoted repurchase price at reporting date and categorised under level 1 of fair value hierarchy.

Fair value of land

Lands owned by the Group are valued by independent valuers to determine the fair values of lands as at reporting date. The fair value of lands subject to revaluation model fall under level 2 of fair value hierarchy.

There were no transfer amongst the levels during the year. Further, there were no changes in the valuation techniques during the year.

45 DISCLOSURE REQUIREMENT FOR COMPANIES NOT ENGAGED IN SHARIAH NON-PERMISSIBLE BUSINESS ACTIVITIES

Following information has been disclosed as required under amended part I clause VII of Fourth Schedule to the Companies Act, 2017 as amended via S.R.O 1278(I)/2024 dated August 15, 2024:

		2025	2024
	Note	(Rupees in '000')	
Financing as per islamic mode			
Long term financing (including current portion)	9	1,058,622	983,136
Short term shariah compliant investments			
Investment in Mutual Fund - at fair value through profit or loss	27	1,003,355	199,566
Shariah compliant bank balances			
Bank balances	28	2,691,664	185,244
Shariah compliant revenue			
Revenue - net	29	27,967,661	23,553,578
Dividend earned on shariah compliant investments			
Dividend income from mutual fund - investments at fair value through profit or loss	30	27,690	54,172
Profit earned from shariah compliant bank balances			
Profit on bank balances	30	179,005	41,353

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

		2025	2024
	Note	(Rupees in '000')	
Exchange gain earned from actual currency			
Exchange gain / (loss)	30 & 31	7,199	(26,469)
Profit paid on islamic mode of financing			
Long term financing	32	145,023	248,179
Source and detailed breakup of other income			
Shariah compliant			
Un-realised gain on investments at fair value through profit or loss	30	25,803	15,145
Others	30	286,725	156,383
Non-Shariah compliant			
Un-realised gain on investments at fair value through profit or loss	30	1,897	-
Profit on bank balances	30	9,364	25,954
Interest income on treasury bills	30	50,946	34,573
Others	30	8,467	1,224

Relationship with sharia compliant financial institutions / takaful operators

Name	Relationship
Al-Baraka Bank (Pakistan) Limited	Funded facility and Bank balance
Meezan Bank Limited	Funded / Non-funded facility and Bank balance
Habib Bank Limited	Funded / Non-funded facility and Bank balance
Dubai Islamic Bank Pakistan Limited	Bank balance
Faysal Bank Limited	Bank balance
Bank Alfalah Limited	Funded facility and Bank balance
First Habib Modaraba	Funded facility
EFU General Insurance Limited	Takaful
Jubilee General Insurance Company Limited	Takaful

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2025

46 OPERATING SEGMENTS

These consolidated financial statements have been prepared on the basis of single reportable segment. All revenue of the Group is earned in Pakistan. All non-current assets of the Group at June 30, 2025 are located in Pakistan. There is no other segment with more than 10% of total revenue of the Group for the year.

47 NON-ADJUSTING EVENT AFTER THE REPORTING DATE

The board of directors of the SIHL in their meeting held on September 06, 2025 has proposed a final cash dividend for the year ended June 30, 2025 @ Rs. 5 per share, amounting to Rs. 316.07 million for approval of the members in the Annual General Meeting to be held on October 25, 2025. The consolidated financial statements for the year ended June 30, 2025 do not include the effect of the final dividend which will be accounted for in the year in which it is approved.

48 CORRESPONDING FIGURES

Corresponding figures have been rearranged and reclassified, wherever considered necessary, for better presentation. However, following reclassification has been made during the year.

2024		
Description	Note	(Rupees in '000')
Reclassification from Stock in trade to Stores, spare parts and loose tools	22 & 23	23,545

49 DATE OF AUTHORISATION FOR ISSUE

These consolidated financial statements were approved and authorised for issue by the board of directors of the SIHL on September 06, 2025.

50 GENERAL

Figures have been rounded off to the nearest one thousand Pak Rupees unless otherwise stated.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

SHAREHOLDERS INFORMATION

AS AT JUNE 30, 2025



PATTERN OF SHAREHOLDING

AS AT JUNE 30, 2025

Number of shareholders	Size of holding of shares		Total shares held
	From	To	
700	1	100	14,849
271	101	500	68,712
1,074	501	1,000	569,689
426	1,001	5,000	728,076
71	5,001	10,000	530,467
65	10,001	15,000	728,848
30	15,001	20,000	517,469
23	20,001	25,000	499,993
12	25,001	30,000	331,420
8	30,001	35,000	256,329
4	35,001	40,000	150,225
8	40,001	45,000	336,842
11	45,001	50,000	516,824
12	50,001	55,000	629,527
3	55,001	60,000	174,091
3	60,001	65,000	188,165
3	65,001	70,000	202,275
4	70,001	75,000	286,327
3	75,001	80,000	233,094
4	80,001	85,000	324,224
6	85,001	90,000	534,134
5	90,001	95,000	459,718
4	95,001	100,000	394,894
3	100,001	105,000	306,000
2	105,001	110,000	215,856
1	110,001	115,000	110,125
1	115,001	120,000	117,104
4	120,001	125,000	490,847
6	125,001	130,000	766,405
1	130,001	135,000	134,527
4	135,001	140,000	553,701
1	140,001	145,000	141,576
1	145,001	150,000	145,219
3	150,001	155,000	457,262
3	155,001	160,000	471,673
1	160,001	165,000	162,792
1	165,001	170,000	165,977
1	170,001	175,000	173,706
1	190,001	195,000	193,187
1	200,001	205,000	205,000
2	205,001	210,000	414,410

Number of shareholders	Size of holding of shares		Total shares held
	From	To	
1	210,001	215,000	211,777
1	235,001	240,000	240,000
3	245,001	250,000	744,586
1	250,001	255,000	251,492
1	255,001	260,000	258,696
1	265,001	270,000	269,780
3	270,001	275,000	816,989
1	280,001	285,000	283,925
1	285,001	290,000	285,350
1	290,001	295,000	291,144
2	305,001	310,000	612,612
1	310,001	315,000	310,041
1	330,001	335,000	334,098
1	335,001	340,000	339,146
1	360,001	365,000	361,457
1	410,001	415,000	412,720
1	420,001	425,000	423,610
1	425,001	430,000	425,340
1	445,001	450,000	448,533
2	450,001	455,000	901,854
1	465,001	470,000	468,506
1	510,001	515,000	513,103
1	540,001	545,000	543,502
1	595,001	600,000	599,993
1	600,001	605,000	603,673
1	605,001	610,000	610,000
1	620,001	625,000	621,596
1	660,001	665,000	662,158
1	705,001	710,000	707,834
1	885,001	890,000	885,205
1	940,001	945,000	941,080
1	1,390,001	1,395,000	1,394,649
1	1,480,001	1,485,000	1,480,781
1	1,810,001	1,815,000	1,810,569
1	1,920,001	1,925,000	1,922,909
1	2,355,001	2,360,000	2,355,253
1	2,995,001	3,000,000	3,000,000
1	3,785,001	3,790,000	3,785,345
1	5,210,001	5,215,000	5,212,633
1	5,385,001	5,390,000	5,385,160
1	7,585,001	7,590,000	7,585,725
2,834			63,214,383

CATEGORIES OF SHAREHOLDING

AS AT JUNE 30, 2025

Categories of shareholders	Number of shareholders	Number of shares held	Percentage
CHARITABLE TRUSTS	13	12,094,424	19.13
FINANCIAL INSTITUTIONS	4	11,503,178	18.20
JOINT STOCK COMPANIES	19	370,222	0.59
MUTUAL FUND	40	5,418,924	8.57
OTHERS	32	997,000	1.58
INSURANCE COMPANIES	4	887,103	1.40
INVESTMENT COMPANIES	1	29,500	0.05
INDIVIDUALS	2721	31,914,032	50.49
Total	2,834	63,214,383	100.00

DISCLOSURE IN CONNECTION WITH THE PATTERN OF SHAREHOLDING AS REQUIRED BY THE CODE OF CORPORATE GOVERNANCE

AS AT JUNE 30, 2025

Categories of shareholders	Number of shareholders	Shares held	Percentage
Directors, Chief Executive Officer, and their spouses and minor children *	13	5,623,476	8.90
Associated Companies, Undertakings and related parties **	5	19,850,730	31.40
Executives	3	4,148	0.01
Banks, Development Financial Institutions, Non Banking Financial Institutions	4	11,503,178	18.20
Shareholders holding 10 % or more voting interest ***	2	15,447,617	24.44
Joint Stock Companies	19	370,222	0.59

* No. of Shares held by Directors, CEO and their spouses

Dr. Habib-Ur-Rahman	412,720	0.65
Dr. Zeeshan Bin Ishtiaque	268,622	0.42
Dr. Manzoor H. Qazi	1,484,549	2.35
Mr. Qasim Farooq Ahmad	2,094,494	3.31
Dr. Samea Kauser Ahmad	1,051,205	1.66
Syed Ilyas Ahmed	11,562	0.02
Dr. Mohammad Naseem Ansari	16,983	0.03
Dr. Mohammad Salim Khan	96,451	0.15
Shah Naveed Saeed	13,798	0.02
Mr. Ioan Philippe Cleaton Jones (Nominee of International Finance Corporation)	-	0.00
Mr. Taimoor Shah	155,613	0.25
Mrs. Shahida Rahman W/o Dr. Habib-Ur-Rahman	13,379	0.02
Mrs. Sana Zeeshan W/o Dr. Zeeshan Bin Ishtiaque	4,100	0.01

** Shares held by related parties

Tameer-e-Millat Foundation	7,861,892	12.44
International Finance Corporation	7,585,725	12.00
Shifa Foundation	4,154,452	6.57
Shifa Tameer-e-Millat University	170,200	0.27
SIHL Employees' Gratuity Fund	78,461	0.12

Shareholders with 10 % or more voting interest

Tameer-e-Millat Foundation	7,861,892	12.44
International Finance Corporation	7,585,725	12.00

[illegible]

FORM OF PROXY

39TH ANNUAL GENERAL MEETING

I/We _____ of _____
being a member of Shifa International Hospitals Ltd. Folio No./CDCA/c No. _____
No. of Shares _____ hereby appoint _____
of _____ Folio No./CDC A/c No. _____ or failing
him/her _____ of _____ Folio
No./CDC A/c No. _____ who is a member of the Company as my/
our proxy in my/our absence to attend and vote for me/us and on my/our behalf at the 39th
Annual General Meeting of the Company to be held at 1100 hours on October 25, 2025, and
at any adjournment thereof.

As witness my hand this _____ day of _____ 2025.

Signed by the said _____

**Revenue
Stamp**

(Signature must agree with the
SPECIMEN signature registered with
the Company)

Witnesses:

1 Signature _____
Name _____
Address _____

CNIC/Passport No. _____

2 Signature _____
Name _____
Address _____

CNIC/Passport No. _____

Important:

1. This form of Proxy, duly completed, signed and stamped must be deposited at the Company's Registered Office situated at Sector H-8/4 Islamabad, not less than 48 hours before the time of holding the meeting.
2. A Proxy must be a member of the Company. Notwithstanding the above, a non-member may be appointed as a proxy by a member participating in General Meetings through e-voting in the manner stipulated under the applicable laws.
3. If a member appoints more than one proxy and more than one instruments of proxy are deposited by a member with the Company, all such instruments of proxy shall be rendered invalid.
4. CDC account holder, sub account holder/shareholder may appoint proxy and the proxy must produce attested copy of his/her CNIC or original passport at the time of attending the meeting.



پراکسی فارم

39 واں سالانہ اجلاس عام

شفا انٹرنیشنل ہسپتال لمیٹڈ

میں / ہم ساکن شیئر ہولڈر شفا انٹرنیشنل ہسپتال لمیٹڈ
 فولیو نمبر / سی ڈی سی اکاؤنٹ نمبر شیئرز کا شمار بذریعہ ہذا تقرر کرتا ہوں
 ساکن فولیو نمبر / سی ڈی سی اکاؤنٹ نمبر
 یا اس کی عدم دستیابی پر ساکن فولیو نمبر / سی ڈی سی اکاؤنٹ نمبر
 جو کہ میری / ہماری غیر موجودگی میں میرے / ہمارے پراکسی (نمائندے) کے طور پر کمپنی کے 39 واں
 سالانہ اجلاس عام میں جو 25 اکتوبر 2025 بروز ہفتہ دن 11:00 بجے یا اس کے التوا کی صورت میں منعقد ہوگا میں میری / ہماری جگہ شرکت
 کرے گا اور ووٹ استعمال کرے گا۔

ریونیومر
 دستخط کمپنی کے پاس موجود نمونہ
 کے دستخط کے مطابق ہونا چاہئے

میں بطور گواہ اس دن 2025
 دستخط مذکورہ بالا

گواہان:

1- دستخط 2- دستخط
 نام نام
 پتہ پتہ
 قومی شناختی کارڈ / پاسپورٹ نمبر قومی شناختی کارڈ / پاسپورٹ نمبر

خصوصی ہدایات :

- 1- یہ پراکسی فارم باقاعدہ طور پر مکمل کر کے، دستخط، گواہان اور مہر کے بعد اجلاس کے انعقاد سے کم از کم 48 گھنٹے پہلے کمپنی کے رجسٹرڈ دفتر واقع سیکٹر 8/4-H، اسلام آباد پہنچ جانا چاہئے۔
- 2- ایک پراکسی کمپنی کا ممبر ہونا ضروری ہے مذکورہ بالا کے باوجود، قابل اطلاق قوانین کے تحت طے شدہ طریقے سے ای ووٹنگ کے ذریعے اجلاس عام میں حصہ لینے والے رکن کے ذریعے غیر رکن کو پراکسی کے طور پر مقرر کیا جاسکتا ہے۔
- 3- اگر ایک ممبر ایک سے زائد پراکسی یا پراکسی کے فارم کمپنی کے پاس جمع کرواتا ہے تو ایسے تمام پراکسی کے فارم کو غیر قانونی تصور کیا جائے گا۔
- 4- سی ڈی سی اکاؤنٹ ہولڈر، سب اکاؤنٹ ہولڈر / شیئر ہولڈر اپنی پراکسی مقرر کرنے کا مجاز ہے۔ اس پراکسی کو اجلاس میں شرکت کے وقت اپنے اصل کمپیوٹر یا ڈیجیٹل قومی شناختی کارڈ یا اصلی پاسپورٹ دکھانا لازمی ہوگا۔



[illegible]

[illegible]



**Shifa
International
Hospitals Ltd.**

Shifa International Hospitals Limited

Pitras Bukhari Road,
Sector H-8/4, Islamabad - Pakistan
Email: info@shifa.com.pk
Website: www.shifa.com.pk

Scan to access the
Annual Report

